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Abstract
The primary objective is to investigate the main factors contributing to GMS expen-
diture on pharmaceutical prescribing and projecting this expenditure to 2026. This
study is located in the area of pharmacoeconomic cost containment and projections
literature. The thesis has five main aims:
1. To determine the main factors contributing to GMS expenditure on pharmaceu-
tical prescribing.
2. To develop a model to project GMS prescribing expenditure in five year intervals
to 2026, using 2006 Central Statistics Office (CSO) Census data and 2007 Health
Service Executive–Primary Care Reimbursement Service (HSE–PCRS) sample
data.
3. To develop a model to project GMS prescribing expenditure in five year intervals
to 2026, using 2012 HSE–PCRS population data, incorporating cost containment
measures, and 2011 CSO Census data.
4. To investigate the impact of demographic factors and the pharmacology of drugs
(Anatomical Therapeutic Chemical (ATC)) on GMS expenditure.
5. To explore the consequences of GMS policy changes on prescribing expenditure
and behaviour between 2008 and 2014.
The thesis is centered around three published articles and is located between the
end of a booming Irish economy in 2007, a recession from 2008–2013, to the beginning
of a recovery in 2014. The literature identified a number of factors influencing pharma-
ceutical expenditure, including population growth, population aging, changes in drug
utilisation and drug therapies, age, gender and location. The literature identified the
methods previously used in predictive modelling and consequently, the Monte Carlo
Simulation (MCS) model was used to simulate projected expenditures to 2026. Also,
the literature guided the use of Ordinary Least Squares (OLS) regression in determin-
ing demographic and pharmacology factors influencing prescribing expenditure.
The study commences against a backdrop of growing GMS prescribing costs, which
has risen from e250 million in 1998 to over e1 billion by 2007. Using a sample 2007
HSE–PCRS prescribing data (n=192,000) and CSO population data from 2008, (Con-
way et al., 2014) estimated GMS prescribing expenditure could rise to e2 billion by
xxvi
2026. The cogency of these findings was impacted by the global economic crisis of 2008,
which resulted in a sharp contraction in the Irish economy, mounting fiscal deficits re-
sulting in Ireland’s entry to a bailout programme. The sustainability of funding com-
munity drug schemes, such as the GMS, came under the spotlight of the EU, IMF,
ECB (Trioka), who set stringent targets for reducing drug costs, as conditions of the
bailout programme. Cost containment measures included: the introduction of income
eligibility limits for GP visit cards and medical cards for those aged 70 and over, intro-
duction of co–payments for prescription items, reductions in wholesale mark–up and
pharmacy dispensing fees. Projections for GMS expenditure were reevaluated using
2012 HSE–PCRS prescribing population data and CSO population data based on Cen-
sus 2011. Taking into account both cost containment measures and revised population
predictions, GMS expenditure is estimated to increase by 64%, from e1.1 billion in
2016 to e1.8 billion by 2026, (ConwayLenihan and Woods, 2015).
In the final paper, a cross–sectional study was carried out on HSE–PCRS pop-
ulation prescribing database (n=1.63 million claimants) to investigate the impact of
demographic factors, and the pharmacology of the drugs, on GMS prescribing expen-
diture. Those aged over 75 (β = 1.195) and cardiovascular prescribing (β = 1.193)
were the greatest contributors to annual GMS prescribing costs. Respiratory drugs
(Montelukast) recorded the highest proportion and expenditure for GMS claimants un-
der the age of 15. Drugs prescribed for the nervous system (Escitalopram, Olanzapine
and Pregabalin) were highest for those between 16 and 64 years with cardiovascular
drugs (Statins) were highest for those aged over 65. Females are more expensive than
males and are prescribed more items across the four ATC groups, except among chil-
dren under 11, (ConwayLenihan et al., 2016).
This research indicates that growth in the proportion of the elderly claimants and
associated levels of cardiovascular prescribing, particularly for statins, will present dif-
ficulties for Ireland in terms of cost containment. Whilst policies aimed at cost con-
tainment (co–payment charges, generic substitution, reference pricing, adjustments to
GMS eligibility) can be used to curtail expenditure, health promotional programs and
educational interventions should be given equal emphasis. Also policies intended to af-
fect physicians prescribing behaviour include guidelines, information (about price and
less expensive alternatives) and feedback, and the use of budgetary restrictions could
yield savings.
xxvii
Chapter 1
Introduction
1.1 Introduction
This thesis charts the time period between 2007 and 2014, and is situated against a
backdrop of cuts in public expenditure on health in response to a global financial crisis,
population growth and growth in the elderly proportion of the population in Ireland.
The focus of this thesis is to investigate the impact of pharmaceutical expenditure, as
Ireland recovers from the impact of austerity policies at a time, when the population is
not only forecasted to rise, but the proportion of those aged 65 (old persons) and over
is projected to rise rapidly. This study is located in the area of pharmacoeconomic cost
containment and projections literature.
The economic downturn has affected many countries within the European Union
(EU1) with many implementing strict austerity policies, such as taxation increases and
public expenditure decreases. General government expenditure as a percentage of Gross
Domestic Product (GDP2) decreased on average by 2.5% between 2009 and 2013 across
Organisation for Economic Co–Operation and Development (OECD3) countries. The
1The EU is a unique economic and political partnership between 28 European countries, (EU, 2015).
2GDP measures the value of the total output of goods and services in the country over a calendar
year, (Leddin and Walsh, 2013).
3The OECD help governments foster prosperity and fight poverty through economic growth and
financial stability. The OECD analyse and compare data to predict short and medium term trends,
(OECD, 2015b).
1
OECD argues that this is a direct consequence of the financial crisis, where there is a
slowdown or a reduction in government expenditure compared to the growth of GDP.
Most OECD countries have cut back on government expenditure, where the biggest cut
backs have occurred in Estonia (7.3%) and Ireland (6.9%). The 2014 OECD data shows
that government expenditure decreased by 10.7% in Greece and by 9.9% in Slovenia
between 2013 and 2014 due to once–off measures of capitalising their domestic banks,
(OECD, 2015a).
Annual growth in health spending per capita decreased in real terms between 2009
and 2012 in 14 of the 28 countries within the EU, reversing a trend of steady increases.
The average annual growth rate in health expenditure per capita (EU28) increased by
4.7% between 2000 and 2009 and fell by 0.6% between 2009 and 2012. The Irish av-
erage annual growth rate in health expenditure per capita increased by 6.3% between
2000 and 2009 and fell by 3.7% between 2009 and 2012. Ireland experienced one of the
biggest decreases in health spending per capita, after Luxembourg (5.1%) and Greece
(9.0%), (OECD, 2014).
Health expenditure accounts for a significant component of GDP. In 2009, it ac-
counted for 11.6% in France, 9.9 % in Ireland, 10.2% of GDP in Greece and Portugal.
Health spending as a share of GDP decreased for many EU countries following the
economic crisis. EU countries (EU28) allocated on average 7.3% of GDP to health
spending in 2000, increasing to 9.0% in 2009, before falling to 8.7% in 2012. Germany
committed 10.4% of GDP to health spending in 2000 and rising to 11.8% in 2009, before
falling to 11.3% in 2012 (one of the highest in the EU),(OECD, 2014). Reductions in
public expenditure on health were achieved through various measures across the EU.
Due to the significant contribution of pharmaceuticals to total health expenditure (25%
in Greece (2007), 21% in Portugal (2008) and 17.5% in Ireland (2009), the pharmaceu-
tical sector was targeted to contribute to a reduction in expenditure, (Vandoros and
Stargardt, 2013). Measures included; price reductions to drug manufacturers, promo-
tion of generic drug prescribing, introduction and increases in co–payments, reference
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pricing, wholesaler margins and Value Added Tax (VAT) rates, (Volger et al., 2011).
During the global economic crisis, the economy was experiencing increasing phar-
maceutical expenditure and challenging economic circumstances in Ireland. The Irish
economy officially fell into recession in the final quarter of 2008, (CSO, 2008). As
depicted by the American definition, an economy is said to be in recession, when it
experiences two consecutive quarters (6 months) of negative economic growth. General
government debt as a percentage of GDP increased rapidly during the economic crisis
from 27.48% in 2007 to 127.85% in 2014. In 2014, out of 33 OECD countries, Ireland
had the 5th highest general government debt as a percentage of GDP (It increased from
68.36% in 2009 to 127.85% in 2014), two places above the OECD weighted average.
General government debt per capita increased from $28,383 in 2009 to $62,531 in 2014.
Ireland had one of the highest rates of all 33 OECD countries only to be exceeded by
Japan ($86,682) in 2013, (OECD, 2015a). Ireland officially exited recession in Septem-
ber 2013, when GDP grew by 0.4% between quarter one and quarter two 2013, (CSO,
2013).
In 2012, Ireland spent 14% of total government expenditure on healthcare which is
comparable with the EU average (EU28). The Netherlands had the highest proportion
at 20% and Cyprus had the lowest proportion at 8%. Irish health spending accounted
for 8.9% of GDP, just above the EU average (EU28) of 8.7%. Netherlands recorded
the highest value at 11.8% and Romania the lowest at 5.6%, (OECD, 2014). In 2013,
Ireland had increased its expenditure on health to 17.4%. The OECD analysis disag-
gregates government expenditure by function for each country. For example, health,
social protection, education etc. According to a 2015 OECD report, Ireland spent 1.3%
less on health between 2007 and 2013, where the government spent 6.4% more on social
protection over the same time period, (OECD, 2015a). This may be explained by in-
creases in unemployment levels and consequently higher unemployment benefits being
paid out by the Social Protection Department. The Irish standardised unemployment
rate increased from 4.7% in 2007 before peaking at 14.7% in 2012, before falling to
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13.1% in 2013, (CSO, 2015b). The OECD reports out-of-pocket (OOP) medical expen-
diture as a share of final household consumption increased from 2.5% in 2007 to 3.2%
in 2012. OOP are borne by the individual patient as the full cost of the health good
or service is not covered by either public or private insurance. The OECD states this
increase is due to the Irish economic crisis, (OECD, 2015a).
Irish pharmaceutical expenditure per capita relative to other OECD countries has in-
creased significantly since 2000. Ireland’s position has moved from 20th highest of 27
countries in 2000 to 3rd highest of 25 countries in 2010. Irish per capita spending on
pharmaceuticals was the highest in the EU and was 34% above the EU average in 2010,
(Brick et al., 2013). Irish pharmaceutical spending per capita in 2012 was the third
highest amongst EU countries at e500, 40% above the EU average (e350), (OECD,
2014). The total cost of General Medical Services (GMS) prescriptions has increased
from e249 million in 1998 to e1.28 billion in 2012, a 414% increase (various annual
PCRS Reports, 1998–2012). The GMS scheme is the largest Community Drug Scheme
(CDS4) in Ireland and all CDS will be explained in detail in chapter two. Those who
are eligible for the GMS scheme are entitled to free prescription drugs and appliances.
GMS expenditure accounted for 9% of the overall health budget in 2012, (Department
of Health, 2012).
Figure 1.1 illustrates cost of GMS medicines between 1996 and 2012. GMS medicines
increased from e215 million in 1996 to e1.29 billion in 2012, an increase of 501%. GMS
medicines increased by approximately e1 billion (487%) between 1996 and 2009. GMS
medicines decreased for the first time (between 1996 & 2010) to e1.23 billion in 2010
and further decreased to e1.21 billion in 2011, before increasing again to e1.29 billion
in 2012.
4There are 11 CDS in Ireland where individuals are entitled to free or subsidised healthcare.
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Figure 1.1: Cost of GMS Medicines (eMillions) between 1996 and 2012
Source: (Various PCRS Reports 1998–2012)
The sustainability of funding these community drug schemes have come under the
spotlight of the EU, International Monetary Fund (IMF5) and European Central Bank
(ECB6) (Troika), who have identified pharmaceutical expenditure as a target area for
cost reductions. The challenge for Ireland and many of our EU counterparts is con-
taining pharmaceutical expenditure, but policies are severely restricted by population
growth and growth in the elderly component of our populations, the main consumers
of prescribed drugs, (Barry et al., 2010) and (Layte et al., 2009).
Thus the focus of this thesis is to investigate the impact of pharmaceutical expen-
diture, as Ireland recovers from the impact of austerity policies at a time, when the
5The IMF is an organisation of 188 countries, which works to foster global monetary co–operation,
secure financial stability, facilitate international trade, promote high employment and sustainable eco-
nomic growth, and reduce poverty around the world, (IMF, 2015).
6The ECB’s main task is to maintain the euro’s purchasing power and thus price stability in the
euro area, (ECB, 2015).
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population is not only forecasted to rise, but the proportion of those aged 65 (old per-
sons) and over is projected to rise rapidly. The Central Statistics Office (CSO) estimate
the number of old persons will almost double from 532,000 in 2011 to 991,000 in 2031,
(CSO, 2013). This introductory chapter outlines the rationale for researching the GMS
scheme and the objective of this research. The methodological approaches applied in
this thesis will be discussed. Lastly, the structure of the thesis will be specified.
1.2 Objective and Aims of the Research
The research problem is focused on GMS expenditure projections and drug prescribing
patterns in Ireland. The research problem is addressed across four journal articles. The
primary objective is to investigate the main factors contributing to GMS expenditure
on pharmaceutical prescribing and projecting this expenditure to 2026. This thesis has
five main aims, which are specified below.
1. To determine the main factors contributing to GMS expenditure on pharmaceu-
tical prescribing.
• To construct and develop projections for population, coverage, claims rates
and average claims cost variables using CSO7 population projections (Census
2006) and sample Health Service Executive8–Primary Care Reimbursement
Service9 (HSE–PCRS) pharmacy data (2007).
2. To develop a model to project GMS prescribing expenditure in five year intervals
to 2026, using 2006 CSO Census data and 2007 HSE–PCRS sample data.
• Quantify the estimated impact on GMS expenditure of these four variables
by old health board region, gender and age cohort in five year intervals to
2026.
7The CSO is responsible for the collection, compilation, extraction and dissemination for statistical
purposes of information relating to economic, social and general activities and conditions in the Irish
State, (CSO, 2015a).
8The public body responsible for the organisation and delivery of health care in Ireland.
9The public body responsible for the processing and reimbursement of GMS claims.
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3. To develop a model to project GMS prescribing expenditure in five year intervals
to 2026, using 2012 HSE–PCRS population data incorporating cost containment
measures, and 2011 CSO Census data.
• To construct and develop projections for population, coverage, claims rates
and average claims cost variables using CSO population projections (Census
2011) and population HSE–PCRS pharmacy data (2012), which incorporates
cost containment policies introduced following the onset of the economic
crisis.
• Quantify the estimated impact on GMS expenditure of these four variables
by old health board region, gender and age cohort in five year intervals
between 2016 and 2026.
4. To investigate the impact of demographic factors and the pharmacology of drugs
(Anatomical Therapeutic Chemical (ATC10)) on GMS expenditure.
• Investigate the impact of regional variation on GMS expenditure by ATC
group.
• Investigate the impact of gender variation on GMS expenditure by ATC
group.
• Investigate the impact of age variation on GMS expenditure by ATC group.
5. To explore the consequences of GMS policy changes on prescribing expenditure
and behaviour between 2008 and 2014.
• Investigate the impact of policy changes on GMS coverage rates between
2008 and 2014.
• Investigate the impact of policy changes on the average cost per claimant
between 2008 and 2014.
• Investigate the impact of policy changes on claims rates between 2008 and
2014.
10The ATC classification system divides drugs into different categories according to the organ or
system on which it is acting upon, (WHO, 1990).
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Aims two and three will project the effects of future changes in population, cover-
age, claims rates and average claims cost on GMS costs in Ireland under three scenarios
to 2026. This thesis projects GMS expenditure based on two years, year before reces-
sion (2007) and 2012, following the introduction of cost containment measures. This
research models GMS costs under a best case scenario (scenario 1), most likely sce-
nario (scenario 2) and worst case scenario (scenario 3). As outlined in the introductory
section, Ireland has one of the highest pharmaceutical expenditure per capita. Taking
account of demographic changes in the population, the Irish economy cannot sustain
this growth in GMS expenditure.
1.3 Publication Plan
This thesis is a compilation of published work over the past four years, as depicted
in Figure 1.2. There follows a list of each publication, in the sequence that it was
published or presented, with its title, along with the journal or conference in which
the work has been disseminated. It is noted that Aisling ConwayLenihan, the author
of this thesis, has been the primary author on all publications. This work has been
based on a research question developed by the author under the primary guidance of
Dr. Noel Woods.
1. ‘The implications of regional and national demographic projections for future
GMS costs in Ireland through to 2026’. This paper was published in the BioMed
Central (BMC11) Health Services Research journal in October 2014.
2. ‘Irish population and GMS coverage projections by health board region, gender
and age cohort out to 2026’. This has been submitted and is currently under
review in the Irish Business Journal.
3. ‘Irish GMS Cost Projections and its Implications between 2016 and 2026’. This
paper was published in the Pharmacoeconomics Open Access Journal in Novem-
ber 2015.
11BMC is an open access, peer-reviewed journal that publishes in the area of health services research.
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4. ‘Factors influencing the variation in GMS prescribing expenditure in Ireland’.
This paper was published in the Health Economics Review in March 2016.
Conference Proceedings
5. ‘The Implications of demographic change for GMS costs in Ireland through to
2026’. This paper was presented at the International Society For Pharmacoeco-
nomics and Outcomes Research (ISPOR12) 16th Annual European Congress in
Dublin in November 2013. The proceedings of this conference have been peer–
reviewed and published.
6. ‘The Impact of Increased Coverage Rates on GMS Costs in Ireland’. This pa-
per was presented at the International Health Economics Association/European
Conference on Health Economics (IHEA/ECHE13) 10th World Congress in Dublin
in July 2014. The proceedings of this conference have been peer–reviewed and
published.
7. ‘Regional Variation in GMS expenditure by ATC classification’. This paper was
presented at the Regional Science Association International–British and Irish Sec-
tion (RSAI–BIS) in Dublin in August 2015. The proceedings of this conference
have been peer–reviewed and published.
12ISPOR is an international multidisciplinary professional membership society that advances the
policy, science, and practice of pharmacoeconomics and outcomes research, (ISPOR, 2015).
13Both bodies held a joint congress in Dublin 2014.
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Figure 1.2: Research Aims and Publication Plan
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1.4 Methological Approach
Driven by the objective and aims of this thesis, quantitative methods were employed.
A quantitative methodology was used to derive variable (population, GMS coverage,
average cost per claimant and claims rate) projections and GMS cost projections. A
quantitative method was employed to identify the factors that influence pharmaceutical
expenditure.
1.5 Structure of the Research
This thesis consists of seven chapters, which altogether encompass two peer–reviewed
conference presentations, poster presentation and four journal articles. Chapter one in-
troduces the research topic and outlines the rationale for the research, publication plan
and structure of the thesis. Chapter two is comprised of a comprehensive literature
review. Firstly, pharmaceutical cost containment measures are explored, pharmaceu-
tical expenditure projections and drivers of pharmaceutical expenditure are explored,
followed by a detailed description of the community drug schemes in Ireland, and
specifically the GMS scheme. This chapter also details the methodologies used; Monte
Carlo Simulation Model and Ordinary Least Squares (OLS) Regression. Chapter three
presents the implications of regional and national demographic projections for future
GMS costs in Ireland through to 2026 (Paper 1).
The fourth chapter is comprised of two papers. The first paper updates Irish pop-
ulation (CSO, 2013) and GMS coverage (PCRS, 2012) projections by old health board
region, gender and age cohort (Paper 2). The latter half of chapter 4 updates GMS
expenditure projections using 2012 HSE–PCRS population data (Paper 3) following
the implementation of cost containment measures. Chapter 3 is based on a sample
HSE–PCRS 2007 database and 2008 CSO population projections, whereas chapter 4 is
based on 2013 CSO population projections and 2012 HSE–PCRS population prescrip-
tion database. Chapter five examines the factors that influence the variation in Irish
GMS prescribing expenditure (Paper 4). Chapter six charts the GMS policy changes
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between 2008 and 2014. Chapter seven concludes and summarises the findings of the
research. The recommendations and the scope for future research are also presented in
the final chapter.
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Chapter 2
Literature Review
2.1 Introduction
The purpose of the review of literature is to locate the study in terms of existing re-
search on drug expenditure projections and the factors influencing drug expenditure
globally and particulary in terms of the GMS scheme in Ireland. The examination of
the literature will identify the statistical methods previously employed and variables
used in similar studies. Furthermore, the review will provide an appreciation of the
type of results to expect; this will provide a benchmark for the findings of this research.
As the focus of the research is GMS expenditure projections and factors influencing
drug prescribing expenditure patterns in Ireland, the literature review will concentrate
on this research problem. However, as many of the methodological approaches con-
sidered have been applied outside the area of health economics, literature from other
disciplines are included, where appropriate. Several databases were searched to iden-
tify relevant literature; MEDLINE, CINAHL, EMBASE, EconLit and Business Source
Complete. Searches were also performed in the Database of Abstracts of Reviews
of Effects (DARE), the National Health Service (NHS) Economic Evaluation Database
(EED) and the Cochrane Library methodology register. The search strategy was devel-
oped using combinations of various search terms relevant to the research topic. Searches
were limited to studies in the English language.
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This chapter is structured as follows: in section 2.2, pharmaceutical cost contain-
ment is explored from both an international and an Irish context. In section 2.3, drivers
of drug expenditure are identified. Pharmaceutical expenditure and demographic pro-
jections in Ireland is examined in section 2.4. Community drug schemes are described
in section 2.5 and the GMS scheme, upon which this thesis is primarily based. Section
2.6 details the methodologies used in this thesis. Finally, section 2.7 concludes the
literature review.
2.2 Pharmaceutical Cost Containment (International Lit-
erature)
The purpose of this section is to review the international and Irish literature on pharma-
ceutical cost containment measures. This will identify the cost containment measures
that have been implemented internationally and the savings they have generated where
available. This section will also identify the cost containment measures that have been
implemented in Ireland and their associated savings where available.
Health and pharmaceutical cost containment is a matter of concern for policy mak-
ers and is high on the politicial agenda internationally. (Mousnad et al., 2014) frames
the principle cost containment strategies into four broad categories; educational, man-
agerial, administrative and financial. Educational strategies incorporate continuing
education programmes, practice guidelines, drug committees and patient information
packages. Managerial and administrative strategies can control the regulation of mar-
keting and commerical information, such as direct–to–consumer advertising. Manage-
rial strategies control positive and negative lists, reference pricing (incentive pricing),
reimbursement schemes, disease management strategies and practice guidelines. Ad-
ministrative and financial strategies include fixed or directive budgets for prescribing,
regulation of prices, price and volume agreements, co–payments and financial incentives
to pharmacists to promote generic drugs and improve pharmacy services, (Mousnad
et al., 2014).
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In Germany, a number of pharmaceutical cost initiatives have been introduced.
These include price regulation (fixed prices for drugs), positive (reimbursable drugs)
and negative (non–reimbursable drugs) lists, co–payment charges (user charge paid by
the patient) and caps on physician prescribing, (Schulenburg, 1997) and (Breyer, 2002).
A German study found that savings accummulated from the introduction of reference
pricing1 equated to 9% of total pharmaceutical expenditure in 2001, (Busse, 2001). In
Spain, pharmaceutical cost containment was high on the political agenda between 1996
and 2002. Supply side policies introduced during this time include updated negative
list, reference pricing, payment system to pharmacies and pharmaceutical industry–
government agreements, (Puig-Junoy, 2004). In Turkey, (Vancelik et al., 2007) found
that the influence of pharmaceutical companies on General Practitioner (GP) drug
prescribing through promotional and educational courses, acted as a barrier to cost
containment.
A study examined the effect regulation had on pharmaceutical revenues across 19
countries between 1992 and 2004. (Sood et al., 2009) found increased regulation in
OECD countries over the 12 year period, with direct price controls being the most
common form of regulation. Economic evaluations was found to be the fastest growing
regulation. Two countries had this regulation in place in 1992, increasing to 10 coun-
tries by 2004. Direct price controls and economic evaluations had the biggest impact
on pharmaceutical revenue. (Sood et al., 2009) argued if direct price controls and other
regulations were introduced to an unregulated market, they would greatly reduce phar-
maceutical costs.
A Norwegian study analysed the drug pricing strategies implemented by government
between 1994 and 2004. Norway has focused on pricing systems in the fight against
drug containment costs. (Hakonsen et al., 2009) suggests direct price control through
1Reference pricing is the setting of a standard reimbursement price, or reference price, for a group
of interchangeable medicines.
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international reference pricing is the most successful pricing strategy, as opposed to in-
direct pricing strategies, such as reference based pricing, generic substitution and index
pricing. Reference pricing was introduced in British Colombia in 1995 to contain drug
expenditure of its publicly funded drug benefit plan, Pharmacare, but the cost savings
were lower than expected, (Schneeweiss et al., 2002). (Dylst et al., 2011) undertook a
literature review on the impact of reference pricing systems in 22 European countries.
They found reference pricing led to a decrease in pharmaceutical expenditure growth
in the short term but not in the long term. In 2010, generic pricing was introduced in
Ontario. (Law et al., 2011) estimated that this policy resulted in savings of between
$181 million and $194 million in the final 6 months of 2010. This Canadian study also
found, if Ontario generic prices were applied nationally, Canadian drug expenditure
would reduce by 4.9% to $1.28 billion.
(Ess et al., 2003) reviewed European policies for controlling drug expenditure and
identified three pricing policies; product price control, reference pricing and profit con-
trol (mainly used in the United Kingdom (UK)). They found that countries with a high
drug consumption have lower drug prices (Spain, Greece, France) and countries with
low drug consumption have higher drug prices (Netherlands, Switzerland, Denmark).
This can result in higher drug expenditure per capita in countries with lower price
levels. For example, France had a $337 drug expenditure per person, whereas Denmark
had $165 drug spend per person. Drug expenditures are not found to be lower in coun-
tries with price controls, (Ess et al., 2003).
(Morgan and Astolfi, 2015) analysed the financical impact of the global financial
crisis on health expenditure across OECD countries. Many OECD countries introduced
cost containment measures in 2009 and the measures intensified in 2011. Pharmaceu-
tical expenditure contributes 17.5% of average current health expenditure in OECD
countries. Between 2009 and 2011, Greece reduced pharmaceutical expenditure by
19.5%, approximately e1 billion through cost containment measures. Cost contain-
ment measures included price cuts, the re-introduction of a positive list, changes in the
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profit margins of pharmacies and wholesalers, and tenders for hospital drugs, (Vandoros
and Stargardt, 2013). (Goranitis et al., 2014) argues Greek cost containment measures
were not well targeted and were introduced as a quick and easy fix to fiscal adjustment,
while ignoring the need for structural reform. Portugal and Spain reduced pharmaceuti-
cal expenditure by 20% and 8% respectively. In 2011, Portugal reduced pharmaceutical
expenditure through price reductions, centralised purchasing of drugs and guidelines to
reduce administration costs, (Morgan and Astolfi, 2015). (Almarsdo´ttir and Traulsen,
2005) warns policy makers against a narrow policy focus on reducing pharmaceutical
costs, without considering the broader objective of medicine use and its impact on
health outcomes. Cost containment strategies should be evidence based and consider
the impact they will have on public health.
2.2.1 Cost Containment in Ireland
Pharmaceutical cost containment has been high on the political agenda in Ireland, es-
pecially since the onset of the economic crisis in 2008. (Murphy, 2008) maintains cost
containment is not about cutbacks but about “better strategy, better management,
better service provision and taking the best options”. In 2005, (Tilson et al., 2005)
examined the potential impact of implementing a system of generic substitution on the
community drug schemes in Ireland. This research was motivated by a five fold increase
in the cost of medicines on the community drug schemes. This study highlighted the
potential savings to be made from the introduction of generic substitution. However,
(Tilson et al., 2005) argued that decison makers should also implement incentives for
pharmacists to prescribe generically and for prescribers to allow generic substitution,
so that maximum potential savings could be realised. (Barry et al., 2008) documented
the nature, growth and cost of the Irish community drug schemes between 1997 and
2007. Community drug expenditure increased five–fold over this period to e1.74 bil-
lion in 2007. Price Controls were introduced to the Irish market in 1993, where the
price of medications were linked to the average of the wholesale price in selected EU
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countries. The National Centre for Pharmacoeconomics (NCPE) found this cost con-
tainment measure could potentially result in savings of approximately e16 million in
2004. (Barry et al., 2008) maintains cost containment measures such as price controls,
trade agreements, pharmacoeconomic evaluations and generic substitution could be
threatened by the emergence of expensive cancer and chronic treatments.
(Barry and Tilson, 2010) argue decision makers should consider the reimburse-
ment of new high cost drugs with evidence development. However, they contend reim-
bursement based on evidence development will be the exception, rather than the rule.
Evidence is generated to validate reimbursment decisions and inform future decision
making. A review group explored the scope for further economies in drug usage in the
Irish healthcare setting in 2009, (Barry et al., 2009). The review group developed 11
recomendations with a target of e65 million in savings. Recommendations included;
savings via the Irish Pharmaceutical Healthcare Association (IPHA2)/HSE agreement,
cost–effectiveness of drugs reimbursed under community drug schemes, informing pa-
tients of pricing of medicines to optimise value for money and reduce wastage, generic
prescribing and pricing, GP incentives to enhance cost–effective prescribing, continuity
across hospital and communtiy prescribing and review wholesale margins and payments
to pharmacies, (Barry et al., 2009). (Tilson and Barry, 2010) reviewed developments
in pharmacoeconomic evaluation in furtherance of the cost containment objective. Re-
imbursement decisions underlied by cost–effectiveness for certain medicines were intro-
duced in September 2006 and all medicines were considered from 2009, (Tilson and
Barry, 2010).
(Walshe and Kenneally, 2013) investigated the savings from pharmaceutical cost
containment policies in 2011. Community drug scheme costs are driven by three compo-
nents; number of eligible persons, price of drugs/services and volume of drugs/services
prescribed. Recently, both the number of eligible persons and number of items have
2IPHA represents the international research based pharmaceutical industry in Ireland and its mem-
bers include prescription and non–prescription manufacturers, (IPHA, 2015).
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increased on the GMS scheme, whereas the price of drugs has decreased. Following
the IPHA/HSE agreement in 2006, the price of drugs have decreased and this study
estimated savings of e200 million in 2011. Reductions in retail and wholesale mark–up
and the new dispensing fee structure led to estimated savings of e100 million in 2011.
Restrictions in scheme eligibility and increased co–payments led to estimated savings
of e80 million in 2011. (Walshe and Kenneally, 2013) claim the three cost containment
policies resulted in savings of e380 million for the Irish economy in 2011. Some of
the cost containment policies shifted the cost burden from the public purse to private
individuals, such as co–payment charges, (Thomas and Burke, 2012).
The international literature has shown that some cost containment measures can
be more successful than others in reducing pharmaceutical expenditure. Following the
onset of the economic crisis in Ireland, pharmaceutical cost containment measures came
to the forefront. (Tilson et al., 2005) and (Barry et al., 2008) highlighted the growth
in the cost of medicines on community drug schemes up to 2007. This growth is not
sustainable in Ireland and this thesis seeks to estimate the implications of cost contain-
ment on future cost projections.
2.3 Drivers of Pharmaceutical Expenditure
The purpose of this section is to examine the factors that are influencing Irish and in-
ternational pharmaceutical expenditure. This section examines the results of previous
studies on factors influencing drug expenditure, in order to benchmark the findings of
the subsequent investigation.
It is well documented in the literature that population is a driver of Irish health care
expenditure, (Layte et al., 2007) and (Barry et al., 2010). A Canadian study (Canadian
Institute for Health Information, 2012), identified six cost drivers of drug expenditure;
population growth, population aging, general inflation, price effects, volume effects and
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mix of drugs. They found population growth and population aging had the least effect
on drug spending with volume effects and the mix of drugs having the most significant
effect of the six cost drivers. A British Colombian study found an increase in the older
population and the rate at which they utilised medicines accounted for under half of the
total drug expenditure increase between 1991 and 2001. Changes in the mix of drugs
and the type of drug selected, explained over half of the observed drug expenditure
increase, (Morgan et al., 2004).
(Bech et al., 2010) found increasing life expectancy leads to an exponential increase
in health care expenditure. The literature also points to advances in medical technology
as a driver of health care expenditure (Cutler, 1995), (Newhouse, 1992) and (Fuchs,
1996). A study in Taiwan found an increase in the rate of technological innovation
introduces new pharmaceutical drugs into the health care system, subsequently leads
to a rise in health expenditure, (Hsieh et al., 2013). A systematic review of the fac-
tors influencing pharmaceutical expenditure found that drug utilisation, drug therapies,
price and new drugs were the major drivers of pharmaceutical expenditure, (Mousnad
et al., 2014). The review identified a number of studies, where price changes of drugs
resulted in a positive and negative effect on drug expenditure i.e., a change in the price
of existing drugs results in higher and lower drug expenditure respectively. The most
commonly used methods to model price changes included trend analysis, decomposition
and econometric analysis.
(Mousnad et al., 2014) found changes in drug utilisation and drug therapies had a
major impact on drug expenditure increases. Changes in drug quantities can be mea-
sured by the number of prescriptions (volume) and types of drugs prescribed (mix).
Changes in drug therapies can be measured by the incidences, in which, multiple drug
groups are used (polytherapy). New innovative drugs, which are more effective and
more expensive, was found to influence pharmaceutical expenditure, (Mousnad et al.,
2014).
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Other explanatory variables identified in the literature include age, gender and lo-
cation (region). (Mousnad et al., 2014) found in their systematic review that the age
group 45–64 were more likely to utilise prescription items than the age group 65–84.
A Spanish study examined how gender and age influenced prescription drug use and
found a higher prevalence of prescription drugs in males in younger children, up to 14
years of age, (Ferna´ndez-Liz et al., 2008). A Swedish study found more drugs were
dispensed amongst males under 10 years, (Loikas et al., 2013). An Irish study inves-
tigating prescribing antibiotics trends in a paediatric sub–population found that male
participants (0–4 age cohort) were more likely to receive an antibiotic prescription than
female participants, (Keogh et al., 2012).
It is well documented that females visit doctors more regularly than men, hence
higher female prescribing rates with a resulting effect of higher drug costs. In Spain
(Ferna´ndez-Liz et al., 2008), Sweden (Loikas et al., 2013) and British Colombia (Mor-
gan, 2006), there is a higher incidence of prescribing amongst females compared to
males. (Loikas et al., 2013) found women were dispensed more drugs in all age groups,
except for the age group 0–10, where there was higher dispensing amongst males.
(Ferna´ndez-Liz et al., 2008) found drug prescribing is 23% higher in females than males
and that age is statistically more significant than gender (P<0.05). (Mousnad et al.,
2014) found drug utilisation is higher among females compared to males. (Morgan,
2006) found population change contributed very little to drug expenditure increases
but age, gender, volume and type of drugs prescribed, contributed to a rise in drug
expenditure. (O’Neill et al., 2013) identified the demand and supply factors that are
driving Swedish pharmaceutical expenditure. These factors are applicable to many
international countries. Figure 2.1 summarises the factors that affect the demand for
drugs and the factors that affect the supply of drugs.
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Figure 2.1: Drivers of Pharmaceutical Expenditure - Demand & Supply Factors
Source:(O’Neill et al, 2013)
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In Ireland, two studies explored regional variation. (Naughton et al., 2006) ex-
amined the distribution of chronic conditions across the old health board regions in
Ireland and found the Midlands had the highest prevalence of chronic conditions with
the Western and North–Western regions having the lowest prevalence of chronic condi-
tions. Furthermore, (Usher et al., 2005) examined the prescribing prevalence of insulin
dependent and non-insulin dependent diabetes across regions in Ireland. They found
the Midlands and the Mid–Western regions had the highest prescribing ratios for both
types of diabetes and the North–Western region had the lowest prescribing ratio.
This thesis proposes to explore the factors that are influencing pharmaceutical ex-
penditure in Ireland, such as age, gender and geographical location. This review informs
us of the results to expect, based on existing research.
2.4 Pharmaceutical Expenditure Projections in Ireland
The purpose of this section is to review the literature on pharmaceutical projections
in Ireland and identify the empirical methods utilised. This section also reviews demo-
graphic projection studies and identifies the assumptions, on which population forecasts
were made.
Research is limited in the area of health and drug expenditure projections in Ire-
land. (Bennett et al., 2009) projected the impact of demographic change on the demand
for three community drug schemes (GMS, DPS3, LTI4) in Ireland. They adopted two
models, linear current use model (current trends continue in linear fashion) and a re-
gression model to project future prescribing for three community drug schemes. This
study was based on 2006 data and incorporated population projections (Morgenroth,
2009), where the population is estimated to grow from 4.24 million in 2006 to 5.1 million
in 2021, (Barry et al., 2010). A sensitivity analyis was performed around the current
3Drug Payments Scheme
4Long Term Illness
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use and regression model (± 10%) estimates. They found that drug ingredient costs5
are likely to be between e1.5 billion (current use model) and e2.3 billion (regression
model) for the three community drug schemes (GMS, LTI & DPS) by 2020, with the
GMS scheme accounting for the largest proportion (e806 million, 67.2%). Their anal-
ysis was disaggregated by HSE age cohort ranging from the under 5s to the over 75s.
Drug ingredient costs increase with age reaching a peak among those aged 70 years
and over. The current model projects ingredient costs for the three community drug
schemes for the over 75s to lie between e400,000 and e450,000, whereas the regres-
sion model projects ingredient costs to lie between e500,000 and e600,000. Older age
groups were found to be prescribed a higher volume and more expensive prescription
items, (Bennett et al., 2009).
(Heaney et al., 2009) predicted 2012 community drug expenditure using 2007/2008
annual PCRS Statistical Analysis of Claims and Payments reports. They applied an
autoregressive integrated moving average (ARIMA) model to the national prescrib-
ing database to predict future drug expenditure. The ARIMA model predicted that
community drug expenditure will increase from e2.29 billion in 2008 to between e2.3
billion and e3 billion in 2012. In 2008, 73% of prescription items were prescribed to
GMS persons, 22% to DPS persons, 4% to LTI persons and 1% to the High Tech drugs
scheme.
2.4.1 Demographic Projections in Ireland
The CSO is the primary source of Irish population statistics and projections. The
current CSO projections (CSO, 2013) incorporating international migration and fertil-
ity assumptions, project the national population of the Republic of Ireland to be 5.19
million in 2031. The CSO collects primary population data (Census) every five years,
the most recent being Census 2011. The Irish population is living longer and life ex-
pectancy has significantly improved over the last 85 years. (CSO, 2015a) publishes Life
5The ingredient cost of a drug is comprised of the ex–factory price and the wholesale mark–up.
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Table 2.1: Life Expectancy by Gender 1926–2011
Year Males Females
1926 57.4 57.9
1946 60.5 62.4
1966 68.6 72.9
1986 71.0 76.7
2006 76.8 81.6
2011 78.3 82.7
Source: (CSO, 2015a)
Tables, which details the life expectancies of both genders, as illustrated in Table 2.1.
The most recent Life Table (No.16) was published in 2015, with a reference period
2010–2012. In the 85 year period, life expectancy has improved by approximately 21
years for men and 25 years for women. (CSO, 2015a) attributes this improvement to
decreasing mortality rates and in particular, infant mortality rates.
(Blackwell, J. & Associates, 2001) were commissioned by the Department of the
Environment and Local Government to produce population forecasts, labourforce and
housing demand forecasts for the national spatial strategy. Projections were based on
CSO data (1999–2000) and forecasts were produced in five year intervals out to 2030 by
CSO regions. Twelve scenarios were developed, some of which were used for sensitivity
analysis. (Blackwell, J. & Associates, 2001) estimated the national population will lie
between 4.39 million and 4.95 million in 2020.
A United Nations report found the >60s population in Ireland will increase from
781,000 (17.1%) in 2012 to 1,735,000 (28.7%) in 2050. They also reported a more than
doubling in the over 80s population, from 134,000 (2.9%) to 445,000 (7.4%) between
2012 and 2050, (United Nations, 2012). The size and structure of the population will
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be a key determinant of GMS costs in the future. (Connell and Pringle, 2004) carried
out a report on population aging in Ireland between 2002 and 2021. They estimated
that the older male age group (>65) will increase from 9.7 per cent in 2002 to between
13.9 per cent and 14.1 per cent in 2021. The older female age group (>65) will increase
from 12.5 per cent in 2002, to between 15.8 per cent and 16.4 per cent in 2021.
This thesis will develop population projections and they will be incorporated into
drug expenditure projections. The literature on drivers of drug expenditure (Section
2.3) identified population growth and population aging as factors that influence drug
expenditure.
2.5 Drug Prescribing in Ireland – Community Drug Schemes
The objective of this section is to describe the community drug schemes in Ireland and
the complexity around the eligibility for each scheme. The number of persons eligible
for each scheme and the associated cost, where available, is detailed. At the time of
writing this section, 2012 was the most recent data available. Therefore all data is
based on the year 2012.
There are 11 Community Drug Schemes in Ireland, the largest being the GMS.
The four most expensive CDS in Ireland, where a person has entitlement to free or
subsidised healthcare; is the GMS, DPS, LTI and High Tech Drug (HTD) schemes.
All scheme claims are processed and paid by the PCRS. Other schemes include the
Dental treatment Services Scheme (DTSS), European Economic Area (EEA), Health
Service Executive Community Ophthalmic Services (HSE–COS), Methadone Treat-
ment Scheme (MTS), Health Amendment Act 1996 (HAA) and Primary Childhood
Immunisation scheme.
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The PCRS has two functions. Firstly, the PCRS administers and processes all com-
munity drug claims on behalf of the state and secondly, reimbursement of contractors.
The PCRS arranges payments to contractors, such as GPs, community pharmacists,
dentists and optometrists/ophthalmologists. PCRS expenditure is driven by expendi-
ture on drugs and medical appliances, as opposed to fees and allowances. The Irish
Fiscal Advisory Council found that 70% of PCRS expenditure was on drug and medical
appliances in 2014, (IFAC, 2015). The four most expensive community drug schemes,
cost approximately e1,732 million in 2007 and this increased to e1,923 million in 2012
(11% increase). Figure 2.2 illustrates the payments to pharmacists by community drug
scheme and shows the GMS scheme is the largest of the four drug schemes, it accounted
for approximately 60% of community drug expenditure in 2007.
Figure 2.2: Community Drug Scheme Expenditure (e) 2007 - Payments to
Pharmacists
Source: (PCRS, 2007)
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The LTI scheme is the smallest of the four drug schemes accounting for approxi-
mately 7% of community drug expenditure, (PCRS, 2007). Figure 2.3 illustrates com-
munity drug expenditure for 2012.
Figure 2.3: Community Drug Scheme Expenditure (e) 2012 - Payments to
Pharmacists
Source: (PCRS, 2012)
GMS expenditure as a proportion of CDS expenditure increased to approximately
66% in 2012, a 6 percentage point increase between 2007 and 2012. The LTI scheme
remains the smallest of the four community drug schemes at approximately 6% of ex-
penditure. The HTD scheme increased from approximately 14% to 21% of expenditure
between 2007 and 2012. The most notable change is the DPS scheme, which decreased
from approximately e310 million (18%) in 2007 to approximately e125 million (6%) in
2012, (PCRS, 2012). This decrease in expenditure, may be attributed to the increased
payment contribution by the patient. There was a 55% increase in the payment per
patient, increasing from e85 in 2007 (PCRS, 2007) to e132 in 2012. This was a result
of the implementation of a policy change in budget 2012, (PCRS, 2012).
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2.5.1 General Medical Services Scheme
GMS expenditure is comprised of payments to GPs (fees and/or allowances) and pay-
ments to pharmacists. GP payments are paid on a per capita basis. GPs are also
entitled to claim out-of-hours payments (where patients are seen outside normal prac-
tice hours) or where special services (excisions, suturing, vaccinations, catheterisation,
family planning etc.) are delivered, (Keane et al., 2015). In Figure 2.4, the total cost
of GMS prescriptions is the sum of total payments to GPs and total payments to phar-
macies. In 1998, 62% of the total cost of GMS prescriptions were paid to Pharmacists
and 38% to Doctors. Payments to Pharmacists as a proportion increased to 74% and
payments to GPs decreased to 26% in 2012.
GMS payments increased from e414 million in 1998 to e1.73 billion in 2012, a 318%
increase. The total payments to GPs increased from e156 million in 1998 to e451 mil-
lion in 2012, a 189% increase. The total payments to Pharmacists increased from e258
million in 1998 to e1.28 billion in 2012, a 396% increase, (GMS Payments Board, 1998)
and (PCRS, 2012). The data presented in the GMS (Payments) Board Annual Reports
between 1998 and 2000 is based on the old currency, the Irish Pound. For comparability
purposes, data in 1998 to 2000 reports are converted to the single monetary unit, the
Euro. An exchange rate of £1 = e1.27 was applied and used throughout the thesis,
where required, (Central Bank of Ireland, 2012). Policy measures can be both demand
and supply side. Demand side policies target prescribing physicians, pharmacists and
patients that alter the demand for community drug schemes. Supply side policies affect
the price of drugs. This thesis will primarily focus on demand side policies given the
available data but the penultimate chapter of this thesis will also focus on supply side
policies that have been introduced during the economic crisis to contain drug expendi-
ture.
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Those who are eligible for the GMS scheme (medical card holders) are entitled to
a range of health services (medical benefits) and non–medical benefits free of charge.
Medical Benefits
• General Medical and Surgical Services, including all in–patient services and out–
patient services in a public hospital (including consultant services).
• Medical and Midwifery Care for mothers and infants.
• A choice of General Medical Practitioner from those doctors, who have a contract
with the HSE.
• Supply of prescribed approved medicines and appliances (subject to prescription
charges).
• Dental, Ophthalmic and Aural services.
• A maternity cash grant for each child born.
Source: National GMS Assessment Guidelines, (HSE, 2015)
Non–Medical Benefits
• Medical Card holders whose income is more than e10,036 pay the Universal Social
Charge (USC)6 but at a maximum rate of 4%.
• The Freedom of Information (FOI)7 application fee for a Medical Card holder in
relation to non–personal information is e10 (standard fee is e15).
• Medical Card holders are eligible for reduced charges for appeals under the Access
to Information on the Environment (AIE)8 regulations.
6The USC is a tax payable on gross income and three rates were introduced in 2011, these rates
were revised in 2015, (Revenue, 2015a).
7The FOI Act gives every person the legal right to access official records held by Government
Departments or other public bodies, (FOI, 2015).
8This is information relating to the environment held by, or for, a public authority and must be
made available on request, subject to certain exceptions, (DECLG, 2015).
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• Medical Card holder is an eligibility criterion for Higher Education Access Route
(HEAR), a college and university admissions scheme that offers places on re-
duced points and extra college support to school leavers from socio–economically
disadvantaged backgrounds.
• Medical Card holders may also be exempt from paying school transport charges
in publicly funded second–level schools.
• Medical Card holders may also be exempt from paying State exam fees in publicly
funded second–level schools.
• Medical Card holders can avail of childcare at reduced rates under the Community
Childcare Subvention Scheme.
(Source: Keane et al., 2015)
Eligibility for the GMS is governed by legislation and any person “ordinarily resi-
dent” in the state is considered for a medical card. If you have been resident for the
previous three tax years then you become ordinarily resident from the beginning of the
fourth year. If one leaves the country, one will no longer be “ordinarily resident” if they
have been non–resident for three continuous tax years, (Citizens Information, 2015).
There are three main categories of people entitled to a medical card:
1. Applicants and their dependants, whose asessable income comes within certain
income guidelines (the income guideline is e184 for a single person living alone
who is under 66 years and a couple is e266.50).
2. Applicants and their dependants whose assessable income is in excess of the in-
come guidelines, where the HSE considers that to refuse a medical card would
cause undue hardship (discretionary cases).
3. A person from another EU member state, a person with retention entitlement
under government schemes (can retain their medical card for specified time pe-
riod), a person affected by the drug Thalidomide and Symphysiotomy (regardless
of their income), (HSE, 2015).
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Approximately 40% (1.85 million) of the population were eligible for the GMS in
2012, (PCRS, 2012). In the majority of cases, a completed GMS prescription form by
the GP is presented to a pharmacy that has an agreement with the HSE to dispense
drugs and appliances. In some rural areas, GPs who hold contracts can dispense directly
to the GMS claimant. All GMS claims are processed and reimbursed by the PCRS.
The government introduced patient co–payment charges for medical card holders for
the first time to raise revenue to alleviate the drug expenditure bill. A co–payment is a
fixed payment made by the claimant per prescription item. The aim of a co–payment
is to reduce overall pharmaceutical expenditure and utilisation. Co–payments do not
differ for brand and generic medicines, (Sokol et al., 2005). On the 1st of October 2010,
a 50 cent per item charge subject to a monthly ceiling of e10 per family was intro-
duced. The co–payment increased to e1.50 with a monthly ceiling of e19.50 per family
from the 1st of January 2013. This was further increased for the financial year, 2014,
where the co–payment increased to e2.50 with a monthly ceiling of e25.00 per family.
Any eligible GMS person, who is prescribed a drug or appliance by a registered GP,
registered Dentist or registered nurse prescriber, by a community pharmacy contractor
are liable for this charge. The PCRS redeem this co–payment from the community
pharmacy, (PCRS, 2012).
Since the 1st of July 2001, all persons aged 70 years or over were entitled to a med-
ical card. This entitlement changed on the 1st January 2009 when new medical card
limits were introduced. If a single person earned e700 or more per week (e36,500 per
year) or a couple earned e1,400 or more per week (e73,000 per year), they were no
longer entitled to a medical card, (Barry et al., 2010). From the 5th of April 2013,
income limits were reduced to e600 per week for a single person and e1,200 per week
for a married couple. In Budget 2014, income limits were further reduced to e500
per week for a single person and e900 per week for a couple, (Department of Finance,
2013). Table 2.2 details the impact of this policy change between 2008 and 2009.
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Table 2.2: Number of Eligibile GMS Persons over 70 2008–2012
Year 2008 2009 2010 2011 2012
Eligible Persons 351,853 337,669 345,806 348,519 354,811
% Change - 4.03 2.40 0.78 1.80
Source: (Various PCRS reports 2008–2012)
14,184 fewer persons were eligible for the medical card in 2009, approximately a
4% decrease. The number of eligible persons increased by 2.40% in 2010, 0.78% in
2011 and 1.80% in 2012. The number of eligible persons increased although income
eligibility rates were reduced. The recession may explain this increase through a rise
in the unemployment rate, hence more people being eligible for the GMS scheme.
General Practitioner Visit card
In 2005, the HSE introduced the General Practitioner Visit Card (GPVC). Any per-
son who is ineligible for the GMS scheme but falls within certain income limits, may
apply for a GPVC. This entitles one to visit their GP free of charge. GPVC income
limits are as follows; if a single person aged 70 or over has an income over e500, but
not exceeding e700 per week, that person is eligible for a GPVC. A married couple
aged 70 or over and whose income is over e900, but not exceeding e1,400 per week are
eligible for a GPVC. A single person living alone aged up to 65 years and aged 66 years
and over with a weekly income of e276 and e302 respectively, are eligible for a GPVC,
(HSE, 2015). All claims are processed and reimbursed by the PCRS. On the 31st of
December 2005, 5,079 persons were eligible for the GP visit card, (PCRS, 2005). This
increased to 131,102 by the 31st of December 2012, (PCRS, 2012). The number of GP
visit cards increased steadily between 2005 and 2012. Table 2.3 specifies the number
of GP visit cards issued between 2005 and 2012, 131,102 (2.86%) persons were eligible
for the GP visit card in 2012.
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Table 2.3: Number of GP Visit Cards Issued 2005–2012
Year GP Visit Card % of Population
Covered
2005 5,079 0.13%
2006 51,760 1.22%
2007 75,589 1.78%
2008 85,546 2.02%
2009 98,325 2.32%
2010 117,423 2.77%
2011 125,657 2.74%
2012 131,102 2.86%
Source: (Keane et al. (2015))
2.5.2 Other Community Drug Schemes
Drug Payments Scheme
Any person, who is ineligible for the GMS scheme can benefit, if their spending
on drugs and appliances exceeds e144 in any calendar month, for an individual or
family9. Any dependents between 18 and 23 years of age in full-time education may
also be included. The DPS scheme was introduced on the 1st of July 1999. The monthly
threshold has increased from e120 in January 2010 to e132 in January 2012, to e144
in January 2013. This represents a 20% increase between 2010 and 2013. In order to
avail of the DPS scheme, any person or any family member (<18) must register with
the PCRS. If the monthly threshold is exceeded, the PCRS reimburses the additional
costs to the pharmacist. In 2012, approximately 32% (1.46 million) of the population
availed of this scheme, (PCRS, 2012).
9Individuals with mental or physical impairment who is unable to maintain oneself may also be
included in the family regardless of age.
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Long Term Illness Scheme
Any person who suffers from one or more illnesses10 are entitled to obtain drugs
and appliances free of charge, irrespective of income under the LTI scheme. They must
be resident in Ireland and have a Personal Public Service Number (PPSN11). One must
obtain approval from the HSE for this scheme. In 2012, 1.52% (150,598) of the popu-
lation availed of this scheme, (PCRS, 2012).
High Tech Drugs Scheme
The HTD scheme was introduced in November 1996, (Barry et al., 2009). High
tech medicines are generally only prescribed or initiated in the hospital setting and are
purchased by the HSE. Medicines such as anti–rejection drugs for transplant patients or
medicines used in conjunction with chemotherapy or hormonal therapy are prescribed
through community pharmacies, for which pharmacists receive a patient care fee. In
recognising the complexity of these particular medicines pharmacists are paid a patient
care fee of e62.03 per month to cover dispensing, counselling and advice on their safe
and effective use. The PCRS reimburses pharmacies for the cost of medicines and pa-
tient care fees, (PCRS, 2012).
European Economic Area Scheme
European residents from the EEA may be eligible for emergency GP services, who
are on a temporary visit to the state. They are entitled to see a GP and be dispensed
prescriptions from any pharmacy, who have entered an agreement with the state. On
presentation of a valid E128 form, students, posted workers and their dependents are
eligible for full medical services, (Gorecki et al., 2012).
10Acute Leukaemia, Mental Handicap, Cerebal Palsy, Mental Illness (in a person under 16), Cystic
Fibrosis, Multiple Sclerosis, Diabetes Insipidus, Muscular Dystrophies, Diabetes Mellitus, Parkinson-
ism, Epilepsy, Phenylketonuria, Haemophilla, Spina Bifida, Hydrocephalus, Conditions arising from
the use of Thalidomide.
11The PPSN is allocated by the Department of Social Protection and is a unique reference number
that is to be used by one in all dealings with Public Service Agencies, (Revenue, 2015b)
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Methadone Treatment Scheme
Under the Methadone Treatment scheme, approved clients may be prescribed and
dispensed Methadone by doctors and pharmacists. PCRS reimburses doctors’ capita-
tion fees and the ingredient cost of the Methadone to community pharmacies, (Gorecki
et al., 2012).
Health (Amendment) Act 1996 Scheme
Under this scheme, patients who have contracted Hepatitis C directly or indirectly
from the use of Human Immunoglobulin Anti D or were a recipient of another blood
product or blood transfusion within the state, are eligible for certain health services
without charge. These services include GP services, pharmaceutical services, dental
services and optometric/ophthalmic services and are paid for by the PCRS, (Gorecki
et al., 2012).
Dental Treatment Services Scheme
This scheme allows eligible GMS persons to avail of dental treatments and clinical
procedures, such as routine treatments (are available to all eligible persons) and full
upper and lower dentures. Dental treatments include a free oral examination every
calender year, free emergency dental treatment, two fillings per annum and all extrac-
tions. Dentists may also prescribe medicines as well as treat eligible persons, (Gorecki
et al., 2012).
Primary Childhood Immunisation Scheme
The national primary childhood immunisation scheme aims to eliminate, as far as
possible, conditions such as Diphtheria, Polio, Measles, Mumps, Rubella and Meningo-
coccal C Menigitis by immunising the total child population, (Gorecki et al., 2012).
HSE Community Ophthalmic Services Scheme
This scheme entitles medical card holders and their dependents free eye examina-
tions and spectacles/appliances, (PCRS, 2012).
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These community drug schemes (EEA scheme, Health (Amendment) Act 1996,
Methadone Treatment Scheme, DTSS prescriptions and Pharmacy Training Grants,
payments to dentists and optometrists) accounted for e93.62 million in 2007 (PCRS,
2007) and e110.73 million in 2012 (PCRS, 2012), this represents a 18.28% increase.
The PCRS also reimburse immunisations (Pneumococcal, Influenza, Hepatitis B and
the combined Pneumococcal/Influenza) for GMS eligible persons, as specified under
an agreement, between the Department of Health and the Irish Medical Organisation,
(PCRS, 2012).
Breakdown of Payments to Community Pharmacists under State Schemes
A payment to a Pharmacist consists of the ingredient cost of the drug, pharmacy
dispensing fee and VAT under the GMS and DTSS schemes. VAT is levied at 0 per cent
on oral pharmaceuticals and at the standard rate (23 per cent as of 1st January 2012)
on other pharmaceuticals. Pharmacies are reimbursed the ingredient cost of items dis-
pensed, dispensing fees, mark–up and VAT under the DPS, LTI and EEA schemes.
The ingredient cost of a drug comprises of the ex–factory price and the wholesale
mark-up. It can also include retail mark–up depending on the state scheme. The
ex–factory price is agreed between the state and the representative body of drug man-
ufacturers and importers. The ex–factory price is set with reference to the currency
adjusted average price to the wholesaler in nine nominated EU member states (Belgium,
Denmark, France, Germany, Netherlands, Spain, UK, Finland and Austria), (IPHA,
2012). The wholesale mark–up is 12% for fridge items and 8% for any other drug
items. Wholesale mark–up was reduced from 17.66% in March 2008 to 8% in June
2011. Pharmacists receive a 20% retail mark–up on items dispensed under the LTI
and DPS schemes. In July 2009, pharmacy retail mark–up was reduced from 50% to
20%. No retail mark–up is applied to items dispensed under the GMS scheme, (Gorecki
et al., 2012). The dispensing fee varies between e3.50 and e5.00 for the GMS, DPS,
LTI, EEA and HAA (1996) schemes. The pharmacy receives e5.00 for each of the first
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1,667 items dispensed, e4.50 for each of the next 833 items dispensed and e3.50 for
each other item dispensed in that month, (Government of Ireland, 2011). Figure 2.5
disaggregates the payment to Pharmacists by ingredient cost, dispensing fee and VAT.
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Ingredient cost increased from e85 million (77%) in 1994 to e743 million (80%) in
2006 and e932 million (73%) in 2012. The ingredient cost proportion of prescriptions
is declining since 2007. The dispensing fee, as a proportion of the total cost of pre-
scriptions has increased from e23 million (21%) in 1994 to e309 million (24%) in 2012.
The dispensing fee proportion fluctuated between 1994 and 2008, but has increased
thereafter. This increase may be explained by a change in dispensing fee structure.
Pharmacists were paid e3.60 per item up to 2008. This changed in 2009 when a sliding
fee structure (e3.50–e5.00) was introduced, (Gorecki et al., 2012). VAT as a propor-
tion of total cost of prescriptions has remained constant at 2% between 1994 to 2010,
but increased slightly to 3% in 2011 and 2012 respectively. This may be explained by
the VAT increase from 21% to 23% on the 1st of January 2012.
This thesis will focus on one community drug scheme only, the GMS scheme. The
GMS scheme is the largest of the community drug schemes, where approximately 40%
of the Irish population were eligible in 2012. The GMS scheme accounted for approx-
imately 66% of payments to pharmacists for community drug expenditure in 2012, up
from 60% in 2007.
2.6 Methodologies
The purpose of this section is to review the literature and identify empirical methods
on pharmaceutical cost projections. This section will inform the modelling of pharma-
ceutical cost projections in chapters 3 and 4 and modelling the factors that influence
GMS prescribing expenditure in Chapter 5.
2.6.1 Predictive Modelling
Predictive modelling uses a statistical model to predict furture outcomes. Modelling
health and drug expenditure projections varies considerably internationally. In Spain,
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(Calderon-Larranaga et al., 2010) applied diagnosis and pharmacy based risk models
to predict drug use and found predictive models based on pharmacy data had a higher
capacity to predict pharmacy costs than models based on diagnostic data. A number
of predictive studies have been undertaken in the United States (US) on future health
care costs, which inform future prescribing costs, (Zhao et al., 2005), (Wrobel et al.,
2004), and (Sales et al., 2003). (Zhao et al., 2005) also found that drug based models
using (Ordinary Least Squares (OLS) Regression) are superior in predicting pharmacy
costs compared to diagnosis models. These studies predicted drug expenditures for the
Medicare scheme (Wrobel et al., 2004) and a veteran health population (Sales et al.,
2003), respectively, and their models included demographic and health status variables.
(Sales et al., 2003) predicted drug costs in the US using a pharmacy based measure of
risk adjustment. Both studies found combined drug and diagnostic data are superior
in predicting total health care costs. (Powers et al., 2005) compared cost modelling
approaches for predictive modelling of healthcare and pharmacy costs. They found
pharmacy claims data used with a simple OLS model provides similar predictive accu-
racy than more advanced econometric models.
A number of studies on drug expenditure projections have been carried out in the
United States, (Hoffman et al., 2013), (Shah et al., 2003) and (Burner and Waldo, 1995).
Projections were primarily based on historical trends in health expenditure, (Cuckler
et al., 2013), (Keehan et al., 2012) and (Sisko et al., 2014). The three studies estimated
national health expenditure based on assumptions around economic (varying levels of
economic growth) and demographic variables for a 10 year period. (Cuckler et al.,
2013) estimated that health spending will grow on average by 5.8% annually to $2.4
trillion between 2012 and 2022 based on a sluggish economic recovery in 2013, coupled
with an expansion in coverage due to the Affordable Care Act and an aging population.
(Schumock et al., 2015) developed projections on drug expenditure and incorporated
historical trends in drug expenditure and expected changes in the drugs market that
may influence drug expenditure in 2015. They projected 12% to 14% increases in total
drug expenditures in clinics, and 5% to 7% increases in hospitals. Health care and drug
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expenditure projections are based on a particular set of assumptions, which may or may
not be true. (Van Vliet, 1992) argues 80% of the variation in individual annual health
care expenditures is “fundamentally unpredictable” and variation in older persons is
more predictable than for younger persons.
(O’Neill et al., 2013) highlights the limited amount of literature for drug expendi-
ture projections. They put forward two approaches for drug expenditure projections.
The first method is a top down approach, based on assumptions around macroeco-
nomic variables, such as GDP and demography. The second method is a bottom up
approach, based on quantities and prices of drugs and future developments that will
affect these. The NHS study projected drug expenditure between 2012 and 2015 tak-
ing account of both demand and supply factors, with specific focus on supply factors.
This study projected the total UK medicines bill to increase between 3.1% and 4.1%
between 2011 and 2015, based on three scenarios and certain assumptions, (O’Neill
et al., 2013). (Thie´baut et al., 2013) forecast French national drug expenditure based
on demographic and epidemiological (chronic illness) factors out to 2029. They used a
Markovian micro–simulation model based on a representative sample of 10,328 obser-
vations.
They found that drug expenditure will increase annually by between 1.1% and 1.8%
for the over 25s, they attribute the increase to the aging population and changes in
health status. (Wettermark et al., 2010) forecast drug expenditure in the region of
Stockholm, Sweden over a two year period, 2010–2011. They used a linear regression
analysis and applied it to historical drug sales between 2006 to 2009. They predicted
drug expenditure (ambulatory and hospital) would increase by 2% in 2010 and 4% in
2011 and their model would act as an “early warning system”.
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2.6.2 Monte Carlo Method
The Monte Carlo method is a statistical sampling technique invented by Stanislaw
Ulam during World War II in 1946. He was working on the US Manhattan project
with John Von Neumann. Ulam was contemplating the probabilities of winning a card
game of Solitaire, when he developed the Monte Carlo Method. In 1949, the Monte
Carlo method was first published in the journal of the American Statistical Association,
(Metropolis and Ulam, 1949). Monte Carlo simulation (MCS) is based on running a
computer algorithm a number of times and drawing on random numbers, using ran-
dom number generators. MCS is based on repeatedly sampling from a chance process
and random numbers can be generated through Microsoft Excel. The excel number
generator simulates a uniform (0,1) distribution, where every number between 0 and 1
are likely to be selected. The distribution of results may be examined visually through
histograms, (Barreto, 2006).
MCS is becoming more popular across a number of different fields and is widely
used in economic evaluations of pharmaceuticals and other healthcare technologies to
aid decision making, (Weinstein et al., 2003). This paper also states a study based on
good modelling makes all the assumptions explicit and transparent and clearly indi-
cates all results are conditional on assumptions made. (O’Kelly et al., 2012) produced
a white paper on lifecycle modelling and simulation. They suggested that simulation
methods like Monte Carlo are advancing fields such as Physics, Chemistry and Eco-
nomics and there is a need for modelling and simulation to improve drug development.
They suggest that full exploitation of computational models could reduce the expendi-
ture on drug development by as much as 50%.
The objective of a model is to inform decision making and allocation of health care
resources. Model based analysis generate specific estimates or outcomes and modelers
have a responsibility to report uncertainty around these outcomes, (Briggs et al., 2012).
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Drug utilisation and expenditure is difficult to forecast due to a number of uncertain-
ties. These uncertainties include the rate of adoption of new medicines, various ongoing
health care reforms, and activities to improve the quality and efficiency of prescribing.
MCS is a numerical model that employs statistical sampling to forecast under uncer-
tainty. (Briggs et al., 2012) differentiates between four types of uncertainty associated
with decision modeling; Stochastic uncertainty, parameter uncertainty, heterogeneity
and structural uncertainty. Stochastic uncertainty (first order uncertainty) refers to the
random variability in outcomes between patients. Parameter uncertainty (second order
uncertainty) is characterised by the uncertainty in the estimation of the parameter.
Heterogeneity refers to the variability between patients due to different attributes (age,
gender) of those patients. Structural uncertainty can be underlied by the assumptions
of the model.
The Monte Carlo model is an appropriate model to use when there is uncertainty
around the input parameters. Parameter uncertainty refers to the accuracy of an input
parameter estimation. Imprecision in parameters can arise due to limited knowledge
and evidence. A probability distribution is used to characterise the uncertainty in input
parameters (O’Hagan et al., 2005). The uncertainty can be generated through MCS to
determine uncertainty in the model output. (O’Hagan et al., 2005) refer to this process,
as Probability Sensitivity Analysis (PSA). (Briggs et al., 2012) argue that parameter
uncertainty may be represented by PSA or Deterministic Sensitivity Analysis (DSA).
PSA addresses joint uncertainty through probability distributions in input parame-
ters. There are three features of a PSA: characterising uncertainty in input parameters,
propagate parameter uncertainty through the model using MCS and reporting the im-
plications of parameter uncertainty (Briggs et al., 2006). “In a DSA, parameter values
are varied manually to test the sensitivity of the model’s results to specific parameters
or sets of parameters”, (Briggs et al., 2012, 837). (Briggs et al., 2012) argue PSA is
a preferable method of addressing uncertainty in input parameters. Probability distri-
butions are applied to input parameters to characterise the uncertainty. Probability
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distributions such as Normal, Binomial, Poisson, Beta distributions etc. (Sugiyama,
2007) highlighted the importance of assigning an appropriate probability distribution
to uncertain variables in developing a comprehensive MCS model. MCS is used to
propagate the parameter uncertainty through a set number of iterations, for example,
100,000 iterations. This entails a random draw from each uncertain input parame-
ter. This will generate 100,000 expected costs for each age cohort, region and gender
(O’Hagan et al., 2005). (Briggs et al., 2012) suggests that a tornado diagram is an
appropriate way of presenting PSA. The model outcome is displayed along the hori-
zonatal axis and the model parameters along the vertical axis. The longest bar on the
top of the tornado diagram reflects the parameter with the widest uncertainty and the
other bars are displayed in descending order of length.
Decision analytical modelling is used to complement cost effectiveness analysis/evaluations.
Quantitative methods are employed to examine the clinical, epidemiological and eco-
nomic evidence base of the technology/decision under review. This generates a specific
outcome and reports the uncertainty surrounding this outcome and informs health de-
cisions, (Briggs et al., 2012). The benefit of such a model is that it allows “what if”
scenarios to explore the sensitivity of projections to changes in variables. (Nuijten,
2004) identified and evaluated statistical uncertainty and the negligence of statistical
uncertainty in modelling studies. This study found a health economic model might
be severely biased if statistical uncertainty is not taken into account. An MCS model
was deemed an appropriate methodology to use for this research, given the uncertainty
around the input parameters. This research is not focused on decision analytical mod-
elling for health economic evaluations. MCS model was adopted to forecast GMS costs
through to 2026 and inform future health policy. This methodology was applied to
journal papers 1 and 3.
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2.6.3 Modelling variation in Pharmaceutical Expenditure
This section aims to explore the various methodologies used to model the variation
in pharmaceutical expenditure. The literature will inform modelling the factors that
influence GMS drug expenditure in Ireland, which will be investigated in chapter 5.
A number of studies use OLS regression to model the variation in pharmaceuti-
cal drug expenditure. Other models that are used include logistic regression, mixed
model, tobit model and poisson regression models. (Aguado et al., 2008) modelled the
variability in prescription drug expenditure using a two part model in a Catalonian
population. The first part was a logistic regression which was applied to predict the
incurrence of drug expenditure and the second part used a linear mixed model. The
proportion of variance of the incurrence of expenditure explained by Adjusted Clinical
Groups (ACG12) was 0.29 in adults and 0.21 in children. ACGs explained 35.4% of
cost in adults and 22.4% in children. A Catalonian study used a Tobit and OLS model
to explain drug expenditures, (Garc´ıa-Gon˜i and Ibern, 2008).
An Italian study investigated the physician and patient characteristics associated
with prescription costs. They ran poisson regression models to estimate the incidence
rate ratio (IRR) of prevalence. The IRR assessed the prevalence of using drugs by
gender and geographical area. Linear regression models were performed to test the
possible association between average drug expenditure and physicians characteristics.
They found that age was a predicitive factor in drug expenditure and it was significantly
higher for females. They also found that physician prescribing decisions are influenced
by a myriad of external factors, (Orzella et al., 2010).
12The Adjusted Clinical Group (ACG) estimates individual health status and risk for health services
use based on age, gender and diagnoses assigned over a specific time period, usually a year, (Aguado
et al., 2008).
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(Ferna´ndez-Liz et al., 2008) ran a multivariable regression analysis to investigate
the association between the average cost per patient, age and gender. Expenditure per
patient was observed to increase with age. Patients in the 65–74, 75–84 and over 85
age cohorts were 16.1, 19.7 and 18.8 times higher than those in the reference age cohort
(0–4). They found gender had no statistical significant difference between males and
females. A Spanish study used an OLS model (4 variants) to explain the variation in
pharmacy expenditure. The dependent variable was total pharmacy cost per person
and independent variables included both demographic variables and chronic conditions.
The fourth model explained 57% (R2=0.57) of the variation in total pharmacy cost,
(Vivas et al., 2011).
A study in Uganda identified predictors of pharmaceutical expenditure to aid bud-
get decisions and allocations. The dependent variable had four different specifications;
total pharmaceutical expenditure, per capita district pharmaceutical expenditure, phar-
maceutical expenditure per district health facility and pharmaceutical expenditure per
outpatient department visit. The study used the Andersens behaviour model of health
services utilisation to identify independent variables likely to influence health care util-
isation and pharmaceutical expenditure. They used OLS to estimate the parameters
and the models had explanatory power ranging from 51% to 82%. The log–linear model
explained approximately 79% (R2=0.79) of the variation in the logarithm of total phar-
maceutical expenditure among the study districts, (Mujasi and Puig-Junoy, 2015).
A more recent Spanish study used linear regression models (2) to explain pharma-
ceutical expenditure in primary health care. The models were estimated using OLS
and both models had a similar level of explanatory power, 52.5% (model 1) and 47.5%
(model 2), (Vivas-Consuelo et al., 2014). Three American studies used OLS regres-
sion models to examine the predictability of drug expenditure, (Wrobel et al., 2004),
(Zhao et al., 2005) and (Powers et al., 2005). (Wrobel et al., 2004) examined the pre-
dictability of drug expenditures (6 models) for the Medicare population, using 2000
data. Their key finding suggested it was possible to predict approximately 23% of the
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variation in Medicare drug expenditures using a prospective model, that included basic
demographic characteristics and health status measures. Demographic variables only
explained 5% of the variation in pharmaceutical expenditure.
(Zhao et al., 2005) compared the predictive performance of three models and found a
model containing both drug and diagnostic data predicted health costs better (R2=0.168)
than a model including either type of data alone. This study used weighted OLS esti-
mates. (Powers et al., 2005) compared alternative econometric cost modeling techniques
to model healthcare costs using pharmacy claims data. Models examined included OLS
regression, Log–transformed OLS regression with smearing estimator and 3 two–part
models using OLS regression, Log–OLS regression with smearing estimator, and gener-
alised linear modeling. They found a simple OLS model may provide similar predictive
accuracy to more advanced econometric models. An OLS model including age, gender
and annual pharmacy cost had higher explanatory power (R2=0.089) than the other
models.
2.6.4 Regression modelling and Ordinary Least Squares
A linear model is used to summarise the relationship between two variables, β1 in-
forms the model shape (slope) and β0 informs the location (intercept) of the model,
as summarised in Equation 2.1. The model predicts values on the outcome (depen-
dent) variable from the predictor (independent) variable. This is known as a simple
regression.
Yi = β0 + β1Xi + i (2.1)
Yi = Outcome variable
β0 = Y intercept
β1 = Parameter
X1 = Predictor variable
ei = error term
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A multiple regression model consists of a number of predictor (independent) vari-
ables, as detailed in Equation 2.2, (Field, 2012).
Yi = β0 + β1Xi + β2Xi + βnXni+ i (2.2)
Yi = Outcome variable
β0 = Y intercept
β1 = Parameter
X1 = Predictor variable
X2 = Another predictor variable
Xn = nth predictor variable
ei = error term
OLS is used to estimate the parameters (B -values) associated with each predictor
variable. OLS is a mathematical regression technique, in which the parameters of the
model are estimated using the method of least squares. The (B -values) describe the
model that minimises the sum of squared differences. The differences between what the
model predicts (predicted values) and the observed values is known as residuals. The
residuals are the vertical distances between what the model predicted and the observed
data. Residuals can be visualised by plotting an outcome and predictor variable on
a scatterplot. Figure 2.6 illustrates the linear trend between two variables, album
sales (dependent variable) and advertising budget (independent variable). The vertical
dotted lines represent the residuals, the differences between the trend line and actual
data. Residuals can be positive or negative, when they are squared, it cancels out the
negatives. The sum of squared residuals (SSR) assesses the error in the model. The
SSR determines how well a certain line fits the data. If the squared differences are
large, the line is not representative of the data and if the squared differences are small,
the line is representative of the data. The OLS model is used to estimate the B -values,
that explains the regression model, that best fits the data, (Field, 2012).
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Figure 2.6: Scatterplot of an Outcome Variable and Predictor Variable
Source:(Field, 2012)
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Following a review of the literature and expert opinion, the Monte Carlo (Chapter 3
& 4) and OLS regression (Chapter 5) models were deemed the most appropriate models
to use. Expert13 opinion on the Monte Carlo model was sought from a statistician in
Darmstadt University, Germany and expert opinion on the OLS regression model was
sought from a statistician in University College Cork, Ireland.
2.7 Conclusion
This chapter examined the pharmaceutical cost containment measures from both a
global and domestic level. (Sood et al., 2009) examined the effect pharmaceutical
revenue had on 19 OECD countries and found that direct price controls and economic
evaluation were more successful in reducing pharmaceutical expenditure than other reg-
ulations. A number of pharmaceutical cost containment measures have been introduced
in Ireland and (Walshe and Kenneally, 2013) found that cost containment measures (on
pricing, mark–up, dispensing fees, restrictions to eligibility and co–payments) led to es-
timated savings of e380 million in 2011. The literature has identified the key factors
driving pharmaceutical expenditure. Previous results indicate that we can expect that
age, gender and geographical location will be influential in contributing to pharmaceu-
tical expenditure.
The literature has shown that very little research has been carried out on pharma-
ceutical cost projections in Ireland, (Bennett et al., 2009) and (Heaney et al., 2009).
The main contribution of this thesis will include pharmaceutical cost projections for
the GMS scheme in Ireland. The CSO has been the main source of population pro-
jections for many researchers, albeit some adjustments have been made to CSO data.
This thesis will use CSO population projections and make the necessary adjustments
to regions and age to match the structure of the health dispensing data. The literature
identifies the 11 community drug schemes in Ireland. This thesis is focusing on the
13I consulted an experienced statistician for both the Monte Carlo Method and the OLS regression
and we teased out the appropriate model to use, given the data available.
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largest community drug scheme, the GMS scheme. Overall GMS payments (includ-
ing GP & Pharmacy) increased from e414 million in 1998 to e1.73 billion in 2012, a
318% increase. This increase has mainly been driven by the increase in the payments
to pharmacists. In modelling pharmaceutical cost projections, the literature identifies
various modelling approaches. This thesis focused on the Monte Carlo method follow-
ing a review of the literature and discussions with with my supervisor and a statistician.
This study is located in the area of pharmacoeconomic cost containment and projec-
tions literature. A review of the literature identified the methodologies used to explain
the factors influencing drug expenditure. Numerous studies have used an OLS regres-
sion to model drug expenditure variation. An OLS regression model was adopted to
model the factors influencing Irish pharmaceutical expenditure. The literature review
has provided the theoretical background, methodological foundation and expected re-
sults for this thesis. The next chapter uses the Monte Carlo method to project GMS
expenditure in five year intervals to 2026.
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Chapter 3
Implications of Regional and
National Demographic
Projections for future GMS costs
in Ireland through to 2026 (2007
data)
3.1 Introduction
Expenditure on pharmaceuticals is one of the fastest growing elements of total health
spending within the EU. Pharmaceutical expenditure within the EU exceeded e180
billion in 2008 and accounted, on average, for approximately 17 per cent of EU coun-
tries total expenditure on health, (Walshe and Kenneally, 2013). In 2009, Ireland had
one of the highest pharmaceutical spends per capita of the OECD countries after the
US, Canada and Greece, (Gorecki et al., 2012). In Ireland, pharmaceutical expenditure
accounted for 16.9 per cent of total health expenditure in 2007 and pharmaceutical
spend per capita was $602.6 and peaked at 17.9 per cent and $677 in 2010, (OECD,
2013). The four most expensive CDS schemes in Ireland accounted for approximately
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85 per cent of total drug expenditure in Ireland in 2007, (OECD, 2013). The annual
cost of medicines under community drug schemes in Ireland increased from e564m in
2000 to e1,961m in 2009, before falling by an estimated 8 per cent by 2011 following a
series of cost containment measures, (Walshe and Kenneally, 2013). Following a sharp
contraction in the Irish economy in 2008, resulting in mounting fiscal deficits, the sus-
tainability of funding these community drug schemes have come under the spotlight of
the EU, IMF and ECB (Troika) who have set stringent targets for reducing drug costs
as conditions of the bailout1 programme. Whilst the Troikas’ main cost containment
measure is on the substitution from proprietary to generic prescribing, the challenge
for Ireland and many of our EU counterparts in containing expenditure on pharmaceu-
ticals is severely restricted by the growth in the elderly component of our populations,
the sub–group with the greatest consumption of prescribed drugs.
This chapter projects regional and national demographic projections and its impli-
cations on GMS costs for 2016, 2021 and 2026. It aims to project the cost implications
of future changes in population (section 3.2), GMS coverage (section 3.3), average cost
per claimant (section 3.4) and claims rate (section 3.5) on GMS costs. The data used
for the analysis is based on a PCRS sample (n=192,000) for 2007. The cost projection
model is explained in section 3.6. To address the uncertainty around projections, the
most likely (mean) scenario and a high (maximum) and low (minimum) scenario were
modelled. MCS model will be employed to forecast GMS costs through to 2026 in
section 3.7. MCS is a numerical model that employs statistical sampling to forecast
under uncertainty. The results are detailed in section 3.8 and discussed in section 3.9.
Conclusions are summarised in section 3.10.
1Ireland received e85 billion of financial aid as part of the EU–IMF programme, of which e17.5
billion came from the national pension reserve fund and other domestic cash resources. e50 billion was
allocated to the day-to-day running of the state and e35 billion to the banking system, (Oireachtas,
2010).
55
3.2 Population
The principal data source is the CSO Regional Population Projections 2011–2026, which
will project both regional and national demographics. The CSO incorporated three as-
sumptions into their projections; mortality, fertility and international migration. The
CSO determined six scenarios for the national projections; M1F1, M1F2, M2F1, M2F2,
M0F1 and M0F2. The CSO only considered two of these for regional population projec-
tions; M2F1 and M0F1. The regional projections were classified by year of age, gender
and region. M2 represents continuing but declining international migration, whereas
M0 sets net international migration to a value of zero. F1 represents the fertility as-
sumption. Fertility is the number of births as a function of the number of women of
child bearing age (15–49). The CSO focused on the age group (20–39), as 90% of births
are borne to women of this age. F1 represents assumes the Total Fertility Rate (TFR2)
will remain constant (TFR =1.9) at the 2006 level for the lifetime of the population
projections, (CSO, 2008).
The national assumptions around mortality were applied uniformly across all re-
gions. Mortality will decrease in line with increases in life expectancy. For males, life
expectancy will increase by 7.6 years from 76.7 years in 2006 to 84.3 years in 2026.
For females, life expectancy will increase by 4.8 years from 81.5 years in 2006 to 86.3
years in 2026. The CSO made assumptions around internal migration, using a recent3
and traditional4 scenario based on inter–regional flows. The M2F1 traditional scenario
(M2F1T) was the principal scenario used in the CSO projections, (CSO, 2008). Hence
this scenario was adopted as the central scenario for population projections for this
thesis. The M2 scenario was also used by (Layte et al., 2009, 10), in projecting popu-
lation to 2021; they described it as a more “plausible” migration outcome.
2TFR is defined as the number of children that would be born to a woman if she were to live to the
end of her childbearing years and bear children in accordance with current age–specific fertility rates,
(The World Bank, 2015).
3Recent Scenario: The pattern of inter–regional flows observed in the year to April 2006 is applied
up to 2026, (CSO, 2008).
4Traditional Scenario: The 1996 pattern of inter–regional flows is applied in 2016 and kept constant
thereafter, with the difference between the 2006 and 1996 patterns apportioned over the years between
2006 and 2016, (CSO, 2008).
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(Morgenroth, 2009) utilised the M2 scenario as its principal scenario for population
projections.
3.2.1 Age and Region Adjustments
The CSO population data was reconciled to conform to the HSE old health board re-
gions and age cohorts.
Age Adjustment
The CSO data was detailed by year of age, gender, county and region. In order to
conform to HSE age cohorts, the CSO data was reconciled into eleven age cohorts, as
detailed in Table 3.1.
Table 3.1: HSE Age Classifications
Age Category
< 5
5–11
12–15
16–24
25–34
35–44
45–54
55–64
65–69
70–74
> 75
Source: (PCRS, 2007)
Regional Adjustments
The CSO5 and HSE6 regional composition is comparable for five out of the eight
regions. The HSE Eastern, North–Eastern and North–Western regions are not compa-
rable with the CSO Border, Dublin and Mid–East regions. Adjustments were made to
the CSO data to correlate with the three HSE regions using the 2006 Census. Popula-
tion data was ascertained from the 2006 Census for males, females and total for all the
5See Appendix A Table A.1 for details of composition of the CSO regions.
6See Appendix A Table A.2 for details of composition of the HSE regions.
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counties affected in these 3 regions, (CSO, 2007).
Eastern Region
The CSO Dublin and Mid–East 2007 data were combined and classified by the HSE
age cohorts and gender. This region is comparable with the HSE Eastern region ex-
cept for County Meath. An adjustment factor for males and females was established
based on the 2006 Census, which details population by county, age and gender. The
adjustment factor for County Meath7 was established as a proportion of the Eastern
region (Dublin, Meath, Kildare and Wicklow) 2006 data. The adjustment factor was
applied to the Eastern region8 2007 data and it established estimated population data
for County Meath. In order to conform to the HSE Eastern region; Dublin, Kildare and
Wicklow were aggregated and Meath 2007 data was removed. The above method was
applied for the estimated population for the Eastern region for 2011 and the population
projections for 2016, 2021 and 2026 using the 2006 adjustment factor.
North–Eastern and North–Western Regions
The CSO Border region 2007 data was classified by the HSE age cohorts and gen-
der. This region is comparable with the HSE North–Eastern region with the addition
of county Meath and the North–Western region. An adjustment factor9 for males and
females was established for all counties in the border region based on the 2006 Census,
which details population by county, age and gender. The adjustment factor for each
county was established as a proportion of the Border region (Cavan, Donegal, Leitrim,
Louth, Monaghan and Sligo) 2006 data. The adjustment factor was applied to the
Border region 2007 data and it established estimated population data for each county.
Cavan, Louth, Meath and Monaghan were aggregated for 2007 to form the North–
Eastern region10. Donegal, Leitrim and Sligo were aggregated for 2007 to form the
North–Western region11. The above method was applied for the estimated population
7See Appendix A Table A.3 for the Meath adjustment factor.
8See Appendix A Table A.4 for the Eastern region population estimates for 2007.
9See Appendix A Table A.5 for the North–Eastern and North–Western adjustment factors.
10See Appendix A Table A.11 for the North–Eastern region population estimates for 2007.
11See Appendix A Table A.12 for the North–Western region population estimatess for 2007.
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for the North–Eastern and North–Western regions for 2011 and population projections
for 2016, 2021 and 2026 using the 2006 adjustment factors.
Population
The total population for 200712 was calculated by age cohort and gender. Three
scenarios minimum, mean and maximum were developed. The most likely scenario
(mean) is the primary scenario used in the CSO projections; M2F1T. The lower bound
scenario is M0F1T and the upper bound scenario is the difference between the lower
bound and the most likely scenario, as detailed in Table 3.2. The CSO MOF1T sce-
nario sets international migration (M0) to zero, using fertility rates (F1) and internal
migration (traditional) as explained earlier. The three scenarios detailed in Table 3.2
were applied to the population data for each of the five years13. The CSO lower bound
scenario represents an increase in population of 9.03% between 2002 and 2007, 3.54%
between 2007 and 2011, 4.23% between 2011 and 2016, 3.41% between 2016 and 2021
and 2.48% increase between 2021 and 202614.
12See Appendix A Table A.13 for the total population 2007 by age cohort and gender.
13See Appendix A Table A.14 for 2011, 2016, 2021 and 2026 population projections.
14See Appendix A Table A.18 for detailed breakdown of population scenarios.
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Table 3.2: Population Scenarios 2007–2026
Scenarios Population Growth Rate (%)
Scenario 1 Minimum (Lower Bound)
2007 9.03
2011 3.54
2016 4.23
2021 3.41
2026 2.48
Scenario 2 Mean (Most Likely)
2007 10.30
2011 8.45
2016 8.73
2021 6.99
2026 4.49
Scenario 3 Maximum (Upper Bound)
2007 11.58
2011 13.35
2016 13.24
2021 10.57
2026 6.51
3.3 GMS Medical Card Coverage
GMS coverage refers to the population proportion who are eligible for the GMS scheme.
The main source of GMS coverage data is the PCRS Statistical Analysis of Claims and
Payments, Annual Reports. The PCRS published a report in 2007 detailing the number
of persons eligible for the GMS medical card by age cohort, gender and region. The
PCRS report states that 28.85 per cent of the population (1,221,695 persons) were
eligible for the medical card in 2006, whereas 30.10 per cent (1,276,178 persons) were
eligible in 2007. Table 3.3 details the population proportion who were eligible for the
medical card by age, gender and region in 2007. The total number of eligible persons
are expressed as a proportion of the population (Equation 3.1). In 2007, everyone over
the age of 70 was eligible for a medical card, therefore ten age cohorts are presented.
GMS Coverage =
Number of GMS Persons
Population
(3.1)
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Table 3.3: Population Proportion with GMS card in 2007
Region 0–5 5–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 >70
Eastern
Males 0.26 0.30 0.26 0.10 0.08 0.13 0.14 0.20 0.34 1.00
Females 0.26 0.30 0.26 0.16 0.15 0.18 0.17 0.25 0.43 1.00
Midlands
Males 0.28 0.31 0.30 0.16 0.12 0.17 0.19 0.29 0.45 1.00
Females 0.29 0.32 0.31 0.24 0.22 0.23 0.23 0.36 0.56 1.00
Mid–Western
Males 0.29 0.33 0.29 0.18 0.14 0.19 0.20 0.30 0.47 1.00
Females 0.30 0.32 0.31 0.25 0.24 0.24 0.24 0.36 0.55 1.00
North–Eastern
Males 0.24 0.28 0.26 0.15 0.11 0.15 0.18 0.28 0.43 1.00
Females 0.24 0.28 0.27 0.23 0.19 0.20 0.21 0.34 0.54 1.00
North–Western
Males 0.41 0.44 0.42 0.28 0.23 0.30 0.32 0.43 0.62 1.00
Females 0.39 0.43 0.42 0.38 0.34 0.35 0.35 0.48 0.66 1.00
South–Eastern
Males 0.30 0.32 0.30 0.18 0.15 0.18 0.21 0.32 0.49 1.00
Females 0.29 0.32 0.30 0.27 0.25 0.24 0.25 0.39 0.60 1.00
Southern
Males 0.28 0.29 0.27 0.15 0.13 0.17 0.20 0.30 0.47 1.00
Females 0.28 0.28 0.26 0.21 0.21 0.22 0.23 0.36 0.57 1.00
Western
Males 0.31 0.34 0.33 0.19 0.14 0.21 0.25 0.37 0.53 1.00
Females 0.30 0.34 0.33 0.26 0.22 0.26 0.27 0.40 0.63 1.00
Table 3.3 highlights the regions with the lowest and highest coverage rates. The
North–Eastern region had the lowest male and female GMS coverage in the <5 and
5–11 age cohorts. The Eastern region has the lowest male and female GMS coverage
in the seven age cohorts up to 70 years. However, the North–Western region has the
highest male and female GMS coverage in the nine age cohorts. The Eastern region
had the lowest number of persons eligible for the GMS scheme with 24.08 per cent in
2006 and 24.87 per cent in 2007. In contrast, the North–Western region had the highest
number of persons eligible for the GMS scheme with 43.38 per cent in 2006 and 44.48
per cent in 2007, (PCRS, 2007, 43).
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The PCRS report also details the percentage of the population who were eligible for
the GMS scheme by age cohort, gender and county in 200615 and 2007. Meath (19.97%)
and Kildare (23.43%) had the lowest number of persons eligible in 2006 and 2007 and
Donegal had the highest number of persons eligible with 48.35 per cent in 2006 and
49.29 per cent in 2007, (PCRS, 2007, 43). In recent PCRS reports (2009–2011), the
HSE region classifications are not comparable to the 2007 region classifications for GMS
eligibility16. There are eight HSE regions in the PCRS 2007 report but there are four
HSE regional classifications in the 2009 report and subsequent reports. Therefore, no
comparisons on eligibility for the GMS scheme were made due to regional classification
differences. Figure 3.1 illustrates for both males and females, the Midlands is the most
expensive region and the North–Western region is the least expensive for the average
GMS cost of medicines per person.
Figure 3.1: Average GMS Cost of Medicines per person by Gender & Region
2007
15See Appendix A Table A.19 for the number of eligible persons for the GMS scheme by region in
2006 and 2007.
16Table 9, PCRS Reports 2009 & 2011
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As stated earlier, the North–Western region had the highest number of persons eli-
gible for the GMS scheme in 2007, yet they are the least expensive in terms of average
cost of medicines per person. The estimated population for the North–West is 242,406
and 258,707 for the Midlands in 2007. The North–West has an older population, where
3.14 per cent of the total population are between 70 and 74 and 5.92 per cent are over
75 compared to 2.82 per cent and 4.9 per cent for the Midlands. Although the North–
West17, has an older population and higher GMS eligibility, it is the least expensive of
the eight regions.
Table 3.4 details the average GMS cost of medicines per person by gender and re-
gion. The average GMS cost for a male in the Midlands is e831.85 and e828.14 for
females compared to e576.72 and e591.04 in the North–West. Table 3.5 specifies the
cost of medicines by age cohort and region.
17See Appendix A Table A.20 for the projected population for the North–West and the Midlands
region.
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Table 3.4: Average GMS Cost of Medicines per Person by Gender & Region, 2007
Region Gender Average GMS
Cost (e)
Eastern Male 730.70
Eastern Female 734.43
Midlands Male 831.85
Midlands Female 828.14
Mid–Western Male 736.75
Mid–Western Female 735.78
North–Eastern Male 703.10
North–Eastern Female 692.06
North–Western Male 576.72
North–Western Female 591.04
South–Eastern Male 744.80
South–Eastern Female 737.37
Southern Male 774.92
Southern Female 764.58
Western Male 660.02
Western Female 663.55
Source: (PCRS, 2007)
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The North–West region has the lowest GMS cost of medicines per person in the 11
age cohorts. The Mid–West region has the highest GMS cost of medicines per person
for under–fives and the Southern region has the highest cost of medicines between the
ages 5 and 24 and between 35 and 44 years. In the remaining six age categories, the
Midlands is the most expensive region. The Midlands is between 23 per cent18 and 38
per cent more expensive than the North–West in the five oldest age categories. Fig-
ure 3.2 illustrates the mean cost, maximum cost and minimum cost of medicines per
person by age cohort and region in 200719.
Figure 3.2: Average Regional Variation in GMS cost of Medicines per person
(e) 2007
3.4 Average Cost per claimant
The average cost per claimant20 is the total cost of claimants divided by the number of
claimants and this was estimated from the sample 2007 PCRS database (Equation 3.2).
18See Appendix A Table A.22 for the regional variation (Midlands & North–West) in GMS cost of
medicines per person 2007.
19See Appendix A Figure A.1 for the average regional variation in GMS cost of medicines per person
2007.
20See Appendix A Table A.23 for the average cost per claimant 2007.
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A claimant is a person who makes a claim on a GMS medical card.
Average Cost per Claimant =
Total Cost of Claimants
Number of Claimants
(3.2)
3.4.1 Description of Sample PCRS Database
The sample database consists of 192,000 observations extracted from the 2007 PCRS
GMS population data. The geographical area is the former Health Board, of which there
are 8. The are 100 observations by gender and age cohort in each monthly file used in
this analysis. For example, 0–5 Eastern male, there are 100 observations. 192,000/100
= 16,000 in each month. The variables include; ingredient cost, VAT, dispensing fee,
total cost, number of prescription items and number of prescription forms, and are dis-
aggregated by month (12), age cohort (10), gender (2) and region (8). Ingredient cost
refers to the cost of the drug before VAT and dispensing fees are added. VAT is the
level of tax each drug determines. The dispensing fee is the amount each Pharmacist
receives for prescribing each drug. Total cost is the sum of the ingredient cost, VAT
and dispensing fee. All variables are expressed in euros. Number of items refers to the
number of individual drug items dispensed on each form. The number of forms refers
to the number of prescriptions issued to each GMS claimant.
3.5 Claims Rate
The claims rate21 was estimated using both the PCRS 2007 annual report and the
sample 2007 PCRS database. The claims rate is the proportion of medical card hold-
ers who make a claim (Equation 3.3). Of the 1,276,178 medical card holders in 2007,
1,225,131 made a claim on the card giving a claims rate of 96 per cent in 2007.
21See Appendix A Table A.24 for the claims rate 2007.
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Claims Rate =
Number of Claimants
GMS Population
(3.3)
3.6 Cost Projection Model
The cost projection model will incorporate four variables; population, GMS coverage,
average cost per claimant and the claims rate (Equation 3.4) to estimate total costs.
Total Cost = f (GMS Coverage,Average Cost per Claimant,Claims Rate,Population)
(3.4)
Population estimates and projections will be based on CSO projections. GMS
coverage is the estimated proportion eligible for the medical card in 2007. Coverage
projections will be based on 2011 data as this is the most up to date data available at
the time of projections. Average cost per claimant will be estimated for 2011 and pro-
jected in time intervals from 2016 through to 2026, based on 2007 sample data. Claims
rates were assumed to remain constant for the lifetime of the projections. The HSE
have not published any claims data in 2007 by region, age cohort and gender, so an
estimate for average cost per claimant and the claims rate was established, based on the
2007 PCRS sample database. The four variables were classified by region, gender and
age cohort. In the sample 2007 PCRS database, there are 10 age groupings, whereas
there are 11 HSE age groupings. For the purpose of cost projections, the two HSE age
cohorts (<5 and 5–11) were aggregated to form 0–11 age cohort to correspond with the
PCRS sample database. For population data, the two age cohorts were aggregated.
For GMS coverage, an adjustment was applied to the two age cohorts based on
population weightings. Population weightings22 were established based on the total
22See Appendix A Table A.25 for population weightings that were applied to the coverage parameter.
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population in 2007. For example, there is an estimated 55,247 males in the Eastern
region under five and 68,969 males between five and eleven years in 2007. The former
figure was expressed as a proportion of 124,216 (55,247 + 68,969) to give the population
weighting for a male <5 in the Eastern region. This method was applied to all 8 regions
by gender and age cohort. These weightings were multiplied by the GMS coverage in
2007 for the age cohorts <5 and 5–11 and aggregated and replaced by the age cohort
0–11. The ten age cohorts are now comparable with the 2007 PCRS sample database.
Three scenarios were developed for each variable; minimum, mean and maximum.
3.6.1 Variable 1: Population Estimates and Projections
The population of Ireland is projected to grow rapidly with a sharp increase in both the
birth rate and in the elderly population. The following results are based on the most
likely population scenario. Figure 3.3 estimates the population of Ireland will increase
from 4,320,760 in 2007 to 5,696,000 in 2026, an estimated increase of 31.83 per cent.
The male population is estimated to increase from 2,163,340 in 2007 to 2,886,398 in
2026, an increase of 33.42 per cent. The female population is estimated to increase from
2,157,420 in 2007 to 2,809,602 in 2026, an increase of 30.23 per cent. Male population
is increasing at a marginally faster rate than the female population, as illustrated in
Figure 3.3. For example, the male population is estimated to increase by 9.13 per cent,
whereas the female population is set to increase by 8.33 per cent between 2011 and
2016.
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Figure 3.3: Population Growth 2007 – 2026
The number of old persons (65 years and over) as classified by the CSO will almost
double over the lifetime of the population projections. In 2007, there are 144,239 per-
sons between 65 and 69 years, this increases by 82.88 per cent to 263,789 in 2026. In
the 70 to 74 age category there is an 85.36 per cent increase from 119,950 in 2007 to
222,340 in 2026. The >75s realises the largest increase over the lifetime of the pro-
jections, where the population more than doubles from 208,756 in 2007 to 422,859 in
2026, an increase of 102.43 per cent. The >70s includes two age cohorts; 70–74 and
>75. These two age cohorts were summed together for the purpose of this analysis.
Figure 3.4 shows that population of the over 70s will increase in the first three time
periods (2007–2011, 2011–2016 and 2016–2021) and will increase at a slower rate of
22.58 per cent between 2021 and 2026.
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Figure 3.4: Population Growth over 70s, 2007 – 2026
This is also a feature of the male and female population growth rates. The male
population is growing at a faster rate than the female >70s population. For example,
the male population is growing by 24.05 per cent, whereas the female population is
growing by 15.89 per cent between 2011 and 2016. The total population is projected
to grow by 96.28 per cent over the lifetime of the projections. Table 3.6 compares the
CSO national population projections with the population projections reconciled with
the HSE regions using the M2F1T scenario.
71
Table 3.6: Comparison of National Population Projections (M2F1T Scenario)
Year CSO
Projections
Projections reconciled
with HSE Regions
2007 4,339,000 4,320,760
2011 4,686,300 4,685,743
2016 5,095,000 5,095,004
2021 5,451,000 5,451,088
2026 5,696,000 5,696,000
Estimated population23 for 2007, 2011, 2016, 2021 and 2026 are classified by gender,
age cohort and region. Following the age and region adjustments, there is very little
difference between the CSO projections and the estimated projections for this research.
Regional Population Estimates and Projections
Regional population is expressed as a proportion of total population. In terms of
regional population change, the Eastern region consisted of 35.46 per cent of the overall
population in 2007, that proportion is projected to increase to 38.20 per cent by 2026,
whereas the Southern region will decrease from 14.56 per cent in 2007 to 13.62 per cent
in 2026. Regional population was estimated for 2007, 201124 and projected for 201625,
202126 and 2026. The remaining regions will see a decrease in population apart from
the Western region, which will remain constant. Figure 3.5 and Figure 3.6 illustrate
the regional population changes between 2007 and 202627.
23See Appendix A Table A.26 for population estimates and projections for 2007, 2011, 2016, 2021
and 2026.
24See Appendix A See Figure A.2 for the regional population proportion 2011.
25See Appendix A See Figure A.3 for the regional population proportion 2016.
26See Appendix A See Figure A.4 for the regional population proportion 2021.
27See Appendix A See Figure A.5 for the regional population proportion compared, 2007 and 2026.
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Figure 3.5: Regional Population Proportions 2007
Figure 3.6: Regional Population Proportions 2026
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Table 3.7: Population Growth (%) by Region and Gender
Region 2007–2011 2011–2016 2016–2021 2021–2026
Eastern
Males 10.11 11.27 9.53 6.72
Females 9.14 10.7 9.30 6.64
Total 9.62 10.98 9.42 6.68
Midlands
Males 10.37 8.25 5.02 2.15
Females 8.58 6.18 3.13 0.76
Total 9.49 7.24 4.11 1.48
Mid–Western
Males 7.23 7.91 6.45 4.17
Females 5.93 5.55 3.97 1.97
Total 6.59 6.75 5.24 3.12
North–Eastern
Males 8.93 8.96 6.89 4.05
Females 8.14 8.22 6.38 3.82
Total 8.54 8.60 6.64 3.94
North–Western
Males 7.85 7.30 5.50 3.31
Females 7.19 6.50 4.82 2.89
Total 7.52 6.90 5.16 3.10
South–Eastern
Males 8.78 8.22 6.03 3.61
Females 7.39 6.36 4.28 2.21
Total 8.09 7.30 5.18 2.93
Southern
Males 7.05 7.06 5.36 2.79
Females 6.66 6.60 5.01 2.62
Total 6.86 6.83 5.18 2.71
Western
Males 8.00 8.27 6.74 4.29
Females 8.79 9.06 7.38 4.77
Total 8.39 8.66 7.06 4.53
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Regional projections by Gender
Table 3.7 shows the Midlands will have the highest population growth between 2007
and 2011 (9.49 per cent). The Eastern region will have the highest population growth
in the three time intervals between 2011 and 2026. The Mid–Western region will see
the lowest increase in population in the two time intervals between 2007 and 2016 and
the Midlands region between 2016 and 2026.
Regional projections by Age
The North–Western region has the highest percentage of 70 to 74 year olds and >75s
for 2007, 2011, 2016, 2021 and 2026. The North–Eastern region has the lowest per-
centage of 70 to 74 year olds for 2007 and 2016, whereas the Eastern region has the
lowest percentage of 70 to 74 year olds for 2011, 2021 and 2026. The Eastern region has
the lowest percentage of >75s for each of the five years. Table 3.8 aggregates the two
age cohorts 70–74 and >75s to form the >70s. The Eastern region will envisage the
largest growth in population between 2007 and 2021 and the Midlands region between
2021 and 2026. This trend is replicated for male population growth for the >70s. The
Eastern region will see the greatest female population growth between 2007 and 2011
and 2016 and 2026. The South–Eastern region will foresee the largest female popula-
tion growth between 2011 and 2016.
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Table 3.8: Population Growth of the >70s by Region and Gender
Region 2007–2011 2011–2016 2016–2021 2021–2026
Eastern
Males 16.37 26.66 29.24 23.97
Females 9.67 17.35 21.75 20.09
Total 12.35 21.21 24.99 21.82
Midlands
Males 11.73 23.61 27.18 25.11
Females 6.60 15.77 20.79 20.08
Total 8.85 19.31 23.78 22.49
Mid–Western
Males 12.82 22.98 26.54 21.53
Females 7.76 16.12 20.96 18.10
Total 9.95 19.17 23.52 19.71
North–Eastern
Males 12.86 23.94 26.53 21.95
Females 7.07 14.33 20.40 18.35
Total 9.54 18.55 23.21 20.05
North–Western
Males 11.20 22.46 25.19 21.09
Females 5.81 12.79 19.66 17.48
Total 8.20 17.18 22.29 19.23
South–Eastern
Males 15.33 23.93 25.60 22.10
Females 8.97 18.03 19.99 18.27
Total 11.73 20.68 22.57 20.08
Southern
Males 13.17 23.48 26.22 21.78
Females 7.88 15.17 19.19 17.17
Total 10.12 18.78 22.37 19.32
Western
Males 9.92 20.08 25.06 21.02
Females 4.35 12.94 19.61 19.27
Total 6.79 16.17 22.16 20.11
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3.6.2 Variable 2: GMS Coverage Estimates and Projections
The GMS coverage28 for 2007 was formulated by dividing the GMS population by
the total estimated population. The GMS population is the number of people who
are eligible for the medical card by region, age and gender, which was published in
the annual 2007 PCRS report. For this research, this was taken as the most likely
coverage rate (mean scenario) for 2007. The estimated population is based on CSO
data. Figure 3.7 detail the percentage of people who were eligible for the medical card
between 1996 and 2011 and Table 3.9 also includes the number of eligible GMS persons.
Figure 3.7: Percentage of Eligible GMS Persons, 1996 – 2011
Source: (Various PCRS Reports, 1996–2011)
28See Table 3.3 for the population proportion who have a GMS card by age, region and gender.
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Table 3.9: Number and Percentage of Eligible GMS Persons, 1996–2011
Year Persons Percentage
1996 1,252,385 34.54
1997 1,219,852 33.32
1998 1,183,554 31.95
1999 1,164,187 31.09
2000 1,148,055 30.32
2001 1,199,454 31.24
2002 1,168,745 29.84
2003 1,158,143 29.11
2004 1,148,914 29.33
2005 1,155,727 29.50
2006 1,221,695 28.85
2007 1,276,178 30.10
2008 1,352,120 31.89
2009 1,478,560 34.87
2010 1,615,809 38.11
2011 1,694,063 36.92
Source: (Various PCRS Reports, 1996–2011)
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Table 3.10: Coverage Scenarios 2007
Scenarios Coverage
Scenario 1 Minimum
28.85 0.958472
Scenario 2 Mean
31.60 1.049967
Scenario 3 Maximum
38.11 1.266113
In order to estimate 2007 coverage rates; three scenarios were established as de-
tailed in Table 3.10. The minimum, mean and maximum scenarios were calculated
based on historical coverage data between 1996 and 201029. 30.10 per cent of the GMS
population were eligible for a medical card in 2007. In order to determine the minimum
scenario, 28.85 was expressed as a proportion of 2007 national coverage rate (30.10%)
to form a weighting. 0.958472 was multiplied uniformly across region, gender and age
cohort by coverage 2007. In order to determine the maximum scenario, 38.11 was ex-
pressed as a proportion of 2007 national coverage rate to form a weighting. 1.266113
was multiplied uniformly across region, gender and age cohort by coverage 2007. The
mean scenario was taken as the most likely coverage rate30.
The Irish economy officially fell into recession in the final quarter of 2008. The cycli-
cal impact is evident between 2008 and 2011. The number of eligible persons increased
from 1,352,120 to 1,694,063, an increase of 341,943 persons, (PCRS, 2011) reports this
as the highest number of medical card holders ever recorded up to 2011. Coverage 2011
was calculated by dividing the GMS population by the estimated mean population for
2011. Three scenarios31 were formulated based on the historical coverage data between
29See Table 3.9 for historical GMS coverage rates between 1996 and 2010.
30See Appendix A Table A.41 for 3 coverage scenarios 2007.
31See Appendix A Table A.44 for 3 coverage scenarios 2011.
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1996 and 2011 (See Table 3.9). A weighting was applied to the mean coverage rate
2011. The minimum and maximum coverage rates were determined from the historical
data and were expressed as a proportion of the national coverage rate. This weighting
was uniformly applied to the mean coverage 2011 rate by region, gender and age cohort.
Scenario 1 and 3 were determined using this methodology. If the >75 age cohort for
each region and gender exceeded 1.00, an adjustment factor (Equation 3.5) was applied.
Adjustment Factor = Min(> 75− λ(1.00− 70 to 74 age cohort)) (3.5)
The >75 value for each region and age cohort was scaled downwards. Lambda
can take any value between 0 and 0.99. For example, if the projected population for
>75 in a given region is 100 but the number of projected GMS eligible persons is 105,
GMS coverage rate is 1.05. As this value exceeds 1.00, the adjustment factor above
was applied, to scale the value below 1.00.
Coverage projections 2016 through to 2026 were based on the reference year 2011
(coverage 2011 data), as this was the most up to date data available at the time of
projections. In order to project coverage 2016, three scenarios; minimum, mean and
maximum were calculated based on the historical coverage data between 1996 and 2011
in Table 3.9. The minimum value (0.2885) was multiplied by the projected total popu-
lation for 2016 (scenario 2, the most likely population) of 5,095,004. This generated an
estimated number of eligible persons of 1,469,909. The difference between total number
of eligible persons 2011 (1,694,063) and 2016 (1,469,909) was derived and expressed as a
proportion (0.867682). This value was multiplied by coverage 2011 to generate scenario
1 coverage 201632 by region, gender and age cohort. Coverage 2016 was multiplied by
population 2016 to determine the number of eligible persons 2016 by region, gender
and age cohort. Population weightings were applied to the coverage age cohorts of <5
and 5–11 to determine the 0–11 age cohort.
32See Appendix A Table A.47 for coverage scenario 1, 2016.
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The mean value (0.3160) was multiplied by the projected total population for 2016
(scenario 2, the most likely population) of 5,095,004. This generated an estimated
number of eligible persons of 1,941,706. The difference between total number of eligible
persons 2011 (1,694,063) and 2016 (1,627,344) was derived and expressed as a propor-
tion (0.960616). This value was multiplied by coverage 2011 to generate scenario 2,
coverage 201633 by region, gender and age cohort. Coverage 2016 was multiplied by
population 2016 to determine the number of eligible persons 2016 by region, gender
and age cohort. Population weightings were applied to the coverage age cohorts of <5
and 5–11 to determine the 0–11 age cohort.
The maximum value (0.3811) was multiplied by the projected total population for
2016 (scenario 2, the most likely population) of 5,095,004. This generated an estimated
number of eligible persons of 1,941,706. The difference between total number of el-
igible persons 2011 (1,694,063) and 2016 (1,941,706) was derived and expressed as a
proportion (1.146183). This value was multiplied by coverage 2011 to generate scenario
3 coverage 201634 by region, gender and age cohort. Coverage 2016 was multiplied by
population 2016 to determine the number of eligible persons 2016 by region, gender
and age cohort. Population weightings were applied to the coverage age cohorts of <5
and 5–11 to determine the 0–11 age cohort.
This methodology was replicated to determine coverage projections 202135 and cov-
erage projections 202636. Three scenarios were calculated for each year. 2021 and 2026
coverage projections were based on the most likely projected population of 5,451,088
and 5,696,000 respectively. An adjustment factor was applied to the >75 age cohort of
scenario 2, 2021 and 2026 coverage rates as the coverage values exceeded 1.00. For sce-
nario 3, the adjustment factor did not scale the data sufficiently below 1.00. Therefore,
33See Appendix A Table A.48 for coverage scenario 2, 2016.
34See Appendix A Table A.49 for coverage scenario 3, 2016.
35See Appendix A Table A.50 for coverage scenarios 1, 2 and 3, 2021.
36See Appendix A Table A.53 for coverage scenario 1, 2 and 3, 2026.
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Table 3.11: Number of GMS eligible persons & Coverage Projections (3 Sce-
narios), 2016–2026
Scenario Year No.of Eligible
Persons
Population Coverage (%)
Mean 2007 1,276,178 30.10
Mean 2011 1,694,063 36.92
Minimum 2016 1,247,958 24.49
Mean 1,768,092 5,095,004 34.70
Maximum 2,153,921 42.28
Minimum 2021 1,463,419 26.85
Mean 2,043,475 5,451,088 37.49
Maximum 2,457,664 45.64
Minimum 2026 1,638,254 28.76
Mean 2,120,627 5,696,000 37.23
Maximum 2,746,658 48.22
0.99 coverage rates were applied uniformly across all regions, genders and age cohorts
for the 70–74 and >75 age cohorts for the years 2021 and 2026. Number of eligible
persons and coverage projections are presented in Table 3.11.
In Table 3.11, 2007 and 2011 are actual figures and 2016 through to 2026 are
projected figures. Coverage rates are based on the most likely population level for each
year. Coverage is estimated to be approximately 34.70 per cent in 2016, 37.49 per cent
in 2021 and 37.23 per cent in 2026. Figure 3.8 estimated the number of eligible GMS
persons will lie between 1.2 and 2.1 million in 2016, 1.5 and 2.5 million in 2021 and 1.6
and 2.7 million in 202637.
37See Appendix A Figure A.6 for GMS coverage Projections (%) 2016 – 2026.
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Figure 3.8: Number of eligible GMS Persons (Projections–3 Scenarios), 2016–
2026
3.6.3 Variable 3: Average Cost per claimant Estimates & Projections
The average cost per claimant38 was estimated from the sample PCRS database 2007
and the PCRS annual report 2007. The (PCRS, 2007) reports that the average phar-
macy cost per eligible GMS person was e856.14 in 2007. The PCRS sample database
estimates the average cost per eligible GMS person as e1,221.06. The PCRS annual
report figures are approximately 30% lower than the estimated figures, therefore the es-
timated figures were scaled downwards based on the regional totals of the annual 2007
report39. Three possible scenarios were generated with the mean cost per claimant
being the most likely scenario. A 95% confidence interval was applied, establishing a
lower bound40 (minimum scenario) and upper bound (maximum scenario) around the
mean cost per claimant using the standard deviation estimated from the PCRS sample
database.
38See Appendix A Table A.23 for the average cost per claimant 2007.
39See Appendix A Table A.56 for comparison of regional totals.
40See Appendix A Table A.57 for 3 average cost per claimant scenarios re–estimated 2007.
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Average Cost (AC) per claimant historical growth rates were determined and an
assumption was made that the historical growth evolution would continue in estimating
the ac per claimant for 2011 and projections between 2016 and 2026. The average GMS
pharmacy cost for 2007 was e856.14 and e761.51 in 2011, a reduction of approximately
11.05 per cent. This reduction was uniformly applied by region, gender and age cohort
to determine AC per claimant 2011 (3 scenarios)41. Historical data (2003–2010) was
used in the formulation of the 2016, 2021 and 2026 projections. The minimum, mean
and maximum average cost per claimant data was determined by each region. For
example, the minimum average cost per claimant for the Eastern region between 2003
and 2010 is e588.26. This figure was subtracted from the minimum Eastern male total
figure and expressed as a proportion. The proportion was multiplied by 2007 minimum
Eastern male to formulate 2016 minimum eastern male. This methodology was applied
across all regions, genders and age cohorts for the mean and maximum scenarios to
formulate 2016 mean and maximum scenarios.
2021 and 2026 average cost per claimant projections were estimated based on the
historical growth rates between 2003 and 2010. For example, the minimum negative
growth for the Eastern region is 10.04% between 2003 and 2010. 2016 minimum Eastern
male and female figures were scaled down by 10.04% to formulate 2021 Eastern male
and female minimum scenario. This method was applied across all regions, genders,
age cohorts and scenarios. 2021 minimum Eastern male and female figures were scaled
down by 10.04% to formulate 2026 Eastern male and female minimum scenario. This
method was applied across all regions, genders, age cohorts and scenarios.
41See Appendix A Table A.64 for three average cost per claimant (e) scenarios by age cohort, gender
and region 2011.
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3.6.4 Variable 4: Claims Rate Estimates and Projections
The claims rate42 is the proportion of medical card holders who make a claim. The
claims rate was estimated to be 57 per cent from the sample PCRS database. The
(PCRS, 2007) reports that more than 96 per cent of eligible GMS persons availed of
services in 2007. A weighted regional adjustment based on Table 9.1 (PCRS, 2007)
was applied to the estimated claims rate data. An adjustment factor (Equation 3.6 &
Equation 3.7) was applied to scale upwards the estimated claims rate data.
Adjustment Factor = raw rate+ λ(1.00− raw rate) (3.6)
raw rate = the estimated 2007 claims rate
λ = Lambda
λ =
Y − Σ(w1r1........w8r8)
1.00− Σ(w1r1........w8r8)
(3.7)
Y = claims rate PCRS Report 2007
w = weightings of numbers covered for each region
r = claims rate estimated from sample database 2007,
r = where r1 is the Eastern region and r8 is the Western region
A 95 per cent confidence interval was applied to the claims data, to establish a lower
bound (minimum) and upper bound (maximum). Three scenarios43 were generated by
region, gender and age cohort.
The Irish government introduced patient co–payment for medical card holders for
the first time on the 1st October 2010. A 50 cent per item prescription charge up to
a maximum of e10 per family per month. This was subsequently increased to e1.50
42See Appendix A Table A.24 for the claims rate 2007.
43See Appendix A Table A.67 for 3 claims rate scenarios 2007.
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Table 3.12: Percentage of Eligible GMS Persons who availed of services, 1998–2011
Year Percentage
1998 88%
1999 88%
2000 88%
2001 88%
2002 90%
2003 94%
2004 96%
2005 95%
2006 95%
2007 96%
2008 91%
2009 94%
2010 93%
2011 93%
Source: (Various PCRS Reports, 1998–2011)
per prescription item in January 2013 and e2.50 per prescription item in December
2013. (Sinnott, Guinane, Whelton and Byrne, 2013) conducted a qualitative study on
the 50 cent Irish co–payment charge. They found that patients were mostly accepting
of the 50 cent charge and it did not affect patient demand for drugs. The national
claims rate has not changed since the co–payment introduction. 93 per cent of eligible
GMS persons availed of services in 2010 and 2011, (PCRS, 2011). Table 3.12 details
proportion of GMS persons who availed of services between 1998 and 2011. This has
remained above 90 per cent since 2002. Therefore, this research will hold claims rate
scenarios constant for the lifetime of the projections.
3.7 Monte Carlo Simulation Model
The MCS model identifies uncertain (explanatory) variables and an uncertain (de-
pendent) function. The uncertain variables are populaton, coverage, claims rate and
average cost per claimant. Each uncertain variable is specified by age cohorts (10),
gender (2) and regions (8) giving a total of 160 cells to be modelled for each variable.
The dependent variable is the estimated historical cost of the GMS scheme for 2007
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and 2011 and the projected cost for 2016, 2021 and 2026. In order to prepare the data
for Monte Carlo Simulations, the probability and cumulative probability of finding a
person within each region, gender and age cohort (RGA) class were calculated. The
MCS model employs statistical sampling to forecast under uncertainty. MCS generates
a large number (100,000) of outcomes which is representative of your decision and as-
sesses your decisions and the impact of risk, allowing for better decision making under
uncertainty. Taking a large number of simulations (100,000), gives an excellent approx-
imation to the true distribution of projected cost. The equation (Equation 3.8) used
for simulations is;
Probable cost = Expected cost + error (3.8)
where error is an ensemble for the Monte Carlo Simulation, having a normal distri-
bution with zero mean and standard deviation of 5% of cost.
The probability is the empirical probability (proportion) calculated by the quotient
of class members over count of all members which lies between 0 and 1. The cumula-
tive probabilities were calculated which gave a weight of occurrence within a particular
RGA class. A macro was written in Visual Basic Editor in Microsoft Excel to run the
simulations. (Sugiyama, 2007) highlighted the importance of assigning an appropri-
ate probability distribution to uncertain variables in developing a comprehensive MCS
model. A Normal distribution was applied to estimate costs to allow for uncertainty in
the model. As the cost nationally is fundamentally based on the sum of costs at an in-
dividual level, the Central Limit Theorem was applied here, which states that the sum
of random variables will be approximately distributed, (Bain and Engelherdt, 1991).
An MCS with 100,000 iterations was used to propagate the uncertainty in the model.
All statistical analyses were performed using Minitab statistical package (Minitab 16).
The MCS results were imported into Minitab for analysis.
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3.8 Results
The MCS projects total pharmacy cost could rise to e1,317 million in 2016 and may
lie between approximately e644 million and e2,150 million. The total pharmacy cost
could rise to e1,626 million in 2021 and may lie between approximately e704 million
and e2,876 million. The total pharmacy cost is projected to rise to e1,985 million in
2026 and may lie between approximately e742 million and e3,672 million, as illustrated
in Figure 3.9. These cost projections are subject to assumptions made around the four
variables.
Figure 3.9: Historical Projections and Projected Pharmacy Cost (eM) to 2026
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Table 3.13: Descriptive Analysis of Average Cost per Claimant (e) 2016–2026
(Scenario 2)
Year ] of
Simulations
Mean SE Mean Standard
Deviation
Min Q1 Median Q3 Max
2016 100,000 272.31 0.912 149.32 69.63 106.19 167.59 286.14 1541.72
2021 100,000 312.61 0.994 314.45 78.65 121.29 190.43 330.86 1579.73
2026 100,000 366.81 1.18 272.28 86.68 135.56 241.10 371.60 1602.28
3.8.1 Descriptive Statistics
The descriptive analysis44 of 100,000 simulations for scenario 2 in 2016 projected an av-
erage cost per claimant of e272.31 (minimum e69.63 and maximum e1,541.72). This
is projected to be e312.61 in 2021 (minimum e78.65 and maximum e1,579.73) and
e366.81 in 2026 (minimum e86.68 and maximum e1,602.28) as detailed in Table 3.1345.
Figure 3.10: Histogram of Average Cost per Claimant (e), Scenario 2, 2016
44See Appendix A Table A.70 for descriptive analysis scenario 1, 2016–2026.
45See Appendix A Table A.71 for descriptive analysis scenario 3, 2016–2026.
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Figure 3.10 illustrates the simulation results for scenario 2, 2016. The majority of
simulations show an average cost per claimant of e600 or less. For scenario 146, the
average cost per claimant is e300 or less and approximately e800 or less for scenario 347.
Figure 3.11 illustrates the simulation results for scenario 2, 2021. The majority of
simulations show an average cost per claimant of e700 or less. For scenario 148, the av-
erage cost per claimant is e300 or less and approximately e1,050 or less for scenario 349.
Figure 3.11: Histogram of Average Cost per Claimant (e), Scenario 2, 2021
Figure 3.12 illustrates the simulation results for scenario 2, 2026. The majority of
simulations show an average cost per claimant of e750 or less. For scenario 150, the av-
erage cost per claimant is e300 or less and approximately e1,400 or less for scenario 351.
46See Appendix A Figure A.7 Histogram of Average Cost per Claimant, Scenario 1 2016.
47See Appendix A Figure A.8 Histogram of Average Cost per Claimant, Scenario 3 2016.
48See Appendix A Figure A.9 Histogram of Average Cost per Claimant, Scenario 1 2021.
49See Appendix A Figure A.10 Histogram of Average Cost per Claimant, Scenario 3 2021.
50See Appendix A Figure A.11 Histogram of Average Cost per Claimant, Scenario 1 2026.
51See Appendix A Figure A.12 Histogram of Average Cost per Claimant, Scenario 3 2026.
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Figure 3.12: Histogram of Average Cost per Claimant (e), Scenario 2, 2026
3.8.2 Statistical Analysis
The statistical analysis for the three scenarios in 2016 identify the effect the three
variables (age, gender and region) have on the average cost per claimant. These results
are illustrated in Figure 3.13. It was found that the main factors driving GMS costs in
2016 were found to be;
• age, and in particular those aged 0–11, and those aged >70
• being resident in the Midlands region
• being female
These results show a similar picture for 202152 and 2026, as illustrated in Fig-
ure 3.14.
52See Appendix A Figure A.13 Statistical Analysis Scenario 1 – Scenario 3, 2021.
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Figure 3.15 (Main Effects Plot) depicts age as the most significant driver of cost
compared to the other two variables.
Figure 3.15: Main Effects Plot Scenario 2, 2016
A Main Effects Plot is used to examine differences between level means for one or
more factors. A Main Effects Plot graphs the response mean for each factor; old health
board region, sex and age cohort. Age cohorts show the greatest response, especially
<11s and >70s. Scenarios 1 and 353 also confirm this result. These results portray
a similar picture for 202154 and 202655. This is further compounded by the interval
plot of cost by region, gender and age cohort. Figure 3.16 forecasts the Midlands as
the most expensive region and the Eastern region as the least expensive for scenario 2,
2016.
53See Appendix A Figure A.14 for Main effects Plot Scenario 1 & Scenario 3, 2016.
54See Appendix A Figure A.15 for Main Effects Plot Scenarios 1 & Scenario 3, 2021.
55See Appendix A Figure A.16 for Main Effects Plot Scenarios 1 & Scenario 3, 2026.
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Figure 3.16: Interval Plot of Cost by Region, Scenario 2, 2016
One can be 95 per cent confident that the average cost per claimant will lie between
e320 and e340 (Midlands region) and e210 and e220 (Eastern Region). The interval
plot of cost by gender forecasts females to be more expensive than males for scenario
2, 2016. One can be 95 per cent confident that the female average cost per claimant
will lie between e295 and e300 and the male average cost per claimant will lie between
e244 and e248 (Figure 3.17).
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Figure 3.17: Interval Plot of Cost by Gender, Scenario 2, 2016
The interval plot of cost by age cohort, forecasts children under 11 and the >75s
as the most expensive age cohorts for scenario 2, 2016. We can be 95 per cent confi-
dent that the average cost per claimant in the under 11 category will be approximately
e1,200 and the average cost per claimant in the >75s category will be approximately
e1,000 (Figure 3.18). Scenario 156 and Scenario 357 forecast similar results for 2016
by region, gender and age cohort to Scenario 2. 202158 scenarios forecast comparative
results to 2016 scenarios, results for scenarios 1 and 3 are presented in Appendix A.
56See Appendix A Figure A.17 Interval Plot of Cost by region, gender & age cohort, Scenario 1,
2016.
57See Appendix A Figure A.18 Interval Plot of Cost by region, gender & age cohort, Scenario 3,
2016.
58See Appendix A Figure A.19 Interval Plot of Cost by Region, Gender and Age Cohort, Scenario 2,
2021.
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Figure 3.18: Interval Plot of Cost by Age Cohort, Scenario 2, 2016
The interval plot of cost by gender and age cohort for 202659 forecasts comparative
results to 2016 and 2021 for each scenario. The interval plot of cost by region forecasts
the South–East as the most expensive region and the Eastern region as the least ex-
pensive (Figure 3.19) for scenario 2, 2026. Scenario 1 and scenario 3 illustrate a similar
picture to previous years, therefore results are presented in Appendix A.
59See Appendix A Figure A.20 Interval Plot of Cost by Gender and Age Cohort, Scenario 2, 2026.
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Figure 3.19: Interval Plot of Cost by Region, Scenario 2, 2026
3.9 Discussion
Population growth and an aging population will be a driver of future Irish health care
costs. It is well documented in the literature that population is a driver of Irish health
care expenditure, (Layte et al., 2007) and (Barry et al., 2010). Population growth is the
effect of changes in the size of the population on health care expenditure, such as drug
spending. Other things being equal, an increase in population size will increase total
drug spending. This research estimates that the Irish population will have increased
by approximately 33 per cent by 2026. Population aging is the effect of changes in the
age distribution of the population on spending. Irish people are living longer. Over
a 20 year period (1986–2006), Irish males are living 5.8 years longer to an age of 76.8
years, whereas Irish females are living 4.9 years longer to an age of 81.6 years, (CSO,
2009). An aging population will result in increased spending if the use and cost of
drugs increase with age for the average individual within the population. CSO projec-
tions forecast the number of elderly people will have grown by 200,000 by 2021, (CSO,
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2008). A Canadian study identified population growth and population aging as two
of six drivers of drug expenditure, (Canadian Institute for Health Information, 2012).
They also identified general inflation, price effects, volume effects and mix of drugs as
drivers of drug spending.
(Bech et al., 2010) argues a shift in the proportion of the population being elderly
caused a shift in the health care expenditure in fifteen EU countries. That is, as people
are living longer, it represents a shift in expenditure from one age group to another. As
mentioned above, both Irish males and females are living longer. This may justify the
addition of a 12th HSE age cohort, the >80s and renaming >75s to 75–79 to represent
a shift in population, where people are living longer.
High birth rates will also contribute to population growth and future health care costs.
The CSO recorded 72,225 births in 2012 in Ireland, which is 19.3 per cent higher than
2002 figures, (CSO, 2012). Eurostat found Ireland had the highest fertility rate (2.05)
in the European Union (EU27) in March 2013, (Eurostat, 2013). Ireland has on average
two live births per woman. This research shows the 0–11 age cohort is a key driver of
future health care costs. Population growth, aging population and high fertility rates
under existing policies will have a knock on effect on future GMS coverage rates. That
is, more people will be eligible for medical cards.
Since July 2001, everyone over the age of 70 had an entitlement to a free medical
card. In January 2009, eligibility for the GMS scheme changed for the >70s. New
medical card income limits were introduced. A single person with an income of e700
per week (e36,500 per year) or a couple with an income of e1,400 per week (e73,000
per year) were no longer entitled to a free medical card, (Barry et al., 2010). Budget
2014 reduced the income limits to e500 per week for a single person and e900 per
week for a married couple, (Department of Finance, 2013). This policy change will
reduce the eligibility rates and reduce overall coverage rates, holding all other factors
constant. Due to the three drivers of future health costs as mentioned above, GMS
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coverage is likely to increase, thus increasing health costs. To counter this increase,
the Irish government needs to consider further decreasing the income limits for medical
cards, while taking account of equity.
The Midlands region is the most expensive and the North–West is the least expen-
sive old health board region between 2003 and 2009 in terms of the average pharmacy
cost per eligible GMS person. The Midlands cost ranged from e649.14 in 2003 to
e943.28 in 2009 and the North–West ranged from e521.91 and e787.19 over the same
time period, (PCRS, 2009). This research shows that this trend is forecasted to continue
to 2026. The regional variation in cost may be explained by the following two studies.
The distribution of chronic conditions was examined across the old health board regions
and it was found the Midlands had the highest prevalence of chronic conditions with
the Western and North–Western regions having the lowest, (Naughton et al., 2006).
The prescribing prevalence of insulin dependent and non-insulin dependent diabetes
was examined across regions, (Usher et al., 2005). They found the Midlands and the
Mid–Western regions had the highest prescribing ratios for both types of diabetes and
the North-Western region had the lowest prescribing ratio. It is well documented that
females visit doctors more regularly than men, hence prescribing rates are higher for
females with a resulting effect of higher health costs. These results confirm this, with
females forecasting higher costs than males for all scenarios.
The claims rate, i.e. the proportion who make a claim on a medical card, has been
above 90 per cent since 2002. The Irish government introduced a patient co–payment
system in October 2010 for medical card holders with a 50 cent per prescription charge,
capped at e10 per month and in Budget 2014, this was increased to e2.50 per pre-
scription item, with a monthly cap of e25, (Department of Finance, 2013). (Sinnott,
Guinane, Whelton and Byrne, 2013) conducted a qualitative study on the 50 cent co–
payment charge and found that patients were mostly accepting of the charge and it did
not affect patient demand for drugs. No research has been done on subsequent increases
in the patient co–payment Irish system. More expensive co–payment charges exist in
100
the UK (Schafheutle, 2008), Italy (Atella et al., 2005) and Australia (Doran et al.,
2005). These studies show that an expensive co–payment system can affect the utili-
sation and demand for drugs. It is well documented in the literature that co–payment
charges can reduce the utilisation of both essential and non–essential medicines in vul-
nerable populations such as the poor, elderly and chronically ill, (Rice and Matsuoka,
2004) and (Lexchin and Grootendorst, 2004). Therefore, the Irish government needs to
be mindful of the ill–effects of future increases in prescription charges as these groups
comprise the GMS population in Ireland.
(Bennett et al., 2009) compiled projections on future prescribing for three of the com-
munity drug schemes; GMS scheme, DPS and LTI scheme. They used two models
to predict trends in future prescribing; a linear current use model (2006 data) and a
regression analysis model. They found ingredient costs are likely to be between e1.5bn
and e2.3bn for the three community drug schemes (GMS, LTI & DPS) in 2020 with
the largest increase in the GMS scheme. This research projects total pharmacy cost
rising to e1.6bn in 2021 for the GMS scheme. The ingredient cost incorporates approx-
imately 80 per cent of the total cost of prescriptions. The total cost of prescriptions
is comprised of the ingredient cost, dispensing fee and VAT. (Bennett et al., 2009)
projections do not take into account the impact of the recession on the demand for
pharmaceuticals, the price reductions under the IPHA/HSE agreement, or the possible
impact of generic substitution and reference pricing. Despite the IPHA/HSE agree-
ment, overall pharmaceutical expenditure continued to increase post 2006 no doubt
reflecting the key drivers of population growth and aging, although there has been a
moderation in expenditure growth. Some of the recent moderation in pharmaceutical
expenditure growth is undoubtedly due to the measures taken by the State and some
by the decline in demand due to the recession, (Gorecki et al., 2012). This research
updates and expands the (Bennett et al., 2009) projections for the GMS scheme only.
In addition, this research includes demographic and regional population changes, policy
variables and provides a Monte Carlo sensitivity analysis of the results.
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A number of predictive studies have been undertaken in the United States on future
health care costs, which also inform future prescribing costs. (Wrobel et al., 2004) and
(Sales et al., 2003) predicted drug expenditures for the Medicare scheme and a veteran
health population respectively and their models included demographic and health sta-
tus variables. These studies found combined drug and diagnostic data is superior in
predicting total health care costs. (Zhao et al., 2005) compared the predictive perfor-
mance of diagnosis and drug based models to predict health care costs in the US. They
found drug based models predict future pharmacy costs more effectively than diagnosis
based models and a combined drug and diagnostic model is a better predictor of future
health care costs than either model alone.
3.10 Conclusion
The results show the sensitivity of GMS cost projections to demographic, coverage,
claims rate and average cost per claimant changes. The projections and simulations
map the likely evolution of GMS cost, given existing policies and demographic trends.
Over the next decade, Ireland’s population will experience rapid growth. This growth
coupled with an aging population will result in an increase in both the coverage rate
and the claims rate, thus the projected increase in overall prescribing costs. However,
these costs can be contained by government policy initiatives. Downward adjustment
of the income eligibility limits can be used to curtail the coverage rates and upward
adjustments to the co–payment patient prescription charges can be utilised to reduce
the claims rate, thus curbing the overall average cost per claimant. These projections
are conditional upon the assumptions and data on which the model is built and remain
subject to substantial uncertainty given the variable nature of future economic trends
and policy decisions. The next chapter projects GMS expenditure using more recent
population GMS data (2012) and CSO (2013) population projections based on Census
2011. The GMS database includes the cost containment measures introduced since the
economic crisis began. Using the more up to date data, an MCS model will be run to
determine GMS expenditure projections in five year intervals between 2016 and 2026.
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Chapter 4
GMS cost projections and its
implications between 2016 and
2026 (2012 data)
4.1 Introduction
This chapter projects GMS expenditure in five year intervals between 2016 and 2026.
The data used for this analysis is based on HSE–PCRS population data (2012) and
CSO Regional Population Projections (2016–2031). To address the uncertainty around
projections, the most likely (mean) scenario and a high (maximum) and low (minimum)
scenario were modelled. A Monte Carlo Simulation model will be employed to forecast
GMS costs through to 2026. In the previous chapter, GMS cost projections were based
on sample 2007 PCRS data and CSO population projections based on 2006 census.
This study estimated GMS expenditure to increase from e1.1 billion in 2011 to e1.9
billion by 2026.
The conclusion drawn in this study was that age (<11 and >70), females and the
Midlands region were found to have the most significant effect on future GMS costs in
Ireland, (Conway et al., 2014). This research was based on a sample database for the
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year 2007, a year before the Irish economy slipped into a deep recession. Since then,
the CSO has revised its population projections downwards, coupled with the impact
of Irish government cost containment measures, this advocates that the projections of
the previous chapter are likely to be overestimated. This research sets out to redress
the overestimate by utilising;
1. 2012 GMS population prescription data.
2. 2013 CSO population projections.
This chapter aims to utilise the most recent available data to project Irish GMS
cost from 2016 to 2026 and to examine the implications of the estimated impact on
GMS expenditure. National and regional population is described in section 4.2. Policy
variables are explored in subsequent sections; GMS coverage (section 4.3), average cost
per claimant (section 4.4), the HSE–PCRS population prescribing database (2012) is
described in section 4.5 and the claims rate (section 4.6). Section 4.7 details the cost
projection model and various methodologies used to project each of the four variables.
The Monte Carlo Simulation model is explained in section 4.8 followed by the descrip-
tive and statistical analysis in section 4.9. The results are discussed in section 4.10 and
conclusions are drawn in section 4.11.
4.2 Demographic variable: Regional and National Popu-
lation
The 2012 population data was estimated by old health board region, sex and age
cohort for comparison purposes with earlier work. There are eight regions (Eastern,
South-Eastern, Southern, Western, Mid–West, Midlands, North–West and North–East)
within the old health board structure in Ireland. The primary data source is the CSO
Regional Population Projections 2016–2031, which projects both regional and national
population. The CSO has made a number of assumptions around international mi-
gration, fertility, mortality and inter–regional flows. The current CSO release (2013)
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applies two international migration assumptions; M2 and M3. Under the M2 assump-
tion, all regions are forecasted to experience positive population growth, whereas the
M3 assumption estimates net negative international migration (positive emigration)
between 2011 and 2031 and varying regional population growth, where some regions
will not experience population growth. The CSO only considered one fertility assump-
tion in the current release, F2. The F2 scenario assumes the total fertility rate will
decrease from 2.1 to 1.6 between 2010 and 2026 and remain constant thereafter. The
most recent CSO population projections (CSO, 2013) have lower projected estimates
compared to the previous population projections (CSO, 2008). The lower projections
are mainly driven by a fall in fertility. The CSO used the national mortality assumption
across all regions, where mortality rates are expected to decrease by 3.5% for males and
2.5% for females per annum. The CSO estimate an improvement in life expectancy for
males from 78.3 years in 2011 to 83 years in 2031. For females, the CSO estimates 82.9
years in 2011 to 86.6 years in 2031, (CSO, 2013).
The fourth assumption was made around internal migration between regions. The
CSO incorporated three scenarios; recent, traditional and a modified scenario into the
current projections. The recent scenario assumes the pattern of inter–regional flows
observed in the year to April 2011 is applied to 2031. The modified scenario assumes a
pattern of increased movement to Dublin at the expense of all other regions, except the
Mid–East. The traditional scenario assumes a gradual reversal of the 1996 pattern of
inter–regional flows by 2021 and remains constant thereafter. The CSO developed dif-
ferent scenarios (6) for their regional population projections, (CSO, 2013). The M2F2
traditional scenario (M2F2T) was the main scenario used in the CSO projections and
is the scenario that has been adopted for this research.
This was deemed the most appropriate1 scenario to use at the time of population
projections. In the previous chapter, M2F1T was adopted as the central scenario for
1Personal Communication: A conversation took place between the CSO population statistician and
the researcher to confirm the M2F2T was the most appropriate scenario to use.
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population projections through to 2026, which was deemed to be the most appropriate
at the time of projections, (CSO, 2008).
The CSO projections are classified by year of age, sex and region. In order to
reconcile the CSO data with the HSE–PCRS data structure, two adjustments (age ad-
justment and region adjustment) were applied to the data. The HSE identifies eleven
age cohorts ranging from the <5s to the >75s. The CSO data was aggregated accord-
ing to each HSE age cohort. CSO regions are not comparable with three of the HSE
regions. The HSE Eastern, North–Eastern and North–Western regions are not compa-
rable with the CSO Border, Dublin and Mid–East regions. An adjustment factor was
estimated using the 2011 Census data for the three regions as this was the most up
to date Census data available at the time of calculations. The same methodology was
applied using the 2006 Census in the previous chapter.
For example, to estimate the Eastern region (Dublin, Kildare and Wicklow), the
CSO Mid–East (Meath, Kildare and Wicklow) and Dublin data was aggregated. From
the 2011 CSO Census, the number of persons in Meath, Kildare, Wicklow and Dublin
were aggregated by age cohort and sex. County Meath was expressed as a proportion
of the total region to form a weighting by age cohort and sex. This weighting was
multiplied by the Eastern region 2012 to estimate Meath 2012 by age cohort and sex.
Meath values were taken from the Eastern region to estimate the HSE Eastern region
(Dublin, Kildare & Wicklow) 2012. The same methodology using the Census 2011 to
establish weights was applied to estimate the HSE North–West and North–East regions.
Regional and national population projections were estimated for 2016, 2021 and 2026
by age cohort, sex and HSE region using the same methodology. A lower and upper
bound scenario were also developed around the mean population scenario for each pro-
jected year. The CSO M3F2T2 scenario was used to develop projections for the lower
bound scenario. An upper bound scenario was estimated as follows; (M2F2T–M3F2T)
+ M2F2T.
2Lower population estimates due to positive emigration.
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Table 4.1: Population Scenarios 2012–2026
Scenarios Population Population Growth Rate (%)
Scenario 1 Population (M3F2T) Minimum (Lower Bound)
2006 4,239,848
2012 4,586,796 8.18
2016 4,669,239 1.80
2021 4,779,069 2.35
2026 4,853,886 1.57
Scenario 2 Population (M2F2T) Mean
2006 4,239,848
2012 4,586,796 8.18
2016 4,687,000 2.18
2021 4,876,000 4.03
2026 5,044,000 3.45
Scenario 3 (M2F2T - M3F2T) + M2F2T Maximum (Upper Bound)
2012 (8.18 - 8.18) + 8.18 8.18
2016 (2.18 - 1.80) + 2.18 2.57
2021 (4.03 - 2.35) + 4.03 5.71
2026 (3.45 - 1.57) + 3.45 5.33
The total population for 20123, 20164, 20215 and 20266 was calculated by region, age
cohort and sex. A lower bound and upper bound scenarios were determined around the
mean population. Table 4.1 specifies the population scenarios. The minimum scenario
estimates the population will grow by 1.80% between 2012 and 2016, 2.35% between
2016 and 2021 and 1.57% between 2021 and 2026.
3See Appendix C Table C.1 for the estimated population 2012.
4See Appendix C Table C.2 for the estimated population 2016.
5See Appendix C Table C.3 for the estimated population 2021.
6See Appendix C Table C.4 for the estimated population 2026.
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4.3 Policy Variable: GMS Coverage
GMS coverage is the proportion of the population who are eligible for the GMS scheme.
GMS coverage projections through to 2026 is updated using PCRS Statistical Analysis
of Claims and Payments, Annual Report 2012 and updated CSO population projec-
tions (2013). Minimum, mean and maximum GMS coverage rates were determined
from the historical data between 1996 and 2012. The PCRS report states that 40.40%
of the population (1,853,877 persons) were eligible for the medical card in 2012, the
highest level since data was published in 1996 (1,252,385, 34.54%), (PCRS, 2012). The
mean coverage rate is the number of eligible GMS persons divided by the estimated
population for 2012. Table 4.2 details the estimated population proportion who had
the medical card by age, sex and HSE region in 2012. GMS coverage rates for 2012
show a similar trend to 2007 coverage rates. Table 4.2 indicates the Eastern region has
the lowest male and female GMS coverage for all age cohorts except 12–15 (Southern)
and the North–Western region has the highest male and female GMS coverage in all
11 age cohorts.
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4.4 Policy Variable: Average Cost per Claimant
The average cost per claimant is the total cost of claimants divided by the number of
claimants (Equation 4.1) and this was calculated using the population 2012 HSE–PCRS
database.
Average Cost per Claimant =
Total Cost of Claimants
Number of Claimants
(4.1)
The average cost per claimant was determined for each year between 2009 and 2012
from the HSE–PCRS population database, as this was the only available data. This
estimate was based on four years of population data, whereas in the last chapter, this
variable was estimated using one single year of sample data. There is considerable
variation in the data year on year. For example, the average cost per claimant for a
male in the 12–15 age cohort in the Eastern region grew by 10.97% between 2009 and
2010, decreased by 2.32% between 2010 and 2011 and increased by 6.19% between 2011
and 2012.
This variation may be explained by the economic crisis, an increase in GMS eligi-
bility rates and the Irish government objective of containing drug costs. Due to the
variation in the cost data, it was decided to take a four year average cost per claimant
between 2009 and 2012 and this was taken as the base for projections of this variable.
Table 4.3 details the 2012 average cost per claimant by region, sex and age cohort. The
average cost per claimant for a female in the > 75 age cohort is e1,739.97, which is
18 times the average cost per claimant of a female in the 0–11 age cohort (e98.80) in
the Eastern region. The average cost per claimant for a male in the > 75 age cohort
is e1,664.57, which is 15 times the average cost per claimant of a male in the 0–11 age
cohort (e113.48) in the Eastern region.
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Average cost per claimant percentiles were calculated to determine a lower bound
and upper bound scenario. Percentiles (1%, 5%, 10%, 20% and 80%, 90%, 95% and
99%) were calculated by region, sex and age cohort. These calculations showed sig-
nificant variation in the data. For example, the mean average cost per claimant for a
male in the 0–11 age cohort in the Eastern region is e124.28. The 10% percentile for
this cohort was e8.47 and the 90% percentile for this cohort was e192.49. In the older
age cohorts there is more pronounced variation. For example, the mean average cost
per claimant for a male in the over 75s age cohort in the Eastern region is e1,673,22.
The 10% percentile for this cohort was e217.45 and the 90% percentile for this cohort
was e3,625.64. The inter–quartile range values were also calculated, these values also
showed significant variation around the mean. Therefore, the mean values (Table 4.3)
were reduced uniformly by 5%7 for the lower bound scenario and increased uniformly
by 5%8 for the upper bound scenario.
4.5 Description of 2012 HSE–PCRS Population Database
The GMS population data for the year 2012 was sourced from the HSE–PCRS database.
The database is compiled of approximately 60 million observations. The 2012 database
denotes one observation as one prescription item. For example, if a prescription form
contains five items, this will be represented as five separate observations in the database.
The 2007 PCRS sample database is detailed per prescription form, per month and the
data was aggregated by claimant. Forty variables are quantified in this database, of
which, seven variables are specific to this research. The HSE Local Health Office (LHO)
number, year of age, sex, dispense number and total cost (ingredient cost, VAT and
dispensing fee).
7See Appendix C Table C.5 for 2012 Average cost per Claimant scenario 1.
8See Appendix C Table C.6 for 2012 Average cost per Claimant scenario 3.
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Table 4.4: Local Health Offices (LHO Codes) by Old Health Board
Region (Old
Health Board)
LHO Codes
Eastern Dublin South (1), Dublin South East (2), Dublin South City (3),
Dublin South West (4), Dublin West (5), Kildare/West Wicklow (6),
Wicklow (7), Dublin North West (10)
Dublin North Central (11), Dublin North (12)
Midlands Laois/Offaly (8), Longford/Westmeath (9)
Mid–Western Clare (21), North Tipperary/East Limerick (22), Limerick (23)
North–Eastern Cavan/Monaghan (13), Louth (14), Meath (15)
North–Western Donegal (19), Sligo/Leitrim (20)
South–Eastern Carlow/Kilkenny (29), Waterford (30), South Tipperary (31), Wexford (32)
Southern South Lee Cork (24), North Lee Cork (25), West Cork (26)
Kerry (27), North Cork (28)
Western Galway (16), Mayo (17), Roscommon (18)
4.5.1 Description of Variables
HSE LHO Number: Any person can register with their local health office (32 offices
in Ireland) to determine eligibility for the GMS scheme, (Department of Social and
Family Affairs, 2014). If successful, a person will be granted a GMS card which will
contain personal information such as name, medical card number and time period
the medical card is valid for. The LHO areas were aggregated into the old health
board regions, which this analysis is based on; Eastern, North–Western, North–Eastern,
Midlands, Mid–West, South–Eastern, Southern and Western regions. Table 4.4 details
the local health offices in each region.
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Year of Age: The data was detailed by year of age. The age at the start of the
year was taken as the age for the full year and aggregated into the relevant age cohort.
The year of age data was aggregated by each HSE age cohort (10) ranging from 0–11
to the >75s.
Sex: The data is compiled of male and female observations.
Dispense Number: A dispense number is allocated when a single medical card
is issued. If a single individual gets a medical card in January of a specific year and
doesn’t misplace it during the year, all of the individual’s prescription items for that
year will have the same dispense number. However, if a single individual gets a medical
card in January and gets one replacement card during the year, there will be two dis-
pense numbers relating to that individual’s prescription items for that year. Personal
communication from the PCRS informed the researcher that if a new medical card is
issued, a new dispense number is generated. For example, if a medical card is lost, a
new medical card is issued and a new dispense number is generated.
Total cost: Total cost is the sum of the ingredient cost, VAT on the ingredient cost,
dispensing fee and VAT on dispensing fee. The ingredient cost of a drug is comprised of
the ex–factory price and the wholesale mark–up. The wholesale mark–up is 12 per cent
for fridge items and 8 per cent for any other drug items. The retail mark–up is zero for
any items dipensed under the GMS scheme, (Brick et al., 2013). A zero per cent VAT
rate is levied on oral drugs and all other drugs are levied at the higher rate of 23 per cent.
Summary Statistics of PCRS Population database, 2012
• Mean cost per Claimant – e751.09
• Median Cost per Claimant – e210.70
• Standard Deviation – e1,323.10
• Inter–Quartile Range – e44.83 – e936
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4.6 Policy Variable: Claims Rate
The claims rate is the proportion of the GMS population who make a claim. 1,853,877
held medical cards in Ireland in 2012, of which, 1,649,950 made a claim (claims rate
= 89%). The national and regional claims rate totals were determined from the 2012
PCRS Annual Report.
In order to determine a mean claims rate by old health board region, sex and age
cohort, a weighting was calculated based on the number of eligible GMS persons in
2012. A weighted regional adjustment was applied to the estimated 2007 claims rate
data (Conway et al,. 2014) by region, sex and age cohort (Equation 4.2).
λ =
Y − Σ(w1r1........w8r8)
1.00− Σ(w1r1........w8r8)
(4.2)
Y = claims rate totals PCRS Report 2012
w = weightings of numbers covered for each region 2012
r = claims rate estimated from sample database 2007,
r = where r1 is the Eastern region and r8 is the Western region
This methodology was replicated for the eight regions. An adjustment factor (Equa-
tion 4.3) was applied to the 2007 claims rate incorporating the lambda value for each
region to calculate the 2012 claims rate, the most likely scenario (Table 4.5).
Adjustment Factor = raw rate+ λ(1.00− raw rate) (4.3)
raw rate = the estimated 2007 claims rate
λ = Lambda
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Table 4.5: Mean (Scenario 2) Claims Rate 2012
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 70–74 >75 Total
Eastern
Males 0.73 0.51 0.60 0.65 0.69 0.75 0.82 0.88 0.89 0.93 0.75
Females 0.68 0.53 0.71 0.75 0.76 0.80 0.88 0.89 0.92 0.90 0.78
Midlands
Males 0.93 0.88 0.90 0.91 0.92 0.94 0.97 0.97 0.97 0.98 0.94
Females 0.93 0.88 0.93 0.94 0.94 0.96 0.98 0.98 0.98 0.98 0.95
Mid–Western
Males 0.89 0.81 0.84 0.86 0.87 0.91 0.94 0.95 0.95 0.98 0.90
Females 0.89 0.82 0.90 0.89 0.90 0.93 0.94 0.97 0.96 0.96 0.92
North–Eastern
Males 0.82 0.74 0.77 0.79 0.81 0.87 0.89 0.93 0.91 0.93 0.85
Females 0.82 0.74 0.87 0.85 0.86 0.88 0.92 0.92 0.93 0.93 0.87
North–Western
Males 0.85 0.78 0.80 0.81 0.82 0.86 0.90 0.92 0.94 0.93 0.86
Females 0.83 0.78 0.85 0.87 0.87 0.88 0.91 0.94 0.94 0.94 0.88
South–Eastern
Males 0.85 0.76 0.78 0.80 0.83 0.87 0.92 0.94 0.92 0.95 0.86
Females 0.86 0.76 0.86 0.87 0.87 0.89 0.93 0.96 0.95 0.97 0.89
Southern
Males 0.91 0.85 0.88 0.88 0.90 0.93 0.95 0.95 0.96 0.97 0.92
Females 0.90 0.85 0.92 0.91 0.93 0.94 0.97 0.97 0.97 0.98 0.93
Western
Males 0.84 0.77 0.80 0.82 0.84 0.87 0.90 0.91 0.93 0.93 0.86
Females 0.84 0.77 0.87 0.86 0.86 0.88 0.92 0.93 0.94 0.94 0.88
Total 0.85 0.77 0.83 0.84 0.85 0.88 0.92 0.94 0.94 0.95 0.88
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A lower bound and upper bound claims rate scenarios were determined using his-
torical data. National and regional claims rate scenarios were determined between 2005
and 2012. Although annual PCRS reports are available from 1998, only annual reports
from 2005 onwards were included in this analysis. Cost of medicines data was not avail-
able in the format required prior to 2005. The minimum (lower bound) and maximum
(upper bound) national and regional claims rate were determined. The lowest national
claims rate was 88% and highest national claims rate was 96% (2007 level) and these
formed the minimum and maximum scenarios respectively. Equation 4.4 was applied
by region (8), sex (2) and age cohort (10) across 160 cells.
Claims Rate 2012 Scenario 1 = raw rate+ (raw rate ∗min rate) (4.4)
raw rate = the estimated 2012 mean claims rate
min rate = the minimum claims rate 2005–2012
The mean claims rate in 2012 was scaled by the minimum national and regional
claims rate values to determine the lower bound claims rate scenario 2012 by region,
sex and age cohort. As the maximum claims rate was 96%, 2007 claims rate from the
previous chapter was taken as the upper bound scenario. The lower and upper bound
scenarios9 were generated by region, sex and age cohort.
9See Appendix C Table C.7 for claims rate scenarios 1 & 3, 2012.
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4.7 Cost Projection Model using 2012 data
In order to project total GMS costs (Equation 4.5) through to 2026, four variables will
be used; population, GMS coverage, average cost per claimant and the claims rate.
Total Cost = f (Population,GMS Coverage,AC per Claimant,Claims Rate)
(4.5)
Population estimates and projections will be based on CSO data projections. The
most recent CSO population projections are based on Census 2011. The previous chap-
ter is based on CSO population projections, which are underpinned by Census 2006.
Coverage projections will be based on 2012 data as this is the most up to date data
available at the time of projections. Average cost per claimant and claims rate pro-
jections will be based on HSE–PCRS 2012 population data and projected in five year
intervals between 2016 through to 2026. The four variables were classified by region,
sex and age cohort. To maintain consistency and comparability with the previous pro-
jections (Chapter 3), the two HSE age cohorts (<5 and 5–11) were aggregated to form
0–11 age cohort.
For GMS coverage, an adjustment was applied to the two age cohorts based on
population weightings. Population weightings10 were established based on the total
population in 2012. For example, there is an estimated 65,673 males in the Eastern
region under five and 76,185 males between five and eleven years in 2012. The former
figure was expressed as a proportion of 141,858 (65,673 + 76,185) to give the population
weighting (0.462947) for a male, under five in the Eastern region. This method was
applied to all 8 regions by sex and age cohort. These weightings were multiplied by the
GMS coverage in 2012 for the age cohorts <5 and 5–11 and aggregated and replaced
by the age cohort 0–11. Population weightings were established and applied for 2016,
2021 and 2026. Three scenarios were developed for each variable.
10See Appendix C Table C.9 for population weightings that were applied to the coverage parameter.
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Variable 1: Population Estimates and Projections
The population of Ireland is projected to grow over the lifetime of the projection pe-
riod. The following results are based on the most likely population scenario. Figure 4.1
estimates the population of Ireland will increase from 4,586,388 in 2012 to 5,043,894 in
2026, an estimated increase of 9.98 per cent.
Figure 4.1: Estimated Population Growth 2012 – 2026
The male population is estimated to increase from 2,274,357 in 2012 to 2,489,827 in
2026, an increase of 9.47 per cent. The female population is estimated to increase from
2,312,031 in 2012 to 2,554,067 in 2026, an increase of 10.47 per cent. Female population
is increasing at a marginally faster rate than the male population, as illustrated in Fig-
ure 4.1. The updated CSO population projections (CSO, 2013) are more conservatve
than population projections (CSO, 2008). The number of old persons (65 years and
over) will see a significant increase over the lifetime of the population projections. In
2012, there are 180,872 persons between 65 and 69 years, this increases to 252,016,
an increase of 39.33 per cent in 2026. In the 70 to 74 age category there is an 60.03
per cent increase from 132,510 in 2012 to 212,050 in 2026. The >75s experience the
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largest increase over the lifetime of the projections, where the population increases from
235,122 in 2012 to 390,800 in 2026, an increase of 66.21 per cent. The >70s includes
two age cohorts; 70–74 and >75. These two age cohorts were summed together for the
purpose of this analysis. Figure 4.2 shows that the total >70 population is projected
to grow by 63.98 per cent over the lifetime of the projections.
Figure 4.2: Estimated Population Growth Over 70s, 2012 – 2026
The male population is expected to grow at a higher rate than the female>70s pop-
ulation. The male population is expected to grow by 72.20 per cent, whereas the female
population is expected to grow by 57.63 per cent between 2012 and 2026. Table 4.6
compares the CSO national population projections with the population projections
reconciled with the HSE regions using the M2F2T scenario and previous population
projections. Estimated population11 for 2012, 2016, 2021 and 2026 are classified by
sex, age cohort and region.
11See Appendix C Table C.10 for population scenario projections for 2012–2026.
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Table 4.6: Comparison of National Population Projections (M2F2T Scenario)
Year CSO Projections Current Projections
reconciled with HSE
Regions
Previous Projections -
M2F1T (Conway et al,.
2014)
2012 4,586,796 4,586,388 4,685,743
2016 4,687,000 4,686,790 5,095,004
2021 4,876,000 4,876,368 5,451,088
2026 5,044,000 5,043,894 5,696,000
Dependency Ratio
The dependency ratio (ratio of population aged >65 to the population aged 18–64)
indicates the likely impact of population aging. The dependency ratio is estimated to
increase from 0.21 in 2016, to 0.24 in 2021 and to 0.27 in 2026. The inverse (ratio of
population aged 18–64 to the population aged >65 shows those of working age who
support the older population of >65 can be more informative, (Barrett et al., 2011).
It decreases from 4.54 in 2016, to 3.95 in 2021 to 3.49 in 2026.
Regional Population Estimates and Projections
Regional population is expressed as a proportion of total national population, as illus-
trated in Figure 4.3. The Eastern region will see an increase in population over the
lifetime of the projections. The seven other regions will see a reduction in population
between 2012 and 2026. The Eastern region is projected to grow from 35.26 per cent in
2012 to 37.17 per cent of the population in 2026. This increase is at the expense of all
other regions. The Western region experiences the largest decrease over the lifetime of
the projection period from 9.60 per cent in 2012 to 9.03 per cent in 2026, as illustrated
in Figure 4.4.
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Figure 4.3: Regional Population Proportions 2012
Figure 4.4: Regional Population Proportions 2026
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Variable 2: GMS Coverage Estimates and Projections
The GMS coverage12 for 2012 was formulated by dividing the GMS population by the
total estimated population. The GMS population is the number of people who are
eligible for the medical card by region, age and sex. Figure 4.5 and Table 4.7 detail the
percentage and number of people who were eligible for the medical card between 1996
and 2012.
Figure 4.5: Percentage of Eligible GMS Persons, 1996 – 2012
Source:(Various PCRS Reports, 1996-2012)
12See Table 1.2 for the population proportion who have a GMS card by age, region and sex, 2012.
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Table 4.7: Number & Percentage of Eligible GMS Persons, 1996–2012
Year Persons Percentage Percentage
Change
1996 1,252,385 34.54
1997 1,219,852 33.32 -1.22
1998 1,183,554 31.95 -1.37
1999 1,164,187 31.09 -0.86
2000 1,148,055 30.32 -0.77
2001 1,199,454 31.24 0.92
2002 1,168,745 29.84 -1.40
2003 1,158,143 29.11 -0.73
2004 1,148,914 29.33 0.22
2005 1,155,727 29.50 0.17
2006 1,221,695 28.85 -0.65
2007 1,276,178 30.10 1.25
2008 1,352,120 31.89 1.79
2009 1,478,560 34.87 2.98
2010 1,615,809 38.11 3.24
2011 1,694,063 36.92 -1.19
2012 1,853,877 40.40 3.48
Source:(Various PCRS Reports, 1996–2012)
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Table 4.8: Coverage Scenarios 2012
Scenarios Coverage Percentage change Coverage
Scenario 1 Minimum Percentage Change Minimum
28.85 -1.40 0.986000
Scenario 2 Mean Percentage Change Mean
32.43 0.37 1.003663
Scenario 3 Maximum Percentage Change Maximum
40.40 3.48 1.034800
In order to estimate 2012 coverage rates; three scenarios were established as detailed
in Table 4.8. The minimum, mean and maximum scenarios were calculated based on
historical coverage data between 1996 and 201213. In order to determine the minimum
and maximum scenarios for 2012, the minimum and maximum percentage coverage
change was determined from the data in Table 4.7. Coverage 2012 was scaled down
by 1.40% uniformly across region, sex and age cohort to estimate coverage 2012, sce-
nario 114. In order to determine the 2012 maximum coverage scenario (scenario 3)15,
coverage 2012 was scaled up by 3.48% uniformly across region, sex and age cohort. The
mean scenario was taken as the most likely coverage rate. The three scenarios were
formulated by region, age cohort and sex. The number of eligible persons increased
from 1,352,120 in 2008 to 1,853,877 in 2012, an increase of 501,757 persons (37.11%
increase). (PCRS, 2012) reports this as the highest number of medical card holders
ever recorded in Ireland.
An adjustment factor (Equation 4.6) was applied to the 2012 coverage data. If
the >75 age cohort for each region and sex exceeded 1.00, an adjustment factor was
applied. The >75 value for each region and age cohort was scaled downwards below
13See Table 4.7 for historical GMS coverage rates between 1996 and 2012.
14See Appendix C Table C.22 for the 2012 coverage scenario 1.
15See Appendix C Table C.23 for the 2012 coverage scenario 3.
125
1.00. For example, if the projected population for the >75 in a given region is 100
but the number of projected GMS eligible persons is 103, GMS coverage rate is 1.03.
As this value exceeds 1.00, the adjustment factor below was applied to scale the value
below 1.00.
Adjustment Factor = Min(> 75− λ(1.00− 70 to 74 age cohort)) (4.6)
Coverage projections 2016 through to 2026 were based on the reference year 2012
(coverage 2012 data), as this was the most up to date data available at the time
of projections. In order to project coverage 2016, three scenarios; minimum, mean
and maximum were calculated based on the historical coverage data between 1996
and 2012 (Table 4.7). The minimum value (0.2885) was multiplied by the projected
total population for 2016 (scenario 2, the most likely population) of 4,686,790. This
generated an estimated number of eligible persons of 1,352,139. The difference between
total number of eligible persons 2012 (1,853,877) and 2016 (1,352,139) was derived and
expressed as a proportion (0.729357). This value was multiplied by coverage 2012 to
generate scenario 1 coverage 201616 by region, sex and age cohort. Coverage 2016
was multiplied by population 2016 to determine the number of eligible persons 2016
by region, sex and age cohort. Population weightings were applied to the coverage age
cohorts of <5 and 5–11 to determine the 0–11 age cohort. A 2016 population weighting
(Equation 4.7) for the <5 age cohort is expressed as follows:
Population Weighting < 5 =
68,112
68,112 + 85,993
= 0.441984 (4.7)
The population weighting for the 5 to 11 age cohort is 0.558016. The weightings
(0.441984 & 0.558016) were multiplied by the coverage rates; 0.23 and 0.30 to form the
coverage rate for the 0–11 (0.27) age cohort. The mean value (0.3243) was multiplied
16See Appendix C Table C.24 for coverage scenario 1, 2016.
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by the projected total population for 2016 (scenario 2, the most likely population) of
4,686,790. This generated an estimated number of eligible persons of 1,519,926. The dif-
ference between total number of eligible persons 2012 (1,853,877) and 2016 (1,519,926)
was derived and expressed as a proportion (0.819863). This value was multiplied by
coverage 2012 to generate scenario 2, coverage 201617 by region, sex and age cohort.
Coverage 2016 was multiplied by population 2016 to determine the number of eligible
persons 2016 by region, sex and age cohort. Population weightings were applied to the
coverage age cohorts of <5 and 5–11 to determine the 0–11 age cohort.
The maximum value (0.4040) was multiplied by the projected total population for
2016 (scenario 2, the most likely population) of 4,686,790. This generated an estimated
number of eligible persons of 1,893,463. The difference between total number of eligible
persons 2012 (1,853,877) and 2016 (1,893,463) was derived and expressed as a pro-
portion (1.021353). This value was multiplied by coverage 2012 to generate scenario
3 coverage 201618 by region, sex and age cohort. Coverage 2016 was multiplied by
population 2016 to determine the number of eligible persons 2016 by region, sex and
age cohort. Population weightings were applied to the coverage age cohorts of <5 and
5–11 to determine the 0–11 age cohort. An adjustment factor was applied to the >75
age cohort of scenario 3, 2016 as the coverage values exceeded 1.00. For the >75 age
cohort, the adjustment factor did not scale the data sufficiently below 1.00. Therefore,
0.99 coverage rates were applied uniformly across all regions and genders.
This methodology was replicated to determine coverage projections 202119 and cov-
erage projections 202620. Three scenarios were calculated for each year. 2021 and 2026
coverage projections were based on the most likely projected population of 4,876,368
and 5,043,894 respectively. An adjustment factor was applied to the 70–74 age cohort
of scenario 3, 2021 and 2026 coverage rates as the coverage values exceeded 1.00.
17See Appendix C Table C.25 for coverage scenario 2, 2016.
18See Appendix C Table C.26 for coverage scenario 3, 2016.
19See Appendix C Table C.27 for coverage scenarios 1, 2 and 3, 2021.
20See Appendix C Table C.30 for coverage scenarios 1, 2 and 3, 2026.
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Table 4.9: GMS Coverage Projections 2016–2026 based on 2012 data
Scenario Year No. of Eligible
Persons
Population Coverage (%)
Mean 2012 1,853,877 40.40
Minimum 2016 1,366,229 29.15
Mean 1,557,570 4,686,790 33.23
Maximum 2,016,889 43.03
Minimum 2021 1,512,215 31.01
Mean 1,724,002 4,876,368 35.35
Maximum 2,082,718 42.71
Minimum 2026 1,646,661 32.65
Mean 1,877,198 5,043,894 37.22
Maximum 2,345,123 46.49
For the >75 age cohort, the adjustment factor did not scale the data sufficiently below
1.00. Therefore, 0.99 coverage rates were applied uniformly across all regions and gen-
ders.
Number of eligible persons and coverage projections are presented in Table 4.9. In
Table 4.9, 2012 are actual figures and 2016 through to 2026 are projected figures. Cov-
erage rates are based on the most likely population level for each year. The most likely
coverage rate is estimated to be approximately 33.23 per cent in 2016, 35.35 per cent
in 2021 and 37.22 per cent in 2026, as illustrated in Figure 4.6. It is estimated that the
number of eligible GMS persons will lie between 1.3 million and 2.0 million in 2016, 1.5
million and 2.0 million in 2021 and 1.6 million and 2.3 million in 202621.
21See Appendix C Figure C.1 for Number of Eligible Persons updated Projections 2016 – 2026.
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Figure 4.6: GMS Coverage Projections Updated (%) 2016–2026
Variable 3: Average Cost per claimant Estimates and Projections
The four year average cost per claimant plus or minus 5% formed the basis of pro-
jections between 2016 and 2026. Average cost per claimant data was only available
between 2009 and 2012 and this was analysed for projection purposes. Historical an-
nual growth rates were calculated between 2009 and 2012. The minimum, mean and
maximum growth rates were determined over this time period by region, sex and age
cohort. The historical growth rates showed huge variation in the data across all age
cohorts during this recessionary period. Therefore, a four year average of the Irish
health inflation rate Consumer Price Index (CPI22) was determined between 2009 and
2012. There is also inflation variation year on year during this time period, as described
in Table 4.10. The four year average of 2% was applied annually to determine average
cost per claimant for 2016, 2021 and 2026 for all 3 scenarios.
22The CPI measures the overall change in the prices of goods and services of a typical basket of goods
and services every month, (CSO, 2015a).
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Table 4.10: Consumer Price Index (All items, health items)
2008 - 2012, Ireland (Base Dec2011 = 100)
Year 2008 2009 2010 2011 2012 4 year average
Health Items 92.9 96.2 96.8 100.0 100.5
Annual % Change In CPI - 3.5 0.6 3.4 0.5 2.0
Source:(CSO, 2012)
The minimum 2012 average cost per claimant (scenario 1) values by region, sex and
age cohort were uniformly increased by 2% to determine 2016 scenario 1 average cost
per claimant by region, gender and age cohort. Equation 4.8 was applied to males in 0–
11 age cohort in the Eastern region to determine the minimum (scenario 1) 2016 value
for males in the 0–11 age cohort in the Eastern region. There is a four year interval
between 2012 and 2016 so all values were compounded by 4. This methodology was
applied across all data values to estimate 2016 scenario 123, scenario 224 and scenario
325 average cost per claimant.
Min 2016 = Min2012(1 + 0.02)4 (4.8)
The minimum 2016 average cost per claimant (scenario 1) values by region, sex and
age cohort were uniformly increased by 2% to determine 2021 scenario 1 average cost
per claimant by region, gender and age cohort. Equation 4.9 was applied to males in 0–
11 age cohort in the Eastern region to determine the minimum (scenario 1) 2021 value
for males in the 0–11 age cohort in the Eastern region. There is a five year interval
between 2016 and 2021 so all values were compounded by 5. This methodology was
applied across all data values to estimate 2021 scenario 126, scenario 227 and scenario
328 average cost per claimant.
23See Appendix C Table C.33 scenario 1 average cost per claimant 2016.
24See Appendix C Table C.34 scenario 2 average cost per claimant 2016.
25See Appendix C Table C.35 scenario 3 average cost per claimant 2016.
26See Appendix C Table C.36 scenario 1 average cost per claimant 2021.
27See Appendix C Table C.37 scenario 2 average cost per claimant 2021.
28See Appendix C Table C.38 scenario 3 average cost per claimant 2021.
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Min 2021 = Min2016(1 + 0.02)5 (4.9)
The minimum 2021 average cost per claimant (scenario 1) values by region, sex and
age cohort were uniformly increased by 2% to determine 2026 scenario 1 average cost
per claimant by region, gender and age cohort. Equation 4.10 was applied to males
in 0–11 age cohort in the Eastern region to determine the minimum (scenario 1) 2026
value for males in the 0–11 age cohort in the Eastern region. There is a five year interval
between 2021 and 2026 so all values were compounded by 5. This methodology was
applied across all data values to estimate 2026 scenario 129, scenario 230 and scenario
331 average cost per claimant.
Min 2026 = Min2021(1 + 0.02)5 (4.10)
Variable 4: Claims Rate Projections
In the previous chapter, claims rate projections based on 2007 data were held con-
stant throughout the lifetime of the projections. Claims rate scenarios have been re
estimated based on 2012 data and these estimates will form the basis of projections
for 2016, 2021 and 2026. The three claims rate scenarios are to remain at 2012 levels
throughout the lifetime of the projections. The 2012 data incorporates policy changes
implemented as a result of the economic crisis beginning in 2008. The recession and
subsequent bailout put pressure on public health spending and various revenue raising
measures were introduced across the community drug schemes, including the GMS.
The Department of Health introduced a prescription charge, a 50 cent charge per pre-
scription item for all GMS card holders on the 1st of October 2010.
29See Appendix C Table C.39 scenario 1 average cost per claimant 2026.
30See Appendix C Table C.40 scenario 2 average cost per claimant 2026.
31See Appendix C Table C.41 scenario 3 average cost per claimant 2026.
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4.8 Monte Carlo Simulation Model
A MCS model was employed due to the uncertainty around the input parameters. MCS
was employed to propagate the parameter uncertainty through 100,000 iterations. The
MCS model identifies uncertain variables and an uncertain function. The uncertain
variables are population, coverage, claims rate and average cost per claimant. Each
uncertain variable has age cohorts (10), sex (2) and regions (8) giving a total of 160
cells to be modelled for each variable. The dependent variable is the projected total
cost for 2016, 2021 and 2026. In order to prepare the data for Monte Carlo Simulations,
the probability and cumulative probability of finding a person within each region, sex
and age cohort (RSA) class were calculated.
The probability is the empirical probability (proportion) calculated by the quotient
of class members over count of all members, which lies between 0 and 1. The cumulative
probabilities were calculated, which gave a weight of occurrence within a particular
class (RSA). A macro was written in Visual Basic Editor in Microsoft Excel to run
the simulations. A Normal distribution was applied to estimate costs to allow for
uncertainty in the model. The Central Limit Theorem can be applied, which states
that the sum of random variables (4 variables) will be approximately distributed, (Bain
and Engelherdt, 1991). The MCS results were imported into Minitab for analysis. All
statistical analyses were performed using Minitab statistical package (Minitab 17).
4.9 Descriptive and Statistical Analysis
Table 4.11 details the projected total pharmacy cost is expected to lie between e869
million and e1.68 billion in 2016, e1.27 billion and e2.07 billion in 2021 and e1.47
billion and e2.47 billion in 2026.
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Table 4.11: Comparison Conway et al (2014) Previous Projections with cur-
rent GMS Cost (eM) projections, 2012 – 2026, Scenarios 1 – 3
Year Scenario 1 (e) Scenario 2 (e) Scenario 3 (e)
2016 644 869 1,317 1,111 2,150 1,678
2021 703 1,272 1,626 1,435 2,876 2,075
2026 742 1,474 1,985 1,837 3,672 2,466
The most likely scenario (scenario 2) projects total pharmacy cost will be e1.11
billion in 2016, e1.43 billion in 2021 and e1.84 billion in 2026. The cost projections
are subject to assumptions around the four variables. Comparing these total pharmacy
cost estimates with the previous chapter projections based on 2007 data, this set of
projections are tighter around the mean scenario estimates, as illustrated in Figure 4.7.
Figure 4.7: Total Pharmacy Cost(eM) Estimates and Projections 2012–2026
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The range is not as large as previous projections between scenario 1 and scenario 3
estimates. For example, the 2007 based projections lie between e644 million and e2.15
billion in 2016, e703 million and e2.88 billion in 2021 and e742 million and e3.67 bil-
lion in 2026. The most recent cost projections in Table 4.11 are based on the most up
to date CSO population projections, which are more conservative than the population
projections used in the previous chapter. This contributed to more conservative GMS
cost projections compared to previous projections.
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Table 4.12: Descriptive Analysis of Average Cost per Claimant (e) 2016–2026
(Scenario 2)
Year ] of Simulations Mean St.Dev Min Q1 Median Q3 Max
2016 100,000 249.96 348.24 21.25 46.02 106.22 253.43 1573.57
2021 100,000 307.45 418.28 24.58 53.49 131.46 317.64 1806.92
2026 100,000 384.13 508.22 28.14 62.34 166.06 384.36 2063.84
4.9.1 Descriptive Analysis
The descriptive analysis of 100,000 simulations for 2016, 2021 and 2026 is detailed in
Table 4.12. These results reflect the most likely scenario (scenario 2). There is consid-
erable variation in the cost results with 25% of the data lying below e46.02 and 75%
of the data lying above e253.43 in 2016. Q1 increases to e53.49 in 2021 and e62.34
in 2026, while Q3 is estimated as e317.64 in 2021 and e384.36 in 2026. The average
cost per claimant is estimated to be e249.96 in 2016, e307.45 in 2021 and e384.13 in
2026. The median is estimated to be e106.22 in 2016, e131.46 in 2021 and e166.06 in
2026. The variation in the minimum and maximum cost values indicate the difference
between claimants in 2012. For example, the lowest average cost per claimant is e21.25
and the highest average cost per claimant is e1,573.57. This variation is also evident
in 2021 and 2026. Figure 4.8 quantifies the proportion of cost in each old health board
region.
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Figure 4.8: Pie Chart of Cost (e), Scenario 2 2016
35.7% of cost can be attributed to the Eastern region, 14.4% to the Southern region,
10.8% to the South–Eastern region, 9.6% to the North–Eastern region, 9.5% to the
Midlands region, 8.1% to the Mid–Western region, 6.3% to the Midlands region and
5.6% to the North–Western region. A similar picture is estimated for 202132 and 202633.
4.9.2 Statistical Analysis
The histogram plots the distribution of cost with a higher frequency of claimants having
a lower average cost per claimant and a lower frequency having a higher average cost
per claimant, as illustrated in Figure 4.9.
32See Appendix C Figure C.2 Pie Chart of Cost (e), Scenario 2 2021
33See Appendix C Figure C.3 Pie Chart of Cost (e), Scenario 2 2026
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Figure 4.9: Histogram of Cost (e), Scenario 2 2016
The histogram reiterates the descriptive analysis in Table 4.12, there is significant
variation in cost with the lowest claim of e21.25 and the highest claim of e1,573.57
in 2016. The estimated distribution and frequency of cost shows a similar picture for
2021 and 202634.
Interval Plot of Cost by Region, Sex and Age Cohort
In Figure 4.10, one can be 95% confident that the average cost for a claimant in the
Midlands region is e300 and approximately e200 for a claimant living in the Eastern
region in 2016.
34See Appendix C Figure C.4 Histogram of Cost 2021 & 2026
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Figure 4.10: Interval Plot of Cost by Region, Scenario 2 2016
The average cost for a claimant living in the remaining six regions lies between e200
and e300. In 202135, the projections show one can be 95% confident that the average
cost for a claimant in the South–Eastern region is e375 and approximately e225 for
a claimant living in the Eastern region. In 202636, the projections show one can be
95% confident that the average cost for a claimant in the Midlands region is e475 and
approximately e300 for a claimant living in the Eastern region.
In 2016, one can be 95% confident that the average cost per claimant lies between
e1,300 and e1,400 for the 0–11 age group, lies between e700 and e800 for the 70–74
age group and between e1,100 and e1,200 for the over 75s, as illustrated in Figure 4.11.
35See Appendix C Figure C.6 Interval Plot of Cost by Region, Scenario 2 2021
36See Appendix C Figure C.7 Interval Plot of Cost by Region, Scenario 2 2026
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Figure 4.11: Interval Plot of Cost by Age Cohort, Scenario 2 2016
Estimates for these high cost groups continue for 2021 and 2026. In 202137, one can
be 95% confident that the average cost per claimant lies between e1,500 and e1,600 for
the 0–11 age group, lies between e700 and e800 for the 70–74 age group and between
e1,200 and e1,300 for the >75s. In 202638, one can be 95% confident that the average
cost per claimant will be approximately e1,750 for the 0–11 age group, lies between
e800 and e1,000 for the 70–74 age group and approximately e1,500 for the >75s.
In 2016, one can be 95% confident that the average cost per claimant lies between
e270 and e280 for a female and between e225 and e230 for a male, as illustrated in
Figure 4.12.
37See Appendix C Figure C.8 Interval Plot of Cost by Age Cohort, Scenario 2 2021
38See Appendix C Figure C.9 Interval Plot of Cost by Age Cohort, Scenario 2 2026
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Figure 4.12: Interval Plot of Cost by Sex, Scenario 2 2016
In 202139, one can be 95% confident the average cost per claimant increases to
between e330 and e340 for females and between e280 and e290 for males. One can
be 95% confident, the average cost per claimant increases to between e415 and e425
for females and between e345 and e355 for males in 202640. In Figure 4.13, the Main
Effects Plot examines the differences between the three variables; old health board re-
gion, sex and age cohort.
39See Appendix C Figure C.10 Interval Plot of Cost by Sex, Scenario 2 2021
40See Appendix C Figure C.11 Interval Plot of Cost by Sex, Scenario 2 2026
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Figure 4.13: Main Effects Plot, Scenario 2 2016
A Main Effects Plot is used to examine differences between level means for one
or more factors. There is a main effect when different levels of a factor affect the
response differently. A Main Effects Plot graphs the response mean for each factor;
old health board region, sex and age cohort. Sex is showing no main effect with 6 of
the 8 old health board regions showing some effect; Mid–Western, Midlands, North–
Western, South–Eastern, Southern and Western regions. Age cohorts show the greatest
response, especially <11s, 65–69 and the >70s. These three age cohorts were further
analysed. Figure 4.14 shows that males, Mid–Western and South–Eastern regions are
driving costs in the <11s age group.
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Figure 4.14: Main Effects Plot 0–11, Scenario 2 2016
These results were also found in 202641. However, the projected results for scenario
2, 2021 show a different picture. Females in the North–West and South–Eastern regions
are driving the average cost per claimant for the age cohort 0–1142 in said regions. In
Figure 4.15, females, the Midlands and Southern regions are driving costs in the >70s
in 2016. These results were also found in 202643. Females and alternativley the Mid–
Western and South–Eastern regions are driving average costs per claimant in 202144.
41See Appendix C Figure C.12 Main Effects Plot 0–11, Scenario 2 2026.
42See Appendix C Figure C.13 Main Effects Plot 0–11, Scenario 2 2021.
43See Appendix C Figure C.14 Main Effects Plot >70, Scenario 2 2026.
44See Appendix C Figure C.15 Main Effects Plot >70, Scenario 2 2021.
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Figure 4.15: Main Effects Plot >70, Scenario 2 2016
Average cost per claimant (e) by sex and region, Scenario 1–Scenario 3
The average cost per claimant scenarios 1, 2 and 3 are illustrated in Figure 4.16.
The Midlands and the Southern regions are the most expensive regions and the Eastern
and Western regions are the least expensive regions for all three scenarios. Females are
driving costs more than males for all three scenarios. The <11s and the older age
cohorts are driving costs for all three scenarios. Similar trends were found for sex and
age in 2021 and 2026. In 202145 and 202646, the South–Eastern and the Midlands
regions are estimated to be the most expensive regions, while the Eastern and North–
Eastern regions are estimated to be the least expensive regions.
45See Appendix C Figure C.16 Average cost per Claimant (e) by old health board region, sex & Age
cohort, Scenario 1 - Scenario 3 2021.
46See Appendix C Figure C.17 Average cost per Claimant (e) by old health board region, sex & Age
cohort, Scenario 1 - Scenario 3 2026.
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4.10 Discussion
In this chapter, the factors influencing GMS costs were identified. These include growth
in the overall population, growth in the proportion over 70, age, gender and region.
Irish population is projected to grow by approximately 10% between 2012 and 2026.
The over 70s population is estimated to grow by 64% with males over 70 estimated to
grow by 72% over the projection period. An aging population will significantly con-
tribute to overall GMS costs and has the potential to cause an increase in GMS coverage
rates, claims rates and average cost per claimant. According to a WHO report, a key
driver of health care costs is growth in the overall size of the population. Population
aging is also a driver of health care costs, but not to the same extent, (Thomson et al.,
2014).
(Barrett et al., 2011) reported in an Irish study on aging, that the dependency ratio
was 0.18 in 2011 rising to 0.23 in 2021. This research shows similar estimates for 2021,
with a dependency ratio of 0.24. (Barrett et al., 2011) argued the inverse of the de-
pendency ratio was more informative and they estimated a value of 5.7 in 2011 falling
to 4.4 in 2021. In this research, the inverse is estimated to be 3.95 in 2021. An aging
population, leading to an increased dependency ratio, will put financial pressures on
future health costs.
The current GMS cost projections are more conservative than the previous projec-
tions. (Conway et al., 2014) estimate GMS cost projections will rise to e1.3 billion in
2016, e1.6 billion in 2021 and e2 billion in 2026. The updated research estimated GMS
cost projections will rise to e1.1 billion in 2016, e1.4 billion in 2021 and e1.8 billion
in 2026. The updated projections are more conservative because, the 2012 health data
includes cost containment measures and the CSO population projections are based on
lower expected fertility rates.
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(Conway et al., 2014) found that females, age (<11 & >70) and the Midlands re-
gion were driving GMS costs out to 2026. The updated research confirms those findings
and contributes the following; males, the Mid–Western and South–Eastern regions are
driving GMS costs in the under 11s in 2016 and 2026. Females, Midlands and Southern
regions are driving GMS costs in the over 70s in 2016 and 2026. However, females,
North–Eastern and South–Eastern are estimated to drive GMS costs in the under 11s
in 2021. Females, Mid–Western and South–Eastern regions are estimated to drive GMS
costs in the over 70s in 2021.
The updated results show that younger male children (<11) are a driver of GMS
costs in Ireland. This may be explained by a higher incidence of drug prescribing
amongst male children. An Irish study investigating prescribing antibiotics trends in
a paediatric sub–population found that male participants (0–4 age cohort) were more
likely to receive an antibiotic prescription than female participants, (Keogh et al., 2012).
A Spanish study examined how gender and age influenced prescription drug use and
found a higher prevalence of prescription drugs in males aged 0–4 and 5 to 14 years of
age, (Ferna´ndez-Liz et al., 2008). A Swedish study found more drugs were dispensed
amongst males under 10 years, (Loikas et al., 2013).
In 2011, a new government was formed in Ireland with an objective of implementing
a single–tier health service through the introduction of universal health insurance with
free medical care for all, (Government of Ireland, 2011). In Budget 2015, the Irish
government partially met this objective, by announcing free General Practitioner (GP)
care for all children under 6 years of age. As this is one of the most expensive age
groups, the Irish government may have been better advised to implement this policy
in a less expensive age group, such as adolescents, as a pilot measure.
Females over 70 years are driving GMS costs in Ireland. In Spain (Ferna´ndez-Liz
et al., 2008), Sweden (Loikas et al., 2013) and British Colombia (Morgan, 2006), there
is a higher incidence of prescribing amongst females compared to males. (Morgan,
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2006), found that population aging only explained 1 point of the observed annual drug
expenditure growth. The drug expenditure growth is largely explained by the increase
in the age/sex specific numbers of prescriptions filled per patient and mix of products
selected per prescription.
The Midlands region is the most expensive region and the Eastern region is the
least expensive region for GMS costs. Upon further investigation at age cohort level,
GMS costs differ across the eight regions. The Mid–Western and South–Eastern are
the most expensive regions for the under 11s , the Midlands for the over 70s and the
Eastern region is the least expensive region for both age cohorts. A high prevalence of
chronic conditions in the Midlands region (Naughton et al., 2006) coupled with (Usher
et al., 2005) findings, that the Midlands and the Mid–Western regions had the highest
prescribing rates for type 1 and type 2 diabetes may explain high GMS expenditure in
this region.
In terms of policies on cost containment, in November 2012, a three year agreement
was formulated between IPHA, the Department of Health and the HSE. The agreement
applies to medicines prescribed and reimbursed on the community drugs scheme, includ-
ing the GMS. This agreement led to reductions in the cost of in–patent and off–patent
pharmaceuticals, (IPHA, 2012). It was widely reported that this agreement would yield
over e400 million for the Irish state over three years. The Irish government estimated
e16 million in drug savings in 2012 across all community drug schemes47, e116 million
in 2013, e136 million in 2014 and e150 million in 2015, (Oireachtas, 2012a). According
to a recent WHO report (Nolan et al., 2015), the agreement resulted in actual savings
of e190 million. In 2013, a number of cost containment measures were introduced.
GMS eligibility income criteria were lowered, co–payment charges were increased and
new legislation was enacted on reference pricing and generic substitution. These policy
changes will reduce future GMS expenditure.
47Minister for Health, James Reilly stated a breakdown in projected savings was not available by
community drug scheme.
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Limitation
The researcher investigated the possibility of developing estimates of the variables
by the current regional HSE structure, which incorporates four regions (Dublin Mid–
Leinster, Dublin North–East, West & South). However, this was not possible for the
population variable48. Further research investigating the 2013 policy changes on future
GMS expenditure would be very useful.
4.11 Conclusion
Growth in population and population aging will contribute to future GMS expenditure
growth through the channels of increased average cost per claimant, GMS coverage
and claims rates. However, cost containment measures; co–payment charges, generic
substitution, reference pricing and GMS eligibility criteria can decelerate the pace of
GMS expenditure growth. Co–payment charges are likely to reduce claims rates. Ref-
erence pricing and generic substitution are likely to reduce average cost per claimant
and eligibility criteria will lower GMS coverage rates. These projections are condi-
tional upon the assumptions and data on which the model is built and remain subject
to substantial uncertainty. The health sector in Ireland has a rapidly changing policy
environment and this research went in some way to address these changes given the
data that were available. The next chapter will identify the factors that are influencing
GMS prescribing expenditure, using the population 2012 HSE–PCRS database.
48Personal Communication: with a CSO population Statistician and I was advised that the popu-
lation data was only available by county but I required further disaggregation. For example, North
Tipperary resides in HSE West and South Tipperary resides in HSE South. Therefore the research was
based on the 8 old health board regions when further disaggregation was not available.
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Chapter 5
Factors influencing the variation
in GMS prescribing expenditure
in Ireland
5.1 Introduction
This chapter investigates the composition and drivers of GMS drug expenditure in Ire-
land in 2012. Pharmaceutical expenditure is a considerable and growing cost to the
health care system in many EU countries, including Ireland. Pharmaceutical expendi-
ture growth is not a recent phenomenon but has been growing faster than GDP in all
European countries since the 1980s, (Ess et al., 2003). Therefore, it is important to
explain the factors that are influencing this expenditure to ensure the sustainability of
the Irish health care system. A knowledge of pharmaceutical expenditure trends would
aid policy makers in decisions around limited resource allocation, optimum budget al-
location, and future policy decisions.
The GMS is a community drug scheme in Ireland, where eligible persons are entitled
to free medication and appliances. The GMS scheme is means tested and eligibility is
based on income. In July 2001, all persons over 70 were granted a free medical card.
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Due to the economic crisis, eligibility criteria were introduced on the 1st of January
2009, where all persons over 70 are means tested. GMS prescription expenditure rose
rapidly after 2000, as illustrated in Figure 5.1.
Figure 5.1: Total Cost (eM) of GMS Prescriptions between 1998–2012
Source:(Various PCRS Annual Reports, 1998-2012)
The total cost of GMS prescriptions has increased from e249 million in 1998 to
e1.24 billion in 2009, this represents a 400% increase between 1998 and 2009. The
total cost of GMS prescriptions decreased in 2010 and 2011 before increasing again to
e1.28 billion in 2012. These reductions may be explained by reductions in the health
budget. Overall, the total cost of prescriptions increased by 414% between 1998 and
2012. During this time, GMS coverage rates increased from 34.54% of the population
in 1998 to 40.40% in 2012. GMS coverage refers to the proportion of the population
who have a medical card.
The government has introduced cost containment measures during the economic
crisis to combat this trend, such as co–payment charges, GMS eligibility criteria, refer-
ence pricing and generic substitution, (Nolan et al., 2015). Co–payment charges have
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been increased on a phased basis since 2010. In 2010, a 50 cent per item was introduced,
this increased to e1.50 in 2013 and to e2.50 in 2014. Reference pricing and generic
substitution legislation was passed in 2013 with the objective of increasing the usage of
generics and reduce the price of interchangeable pharmaceuticals, (Government of Ire-
land, 2013). Despite these cost containment measures, Irish pharmaceutical spending
per capita as a share of GDP in 2012 was the third highest amongst 25 EU countries
at e500, 40% above the EU average (e350). Belgium had the highest spend per capita
at e550 and Denmark had the lowest spend per capita at e195, (OECD, 2014).
According to (Gorecki et al., 2012), approximately 14% of public health expenditure
is spent on pharmaceuticals in Ireland. Public expenditure on health peaked in 2009
at e15.5 billion and decreased by 11% between 2009 and 2014, as shown in Figure 5.2,
(Nolan et al., 2015).
Figure 5.2: Public Expenditure on Health (eBn) in Ireland between 2006–2014
e – estimate Source:(Nolan et al, 2015)
In Table 5.1, Ireland spent 14% of total government expenditure on health, which
is comparable with the EU28 average. The Netherlands had the highest proportion at
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Table 5.1: Health Expenditure as a share of total Government Expenditure 2012
EU28 % of Total
Gov Exp
EU28 % of Total
Gov Exp
Netherlands 20% EU28 14%
Germany 19% Luxembourg 14%
Austria 16% Portugal 13%
United Kingdom 16% Malta 13%
France 16% Croatia 13%
Denmark 16% Romania 12%
Slovak Republic 15% Lithuania 12%
Sweden 15% Finland 12%
Belgium 15% Estonia 12%
Czech Republic 14% Bulgaria 12%
Ireland 14% Greece 12%
Italy 14% Poland 11%
Spain 14% Hungary 10%
Slovenia 14% Latvia 9%
Cyprus 8%
Source:(OECD, 2014)
20% and Cyprus had the lowest proportion at 8%. Irish health spending accounted for
8.9% of GDP, just above the EU28 average of 8.7%, (OECD, 2014).
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Netherlands recorded the highest health expenditure as a percentage of GDP (11.8%)
and Romania recorded the lowest (5.6%), as illustrated in Figure 5.3, (OECD, 2014).
Figure 5.3: Health Expenditure as a share of GDP (%), 2012
Source:(OECD, 2014)
Irish pharmaceutical expenditure per capita relative to other OECD countries has
increased significantly since 2000. The threefold increase in the cost of GMS medicines
contributed to this increase, as shown in Figure 1.1 (Chapter 1). Ireland’s position has
moved from 20th highest of 27 countries in 2000 to 3rd highest of 25 countries in 2010.
Irish per capita spending on pharmaceuticals was the highest in the EU and was 34%
above the EU average in 2010, as reported by (Brick et al., 2013). (Conway et al.,
2014) projected GMS costs for Ireland in five year intervals to 2026. This study found
GMS expenditure is expected to rise to e2 billion by 2026. There are fourteen ATC
groups as specified in Table 5.2.
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Since 1998, between 67% and 70% of total annual GMS expenditure has been ac-
counted for, by four of the ATC groups; Nervous (N) system, Cardiovascular (C) sys-
tem, Alimentary Tract and Metabolism (A) system and Respiratory (R) system, as
detailed in Table 5.3 (Various Annual PCRS Reports). In 1998, the sum of the four
ATC groups (N, C, A & R) was e136 million of total GMS expenditure (14 ATC
groups) e203 million (67%) (PCRS, 2008), this peaked in 2010 at e848 million of a
total GMS expenditure of e1.2 billion (70%). In 2012, e872 million of total GMS
expenditure (e1.29 billion) was recorded across the four ATC groups equating to 68%
of GMS expenditure, (PCRS, 2012). Given the rise in GMS expenditure, the objec-
tive of this research is to investigate the significant drivers of GMS expenditure, whilst
controlling for age, gender, regional disparities, and the ATC groups.
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Table 5.3: GMS ATC Expenditure(eM) 1998–2012
Year A C N R Total GMS
Cost
Total GMS
Cost
% Total
(4 ATC
Groups)
(14 ATC
Groups)
1998 31.34 42.76 38.67 23.39 136.16 203.15 67%
1999 35.72 48.37 44.34 25.44 153.87 229.30 67%
2000 42.07 57.07 52.66 28.07 179.87 266.83 67%
2001 67.71 93.46 87.10 43.58 291.85 434.02 67%
2002 84.55 121.59 111.12 52.00 369.26 550.90 67%
2003 50.26 72.87 48.69 38.65 210.47 315.83 67%
2004 114.93 178.90 150.83 68.21 512.87 763.32 67%
2005 126.64 200.68 164.84 74.44 566.60 831.44 68%
2006 142.82 228.67 187.98 83.92 643.39 940.22 68%
2007 161.19 250.85 215.04 94.29 721.37 1,048.40 69%
2008 177.09 269.76 237.95 102.45 787.25 1,145.29 69%
2009 194.94 291.07 268.53 117.19 871.73 1,260.25 69%
2010 183.40 276.68 272.50 115.01 847.59 1,207.34 70%
2011 169.87 245.10 289.18 113.35 817.50 1,207.34 68%
2012 172.76 239.06 302.85 115.34 830.01 1,224.87 67%
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
Source:(PCRS Annual Reports 1998–2012)
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5.2 Methodology
5.2.1 Study Population
A cross-sectional study was carried out on the Irish HSE–PCRS pharmacy claims
database for the year 2012. The data is detailed per prescription item (observation) and
each GMS claimant is identified by a unique dispense number. This number identifies
the number of items each GMS claimant has been prescribed in that particular year.
There are approximately 60 million observations in the database and following aggre-
gation by GMS claimant, one observation was created per GMS claimant. There are
1,630,775 GMS claimants in the population database. There are forty variables in this
database, of which seven are pertinent to this research. These include demographic in-
formation (age, sex, region), cost data (ingredient cost, VAT, dispensing fees) and ATC
group. For the purpose of this analysis, total cost is the sum of ingredient cost, VAT
and dispensing fees. These variables were described in the previous chapter (Chapter 4).
The ATC code on the first level of the ATC classification system is used throughout
this study. In the ATC classification system, the active substances are divided into
different groups according to the organ or system on which they act and their ther-
apeutic, pharmacological and chemical properties. Drugs are classified in groups at
five different levels. The drugs are divided into fourteen main groups (1st level), with
pharmacological/therapeutic subgroups (2nd level). Prescribing data is coded using the
World Health Organisation (WHO1) ATC classification system, (WHO, 2007).
The data were analysed by the four HSE regions; Dublin Mid–Leinster (ML), Dublin
North–East (NE), West and South. The West has the largest number of GMS eligible
persons in 2012 with 501,055 persons (27%), followed by the South with 498,597 persons
(27%), Dublin ML wth 463,481 persons (25%) and Dublin NE with 390,744 (21%),
(PCRS, 2012). Analysing the data at LHO level was considered, but a number of GMS
1The WHO primary role is to direct and co–ordinate international health within the United Nations
system, (WHO, 2015).
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claimants were found claiming from different LHOs therefore not providing an accurate
individual total cost in one single location. Data is available by year of age and was
aggregated into the eleven HSE age cohorts; <5s, 5–11, 12–15, 16–24, 25–34, 35–44,
45–54, 55–64, 65–69, 70–74 and the >75s. Data management and analysis was carried
out in SPSS 22 and Microsoft Excel.
5.2.2 Empirical Model
The dependent variable is the log of annual pharmaceutical expenditure by GMS
claimant for all models. The log of total cost was used as the cost data is positively
skewed (Skewness = 16.140). A log transformation was applied to normalise the data
and this approach has been previously used by, (Powers et al., 2005) and (Aguado et al.,
2008). Three models were developed to investigate the association between the total
GMS cost per claimant and the independent variables. The first model (Equation 5.1)
estimated the impact on the log of annual total cost per claimant using OLS regression
whilst controlling for age, sex, and HSE region (3 levels – 1 Dublin ML, 2 Dublin NE,
3 South). The square and cube of age (age2 and age3) were considered as age has
a non–linear relationship with the Log of total cost2. The inclusion of these two vari-
ables did not add to the explanatory power of the model, so they were excluded. The
reference categories were, Dublin NE, Males, 12–15 age group and the ATC group ‘R’
as these were the least expensive in their respective categories.
Yi = β0 + β1X1 + β2X2 + β3X3 + β4X4 + β5X5 + i (5.1)
Yi = Log of Total Cost
β0 = Y intercept, the constant of the model
X1 = Age
X2 = Sex (F)
X3 = Dublin ML
X4 = West
2See Appendix F Figure F.1 for the Log of Total Cost, which shows that age is not linear with cost.
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X5 = South
β = is the coefficient corresponding to each independent variable
ei = error term
The second model (Equation 5.2) included eight independent variables. It included
the five demographic variables from model 1 and the three ATC groups, ‘N’, ‘C’ and
‘A’. The impact of the independent variables on the log of total cost was estimated.
Yi = β0 + β1X1 + β2X2 + β3X3 + β4X4 + β5X5 + ......+ β8X8 + i (5.2)
Yi = Log of Total Cost
β0 = Y intercept, the constant of the model
X1 = Age
X2 = Sex (F)
X3 = Dublin ML
X4 = West
X5 = South
X6 = Alimentary Tract & Metabolism
X7 = Cardiovascular
X8 = Nervous
β = is the coefficient corresponding to each independent variable
ei = error term
The third model (Equation 5.3) included 17 independent variables. The year of age
variable is replaced by ten dummy variables for age cohort and the ATC groups and
demogrpahic variables (regions and sex) are retained.
159
Yi = β0 + β1X1 + β2X2 + β3X3 + β4X4 + β5X5 + ......+ β17X17 + i (5.3)
Yi = Log of Total Cost
β0 = Y intercept, the constant of the model
X1 = Sex (F)
X2 = Dublin ML
X3 = West
X4 = South
X5 = Alimentary Tract & Metabolism
X6 = Cardiovascular
X7 = Nervous
X8–X17 = 10 Age Cohorts
β = is the coefficient corresponding to each independent variable
ei = error term
Assumptions of Multiple Regression
The models were estimated by OLS regression. OLS estimates the parameters
(B -values) associated with each predictor variable. The differences between what the
model predicts (predicted values) and the observed values is known as residuals. The
assumptions of multiple regression can be checked from the residuals output, (Field,
2012). The residuals were tested for normality, homoscedasticity and linearity for each
of the three models, (Pallant, 2007). Normality can be checked by inspecting the His-
togram3 of the dependent variable (Log of Total Cost). The residuals are normally
distributed around the dependent variable.
3See Appendix F Figure F.2 for the Histogram of the dependent variable for model 1, model 2
(Figure F.3) and model 3 (Figure F.4).
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Linearity can be checked by inspecting the Normality Probability Plot4. In the
Normal Probability Plot, the points are lying in a relatively straight line from bot-
tom left to top right, indicating no major deviations from normality, (Pallant, 2007).
Homoscedasticity can be checked by inspecting the Scatterplot5 of the standardised
residuals.
Multicollinearity is the relationship between the independent variables of the model
that exists, when the independent vaiables are highly correlated (r=0.9). Multicollinear-
ity can be checked using the correlations output of the model. This output also checks
for the relationship between the independent variables and dependent variable with a
correlation coefficient of 0.3 or above. Collinearity Diagnostics including the Variance
Inflation Factor (VIF) and Tolerance factors were obtained to test for Multicollinear-
ity. Tolerance produces output values for each independent variable and shows how
much of the variability of one independent variable is not explained by the other inde-
pendent variables in the model. If the Tolerance values are less than 0.1, it indicates
multicollinearity exists. The VIF is the inverse of the Tolerance value and if the val-
ues exceed 10, multicollinearity is evident. The Tolerance values for models 1 to 3 in
this study are greater than 0.1 and VIF values are less than 10, indicating the multi-
collinearity assumption is not violated, (Pallant, 2007).
Outliers were checked by inspecting Mahalanobis and Cook’s Distances. Cook’s
Distance and leverage (Mahalanobis Distance) measure the influence of outliers on a
model and determines the influence of the observed value of the outcome variable over
the predicted values, (Field, 2012). In order to identify outliers, a critical chi–square
value was determined. The number of independent variables determines the critical
value. In model 1, there are 5 independent variables, therefore the critical value is
20.52, (VassarStats: Website for Statistical Computation, 2015). From the residuals
4See Appendix F Figure F.5 for the Normality Probability Plot for model 1, model 2 and model 3.
The linearity plot is the same for the 3 models, so one visual is in Appendix F.
5See Appendix F Figure F.6 for the Scatterplot for model 1, model 2 (Figure F.7) and model 3
(Figure F.8).
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output table, the maximum Mahalanobis distance value is 11.589, which is less than
the critical value of 20.52.
In model 2, there are 8 independent variables and the critical value is 26.12, (Vas-
sarStats: Website for Statistical Computation, 2015). The maximum Mahalanobis
distance value is 27.387, which exceeds the critical value of 26.12 slighlty. In model 3,
there are 17 independent variables and the critical value is 40.80, (VassarStats: Web-
site for Statistical Computation, 2015). The maximum Mahalanobis distance value is
39.067 , which is less than the critical value of 40.80. The Cook’s Distance identifies if
any of the outliers have any undue influence on the model. If the maximum value for
Cook’s Distances is greater than 1, this suggests outliers may influence the model, (Pal-
lant, 2007). For all three models, the maximum value for Cook’s Distances is less than 1.
The Casewise Diagnostics present information on standardised residual values above
3.0 or below -3.0. In a normally distributed dataset, one would expect 1% of cases to
fall outside this range, (Pallant, 2007). In model 1, 8,373 cases of 1,630,775 were outside
this range and is less than 1% of GMS claimants (0.5%). Therefore, the outliers will
have a relatively small impact on the model. Both model 2 (7,175 cases, 0.4%) and
model 3 (8,734 cases, 0.53%) have less than 1% of total GMS claimants. Statistical
significance was reported at the 0.05 level.
5.3 Population Results – Descriptive Statistics
This section reports the descriptive statistics of the population HSE–PCRS database
of 60 million observations. The results are reported by sex, region, age cohort, ATC
group and average cost per claimant. In each subsection, results are initially reported
as a proportion of total GMS expenditure (14 ATC groups) and subsequently reported
by GMS expenditure (4 ATC groups – N, C, A & R). With reference to the ATC
groups, 52% were prescribed an ‘N’ prescription item, 45% an ‘A’ prescription item,
39% an ‘R’ prescription item and 36% a ‘C’ prescription item. Of all GMS claimants,
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316,950 (19%) are not prescribed any ATC (N, C, A, R) item and they account for
approximately e19 million of total cost and they determine an average cost of e60.82
per GMS claimant. The following descriptive analysis will be based on the remaining
GMS claimants (1,313,825), who were prescribed an ‘N’, ‘C’, ‘A’ or ‘R’ prescription
item.
Table 5.4 reports the summary descriptive statistics of 1.63 million GMS claimants.
The average cost of a GMS claimant is e751.09 and the mean cost varies, depending
on the variable. The mean cost increases with age cohort, with the over 75s having the
highest mean cost per claimant (e1,686). A number of variables have a minimum cost
of e3.27, which is a non–dispensing fee. A pharmacist receives a non–dispensing fee
when a GMS claimant presents a prescription form of three items and they only require
two items on the form. The pharmacist will receive a non–dispensing fee for the third
item. The maximum cost of e298,167 indicates the GMS claimant was male, residing
in the Dublin NE region and in the 45 to 54 age group.
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Table 5.5: 2012 GMS Prescription Expenditure (eM) by ATC Group & Sex
ATC
Group
Female Male GMS Prescription
Cost (e)
% of Total GMS
Prescription Cost
N 178.02 (59%) 124.82 (41%) 302.85 25%
C 125.31 (52%) 113.75 (48%) 239.06 20%
A 96.23 (56%) 76.53 (44%) 172.76 14%
R 62.80 (54%) 52.54 (46%) 115.34 9%
Total (e) 462.37 367.64 830.01 68%
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
5.3.1 Total Cost by ATC Group & Sex
In 2012, 56% (e687m) of total GMS expenditure was accounted for by females and
44% (e538m) was accounted for males. There is variation by ATC groups amongst
females and males. In Table 5.5, the ATC group ‘N’ accounted for 25% (e303m)
of total GMS cost (e1.225bn), ‘C’ accounted for 20% (e239m), ‘A’ accounted for
14% (e173m) and ‘R’ accounted for 9% (e115m). At the extremes, 59% (e178m)
of the nervous system expenditure is accounted for by females and 41% (e125m) by
males, whereas 52% (e125m) of cardiovascular expenditure is accounted by females and
48% (e114m) by males. Whereas, 56% (e96m) of the alimentary & tract metabolism
system expenditure is accounted for by females and 44% (e86m) by males, whereas
54% (e63m) of respiratory expenditure is accounted by females and 46% (e52m) by
males. Females represent a higher proportion of GMS expenditure across the four most
expensive ATC groups.
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Table 5.6: Number & Percentage of GMS Claimants by ATC group & Sex
ATC Group Female Male
N 503,107 (31%) 349,877 (29%)
C 330,333 (20%) 263,635 (22%)
A 432,901 (27%) 301,194 (25%)
R 352,789 (22%) 276,878 (23%)
Total 900,561 (55%) 730,214 (45%)
N = nervous System, C = cardiovascular System, A = alimentary tract & Metabolism,
R = respiratory System
In Table 5.6, both males and females account for a higher proportion of nervous
drugs and a lower proportion of cardiovascular drugs. Of the 900,561 female GMS
claimants, and 730,214 male GMS claimants, 31% and 29% were prescribed ‘N’ items
respectively. As reported in Table 5.5, the nervous system is the most expensive ATC
group for females and males. Females record a higher porportion of prescription items
for ATC groups ‘N’ and ‘A’ but males record a higher proportion of prescription items
for the ATC groups ‘C’ and ‘R’.
5.3.2 Total Cost by ATC Group & Region
In 2012, 27% (e325m) of total GMS expenditure (14 ATC Groups) was recorded in
Dublin ML, 19% (e236m) was recorded in Dublin NE, 26% (e315m) was recorded in
the West and 28% (e349m) was recorded in the South. There is some regional variation
by ATC Group in Table 5.7. The South makes up 29% of the total ATC cost, Dublin
ML 26%, West 26% and Dublin NE 19%. A 10% difference exists between the most
expensive region (South) and the least costly region (Dublin NE).
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Table 5.7: 2012 GMS Expenditure (eM) by ATC Group and Region
Region N C A R Total (e) % of Total
ATC Cost
(4 ATC
Groups)
Dublin ML 79.85 61.18 46.26 31.39 218.67 26%
Dublin NE 56.05 46.45 33.05 22.46 158.01 19%
West 78.91 60.38 44.25 29.36 212.91 26%
South 88.04 71.05 49.20 32.13 240.42 29%
Total (e) 302.85 239.06 172.76 115.34 830.01 100%
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
Although the South is the most expensive region across the four ATC groups, it
does not record the highest proportion across all of the 4 ATC groups. The percentage
of GMS claimants prescribed drugs varies slightly across the regions. The ATC group
‘N’ records the highest proportion across the four regions. Dublin ML and Dublin NE
record the highest proportions in two ATC groups (N & R) and the West and South
record the highest percentage of cardiovascular GMS patients. Dublin ML and Dublin
NE record the lowest proportions for the ATC group ‘C’ and the West and South record
the lowest percentage for the ATC group ‘R’.
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Table 5.8: Number & Percentage of GMS Claimants by ATC group & Region
Region N C A R Region
Total
Dublin ML 230,292 (31%) 153,403 (20%) 196,099 (26%) 168,980 (23%) 427,257
(26%)
Dublin NE 165,028 (31%) 110,042 (21%) 139,845 (26%) 120,642 (23%) 319,464
(20%)
West 238,250 (30%) 158,186 (22%) 193,039 (26%) 163,219 (22%) 431,976
(26%)
South 219,414 (30%) 172,337 (22%) 205,112 (26%) 176,826 (22%) 452,078
(28%)
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
In Table 5.8, of the 427,257 GMS persons in Dublin ML, 31% were prescribed
nervous drugs, whereas only 20% were prescribed cardiovascular drugs. Of the 431,976
GMS persons in the Western region, 30% were prescribed nervous drugs, whereas 22%
were prescribed cardiovascular drugs. Of the 319,464 GMS persons in Dublin NE, 31%
were prescribed nervous drugs, whereas 21% were prescribed cardiovascular drugs. Of
the 452,078 GMS persons in the South, 30% were prescribed nervous drugs, whereas
22% were prescribed cardiovascular drugs.
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Figure 5.4: Number of GMS Eligible Persons and Claimants, 2012
Figure 5.4 illustrates the number of eligible GMS persons, percentage of total GMS
cost and the number of claimants. A claimant is a person who has a GMS medical
card and makes a claim. The South has the highest number of claimants (452,078)
and generates the highest proportion of total GMS cost (29%). Dublin NE has the
lowest number of claimants (319,464) and generates the lowest proportion of total cost
(19%). The proportion of claimants for each region from the pharmacy database is as
follows; South is 28%, Dublin ML is 26%, West is 26% and Dublin NE is 20%. This
research shows for ATC ‘R’, ‘N’ and ‘C’ the Southern region is the most costly region
and Dublin NE is the least costly region. When age and sex are incorporated into the
analysis, this regional trend continues6 7 8.
6See Appendix F Table F.1, the 3 age groups up to 15 years, the analysis represents an averaging
across three age cohorts (<5, 5–11, 12–15). The Southern region contributes on average 31% of total
ATC cost (M–30%, F–31%) and Dublin NE has the lowest average contribution (18%) of total ATC
cost (M–18%, F–19%).
7See Appendix F Table F.2 and Table F.3, for the 5 age groups from 16 to 64 years, the nervous
system analysis represents an averaging across five age cohorts, the Southern region contributes the
highest average proportion (30%) of total ATC cost (M–31%, F–30%) and Dublin NE has the lowest
average contribution (18%) of total ATC cost (M–17%, F–18%).
8See Appendix F Table F.4, for the 3 older age cohorts (65+), the cardiovascular system analysis
represents an averaging across three age cohorts (65–69, 70–74, >75). The Southern region contributes
on average 30% of total ATC cost (M–30%, F–30%) and Dublin NE has the lowest average contribution
(20%) of total ATC cost (M–19%, F–20%).
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Table 5.9: 2012 GMS Expenditure (e000) by Age Cohort
Age Cohort Total GMS
Cost (e000)
% of Total
GMS Cost
<5 15,194 1.24%
5–11 17,169 1.40%
12–15 10,161 0.83%
16–24 33,086 2.70%
25–34 63,975 5.22%
35–44 93,361 7.62%
45–54 130,263 10.63%
55–64 186,397 15.22%
65–69 123,625 10.09%
70–74 157,289 12.84%
>75 394,347 32.20%
Total 1,224,867 100%
5.3.3 Total Cost by ATC Group & Age Cohort
In 2012, total GMS expenditure varied with age. In Table 5.9, total GMS cost increases
with age up to 12 years, where we see a reduction, before increasing from 16 years
upwards. The over 75s accounted for 32.20% (e394m) of total GMS cost. The 55–64
age group records the second highest proportion of 15.22% (e186m). There is variation
in GMS costs by ATC groups between age cohorts, as portrayed in Table 5.10.
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Table 5.10: GMS Expenditure (eM) by ATC group and Age Cohort
Age Cohort N C A R Total
<5 0.57 0.35 0.88 2.01 3.81
5–11 1.78 0.29 1.13 4.33 7.53
12–15 1.87 0.11 0.97 2.15 5.10
16–24 9.32 0.52 3.44 3.91 17.20
25–34 27.11 1.80 7.29 5.32 41.52
35–44 39.83 6.83 12.39 7.62 66.68
45–54 46.03 19.31 19.79 11.32 96.45
55–64 46.33 40.68 29.53 18.56 135.11
65–69 23.58 31.59 19.27 13.06 87.49
70–74 27.10 43.61 23.28 15.22 109.21
>75 79.32 93.97 54.78 31.85 259.92
Total (e) 302.85 239.06 172.76 115.34 830.01
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
One must bear in mind the age bandwidths are not equal across the 11 HSE age
cohorts. The respiratory system is driving GMS costs up to the age of 15 years. The
three age cohorts account for 52% (e8.5m) of total ATC cost for these age groups. The
nervous system is driving GMS costs, from 16 years to 64 years. The five age cohorts
account for 47% (e168m) of total ATC cost for these age groups.
In the older age cohorts (65+), of the four ATC groups, the cardiovascular system
accounts for the highest expenditure. The three age cohorts account for 37% (e169m)
of total ATC cost for these age groups. Apart from the over 75s, the 55–64 age cohort is
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Table 5.11: Number & % of GMS Claimants by ATC group & Age Cohort
Age Cohort N C A R
<5 14,650 (16%) 1,510 (2%) 29,879 (32%) 45,562 (51%)
5–11 9,479 (10%) 1,544 (2%) 21,685 (24%) 59,026 (64%)
12–15 15,824 (28%) 1,070 (2%) 11,601 (20%) 28,226 (50%)
16–24 68,535 (40%) 8,329 (5%) 42,384 (25%) 53,556 (31%)
25–34 105,699 (42%) 19,746 (8%) 63,928 (26%) 60,275 (24%)
35–44 117,954 (39%) 37,804 (13%) 76,408 (26%) 66,547 (22%)
45–54 105,991 (34%) 64,603 (21%) 80,690 (26%) 60,627 (19%)
55–64 109,098 (29%) 103,347 (27%) 98,186 (26%) 66,717 (18%)
65–69 60,627 (26%) 70,251 (30%) 61,176 (26%) 39,768 (17%)
70–74 75,234 (26%) 93,863 (32%) 77,671 (26%) 47,999 (16%)
>75 169,893 (27%) 191,901 (30%) 170,487 (27%) 99,263 (16%)
Total 852,984 (52%) 593,968 (36%) 734,095 (45%) 629,667 (39%)
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
the biggest driver of GMS costs across the 4 ATC groups, it accounts for 16% (e135m)
of total ATC costs (e830m) (Table 5.10).
In Table 5.11, 51% of GMS claimants in the under 5s age group are prescribed ‘R’
prescription items, whereas only 2% are prescribed ‘C’ prescription items. In the 25–
34 age group, 42% of GMS claimants were prescribed ‘N’ drugs, whereas only 8% are
prescribed ‘C’ prescription items. In the over 75s age cohort, 30% of GMS claimants
were prescribed ‘C’ drugs, whereas only 16% are prescribed ‘R’ prescription items. In
Table 5.11, the highest proportions are highlighted. Respiratory drugs recorded the
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highest proportion and expenditure (Table 5.10 & Table 5.11) in the three age cohorts
up to 15 years. Montelukast (R03DC03), which treats obstructive airway diseases, such
as asthma is the most costly drug up to 15 years. This drug represents 29% (e2.4m)
of total ‘R’ costs (e8.5m).
The Nervous system recorded the highest proportion and expenditure (Table 5.10 &
Table 5.11) in the five age cohorts between 16 and 64 years. Escitalopram (N06AB10),
which treats depression and anxiety is the most costly drug for 16 to 24 year olds. It
represents 8% (e734m) of total ‘N’ expenditure (e9.3m) for that age cohort. Olanza-
pine (N05AH03), which treats psychotic conditions, such as Schizophrenia and Bipolar
disorder is the most costly drug for 25 to 34 year olds. It represents 9% (e2.5m)
of total ‘N’ expenditure (e27m) for that age cohort. Pregabalin (N03AX16), which
treats conditions, such as Epilepsy is the most costly drug for the three age cohorts
between 35 and 64 years. It accounts for 13% (e17m) of total ‘N’ expenditure (e132m).
Cardiovascular drugs recorded the highest proportion and expenditure (Table 5.10 &
Table 5.11) in the three age cohorts over 65. Atorvastatin (C10AA05), which treats
high cholesterol is the most costly drug for the over 65s. It represents 24% of total
‘C’ expenditure (e169m). Esomeprazole (A02BC05) is the most expensive alimentary
tract and metabolism drug in 2012. Esomeprazole is proton pump inhibitor (PPI),
which is used to treat certain stomach and oesophagus conditions, such as ulcers and
acid reflux. It accounts for 18% (e31m) of total ‘A’ expenditure (e173m).
Females were more expensive than males, except for children and adolescence. When
age cohort was analysed by sex and region, males were more expensive than females
up to 15 years for the respiratory system, as detailed in Table 5.12. Males record a
higher proportion for those up to 15 years in two ATC groups (R & C) and a higher
proportion up to 11 years for the ATC group ‘N’9. Females record a higher proportion
in the remaining age cohorts.
9See Appendix F Table F.5, Table F.6 and Table F.7 for the crosstabulation of age cohort, sex and
ATC group (R, C & N).
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Table 5.12: Respiratory GMS Expenditure (e) by Region and Sex, 0–15
Region Female Male Total GMS Cost (e)
(Under 5)
Dublin ML 194,707 295,397 490,104
Dublin NE 154,078 231,784 385,862
West 195,501 310,445 505,946
South 261,969 364,911 626,880
Total 806,255 1,202,537 2,008,792
(5–11)
Dublin ML 417,999 628,912 1,046,911
Dublin NE 326,158 505,103 831,261
West 455,184 694,747 1,149,931
South 517,314 785,288 1,302,602
Total 1,716,656 2,614,050 4,330,705
(12–15)
Dublin ML 202,551 335,747 538,298
Dublin NE 147,628 214,218 361,847
West 232,378 355,887 588,265
South 263,584 401,880 665,464
Total (e) 846,141 1,307,733 2,153,874
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Table 5.13: GMS Average Cost per Claimant (e) by ATC Group & Age
Cohort
Age Cohort N C A R
<5 4.47 2.75 6.94 15.82
5–11 12.97 2.10 8.20 31.52
12–15 26.32 1.48 13.61 30.25
16–24 56.98 3.21 21.05 23.89
25–34 143.84 9.56 38.70 28.21
35–44 208.67 35.77 64.92 39.93
45–54 287.34 120.52 123.53 70.65
55–64 289.68 254.39 184.69 116.08
65–69 258.16 345.80 210.95 142.93
70–74 234.36 377.19 201.33 131.60
>75 352.29 417.35 243.28 141.46
N = nervous System, C = cardiovascular System, A = alimentary tract & metabolism,
R = respiratory System
Average Cost per Claimant
Table 5.13 portrays the average cost per GMS claimant in 2012. The average cost
per claimant up to 15 years is the highest for the respiratory system across the four
ATC groups, it is the highest between 16 and 64 years for the nervous system and the
highest average cost per claimant for 65 years and over is the cardiovascular system.
These findings correspond to earlier findings reported in Table 5.10, the respiratory
system is the most costly ATC group up to 15 years, the nervous system between 16
and 64 years and the cardiovascular system for the over 65s.
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Figure 5.5 illustrates average GMS cost per claimant by age category and region.
Figure 5.5: Average Cost per Claimant by Age Category & Region, 2012
Very little difference is evident between the regions up to 44 years. The West is
the least expensive region from 45 years upwards and Dublin NE is the most expen-
sive region for the over 70s. The average cost rises steadily to 69 years, then levels
out slightly, before increasing again from 75 years. The average cost per claimant for
the population is e751.1010 with two regions falling below the average (Dublin NE &
West) and two regions above the average (Dublin ML & South). The average cost per
claimant ranges from e110.1211 in the under 5s in Dublin ML to e1,781.74 in the over
75s. The average cost per claimant ranges from e114.84 in the under 5s in Dublin NE
to e1,851.08 in the over 75s. The average cost per claimant ranges from e123.78 in
the under 5s in the West to e1,685.20 in the over 75s. The average cost per claimant
ranges from e129.59 in the under 5s in the South to e1,718.83 in the over 75s.
10See Appendix F Table F.8 for the total GMS Cost, number of claimants and average GMS cost
per claimant.
11See Appendix F Table F.8 for the total GMS Cost, number of claimants and average GMS cost
per claimant.
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Figure 5.6 compares average GMS cost per claimant by age category and region
across the four ATC groups.
Figure 5.6: Average GMS Cost per Claimant by Age Category, Region &
ATC Group, 2012
Average cost per claimant increases from 44 years for the ATC groups ‘C’, ‘A’ and
‘R’ and at an earlier stage from 24 years for the ATC group ‘N’. The average cost per
claimant for ATC group ‘C’ ranges from e2.52 in the under 5s in the Dublin ML region
to e443.51 in the over 75s in the Dublin NE region. The average cost per claimant for
ATC group ‘N’ ranges from e3.50 in the under 5s to e367.09 in the over 75s in Dublin
ML. The average cost per claimant for ATC group ‘A’ ranges from e6.60 in the under
5s to e247.19 in the over 75s in Dublin ML. The average cost per claimant for ATC
group ‘R’ ranges from e14.04 in the under 5s to e150.81 in the over 75s in Dublin NE.
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Summary of Descriptive Statistics
The descriptive analysis produced the following key results. Females are more ex-
pensive than males across the 4 ATC groups and 4 regions, with the biggest variation
in the nervous system and the smallest variation in the cardiovascular system. How-
ever, boys under 15 are more expensive than girls for the ‘R’ and ‘C’ ATC group. HSE
regions show a greater variation at age cohort level. The respiratory system is the most
costly ATC group up to 15 years, the nervous system between 16 and 64 years and the
cardiovascular system for the over 65s. This finding is augmented by the average cost
per claimant analysis. The South is the most expensive region and the Dublin NE is
the least expensive region. The following section reports the findings of the empirical
analysis.
5.4 Empirical Analysis
Table 5.14 presents the results of the empirical analysis based on estimates from the
three models. Model 1 shows that whilst age, sex and region are all significant drivers
of expenditure, sex (female) makes the strongest unique contribution (β = 0.107)
in explaining total cost, when the variance explained by all the other variables in the
model are controlled for. Of the three regions, the South had the greatest impact
(β = 0.056). However, when the ATC groups are included in model 2, the impact
of sex is diluted, with cardiovascular prescribing most influential (β = 1.229) and
the explanatory power of the model increases from 40.2% to 60.4%. All 8 predictors
have positive (β) coefficients indicating positive relationships and make a statistically
significant contribution (P<0.0005) to the prediction of total cost, except Dublin ML,
which has a negative (β) coefficient (-0.003). Model 3 was expanded to include dummy
variables for the age cohorts. In model 3, the inclusion of age dummies expectedly
shows those aged over 75 (β = 1.195) added most to GMS costs. The explanatory
power of model 3 increases to 60.5%. All variables in each of the three models make a
statistically significant contribution (P<0.0005) to the prediction of total cost.
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5.5 Discussion
The total cost of GMS prescriptions increased by 414% between 1998 and 2012. This
research identified the factors that influenced GMS expenditure by sex, region, age and
ATC group. The explanatory power of the models based on demographic data alone
have been improved by the inclusion of the most significant ATC groups, in terms of
overall contribution to GMS expenditure (R2=0.604). The results show that HSE re-
gions and sex do not make the same contribution in explaining total GMS cost as age
cohorts and the 4 ATC groups. Of GMS claimants, 52% are prescribed nervous system
drugs, and account for 25% of total GMS expenditure. 45% of GMS claimants are
prescribed alimentary tract and metabolism drugs, and account for 14% of total GMS
expenditure. 39% of GMS claimants are prescribed respiratory drugs, and account for
9% of total GMS expenditure. 36% of GMS claimants are prescribed cardiovascular
drugs, and account for 20% of total GMS expenditure.
Similar results are reported in the following studies, (Morgan, 2006), (Gerdtham
et al., 1998), (Vivas et al., 2011) and (Orzella et al., 2010). A Swedish study found
19% of drug spending can be attributed to nervous drugs, 16% to cardiovascular drugs
and 14% to alimentary drugs, (Gerdtham et al., 1998). A Spanish study examined
pharmaceutical expenditure on chronic conditions and attributed 16% of cost to the
cardiovascular system, 11% to the respiratory system and 10% to alimentary tract and
metabolism system, (Vivas et al., 2011). A population study on drug expenditure in
British Colombia in 1996 and 2002 found the top three most expensive ATC groups to
be cardiovascular, nervous system and alimentary tract and metabolism with the ner-
vous sytem accounting for 25% of of total drug expenditure in 2002, (Morgan, 2006).
(Orzella et al., 2010) found the cardiovascular system (highest expenditure) accounted
for 35% of the total expenditure and alimentary tract and metabolism accounted for
14% of total expenditure.
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Respiratory drugs was the main contributor to GMS drug expenditure in children
up to the age of 15 and this finding is supported by the literature, (Mueller et al., 1997)
and (Ferna´ndez-Liz et al., 2008). With an increasing incidence of asthma in developed
countries, its not surprising that drugs for the treatment of obstructive airway diseases,
such as Montelukast, is amongst the greatest contributors to expenditure for ATC
group ‘R’. A childhood study in Ireland reported that cigarette smoke, atopy, and the
presence of certain furry pets, are determinants of respiratory symptoms in children,
(Yarnell et al., 2003). Esomeprazole, a PPI, is the most expensive alimentary tract and
metabolism item. In 2012, PPIs were the second most expensive group of medicines
after statins, (PCRS, 2012). An Australian study investigated the utilisation of PPIs
and found Esomeprazole to be the second most prescribed PPI and the second most
expensive group of medicines after statins, (Hollingworth et al., 2010). An Irish study
on the GMS scheme investigated whether cost savings could be made by changes in
prescribing practice. They found if Esomeprazole was substituted with a less expensive
alternative, it would create savings of approximately e3.3 million, (McGowan et al.,
2005).
These results show the nervous system records the highest proportion (52%) in 2012
and makes the second strongest contribution in explaining total GMS cost in model
2 (Table 5.14). The three most expensive nervous drugs across the age groups are,
Escitalopram (16–24 years), Olanzapine (25–34 years) and Pregabalin (35–64 years).
A study investigating the determinants of prescribing innovation by GPs, using a GMS
prescribing database in Ireland, found the adoption of new prescription drugs, such
as Escitalopram, is not uniform across all GPs, indicating the potential for targeted
intervention to stimulate prescribing innovation, (Bourke and Roper, 2012).
Although cardiovascular prescriptions has the lowest proportion (36%) in this re-
search, it makes the strongest unique contribution in explaining total GMS cost for
model 2 (Table 5.14). This may be explained by the cost per prescription item for
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cardiovascular drugs. In 2012, Statins (Atorvastatin, Rosuvastatin, Pravastatin, Sim-
vastatin and Fluvastatin) were the most expensive GMS medicines by ATC costing
e91.9 million, (PCRS, 2012). Atorvastatin has since come off patent, which should
reduce future cardiovascular expenditure. The substitution of generic prescribing for
these drugs would lead to cost savings. A study based on an elderly Irish population
(70 years) found that cardiovascular disease (CVD) is the most prevalent condition
across all old health board regions, using a 2006 Primary Care Reimbursement Service
pharmacy database, (Naughton et al., 2006).
This research found that females account for more than half of GMS claimants in
2012, and were more expensive across the 4 ATC groups with the highest expenditure
for the nervous system and the smallest in the cardiovascular system. This finding is
supported by the literature. A study conducted amongst men and women on a Swedish
population in 2010, found a greater proportion of men were prescribed cardiovascular
drugs compared to women and a greater proportion of women were prescribed nervous
system drugs, (Loikas et al., 2013). A British Colombian study found a higher female
per capita expenditure on nervous and alimentary tract and metabolism drugs and
males a higher per capita drug expenditure on cardiovascular drugs, (Morgan, 2006).
A Swedish study investigating coronary artery disease found it to be more common in
men over 60 than females, (Johnston et al., 2011). This research reported males under
11 years are prescribed more prescription items than females. An Irish study found
that males under 11 were driving GMS costs, (ConwayLenihan and Woods, 2015). A
Swedish (Loikas et al., 2013) and Catalan study (Ferna´ndez-Liz et al., 2008) reported
a similar finding, higher drug usage in males (<10, <14) compared to females.
The impact of age on expenditure followed a similar pattern as observed in the
literature, highest expenditure on respiratory drugs for those under 15, highest expen-
diture on nervous system drugs for those between 16 and 64, and highest expenditure
on cardiovascular drugs for those aged 65 and over. This research shows that respi-
ratory drugs are driving GMS drug expenditure in children up to 11 years and this
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finding is supported by the literature, (Mueller et al., 1997) and (Ferna´ndez-Liz et al.,
2008). An Irish study found that children (0–11) and the elderly (70+) will be a key
driver of future drug costs, (Conway et al., 2014). A European study of three countries
(UK, Italy & Netherlands) found the respiratory system to be one of three ATC groups
with the highest prevalent rates in children, (Sturkenboom et al., 2008). The results
show the cardiovascular system records the highest usage for those aged 65 and over. A
study in Ireland found that cardiovascular disease is the most prevalent condition in an
elderly population aged 70 and over, (Naughton et al., 2006), indicating the trend has
continued in Ireland between 2004 and 2012. A Danish study investigated the driving
forces of increasing utilisation of cardiovascular drugs, found treatment intensity and
prevalence contributed to drug expenditure costs rather than population aging, (Kilde-
moes et al., 2008).
Results show regional variation in GMS expenditure by ATC group with the South-
ern region recording the highest GMS expenditure and Dublin NE recording the low-
est. Dublin ML records the highest proportion of GMS claimants prescribed a nervous
prescription item and Dublin NE records the lowest proportion of GMS claimants pre-
scribed a cardiovascular prescription item. A recent Irish study investigated regional
variation in medication taking behaviour and found little overall difference between the
regions, (O’Shea et al., 2014). Two Irish studies found variations for Ischaemic heart
disease and diabetes respectively, in prescribing by old health board regions, (Bennett
et al., 2002) and (Usher et al., 2005). They found high prescribing rates in the Mid-
lands and Eastern regions and low prescribing rates in the Western and North–Western
regions. Furthermore, an Irish study found variation in projected drug costs by old
health board regions, where the Midlands region was the most expensive region which
is now part of the Dublin ML region, (Conway et al., 2014).
Research on prescribing in Canada reported that characteristics and the areas where
they live, affect prescription use and this may explain regional variations in prescrip-
tion drug use. For example, area level measures of population health and socioeconomic
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status affected the likelihood of prescription use. They found area level concentrations
of one or more ethnic minorities were negatively associated with purchases of all types
of medicines, except statins, (Morgan et al., 2010).
This study is subject to certain limitations. The HSE has pre–defined age cohorts,
therefore making it difficult to re–construct age cohorts to make comparisons. The age
bandwidths are not equal across the 11 HSE age cohorts. The data showed a number
of GMS persons claiming from different LHOs, therefore, not providing an accurate
individual total cost in one single location. There are 32 LHOs in Ireland, which are
divided across the four regions. It was decided to analyse the data at regional level
given the inaccuracies at LHO level.
5.6 Conclusion
All European countries have common concerns about growing drug expenditures. The
growing proportion of the elderly, the increase in the incidence and duration of chronic
diseases, the continuing development of health technologies, and the increase in health
expectation of society, are common factors across all countries. This research indicates
that growth in the proportion of elderly claimants and associated levels of cardiovas-
cular prescribing, particularly for statins, will present difficulties for Ireland in terms
of cost containment. The primary prevention of CVD is dependent on the effective
reduction of the major risk factors, particularly tobacco control and a healthier diet.
Policies aimed at population–wide CVD prevention, such as legislating for smoke–free
public spaces, banning dietary transfats, or halving daily dietary salt intake are gener-
ally effective and cost saving.
Based on prevalence rates and related prescribing costs of asthma among children
up to the age of 15, it is imperative that public health resources and educational efforts
are targeted to improve asthma control and reduce the disease burden on both the
healthcare system and society.
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Expenditure on nervous system drugs in Ireland are highest for those aged between
16 and 64, in particular, drugs for the treatment of anxiety and depression. The treat-
ment of anxiety and depression is vitally important with the growth in suicidal related
deaths in Ireland. Whilst pharmacological treatments are often necessary, changes
in prescribing practice combined with psychological therapies, cognitive methods, and
self–help strategies, can yield cost savings. Since October 2013, a generic substitute
for Esomeprazole is now available, which could generate substantial savings in alimen-
tary tract prescribing. Whilst policies aimed at cost containment such as co–payment
charges, generic substitution, reference pricing, and adjustments to GMS eligibility
can be used to curtail expenditure, health promotional programs and educational in-
terventions should be given equal emphasis. Furthermore, policies intended to affect
physicians prescribing behaviour include guidelines, information (about price and less
expensive alternatives) and feedback, and the use of budgetary restrictions could also
yield savings.
The following chapter will examine the consequences of GMS policy changes on
prescribing expenditure between 2008 and 2014.
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Chapter 6
GMS Policy Changes between
2008 and 2014
6.1 Introduction
This chapter examines the policies that were introduced in response to the economic
crisis. The main cost containment measures introduced by the government in response
to the recommendations from the Troika will be examined. The impact of these policy
measures on GMS prescribing patterns and expenditure is then investigated. A timeline
of the policy changes is presented for the period between 2008 and 2014. The policy
changes are documented in Table 6.1, Table 6.3 and Table 6.4.
In the 10 year period to 2007, the health budget quadrupled due to rising national
income. This increase went in some way to rectify the decades of under–spending in
health, (Burke et al., 2014). Following the onset of the economic crisis, various efforts
were made in Ireland to reduce drug expenditure from both demand and supply side
factors. This thesis has primarily focused on three policy variables; GMS coverage,
average cost per claimant and claims rate and this chapter will focus on the policy
changes that impact these variables. The policy changes introduced in Ireland between
2008 and 2014 that affect GMS coverage are explored in section 6.2, the policy changes
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that affect the claims rate are explained in section 6.3 and section 6.4 identifies the pol-
icy changes that affected the average cost per claimant. Some research has been done
on the monetary savings resulting from these policy changes, this is included where the
research is available. A summary of the findings is presented in section 6.5.
6.2 GMS Coverage – Policy Changes
GMS coverage refers to the proportion of the population who have a medical card.
Eligibility criteria and income limits influence GMS coverage rates. The following pol-
icy changes affected the proportion of the over 70 population who were eligible for a
medical card. In July 2001, the Minister of Finance, Charlie McCreevy announced free
medical care to all persons over 70 years of age, (Government of Ireland, 2000). The
number of eligible persons increased from 1.1 million in 2000 to 1.2 million in 2001, an
increase of 9.1%, (GMS Payments Board, 2001). This increase may be attributed to the
policy change implemented in July 2001. In the annual GMS (Payments) Board report,
the data is not disaggregated by age, therefore it is not possible to quantify the impact
of the policy change in the over 70s between 2000 and 2001. Table 6.1 overleaf details
the GMS policy changes between 2008 and 2014. In October 2008, Budget 2009 ended
universal healthcare for all those aged 70 years and over. This age group protested
against the policy change and allegedly, approximately 15,000 people protested outside
Dail Eireann. The coalition government succumbed to public protest and partly re-
versed the policy change, (RTE, 2008). The Minister of Health, Mary Harney set the
income limits to e700 for a single person and e1,400 for a married couple on the 1st
January 2009.
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Table 6.1: Summary: GMS Coverage Policy Changes: 2008–2014
Date GMS Policy Change
October 2008 The budget ended the arrangement, whereby medical cards
were free to all over 70 and replaced it with a means test.
This was revised on 21st October 2008 due to public
demand, whereby the majority maintained eligibility over
70.
January 2009 New medical card income limits. e700 per week
and e34,400 per year (single),
e1,400 per week and e72,800 per year (couple).
March 2009 Anyone over 70 had to make a declaration before the end of
March 2009. Since 31st March 2011, 10,182 medical cards
have been returned, a further 9,264 medical cards
were cancelled (HSE verification process).
April 2010 DoH cut entitlements to medical card patients under the
Dental Treatment Services Scheme (DTSS).
July 2011 Medical card issuance is centrally managed by the PCRS &
has been moved from LHOs across the country.
April 2013 New medical card income limits. e600 per week (single),
e1,200 per week (couple).
January 2014 New medical card income limits. e500 per week (single),
e900 per week (couple).
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The government argued that 95% of those aged 70 and over would retain their med-
ical card. Any person over the age of 70 with a medical card was asked to notify the
HSE if they were above the income threshold, before the end of March 2009. In 2008,
351,853 over 70s had medical cards, (PCRS, 2008). In 2009, this decreased to 337,669,
a decrease of 4%. There was an 4.38% reduction of male medical card holders and
3.77% of female medical card holders between 2008 and 2009, (PCRS, 2009). While
there was a reduction in the number of eligible persons over 70, the cost of medicines
for this age group increased. In 2008 for the 70–74 age cohort, the average total cost
of medicines was e1,462.54 (PCRS, 2008) and this increased to e1,640.65 in 2009, a
12.2% increase, (PCRS, 2009). In 2008 for the >75 age cohort, the average total cost
of medicines was e1,805.74 (PCRS, 2008), and this increased to e1,961.04 in 2009,
a 8.6% increase, (PCRS, 2009). (Walshe and Kenneally, 2013) found due to the re-
stricted GMS eligibility for the over 70s, increased monitoring of payments and scheme
verification, combined with increased co–payment of e120 for the DPS scheme led to
estimated savings of e80 million in 2011. There was a 2% (6,047) reduction in the
number of eligible persons of those aged 70 and over between 2008 and 2010, following
the policy change. The average cost per claimant for those aged 70 and over was e1,599
in 2010. This policy change has led to estimated savings of e9.67 milllion.
In Budget 2010, the government cut entitlements to medical card holders under the
DTSS. Medical card holders can avail of dental services under ‘emergency case’ only.
Payments to dentists totalled e86.83 million in 2009, (PCRS, 2009) and this fell to
e52.3 million in 2011, a 39.7% decrease in payments, (PCRS, 2011). This decrease
occurs at a time, when the number of GMS eligible persons increased from 1.5 million
in 2009, (PCRS, 2009) to 1.7 million in 2011, (PCRS, 2011). This policy change has
led to estimated savings of e34.53 milllion.
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In 2011, the processing of medical cards was centralised to one body, the PCRS.
Originally, medical cards were processed at LHO level. The purpose of the centralisation
project was threefold:
1. Provide for a single uniform system of medical card application processing, thereby
replacing the different systems previously operated through more than 100 offices
across the country.
2. Streamline work processes and reduce the numbers of staff involved in medical
card processing from approximately 450 to 150.
3. Ultimately ensure a far more accountable and better managed medical card pro-
cessing system, Source:(HSE, 2012).
As a result of this centralisation project, the PCRS now process 94% of medical
card applications and reviews them within 15 days, (HSE, 2012). The centralisation of
medical cards brought standardisation of eligibility criteria and it allowed government
departments to interlink. Medical cards were reviewed between 2012 and 2014. 65,000
medical cards were withdrawn between September 2013 and March 2014 resulting in
huge public and political discontent, (Nolan et al., 2015). A number of personal sto-
ries were portrayed through the media highlighting some medical conditions, but not
all. Following this discontent, the government suspended reviews of all discretionary
medical cards and set up an expert panel, chaired by Professor Frank Keane with an
objective of reviewing medical need for medical card eligibility. The expert panel re-
viewed media coverage between the 1st of January and May 2014, and found a total of
772 articles relating to discretionary medical cards, (Keane et al., 2015).
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Table 6.2: Number of Discretionary Medical Cards Issued 2009–July 2014
Year Discretionary
Card
% of GMS
Population Covered
2009 79,625 5.4%
2010 80,524 5.0%
2011 74,281 4.4%
2012 63,126 3.4%
2013 50,294 2.7%
July–2014 65,993 3.7%
Source: (Keane et al. (2015))
The expert panel found reduced variation in the assessment of medical card eligibil-
ity following centralisation and that an appropriate level of transparency, consistency
and equity is emerging. In 2013, 50,294 (2.7% of the GMS population) had discre-
tionary medical cards, this increased to 65,993 (3.7% of the GMS population) in July
2014, as specified in Table 6.2. This increase is a likely consequence of the Irish gov-
ernment policy change of suspending the review of medical cards during this period.
The expert panel made 22 recommendations, some of which are listed below.
1. “The expert panel recommends that financial hardship or means testing should
remain the main discriminator for selecting the large majority of those eligible
for a medical card, which is consistent with other health systems in the European
Union.”
2. “The expert panel recommends that in the absence of international objective
and reproducible methods of measuring burden of disease and illness it is neither
feasible or desirable to list conditions in priority order for medical card eligibility.
A listing approach risks inequity by diagnosis and a further fragmentation of
services.”
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3. “The expert panel recommends that, as a working principle, discretionary medi-
cal cards should only be provided to the individual with the index condition, and
not to the entire family.” (Keane et al., 2015)
In April 2013, medical card income limits were reduced for the over 70s to e600
per week for a single person and e1,200 per week for a couple, as detailed earlier in
Table 6.1. If a single person has an income between e600 and e700 and a couple
has an income between e1,200 and e1,400, the medical card will be replaced with a
GP visit card, (Department of Finance, 2012). These limits were further reduced in
January 2014, resulting in less people over 70 being eligible for the GMS scheme. They
were reduced to e500 per week for a single person and e900 per week for a couple,
(Department of Finance, 2013). In 2012, there was 354,811 eligible persons aged 70 and
over and this decreased to 348,616 in 2013, a decrease of 2%. The eligible number of
those aged 70 and over decreased, following the second income limit reduction (policy
change)1.
6.3 GMS Claims Rate – Policy Changes
The claims rate is the proportion of the GMS population who make a claim on their
medical card. Co–payment charges were introduced in the Irish health system in 2010,
where medical card holders made a monetary contribution for every prescription item.
Co–payments have two key objectives; reduce moral hazard and raise revenue, (Drum-
mond and Towse, 2012). Moral hazard is the inefficient use of prescription medicines,
when the cost to the patient (medical card holder) is zero, (Drummond and Towse,
2012). The Irish economy contracted by more than 10% between 2008 and 2010, un-
employment more than trebled to 13.8% in 2010 and debt as a percentage of GDP
rocketed from 25% of GDP in 2005 to more than 100% of GDP in 2010, (Thomas
et al., 2012). The economic downturn in the economy coupled with the banking crisis
1The 2014 annual PCRS report has not yet been published, therefore it is not possible to determine
the impact of the third income limit change.
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Table 6.3: Summary: GMS Claims Rate Policy Changes: 2008–2014
Date GMS Policy Change
October 2010 The budget introduced patient co–payment for medical card
holders with a 50 cent per item charge and a monthly ceiling
of e10 per family.
January 2013 Patient co–payment for medical card holders increase to
e1.50 per item charge and a monthly ceiling of e19.50 per
family.
December 2013 Patient co–payment for medical card holders increase to
e2.50 per item charge and a monthly ceiling of e25 per
family.
put huge budgetary pressures on the public purse and in particular, the health system.
The health budget was cut by approximately e2 billion, a reduction of 17% between
2008 and 2010, (Thomas et al., 2012). The following policy changes were introduced as
revenue raising measures during the Irish economic crisis. The economic climate led to
the introduction of co–payment charges in 2010 and subsequently in 2013, as detailed
in Table 6.3.
On the 1st of October 2010, the government introduced co–payment charges for the
first time for medical card holders. GMS patients were required to pay 50 cent for
each prescription item and was capped at e10 per family per month. The number of
GMS prescriptions increased from 12.79 million in 2004 to 15.65 million in 2008 and
the number of dispensed items increased from 35 million in 2004 to 48.21 million in
2008. To address the associated costs of the GMS scheme, a prescription charge of 50
cent per item was introduced in Budget 2010, (Department of Finance, 2010b). The
government estimated that the co–payment charge would return e15 million in 2010
(partial year) and e25 million in a full year to the exchequer, (Department of Finance,
2010a).
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On the 1st of January 2013, co–payment charges were further increased to e1.50
per prescription item to a maximum for e19.50 per family per month. According to
the 2013 Expenditure Report, the government estimated that prescriptions charges
would raise e51 million, (Department of Finance, 2013). A subsequent increase in
co–payment charges was introduced in Budget 2014. The co–payment charge was in-
creased to e2.50 per prescription item and was capped at e25 per family per month.
The 2014 Expenditure Report estimated this policy change would yield savings of e43
million in 2014, (Department of Finance, 2014). This policy change may have led to a
drop in the annual GMS claims rate. The claims rate decreased from 94% in 2009 to
93% in 2010 and 2011 and 89% in 2012, but increased slightly in 20132 to 90% (Various
PCRS Reports 2009–2013).
An Irish study found following a meta–analysis, an 11% increased odds of non–
adherence to medicines in public insured populations, where co–payments for medicines
are required. (Sinnott, Buckley, O’ Riordan et al., 2013) argue a balance between the
financial benefits and financial repercussions of cost–sharing policies must be achieved.
A subsequent study showed a decrease in use of all medicines with a greater decrease
in less–essential medicines than essential medicines. An essential medicine is one which
improves health benefits and extends life. An exception to this pattern was that ad-
herence to treat mental health issues, such as anti–depressants and anxiolytic/hypnotic
medicines, these medications declined by a larger extent than other essential and less–
essential medicines. This study focused on public insured populations, which typi-
cally comprise of older and low income populations, such as Medicare and Medicaid
in America and the GMS scheme in Ireland, (Sinnott, 2014). Policy makers need to
be mindful of the implications and potential cost of non–adherence. Two European
studies (Schafheutle, 2008) and (Atella et al., 2005) and an Australian study (Doran
et al., 2005) found that an expensive co–payment system can affect the utilisation and
demand for drugs. Co–payment charges can reduce the utilisation of both essential and
2The 2014 annual PCRS report is not yet published so no figures for the 2014 claims rate is available.
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non–essential medicines in vulnerable populations, such as the poor, elderly and chron-
ically ill, (Rice and Matsuoka, 2004) and (Lexchin and Grootendorst, 2004). Therefore
the Irish government needs to be mindful of the ill–effects of future increases in co–
payments as these groups comprise the GMS population in Ireland.
6.4 GMS Average Cost per Claimant – Policy Changes
The average cost per claimant is the total cost of GMS claimants divided by the number
of GMS claimants. The average cost per claimant is influenced by the reimbursement
price for drugs. The reimbursemnt price for GMS drugs is comprised of the ex–factory
price, wholesale mark–up, dispensing fee and VAT. The ex–factory price is determined
by an agreement between the state and the drug manufacturers. The ex–factory price
is agreed between the Department of Health and the HSE (who represent the state) and
the representative body of drug manufacturers and importers. The ex–factory price is
set with reference to the currency adjusted average price to the wholesaler in nine nom-
inated EU member states (Belgium, Denmark, France, Germany, Netherlands, Spain,
UK, Finland and Austria), (IPHA, 2012). (Walshe and Kenneally, 2013) estimated
e200 million in savings in 2011, following price reductions in off–patent and generic
drugs coupled with a GMS rebate from drug manufacturers from 3.53% to 4% (January
2010).
The wholesale mark–up on GMS drugs was reduced from 17.7% in March 2008, to
10% in July 2009, and a final decrease to 8% in June 2011, as described in Table 6.4.
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Table 6.4: Summary: GMS Average Cost per Claimant Policy Changes:
2008–2014
Date GMS Policy Change
March 2008 Wholesale mark–up reductions from 17.7% to 10% in July
2009, to 8% in June 2011.
July 2009 Sliding dispensing fee structure introduced based on the
number of items.
e5 for 1,667 items, e4.50 next 833 items
& e3.50 per subsequent item.
January 2012 VAT increased from 21% to 23% (non–oral medications).
November 2012 IPHA/APMI Agreement
Off–patent drugs will be reduced to 60% of the original price
from 1st November 2012 and to 50%
from 1st November 2013.
Drugs due to go off patent from 1st November 2012 will be
reduced to 70% of the original price and
subsequently to 50%.
Price reductions averaging up to 16% on 400 patent
protected products will be subject to a price review.
May 2013 Health (Pricing & Medical Goods) Act 2013 Reference Pric-
ing and Generic Substitution.
May 2013 Preferred Drugs Initiative.
The wholesale mark–up is 12 per cent for fridge items and 8 per cent for any other
drug items, (Gorecki et al., 2012). The ingredient cost of a drug is the sum of the
ex–factory price and the wholesale mark–up. The dispensing fee is the payment a
pharmacist receives from the state for dispensing GMS drugs. In March 2008, the dis-
pensing fee was e3.60 per item. A sliding dispensing fee structure was introduced in
July 2009. The pharmacy receives e5.00 for each of the first 1,667 items dispensed,
e4.50 for each of the next 833 items dispensed and e3.50 for each other item dispensed
in that month, (Government of Ireland, 2011). Following changes to the pharmacy
dispensing fees, a reduction in retail mark–up for the DPS scheme and a reduction in
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the aforementioned wholesale mark–up, resulted in savings of e100 million in 2011,
(Walshe and Kenneally, 2013). VAT is levied at 0% for oral medications. VAT on
non–oral medications was increased from 21% to 23% on the 1st of January 2012.
On the 1st of November 2012, the state and drug manufacturers agreed the terms
of a new three year agreement. The agreement was formulated between IPHA, APMI3
the Department of Health and the HSE. The agreement applies to medicines prescribed
and reimbursed on the community drugs scheme, including the GMS, DPS, LTI and
HTD scheme. This agreement led to reductions in the cost of in–patent and off–patent
pharmaceuticals, as detailed in Table 6.4. According to the IPHA agreement, the re-
ductions are as follows. “For patent expired medicines whose price is currently above
60% of the original price to wholesaler, the price will reduce on 1st November 2012 to
60% of the original price to wholesaler. Twelve months after the first price reduction,
the price to wholesaler will be reduced to 50% of the original price to wholesaler”.
“For medicines due to go off patent from 1st November 2012, the price will reduce
to 70% of the original price to wholesaler. Twelve months after the first price reduc-
tion, the price to wholesaler will be reduced to 50% of the original price to wholesaler”,
(IPHA, 2012).
The price of up to 400 patent protected products, which have been available on
the HSE Community drug schemes prior to the 1st September 2006 will be subject
to a price review. Price reductions averaging up to 16% are expected from this re-
view process. The price of all patented medicines will be realigned downwards to the
currency–adjusted average price to the wholesaler in the nominated EU member states
in which the medicine is available, (IPHA, 2012). It was widely reported that this
agreement would yield over e400 million for the Irish state over three years. According
3APMI: Association of Pharmaceutical Manufacturers of Ireland, promotes and supports the com-
mon interests of the generic industry in Ireland and are at the forefront of offering quality affordable
medicines to the Irish population, (APMI, 2015).
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to a recent Economic and Social Research Institute (ESRI4) report, when one offsets
the new pharmaceutical costs of e210 million, the agreement results in net savings of
e190 million, (Nolan et al., 2015).
Following a parliamentary question to Minister of Health, James Reilly, requesting
a breakdown of the projected e400 million savings to the state, the actual savings to
the state were disclosed. Minister Reilly estimated that e16 million in drug savings
would be made in 2012, e116 million in 2013, e136 million in 2014 and e150 mil-
lion in 2015. He also stated that a breakdown of savings by scheme is not available
and the cost of new drugs is estimated to be e210 million over the next three years,
(Oireachtas, 2012a). The estimated savings are e402 million over the 3 years. Taking
account of the cost of new drugs, this results in actual savings of e192 million and
not e400 million that was originally claimed. The ESRI report further argues as the
savings were not realised in this deal, it led to the need for a supplementary health
budget in December 2012. The HSE required an additional e360 million, (Oireachtas,
2012b). The Troika (EU/IMF/ECB) expressed concern over health budget overruns
with a particular focus on pharmaceutical prices, costs to the state of private practice
in public hospitals, salary levels and medical card costs, (European Commission, 2013).
On the 28th May 2013, new legislation (Health Pricing & Medical Goods Act 2013)
was enacted. This legislation enables the state more powers to negotiate drug prices
with drug manufacturers other than the agreements. The objective of the Act is to
increase the usage of generics and reduce the price of interchangeable pharmaceuticals.
Generic penetration varies across EU member states. This ranges from less than 20%
by value in Belgium, Finland, France, Greece, Ireland, Italy and Spain, to between 20%
and 40% in Austria, Denmark, Germany, the Netherlands, Portugal, Sweden, Hungary
and the UK, and to over 40% in Poland, (EC, 2009). Previously, when a specific brand
of drug was prescribed for a patient, a pharmacist could only supply that particular
4The ESRI produces economic and social research in Ireland that informs public policymaking,
(ESRI, 2015).
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brand, even when less expensive generic versions of the same drug were available. The
Act now permits pharmacists to substitute drugs prescribed, provided that they have
been designated as safely interchangeable by the Health Products Regulatory Author-
ity (HPRA), formerly the Irish Medicines Board (IMB). The IMB changed its name to
HPRA on the 1st of July 2014. The role of HPRA is to protect and enhance public
and animal health by regulating medicines, medical devices and other health products,
(Health Products Regulatory Authority, 2015).
If a medical card holder would like to receive a particular brand of drug that costs
more than the reference price, then the medical card holder will have to pay the ad-
ditional cost of that product. In cases where substitution is prohibited for clinical
reasons and the doctor prescribes a specific drug, medical card holders will not face
any additional costs, if the prescribed drug costs more than the reference price. As
stated in the previous chapter, Statins were the most expensive (e91.90m) GMS drugs
prescribed in 2012, where Atorvastatin cost the state e61.42 million, (PCRS, 2012).
Following the introduction of the new legislation, the Department of Health reported
the new reference price for Atorvastatin products will be 70% less compared to May
2013 prices. The Department of Health estimate reference pricing will generate savings
in the region of e50 million in 2014, (Department of Health, 2013). (Gemmill et al.,
2008) found in a review article, that generic substitution and reference pricing, increase
competition amongst brand name and generic manufacturers and are effective at low-
ering ex–factory prices for pharmaceuticals.
In 2013, the HSE Medicines Management Programme (MMP) was developed to
encourage safe, effective and cost–effective prescribing. The MMP has undertaken a
number of initiatives aimed at enhancing evidence–based and cost–effective prescribing
nationally, such as the Preferred Drug Initiative. This initiative identifies a single drug
within a therapeutic class, which is evidence based and clinically equivalent to all other
agents in the class, but offers cost–effective advantages. This initiative offers guidance
on selecting, prescribing and monitoring a drug for a particular condition. For example,
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if prescribing a Statin, Simvastatin is recommended and if prescribing a Proton Pump
Inhibitor, Lansoprazole is recommended. This initiative intended to generate savings
of e20 million in 2013, (HSE, 2014).
6.4.1 Pharmacoeconomic Assessment
All new drugs to market are subject to pharmacoeconomic assessment by the Na-
tional Pharmacoeconomic Centre since 2009. The National Pharmacoeconomic Centre
facilitates healthcare decisions on healthcare technologies, such as pharmaceuticals, di-
agnostics and devices. Following the IPHA agreement in 2012, the state has the right
to assess new and existing technologies. Pre–existing items deemed to be non–cost
effective were removed from the reimbursement list e.g., Glucosamine in 2010. Phar-
macoeconomic evaluations can be in the form of Cost–Effectiveness analysis (CEA5)
or Cost–Utility analysis (CUA6). CEA is measured in cost per life year gained (LYG)
and CUA is measured in cost per quality adjusted life year (QALY7). A cost effective-
ness threshold of e45,000/QALY has been adopted by the National Pharmacoeconomic
Centre in accordance with the Irish Health Technology Assessment (HTA8) guidelines,
(Barry et al., 2008).
For example, Pravastatin (Lipostat), which treats coronary heart disease has a cost
per QALY of e42,250, therefore it was reimbursed. Omalizumab (Xolair), which treats
asthma, has a cost per QALY of e57,196, which exceeded the threshold, therefore it was
not reimbursed, (Barry et al., 2009). However, there maybe exceptions. Sunitinib had
a cost per QALY of e57,280 and although it was above the cost effectiveness threshold,
it was funded due to its innovative nature, (Tilson and Barry, 2010). (Bridges et al.,
5CEA is an economic evaluation that compares the costs and outcomes of alternative treatments,
(Kielhorn and Schulenburg, 2000).
6CUA is an economic evaluation that is used to compare costs and benefits of alternative health
treatments where quality of life is paramount, (Kielhorn and Schulenburg, 2000).
7A QALY measures both the quality and quantity of years a patient has, (Kielhorn and Schulenburg,
2000).
8“The HTA guidelines provide an overview of the principles and methods used in assessing health
technologies”, (HTA, 2015).
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2010) puts forward the argument of whether a fixed cost–effectiveness threshold should
be maintained in the United States. Benefits of fixed thresholds, include consistency
and transparency for policymakers, but the rigidity of the fixed threshold may not al-
low for exceptions. The pharmacoeconomic assessment is a key cost saving tool for
the reimbursement of pharmaceuticals in Ireland, as it allows for the use of economic
evaluations, such as CEA and CUA. This tool will be important for containing GMS
and community drug schemes expenditure.
The pharmacoeconomic evaluation is completed in approximately 3 months and
involves the following steps;
• Preliminary rapid review which takes between 2 and 4 weeks.
• Cost–effectiveness threshold – new drugs with an incremental cost–effectiveness
ratio (ICER) below e45,000/QALY, tend to be reimbursed.
• The increasing importance of budget impact assessment in reimbursement deci-
sions.
• Conditional reimbursement.
• Cost–effectiveness evaluation of existing medicines that are currently reimbursed.
(Source: (Tilson and Barry, 2010))
Table 6.5 documents the GMS policy changes that have been enacted and their
associated savings.
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Table 6.5: GMS Policy & Estimated Annual Savings: 2008–2015
GMS Policy Estimated Annual Savings
Eligibility changes for the >70s, 2009 e9.67 million9
DTSS Enitlements changed, 2010 e34.57 million
50 cent co–payment, 2010 e25 million(*)
e1.50 co–payment, 2013 e51 million(*)
e2.50 co–payment, 2013 e43 million(*)
IPHA/APMI Agreement (2012–2015) e190 million(**)
Reference Pricing, 2013 e50 million(***)
MMP, 2013 e20 million(****)
(96,047 less eligible >70s in 2010 compared to 2008, average cost per claimant >70 in
2010 is e1,599.12. 6,047 * e1,599.12 = e9.67m)
(* = Gov Estimate, ** = ESRI Estimate, *** = DOH Estimate, **** = HSE Estimate)
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In Table 6.5, the first two estimated savings are based on researcher’s own calcula-
tions. The annual estimates are based on the year before and after the policy change.
For example, entitlements were cut to the DTSS scheme in April 2010, resulting in a
reduction of 31% of ‘Above the Line10’ (ATL) treatments and 70% reduction in ‘Below
the Line11’ (BTL) treatments. The total cost of the DTSS scheme in 2009 was e86.77
million and reduced to e52.2 million in 2011, a reduction of e34.57 million. Further
research identifying cost savings following the implemetation of GMS policies would
be very useful. In the first four years of the crisis (2008–2012), Ireland achieved some
efficiencies in health and achieved ‘more with less’.
While the number of people covered for free care increased, hospital activity in-
creased with a much lower budget. From 2013 onwards, the number of people covered
decreased and rationing of care (hospital & home care) took hold, (Burke et al., 2014).
6.5 Conclusion
This chapter documents the GMS policy changes and charts the time period pre and
post recession (2008–2014) in Ireland. The GMS policy changes that affected GMS
coverage, claims rates and average cost per claimant are summarised in Table 6.1, Ta-
ble 6.3 and Table 6.4. Some research has been done on the savings generated as a result
of the policy changes and this research has been included, where available. The final
chapter of this thesis will summarise the key findings and identify recommendations.
10ATL treatments are uncomplicated procedures e.g. oral examination, (PCRS, 2011).
11BTL treatments are advanced procedures e.g. Prosthetics, (PCRS, 2011).
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Chapter 7
Conclusion and
Recommendations
7.1 Introduction
The main focus of the thesis is on pharmaceutical expenditure on the publically funded
GMS scheme, which is the largest of the community drug schemes in Ireland, covering
40% of the population in 2012. The research commenced in 2011 as part of a Health
Research Board (HRB) funded grant aimed at identifying the main factors influencing
GMS expenditure on pharmaceutical prescribing and projecting this expenditure over
the coming decade. The research was carried out against a backdrop of growing GMS
prescribing costs, which had risen from approximately e250 million in 1998 to over
e1 billion by 2007. Most observers expected this growth to continue as both the Irish
population, and the proportion of the population aged over 70, was projected by the
CSO to grow strongly over the coming decade. The investigation of the main factors
influencing GMS expenditure on pharmaceutical prescribing and projections in 5 year
intervals to 2026 was undertaken and published (Conway et al., 2014). The projections
were undertaken using a sample of 2007 PCRS prescribing data and CSO population
data, (CSO, 2008).
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The economic backdrop to the GMS expenditure projections of prescribing costs
completely changed following the global economic crisis of 2008, which resulted in a
sharp contraction in the Irish economy and mounting fiscal deficits. Ireland was forced
to enter a now well documented bailout programme. The sustainability of funding the
community drug schemes, such as the GMS, came under the spotlight of the EU, IMF
and ECB (Troika), who set stringent targets for reducing drug costs, as conditions of
the bailout programme. Cost containment measures included: the introduction of in-
come eligibility limits for GP visit cards and medical cards for those aged 70 and over,
introduction of co–payments for prescription items, reductions in wholesale mark–up
and pharmacy dispensing fees. Also, during this period the CSO revised its growth
predictions for the Irish population downward. The population changes coupled with
the impact of cost containment measures on prescribing costs raised questions as the
cogency of the (Conway et al., 2014) paper.
An investigation was undertaken using 2012 HSE–PCRS prescribing population
data following the implementation of the cost containment measures. The CSO popu-
lation data was based on Census 2011. The cost containment measures coupled with
updated CSO population projections were incorporated into the prediction model reval-
uating the impact on projected prescribing costs and were published in (ConwayLenihan
and Woods, 2015).
7.2 Objective and Aims
The primary objective is to investigate the main factors contributing to GMS expen-
diture on pharmaceutical prescribing and projecting this expenditure over the coming
decade. The thesis has five main aims:
1. To determine the main factors contributing to GMS expenditure on pharmaceu-
tical prescribing.
2. To develop a model to project GMS prescribing expenditure in five year intervals
to 2026, using 2006 CSO Census data and 2007 HSE–PCRS sample data.
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3. To develop a model to project GMS prescribing expenditure in five year intervals
to 2026, using 2012 HSE–PCRS population data, incorporating cost containment
measures, and 2011 CSO Census data.
4. To investigate the impact of demographic factors and the pharmacology of drugs
(ATC) on GMS expenditure.
5. To explore the consequences of GMS policy changes on prescribing expenditure
and behaviour between 2008 and 2014.
7.3 Literature Review
The purpose of the literature review was to locate the study in terms of existing liter-
ature on pharmaceutical expenditure projections and the factors influencing pharma-
ceutical expenditure globally. The literature review examined international and Irish
pharmaceutical cost containment measures initially and they were found to be a matter
of concern for policy makers and high on the political agenda globally. (Morgan and
Astolfi, 2015) found many countries introduced cost containment measures in 2009 and
the measures intensified in 2011. For example, Greece reduced pharmaceutical expen-
diture by 19.5%, Portugal by 20% and Spain by 8% between 2009 and 2011. (Sood
et al., 2009) found direct price controls and economic evaluation were more successful
in reducing pharmaceutical expenditure compared to other forms of regulation. (Al-
marsdo´ttir and Traulsen, 2005) warns policy makers that cost containment strategies
should be evidence based and they should consider the impact they will have on public
health. (Tilson et al., 2005) and (Barry et al., 2008) highlighted the growth in the cost
of medicines on community drug schemes in Ireland up to 2007. (Walshe and Kenneally,
2013) investigated the savings from cost containment policies in Ireland in 2011. They
found the IPHA/HSE agreement, reductions in retail and wholesale mark–up, new
dispensing fee structure, restrictions to eligibility and the introduction of co–payment
charges led to savings of e380 million for the Irish economy in 2011.
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The literature identified a number of factors influencing pharmaceutical expendi-
ture. These factors included population growth, population aging, new innovative drugs
and changes in drug utilisation and drug therapies, age, gender and location. Apart
from (Bennett et al., 2009) and (Heaney et al., 2009), very little research has been
carried out on pharmaceutical cost projections in Ireland. There are eleven community
drug schemes in Ireland and the GMS scheme is the largest, where a person has enti-
tlement to free healthcare. This thesis focused primarily on the GMS scheme.
This research is located between the end of a booming Irish economy in 2007 and
traces the steps in government cost containment from the recession in 2008 to the re-
covery in 2014. The literature review has identified the main factors influencing growth
in prescribing expenditure, particularly those relevant to this research, such as popu-
lation growth, population aging, coverage, etc. These were included in the prediction
model. The literature identified the methods previously used in predictive modelling
and consequently, coupled with advice from Darmstadt Statistics Department, a MCS
was used to simulate future GMS expenditure to 2026. Also, the literature guided the
use of OLS regression in determining demographic and pharmacology factors influenc-
ing prescribing expenditure. Finally, the literature review has provided a benchmark
for the type of results to expect.
7.4 Data and Methods
7.4.1 Data
(Conway et al., 2014) was based on CSO population projections (CSO, 2008) and a
HSE–PCRS sample database (2007). The sample database consists of 192,000 obser-
vations extracted from the 2007 PCRS GMS population data. The variables include;
ingredient cost, VAT, dispensing fee, total cost, number of prescription items and num-
ber of prescription forms, and are disaggregated by month (12), age cohort (10), gender
(2) and region (8). Population data was sourced from the CSO regional population pro-
jections 2011–2026. Data was detailed by year of age, gender, county and region, taking
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account of international migration, fertility and inter–regional flows.
(ConwayLenihan and Woods, 2015) were based on CSO population projections
(CSO, 2013) and a population HSE–PCRS database (2012). (ConwayLenihan et al.,
2016) was primarily based on the 2012 population HSE–PCRS database. There are
approximately 60 million observations in the database and the data was aggregated to
create one observation per claimant (n=1.63 million claimants). There are 40 variables
in the database, of which 7 are included in this research. These include demographic
information (age, sex, region), cost data (ingredient cost, VAT, dispensing fees) and
ATC group. The pharmacology is coded using the WHO ATC classification system.
The analysis of the pharmacology is undertaken at the 1st level of the ATC classifi-
cation system. The CSO regional population projections 2016–2031 provided updated
projections based on the 2011 Irish census. Data was detailed by year of age, sex,
county and region, incorporating assumptions around mortality, fertility, international
and internal regional migration.
7.4.2 Methods
Modelling drug expenditure projections varies considerably internationally. A number
of studies in the United States based projections on historical trends, (Cuckler et al.,
2013), (Keehan et al., 2012), (Sisko et al., 2014) and (Schumock et al., 2015) but studies
on drug expenditure projections is limited, (O’Neill et al., 2013). Modelling drug ex-
penditure projections varies from Markovian micro–simulation (Thie´baut et al., 2013),
linear regression (Bennett et al., 2009) and (Wettermark et al., 2010) and Macroeco-
nomic and Microeconomic approaches (O’Neill et al., 2013). Following advice from a
statistician, a Monte Carlo Simulation model was adopted to forecast GMS expenditure
and inform future health policy. Drug utilisation and expenditure is difficult to forecast
due to a number of uncertainties, Monte Carlo Simulation is a numerical model that
employs statistical sampling to forecast under uncertainty, (Briggs et al., 2012).
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A number of studies have used OLS regression to model the variation in pharma-
ceutical drug expenditure. Two Spanish studies used OLS regression to model pharma-
ceutical expenditure, (Ferna´ndez-Liz et al., 2008) and (Vivas et al., 2011). A study in
Uganda (Mujasi and Puig-Junoy, 2015) and three American studies, used OLS regres-
sion models to examine the predictability of drug expenditure, (Wrobel et al., 2004),
(Zhao et al., 2005) and (Powers et al., 2005). Previous results show that age, gender
and geographical location are influential in contributing to pharmaceutical expenditure.
The projections for prescribing expenditure for 2026 was subject to scenario analysis.
7.5 Results
(Conway et al., 2014) reports Ireland’s population will experience rapid growth coupled
with an aging population over the next decade. This will result in an increase in GMS
coverage rates, thus the increase in projected prescribing costs. Those aged 70 and over
and children under 11 will be significant drivers of GMS costs.
(ConwayLenihan and Woods, 2015) reports the Irish population is estimated to
grow by approximately 10% between 2012 and 2026, whereas the over 70s are expected
to grow by 64%. Increased coverage rates are likely, given an increase in population
and the over 70s living longer. The model predicted GMS expenditure is estimated to
increase by 64%, from e1.1 billion in 2016 to e1.8 billion by 2026 (most likely scenario),
ceteris paribus. On the 16th of December 2015, the Minister of Health, Leo Varadkar
announced the HSE National Service Plan for 2016, with an approximate cost of e13
billion. Minister Varadkar reported that approximately 40,000 less medical cards were
issued in 2015 and the HSE estimate 50,000 less medical cards will be issued in 2016,
due to rising employment levels, (HSE, 2015). Given this recent announcement, the
best case scenario may be realised, that GMS expenditure is estimated to increase to
e1.3 billion in 2021 and e1.5 billion in 2026.
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(ConwayLenihan and Woods, 2015) also reported that males, the Mid–Western and
South–Eastern regions are driving GMS costs in the under 11s. Females, Midlands
and Southern regions are driving GMS costs in the over 70s. These projections remain
subject to substantial uncertainty given the variable nature of future economic trends,
policy decisions and assumptions made at the time of projections.
Those aged over 75 (β = 1.195) and cardiovascular prescribing (β = 1.193) were
the greatest contributors to annual GMS prescribing costs. Respiratory drugs, such as
Montelukast recorded the highest proportion and expenditure for claimants under the
age of 15. Drugs prescribed for the nervous system, such as Escitalopram, Olanzapine
and Pregabalin were highest for those between 16 and 64 years with cardiovascular
drugs, such as Statins, were highest for those aged over 65. Females are more expensive
than males and are prescribed more items across the four ATC groups, except among
children under 11, (ConwayLenihan et al., 2016).
7.6 Recommendations
1. Ireland will experience rapid population growth and in particular, the elderly
population (>65) over the next decade. A downward adjustment of the income
eligibility limits can be used to curtail the GMS coverage rates and thus curbing
GMS expenditure for this age group, however equity must be borne in mind.
2. Respiratory drugs that treat asthma and obstructive airway diseases recorded the
highest proportion and expenditure for claimants up to the age of 15 years. This
research recommends that public health resources and educational campaigns are
run to improve asthma control and reduce the disease burden and associated costs
on both the healthcare system and society.
3. Expenditure on nervous system drugs in Ireland are highest for those aged be-
tween 16 and 64, in particular, drugs for the treatment of anxiety and depression.
The treatment of anxiety and depression is vitally important with the growth in
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suicidal related deaths in Ireland. Whilst pharmacological treatments are often
necessary, changes in prescribing practice combined with psychological therapies,
cognitive methods, and self–help strategies, can yield cost savings.
4. Growth in the proportion of elderly claimants and associated levels of cardiovas-
cular prescribing, particularly for statins, will present difficulties for Ireland in
terms of cost containment. The primary prevention of CVD is dependent on the
effective reduction of the major risk factors, particularly tobacco control and a
healthier diet. Policies aimed at population–wide CVD prevention, such as leg-
islating for smoke–free public spaces, banning dietary transfats, or halving daily
dietary salt intake are generally effective and cost saving, (Gerdtham and Lundin,
2004).
5. The Irish government introduced a co–payment of 50 cents for all GMS patients
and subsequently increased it to e1.50 in January 2013 and to e2.50 in December
2013. It is well documented in the literature (Schafheutle, 2008), (Atella et al.,
2005), (Doran et al., 2005), (Rice and Matsuoka, 2004) and (Lexchin and Groo-
tendorst, 2004) that increased co–payments result in a decrease in the demand
for essential medicines. However, Irish research found that both co–payments (50
cent & e1.50) were associated with larger reductions in adherence to less–essential
medicines than essential medicines, with the exception of anti–depressant and
anxiolytic/hypnotic medicines, (Sinnott, Buckley, O’ Riordan et al., 2013) and
(Sinnott, Guinane, Whelton and Byrne, 2013).
This research recommends that the Irish government investigate the adherence
to both essential medicines and less–essential medicines of the e2.50 co–payment
and identify if there is an optimal co–payment between e1.50 and e2.50. Small
co–payments may be of value as a cost sharing policy tool because the reduc-
tions to essential medicines, apart from anti–depressants and anxiolytic/hypnotic
medicines, were minimal. The Irish government may investigate and consider an
alternative method of co–payment, rather than a flat charge. In Spain, pharma-
ceutical co–payment was changed, where pensioners pay 10% of the drug price
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and general workers pay 50%, since April 2012, (Vivas-Consuelo et al., 2014).
GMS claimants pay a percentage of the final price as opposed to a flat charge.
6. The over 75s are the most expensive age cohort for drug expenditure on the GMS
scheme. A regular review of drug items by GPs in the community setting for this
age group should be put in place by the HSE/PCRS. This review may identify
unnecessary drugs and consequently may lead to cost savings.
7. An ESRI report (Gorecki et al., 2012), makes a series of supply side recom-
mendations to promote cost savings around the price and prescribing of drugs.
Supply side measures have been advocated as better policy tools than demand
side measures, such as patient co–payments in controlling expenditure, (Thomson
and Mossialos, 2004). This study supports the recommendations put forward by
(Gorecki et al., 2012).
8. Continued negotiations on drug prices between drug companies and the State,
where ‘value for money’ is secured and the promotion of cost effective prescribing.
Prescribers should have the necessary information available, such as the price
of drugs when administering a prescription form to GMS patients and private
patients. This will help to shift the burden of cost away from the private patient
and/or State.
9. Maximise the support for pharmacies to provide accurate and detailed electronic
GMS data. Following communication with a number of community pharmacists
working in Ireland throughout the course of this research, it became apparent, of
the 11 community drug schemes, pharmacies do not record transactions electron-
ically for two schemes, DTSS and EEA. Pharmacists must manually code each
item on a script each month for patients presenting with DTSS and EEA scripts.
This research recommends all community drug schemes prescriptions be recorded
and sent electronically to the PCRS each month.
Data Analysis Recommendations
10. The annual PCRS report currently presents data in the form of 11 age cohorts,
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these age cohorts are not of equal bandwidth. This research recommends that the
age cohorts should be equalised to ensure standardised and robust data analysis.
It is recommended that we move towards the European model of representing
age cohorts. For example, health data in Spain is analysed using 10 age cohorts1
ranging from the 0–4 to the ≥85, where the intervening age cohorts are of equal
width, (Ferna´ndez-Liz et al., 2008). Similarly, in Italy, health data is analysed
using 9 age cohorts2 ranging from the 0–4 to the ≥75, where the intervening age
cohorts are of equal width, (Orzella et al., 2010).
11. During the course of this research, it became apparent that the CSO and the
HSE do not analyse data by comparable regional structures. It is recommended
that one standard set of regions be established and all Irish organisations should
collect and analyse data according to this regional structure.
12. This research recommends the PCRS produce supporting excel files of the statis-
tical tables in the annual report. The CSO supports many of their publications
with excel files. If the PCRS took a similar approach, it would be of enormous
benefit to health researchers.
7.7 Limitations
HSE–PCRS Prescribing Database
• Chapters 3 and 4 were based on a sample (192,000 observations) and population
(60 million observations) HSE–PCRS prescribing database respectively. This data
is collected by the PCRS to produce annual statistical and claims reports and
only certain variables are included. The incorporation of other variables on socio-
economic status (income, educational status, geographical location) would prove
very useful for research purposes. A well documented limitation of this database is
the lack of a unique health identifier, which precludes the link between pharmacy
1Spain: 0–4, 5–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, ≥85
2Italy: 0–4, 5–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, ≥75
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and other health data, such as mortality data. A unique identifier3 was announced
by the Health Information and Quality Authority (HIQA) on the 5th of August
2015 on a pilot basis. Currently, patients are given a different number in every
health or social service that they utilise. Unique health identifiers would improve
future research and analysis.
• The output of papers 1 to 3 is in the format of the old health board regions. The
old health board regions (8) are no longer comparable to the current HSE regional
structure (4), which was changed in 2010. Personal communication took place
between the researcher and a CSO population statistician. The CSO advised the
population data was only available at county level. The PCRS data is available
at LHO level and some LHOs crossed boundaries. For example, North Tipperary
was part of LHO number 22 along with East Limerick and resided in the West,
whereas South Tipperary was part of LHO number 31 and resided in the South.
If CSO data was available at this disaggregated level, this would prove beneficial
for future analysis.
• The data in this thesis are analysed by the HSE–PCRS age cohorts (11). The
age cohorts are not of equal width, so the total cost of prescriptions is not equally
distributed by age cohort. This limitation must be borne in mind, when analysing
the results of this thesis.
7.8 Future Research
This study has identified a number of avenues for interesting and policy relevant future
research.
• Upon investigation of the 2012 HSE–PCRS database, it was evident that different
data sets existed within the population database. Characteristics of high cost and
low cost drug users in Ireland for the GMS scheme would be both interesting and
informative.
3An individual health identifier is a unique, non–transferable number assigned to all individuals
using health and social care services in Ireland, which will last for their lifetime,(HIQA, 2015).
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• A time series anlysis of GMS drug expenditure charting the time period before,
during and after the economic crisis.
• A comparative study analysing the monetary impact of reference pricing and
generic substitution. A study comparing 2012 (year before policy change) and
2014 (year after policy change) using HSE–PCRS prescribing data.
• This thesis focused on the four principle ATC groups in terms of GMS expendi-
ture, an investigation of the remaining 10 ATC groups would be informative.
• This research identified males under 11 in the Mid–Western and South–Eastern
regions are driving GMS expenditure. This research recommends an analysis of
drug prescribing by each region for this age group. For example, the Mid–Western
region had 26,770 eligible GMS persons and the South–Eastern region had 39,864
persons in 2012, whereas the Eastern region had 101,866 eligible GMS persons.
Yet, the Mid–western and South–Eastern regions are driving GMS costs for this
age group.
• Those aged over 70 in the Midlands and Southern regions have been identified as
a driver of GMS costs. This research recommends an analysis of drug prescribing
by each region for this age group. For example, the Midlands region had 21,365
eligible GMS persons and the Southern region had 55,813 persons in 2012, whereas
the Eastern region had 109,114 eligible GMS persons. Yet, the Midlands and
Southern regions are driving GMS costs for this age group.
• Forecast drug utilisation by ATC group.
7.9 Conclusion
The problem for Ireland’s policy makers is to contain pharmaceutical expenditure dur-
ing a period, where rapid population growth is forecasted, coupled with an aging pop-
ulation profile, with those aged 70 and over projected to increase by 64% between 2012
and 2026. This research indicates that growth in the proportion of the elderly claimants
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and associated levels of cardiovascular prescribing, particularly for statins, will present
difficulties for Ireland in terms of cost containment. Cost containment measures; co–
payment charges, generic substitution, reference pricing and GMS eligibility criteria
can decelerate the pace of GMS expenditure growth. Co–payment charges are likely
to reduce claims rates. Reference pricing and generic substitution are likely to reduce
average cost per claimant and eligibility criteria will lower GMS coverage rates.
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Appendix A
Appendix A (Chapter 3
Appendices)
The tables and charts generated in this Appendix are based on authors own calculations.
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Table A.1: CSO Region Breakdown
1.Border 5.Mid–East
Cavan Kildare
Donegal Meath
Leitrim Wicklow
Louth
Monaghan
Sligo
2.Midlands 6.Mid-West
Laoighis Clare
Longford Limerick City
Offaly Limerick County
Westmeath North Tipperary
3.West 7.South–East
Galway City Carlow
Galway County Kilkenny
Mayo South Tipperary
Roscommon Waterford City
Waterford County
Wexford
4.Dublin 8.South–West
Dublin City Cork City
Dun Laoghaire-Rathdown Cork County
Fingal Kerry
South Dublin
Source: (CSO, 2008)
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Table A.2: PCRS 2007 Region Breakdown
1.Eastern Area 5.North–Western
Dublin Donegal
Kildare Leitrim
Wicklow Sligo
2.Midlands 6.South–Eastern
Laois Carlow
Longford Kilkenny
Offaly Tipperary S.R,
Westmeath Waterford
Wexford
3.Mid–Western 7.Southern
Clare Cork
Limerick Kerry
Tipperary N.R.
4.North–Eastern 8.Western
Cavan Galway
Louth Mayo
Meath Roscommon
Monaghan
Source: (PCRS, 2007)
Table A.3: Meath Adjustment Factor
Age
Category
Males Females
0–5 0.1217 0.1188
5–11 0.1171 0.1174
12–15 0.1098 0.1081
16–24 0.0853 0.0801
25–34 0.0915 0.0916
35–44 0.1113 0.1056
45–54 0.1023 0.0942
55–64 0.0976 0.0901
65–69 0.0872 0.0762
70–74 0.0849 0.0766
> 75 0.0866 0.0777
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Table A.4: Eastern (Dublin, Kildare and Wicklow) Region Population Pro-
jections 2007
Age
Category
Males Females Total
0–5 55,247 52,762 108,009
5–11 68,969 64,981 133,949
12–15 36,963 34,735 71,698
16–24 105,579 106,367 211,946
25–34 155,003 153,021 308,024
35–44 113,788 113,266 227,054
45–54 88,923 92,638 181,562
55–64 68,092 708,27 138,918
65–69 22,773 25,011 47,784
70–74 17,590 21,187 38,777
> 75 23,721 40,778 64,499
Total 756,648 775,573 1,532,221
Table A.5: North–Eastern Region Adjustment Factors – Cavan Adjustment Factor
Age
Category
Males Females
0–5 0.1186 0.1164
5–11 0.1415 0.1444
12–15 0.1358 0.1369
16–24 0.1343 0.1297
25–34 0.1379 0.1300
35–44 0.1406 0.1355
45–54 0.1446 0.1364
55–64 0.1412 0.1297
65–69 0.1377 0.1221
70–74 0.1499 0.1416
> 75 0.1644 0.1478
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Table A.6: Louth Adjustment Factor
Age
Category
Males Females
0–5 0.2728 0.2729
5–11 0.2330 0.2418
12–15 0.2240 0.2269
16–24 0.2413 0.2470
25–34 0.2619 0.2734
35–44 0.2526 0.2492
45–54 0.2240 0.2239
55–64 0.2066 0.2222
65–69 0.2092 0.2232
70–74 0.1929 0.2052
> 75 0.1675 0.2018
Table A.7: Monaghan Adjustment Factor
Age
Category
Males Females
0–5 0.1218 0.1183
5–11 0.1188 0.1135
12–15 0.1213 0.1272
16–24 0.1266 0.1222
25–34 0.1301 0.1176
35–44 0.1176 0.1161
45–54 0.1215 0.1171
55–64 0.1174 0.1152
65–69 0.1059 0.1162
70–74 0.1187 0.1241
> 75 0.1133 0.1170
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Table A.8: North–Western Region Adjustment Factors – Donegal Adjust-
ment Factor
Age
Category
Males Females
0–5 0.3449 0.3453
5–11 0.3286 0.3285
12–15 0.3363 0.3314
16–24 0.3091 0.3053
25–34 0.2896 0.3017
35–44 0.3037 0.3147
45–54 0.3021 0.3087
55–64 0.3225 0.3219
65–69 0.3337 0.3289
70–74 0.3174 0.3125
> 75 0.3148 0.2998
Table A.9: Leitrim Adjustment Factor
Age
Category
Males Females
0–5 0.0478 0.0487
5–11 0.0588 0.0579
12–15 0.0593 0.0572
16–24 0.0565 0.0548
25–34 0.0590 0.0531
35–44 0.0611 0.0589
45–54 0.0704 0.0675
55–64 0.0700 0.0672
65–69 0.0751 0.0678
70–74 0.0777 0.0704
> 75 0.0857 0.0764
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Table A.10: Sligo Adjustment Factor
Age
Category
Males Females
0–5 0.0941 0.0984
5–11 0.1192 0.1139
12–15 0.1233 0.1204
16–24 0.1321 0.1409
25–34 0.1215 0.1242
35–44 0.1243 0.1256
45–54 0.1375 0.1463
55–64 0.1424 0.1438
65–69 0.1384 0.1418
70–74 0.1434 0.1461
> 75 0.1542 0.1572
Table A.11: North–Eastern (Cavan, Louth, Meath and Monaghan) Region
Population Projections 2007
Age
Category
Males Females Total
0–5 16,814 15,623 32,437
5–11 21,427 20,429 41,857
12–15 11,120 10,547 21,667
16–24 25,918 24,547 50,465
25–34 34,933 34,002 68,935
35–44 32,145 30,372 62,517
45–54 24,968 23,611 48,579
55–64 19,047 18,072 37,119
65–69 6,047 5,860 11,907
70–74 4,863 5,170 10,033
> 75 7,014 10,800 17,814
Total 204,297 199,033 403,330
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Table A.12: North–Western (Donegal, Leitrim and Sligo) Region Population
Projections 2007
Age
Category
Males Females Total
0–5 8,689 8,255 16,944
5–11 12,614 11,800 24,414
12–15 7,074 6,570 13,644
16–24 15,922 15,349 31,271
25–34 17,144 17,082 34,226
35–44 17,131 16,936 34,067
45–54 15,443 15,292 30,734
55–64 13,429 12,612 26,041
65–69 4,678 4,430 9,108
70–74 3,769 3,834 7,603
> 75 5,937 8,418 14,355
Total 121,829 120,577 242,406
Table A.13: Estimated Population 2007
Age
Category
Males Females Total
0–5 158,436 150,899 309,335
5–11 208,273 197,580 405,853
12–15 113,157 107,538 220,695
16–24 289,996 282,487 572,483
25–34 381,935 370,087 752,022
35–44 322,509 314,454 636,963
45–54 267,540 264,592 532,132
55–64 210,943 207,389 418,332
65–69 71,674 72,565 144,239
70–74 57,155 62,795 119,950
> 75 81,722 127,034 208,756
Total 2,163,340 2,157,420 4,320,760
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Table A.14: Estimated Population 2011
Age
Category
Males Females Total
0–5 176,288 166,556 342,844
5–11 223,508 213,495 437,003
12–15 119,878 113,272 233,150
16–24 269,361 265,205 534,566
25–34 431,230 415,338 846,568
35–44 361,786 343,581 705,367
45–54 294,035 290,038 584,073
55–64 234,484 231,852 466,336
65–69 86,098 86,958 173,056
70–74 63,099 67,457 130,556
> 75 94,822 137,402 232,224
Total 2354589 2,331,154 4,685,743
Table A.15: Estimated Population 2016
Age
Category
Males Females Total
0–5 192,048 181,207 373,255
5–11 248,383 235,669 484,052
12–15 129,894 124,266 254,160
16–24 266,260 258,780 525,040
25–34 417,702 409,056 826,758
35–44 424,065 396,257 820,322
45–54 329,320 317,944 647,264
55–64 260,221 257,894 518,115
65–69 105,793 106,939 212,732
70–74 79,092 82,644 161,736
> 75 116,812 154,758 271,570
Total 2,569,590 2,525,414 5,095,004
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Table A.16: Estimated Population 2021
Age
Category
Males Females Total
0–5 193,067 182,038 375,105
5–11 271,845 256,900 528,745
12–15 142,822 135,535 278,357
16–24 283,177 274,430 557,607
25–34 363,423 357,989 721,412
35–44 473,138 443,977 917,115
45–54 372,962 351,091 724,053
55–64 291,139 287,855 578,994
65–69 116,643 118,040 234,683
70–74 98,322 102,088 200,410
> 75 150,477 184,130 334,607
Total 2,757,015 2,694,073 5,451,088
Table A.17: Estimated Population 2026
Age
Category
Males Females Total
0–5 179,668 169,255 348,923
5–11 275,391 259,831 535,222
12–15 156,563 147,834 304,397
16–24 303,303 291,326 594,629
25–34 333,798 325,892 659,690
35–44 446,047 428,089 874,136
45–54 430,441 400,425 830,866
55–64 324,740 314,409 639,149
65–69 131,465 132,324 263,789
70–74 109,278 113,062 222,340
> 75 195,704 227,155 422,859
Total 2,886,398 2,809,602 5,696,000
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Table A.18: Population Scenarios
Scenarios Population Population
Growth Rate (%)
Scenario 1 Minimum(Lower Bound)
Year Population (% Growth)
2002 3,917,203
2007 4,270,763 9.03
2011 4,422,000 3.54
2016 4,609,000 4.23
2021 4,766,000 3.41
2026 4,884,000 2.48
Scenario 2 Mean(Most Likely)
Year Population (% Growth)
2002 3,917,203
2007 4,320,760 10.30
2011 4,685,743 8.45
2016 5,095,004 8.73
2021 5,451,088 6.99
2026 5,696,000 4.49
Scenario 3 Maximum(Upper Bound) (% Growth)
2007 [(10.3 - 9.03) + 10.3] 11.58
2011 [(8.45 - 3.54) + 8.45] 13.35
2016 [(8.73 - 4.23) + 8.73] 13.24
2021 [(6.99 - 3.41) + 6.99] 10.57
2026 [(4.49 - 2.48) + 4.49] 6.51
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Table A.19: Eligible persons for the GMS Scheme by Region 2006 & 2007
Region 2006 2007
Number % Number %
Eastern
Dublin 289,790 24.43 298,100 25.11
Kildare 41,116 22.1 43,656 23.43
Wicklow 29,934 23.7 31,251 24.76
Total 360,840 24.08 373,007 24.87
Midlands
Laois 18,173 27.12 19,441 28.99
Longford 13,091 38.10 13,747 39.97
Offaly 20,726 29.36 22,208 31.34
Westmeath 22,329 28.12 23,559 29.69
Total 74,319 29.56 78,955 31.37
Mid–Western
Clare 33,556 30.29 35,484 31.98
Limerick 54,242 29.50 58,352 31.70
Tipperary N.R 21,175 32.09 22,429 33.97
Total 108,973 30.22 116,265 32.20
North–Eastern
Cavan 20,939 32.74 22,429 35.04
Louth 37,809 34.09 38,374 34.49
Meath 32,476 19.97 34,098 20.94
Monaghan 16,527 29.61 17,312 30.92
Total 107,751 27.40 112,213 28.47
North–Western
Donegal 71,058 48.35 72,590 49.29
Leitrim 11,638 40.36 12,309 42.52
Sligo 19,956 32.76 20,566 33.77
Total 102,652 43.38 105,465 44.48
South–Eastern
Carlow 16,840 33.27 18,384 36.51
Kilkenny 20,885 23.90 21,817 24.92
Tipperary S.R 29,150 35.10 30,242 36.34
Waterford 37,414 34.66 39,423 36.52
Wexford 42,679 32.43 44,751 33.97
Total 146,968 31.92 154,617 33.55
Southern
Cork 138,720 28.85 146,072 30.35
Kerry 42,792 30.65 44,687 31.96
Total 181,512 29.25 190,759 30.71
Western
Galway 68,451 29.63 71,692 30.95
Mayo 48,944 39.58 50,867 41.08
Roscommon 21,285 36.26 22,338 38.01
Total 138,680 33.55 144,897 34.98
Source: (PCRS, 2007)
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Table A.20: Midlands Population Projections 2007
Age
Category
Males Females Total % Total
0–5 10,193 9,733 19,926 7.07
5–11 13,762 13,085 26,847 10.38
12–15 7,280 7,018 14,298 5.53
16–24 16,977 16,081 33,058 12.78
25–34 21,244 20,045 41,289 15.96
35–44 19,547 18,830 38,377 14.83
45–54 16,660 15,517 32,177 12.44
55–64 12,566 11,975 24,541 9.49
65–69 4,159 4,077 8,236 3.18
70–74 3,577 3,715 7,292 2.82
> 75 5,199 7,467 12,666 4.90
Total 131,164 127,543 258,707 100.00
Table A.21: North–West Population Projections 2007
Age
Category
Males Females Total % Total
0–5 8,689 8,255 16,944 6.99
5–11 12,614 11,800 24,414 10.07
12–15 7,074 6,570 13,644 5.63
16–24 15,922 15,349 31,271 12.90
25–34 17,144 17,082 34,226 14.12
35–44 17,131 16,936 34,067 14.05
45–54 15,443 15,292 30,734 12.68
55–64 13,429 12,612 26,041 10.74
65–69 4,678 4,430 9,108 3.76
70–74 3,769 3,834 7,603 3.14
> 75 5,937 8,418 14,355 5.92
Total 121,829 120,577 242,406 100.00
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Table A.24: Claims Rate 2007
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 70–74 >75 Total
Eastern
Males 0.52 0.14 0.31 0.39 0.46 0.56 0.69 0.79 0.81 0.89 0.56
Females 0.45 0.18 0.50 0.57 0.58 0.65 0.79 0.81 0.86 0.82 0.62
Midlands
Males 0.50 0.18 0.31 0.38 0.45 0.59 0.78 0.82 0.76 0.85 0.56
Females 0.50 0.21 0.51 0.57 0.57 0.75 0.83 0.87 0.84 0.83 0.65
Mid–Western
Males 0.51 0.16 0.28 0.37 0.41 0.58 0.72 0.78 0.78 0.90 0.55
Females 0.49 0.20 0.55 0.52 0.54 0.68 0.75 0.85 0.83 0.84 0.63
North–Eastern
Males 0.42 0.15 0.26 0.32 0.37 0.56 0.65 0.76 0.72 0.78 0.50
Females 0.42 0.16 0.57 0.51 0.53 0.61 0.74 0.73 0.79 0.78 0.58
North–Western
Males 0.45 0.16 0.25 0.27 0.31 0.47 0.63 0.70 0.78 0.75 0.48
Females 0.35 0.19 0.44 0.50 0.49 0.55 0.66 0.76 0.78 0.76 0.55
South–Eastern
Males 0.48 0.20 0.26 0.33 0.43 0.56 0.71 0.79 0.74 0.85 0.54
Females 0.55 0.18 0.52 0.57 0.55 0.61 0.77 0.85 0.83 0.89 0.63
Southern
Males 0.53 0.21 0.33 0.36 0.47 0.61 0.71 0.76 0.78 0.86 0.56
Females 0.46 0.20 0.55 0.54 0.61 0.67 0.82 0.83 0.85 0.88 0.64
Western
Males 0.41 0.17 0.28 0.35 0.43 0.52 0.64 0.69 0.75 0.77 0.50
Females 0.44 0.17 0.54 0.50 0.51 0.59 0.71 0.75 0.77 0.79 0.58
Total 0.47 0.18 0.40 0.44 0.48 0.60 0.72 0.78 0.79 0.83 0.57
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Table A.25: Population Weightings for Coverage Parameter
Region Gender <5 5–11
Eastern Male 0.444765 0.555235
Eastern Female 0.448114 0.551886
Midlands Male 0.425506 0.574494
Midlands Female 0.426549 0.573451
Mid–Western Male 0.425571 0.574429
Mid–Western Female 0.424115 0.575885
North–Eastern Male 0.439684 0.560316
North–Eastern Female 0.433344 0.566656
North–Western Male 0.407881 0.592119
North–Western Female 0.41161 0.58839
South–Eastern Male 0.422027 0.577973
South–Eastern Female 0.426775 0.573225
Southern Male 0.426503 0.573497
Southern Female 0.423771 0.576229
Western Male 0.423492 0.576508
Western Female 0.425721 0.574279
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Figure A.2: Regional Population Proportions 2011
250
Figure A.3: Regional Population Proportions 2016
Figure A.4: Regional Population Proportions 2021
251
Figure A.5: Regional Population Proportions compared, 2007 and 2026
252
Table A.41: Three Coverage scenarios by age cohort, gender and region 2007
– Scenario 1: Minimum
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 >70
Eastern
Males 0.27 0.25 0.09 0.07 0.12 0.13 0.20 0.33 1.00
Females 0.27 0.25 0.15 0.15 0.17 0.16 0.24 0.41 1.00
Midlands
Males 0.29 0.29 0.15 0.12 0.16 0.18 0.27 0.43 1.00
Females 0.28 0.29 0.23 0.21 0.22 0.22 0.35 0.54 1.00
Mid–Western
Males 0.30 0.28 0.17 0.14 0.18 0.20 0.29 0.45 1.00
Females 0.30 0.29 0.24 0.23 0.23 0.23 0.34 0.53 1.00
North–Eastern
Males 0.25 0.25 0.14 0.11 0.14 0.17 0.26 0.41 1.00
Females 0.25 0.26 0.22 0.18 0.19 0.20 0.32 0.52 1.00
North–Western
Males 0.41 0.40 0.27 0.22 0.28 0.31 0.42 0.59 1.00
Females 0.40 0.40 0.37 0.33 0.34 0.33 0.46 0.64 1.00
South–Eastern
Males 0.30 0.29 0.17 0.14 0.17 0.21 0.31 0.47 1.00
Females 0.29 0.29 0.26 0.24 0.23 0.24 0.37 0.57 1.00
Southern
Males 0.28 0.25 0.15 0.12 0.16 0.19 0.29 0.45 1.00
Females 0.27 0.25 0.20 0.20 0.21 0.22 0.34 0.54 1.00
Western
Males 0.31 0.31 0.18 0.14 0.20 0.24 0.35 0.51 1.00
Females 0.31 0.32 0.25 0.21 0.25 0.26 0.39 0.60 1.00
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Table A.42: Coverage scenario by age cohort, gender and region 2007 – Sce-
nario 2: Mean
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 >70
Eastern
Males 0.29 0.26 0.10 0.08 0.13 0.14 0.20 0.34 1.00
Females 0.28 0.26 0.16 0.15 0.18 0.17 0.25 0.43 1.00
Midlands
Males 0.30 0.30 0.16 0.12 0.17 0.19 0.29 0.45 1.00
Females 0.31 0.31 0.24 0.22 0.23 0.23 0.36 0.56 1.00
Mid–Western
Males 0.31 0.29 0.18 0.14 0.19 0.20 0.30 0.47 1.00
Females 0.31 0.31 0.25 0.24 0.24 0.24 0.36 0.55 1.00
North–Eastern
Males 0.26 0.26 0.15 0.11 0.15 0.18 0.28 0.43 1.00
Females 0.27 0.27 0.23 0.19 0.20 0.21 0.34 0.54 1.00
North–Western
Males 0.43 0.42 0.28 0.23 0.30 0.32 0.43 0.62 1.00
Females 0.42 0.42 0.38 0.34 0.35 0.35 0.48 0.66 1.00
South–Eastern
Males 0.31 0.30 0.18 0.15 0.18 0.21 0.32 0.49 1.00
Females 0.31 0.30 0.27 0.25 0.24 0.25 0.39 0.60 1.00
Southern
Males 0.29 0.27 0.15 0.13 0.17 0.20 0.30 0.47 1.00
Females 0.28 0.26 0.21 0.21 0.22 0.23 0.36 0.57 1.00
Western
Males 0.33 0.33 0.19 0.14 0.21 0.25 0.37 0.53 1.00
Females 0.32 0.33 0.26 0.22 0.26 0.27 0.40 0.63 1.00
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Table A.43: Coverage scenario by age cohort, gender and region 2007 – Sce-
nario 3: Maximum
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 >70
Eastern
Males 0.36 0.33 0.12 0.10 0.16 0.17 0.26 0.43 1.00
Females 0.36 0.33 0.20 0.20 0.23 0.21 0.32 0.55 1.00
Midlands
Males 0.37 0.38 0.20 0.15 0.21 0.23 0.36 0.56 1.00
Females 0.39 0.39 0.30 0.28 0.29 0.30 0.46 0.71 1.00
Mid–Western
Males 0.39 0.37 0.22 0.18 0.24 0.26 0.38 0.60 1.00
Females 0.39 0.39 0.31 0.30 0.31 0.30 0.45 0.70 1.00
North–Eastern
Males 0.34 0.33 0.19 0.14 0.19 0.22 0.35 0.54 1.00
Females 0.34 0.34 0.29 0.24 0.25 0.27 0.42 0.69 1.00
North–Western
Males 0.54 0.53 0.35 0.29 0.37 0.41 0.55 0.78 1.00
Females 0.53 0.53 0.48 0.43 0.44 0.44 0.61 0.84 1.00
South–Eastern
Males 0.40 0.38 0.22 0.19 0.23 0.27 0.41 0.62 1.00
Females 0.39 0.38 0.34 0.32 0.30 0.32 0.49 0.76 1.00
Southern
Males 0.36 0.34 0.19 0.16 0.21 0.25 0.38 0.60 1.00
Females 0.36 0.33 0.26 0.26 0.28 0.29 0.45 0.72 1.00
Western
Males 0.41 0.41 0.24 0.18 0.26 0.32 0.47 0.68 1.00
Females 0.41 0.42 0.33 0.28 0.32 0.34 0.51 0.79 1.00
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Figure A.6: GMS Coverage Projections (%) 2016 – 2026
268
Table A.56: Comparison of regional average cost per claim totals (e) 2007
Region PCRS
Totals (e)
Estimated Sample
Database Totals (e)
Eastern 835.14 1184.20
Midlands 930.43 1315.86
Mid–Western 877.64 1236.86
North–Eastern 859.24 1250.56
North–Western 713.16 1080.03
South–Eastern 866.05 1242.25
Southern 918.41 1259.41
Western 855.40 1199.27
National 856.14 1221.06
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Table A.60: GMS Pharmacy Cost 2007
Region GMS Pharmacy
Cost (e)
Eastern 835.14
Midlands 930.43
Mid–Western 877.64
North–Eastern 859.24
North–Western 713.16
South–Eastern 866.05
Southern 918.41
Western 855.40
National 856.14
Standard Deviation 66.38
Source: (PCRS, 2007)
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Figure A.7: Histogram of Average Cost per Claimant (e), Scenario 1, 2016
285
Figure A.8: Histogram of Average Cost per Claimant (e), Scenario 3, 2016
Figure A.9: Histogram of Average Cost per Claimant (e), Scenario 1, 2021
286
Figure A.10: Histogram of Average Cost per Claimant (e), Scenario 3, 2021
Figure A.11: Histogram of Average Cost per Claimant (e), Scenario 1, 2026
287
Figure A.12: Histogram of Average Cost per Claimant (e), Scenario 3, 2026
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Figure A.14: Main effects Plot Scenario 1 & Scenario 3, 2016
Figure A.15: Main effects Plot Scenario 1 & Scenario 3, 2021
290
Figure A.16: Main effects Plot Scenario 1 & Scenario 3, 2026
291
Figure A.17: Interval Plot of Cost (e) by region, gender & age cohort, Sce-
nario 1, 2016
292
Figure A.18: Interval Plot of Cost (e) by region, gender & age cohort, Sce-
nario 3, 2016
293
Figure A.19: Interval Plot of Cost (e) by region, gender & age cohort, Sce-
nario 2, 2021
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Figure A.20: Interval Plot of Cost (e) by gender & age cohort, Scenario 2,
2026
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The implications of regional and national
demographic projections for future GMS costs in
Ireland through to 2026
Aisling Conway1*, Martin Kenneally2, Noel Woods2, Andreas Thummel3 and Marie Ryan2
Abstract
Background: As the health services in Ireland have become more resource-constrained, pressure has increased to
reduce public spending on community drug schemes such as General Medical Services (GMS) drug prescribing and
to understand current and future trends in prescribing. The GMS scheme covers approximately 37% of the Irish
population in 2011 and entitles them, inter alia, to free prescription drugs and appliances. This paper projects the effects
of future changes in population, coverage, claims rates and average claims cost on GMS costs in Ireland.
Methods: Data on GMS coverage, claims rates and average cost per claim are drawn from the Primary Care
Reimbursement Service (PCRS) and combined with Central Statistics Office (CSO) (Regional and National Population
Projections through to 2026). A Monte Carlo Model is used to simulate the effects of demographic change (by region,
age, gender, coverage, claims rates and average claims cost) will have on GMS prescribing costs in 2016, 2021 and 2026
under different scenarios.
Results: The Population of Ireland is projected to grow by 32% between 2007 and 2026 and by 96% for the over 70s.
The Eastern region is estimated to grow by 3% over the lifetime of the projections at the expense of most other regions.
The Monte Carlo simulations project that females will be a bigger driver of GMS costs than males. Midlands region will
be the most expensive of the eight old health board regions. Those aged 70 and over and children under 11 will be
significant drivers of GMS costs with the impending demographic changes. Overall GMS medicines costs are projected
to rise to €1.9bn by 2026.
Conclusions: Ireland’s population will experience rapid growth over the next decade. Population growth coupled with
an aging population will result in an increase in coverage rates, thus the projected increase in overall prescribing costs.
Our projections and simulations map the likely evolution of GMS cost, given existing policies and demographic trends.
These costs can be contained by government policy initiatives.
Keywords: GMS prescribing, Monte carlo simulation model, Regional variation, Scenario analysis
Background
Many of the developed economies, including Ireland,
are struggling to contain expenditure on health follow-
ing the fiscal crisis in the aftermath of the 2008 global
economic recession. Expenditure on pharmaceuticals
is one of the fastest growing elements of total health
spending within the European Union (EU). Pharma-
ceutical expenditure exceeded €180 billion in 2008
within the EU and accounted, on average, for approxi-
mately 17 per cent of EU countries’ total expenditure
on health [1]. In 2009, Ireland had one of the highest
pharmaceutical spends per capita of the Organisation
for Economic Co-operation and Development (OECD)
countries after the US, Canada and Greece [2]. In Ireland,
pharmaceutical expenditure accounted for 16.9 per cent
of total health expenditure in 2007 and pharmaceutical
spend per capita was €446.37, peaking at 17.9 per cent
and €501.48 in 2010 [3]. Community Drugs Schemes
(CDS) in Ireland consist of the General Medical Services
(GMS), the Long Term Illness (LTI) Scheme, Drug
* Correspondence: aisling.conway@cit.ie
1Department of Management & Enterprise, Cork Institute of Technology,
Rossa Avenue, Bishopstown, Cork City, Ireland
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Payment Scheme (DPS) and the High Tech Drug
Scheme (HTDS). CDS expenditure on medicines accounted
for approximately 85 per cent of total drug expenditure in
Ireland in 2007 [4]. The annual cost of medicines under
community drug schemes in Ireland increased from €564 m
in 2000 to €1,961 m in 2009 before falling by an esti-
mated 8 per cent by 2011 following a series of cost
containment measures [1].
The focus of this paper is the GMS scheme which is
the largest of the schemes with 36.9 per cent of the
population eligible in 2011 [5]. Those who are eligible
for the GMS scheme (medical card holders) are entitled
to free prescription drugs and appliances with a nominal
charge per item (€0.50) introduced in budget 2011 . Cost
of Medicines on the GMS scheme more than trebled be-
tween 2000 and 2009 from approximately €338 million
to €1,260 million. Overall, costs of medicines were ap-
proximately €1,048 million in 2007 and increased by
15.2 per cent to approximately €1,207 million in 2011.
Following a sharp contraction in the Irish economy in
2008, resulting in mounting fiscal deficits, the sustain-
ability of funding these community drug schemes have
come under the spotlight of the EU, International Mon-
etary Fund (IMF) and European Central Bank (ECB)
(Troika) who have set stringent targets for reducing drug
costs as conditions of the bailout programme. Whilst
the troika’s main cost containment measure is on the
substitution from proprietary to generic prescribing, the
challenge for Ireland and many of our EU counterparts
in containing expenditure on pharmaceuticals is severely
restricted by the growth in the elderly component of our
populations, the sub-group with the greatest consumption
of prescribed drugs. Projections by the Central Statistics
Office (CSO) show the number of elderly people in
Ireland will have grown by 200,000 by 2021 [6].
The literature highlights six cost drivers of drug ex-
penditure; population growth, population aging, general
inflation, price effects, volume effects and mix of drugs
[7]. Whilst Irish drug pricing is substantially higher than
our UK counterparts [8], the ESRI identifies population
growth and population aging as the key drivers of future
drug costs [2]. People in developed economies are living
longer, with life expectancy at their highest level and
population projections predicting significant increases in
the total number of older people. The proportion of
people who are very old is growing fastest and this num-
ber is expected to almost double by 2030. According to
the World Health Organisation, the present and future
generations of older people can also expect to live for
considerably longer than their predecessors.
This paper assesses the implications of demographic
change and policy scenarios on future GMS costs in
Ireland from 2007 through to 2026. GMS costs are de-
termined by population, GMS coverage, claims rate and
the average cost per claim and assumptions were made
around these four variables For this analysis, the cover-
age rate is defined as the proportion of the population
eligible for the GMS scheme and the claims rate is the
percentage of those covered who make a claim. The
average cost per claim is the total cost of claimants di-
vided by the number of claimants.
Predictions of drug utilisation and costs have been
undertaken in several international studies [9,10]. A
fixed effects model was used to predict the impact of
regulation on pharmaceutical cost in 19 countries from
1992 to 2004, finding that regulations reduce pharmaceut-
ical revenues significantly [9]. A Spanish study investi-
gated the capacity to predict future high-cost patients in
Spain through c-statistic, sensitivity and specificity param-
eters finding that pharmacy-based predictive models can
assist administrators and medical directors in planning
the health budget and identifying high-cost-risk patients
amenable to care management programs [10]. A number
of predictive studies have been undertaken in the United
States on future health care costs, which also inform fu-
ture prescribing costs [11-13]. These studies predicted
drug expenditures for the Medicare scheme [11] and a
veteran health population [12], respectively, and their
models included demographic and health status variables.
Both [11,12] found combined drug and diagnostic data are
superior in predicting total health care costs. A compari-
son of the predictive performance of diagnosis and drug
based models to determine health care costs in the US
found drug based models predict future pharmacy costs
more effectively than diagnosis based models and a com-
bined drug and diagnostic model is a better predictor of
future health care costs than either model alone [13].
In terms of the most relevant studies in Ireland, a lin-
ear current use model on 2006 data, and a regression
model, was used to project future prescribing for the
three community drug schemes [14]. They predicted
that ingredient costs are likely to be between €1.5bn and
€2.3bn for the three Community drug schemes (GMS,
LTI & DPS) by 2020 with the largest increase in the
GMS scheme. The ingredient cost incorporates approxi-
mately 80 per cent of the total cost of prescriptions. The
total cost of prescriptions is comprised of the ingredient
cost, dispensing fee and VAT. This paper updates and
expands the Bennett et al. (2009) projections for the
GMS scheme only. In addition, this paper includes
demographic and regional population changes, policy
variables and provides a Monte Carlo sensitivity ana-
lysis of the results. A regional examination of chronic
conditions influencing drug prescribing found that regional
factors were highly variable in Ireland and significant [15],
whilst an investigation into the prescribing prevalence of
insulin dependent and non-insulin dependent diabetes
again found a significant variation between regions [16].
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Methods
The main source of data is the PCRS Statistical Analysis
of Claims and Payments, Annual Reports and a sample
2007 PCRS database. The sample database consists of
192,000 observations extracted from the GMS popula-
tion claims data. The base year used is 2007 and the
geographical area is the former Health Board, of which
there are 8. The first 100 observations by gender and
age cohort in each monthly file was used in this analysis.
For example, 0–5 Eastern male, there are 100 observa-
tions. 192,000/100 = 16,000 in each month. The variables
in the database include; ingredient cost, VAT, dispensing
fee, total cost, number of items and number of forms
and are disaggregated by month (12), age cohort (10),
gender (2) and region (8). Claims rate and average cost
per claim were estimated using the sample PCRS data-
base. For our analysis, the data is disaggregated by 10
age cohorts, 2 genders and 8 regions for each of the four
variables. The data used in this paper was granted by the
Health Service Executive (HSE) and is anoymised where
individuals are not identified, the data does not have a
unique user identifier. Therefore, it was unnecessary to
seek ethical approval.
Population data was sourced from the CSO Regional
Population Projections 2011–2026. Data was detailed by
year of age, gender, county and region, taking account of
international migration, fertility and inter-regional flows.
In order to conform to HSE age cohorts, the CSO data
were reconciled into ten age cohorts. The CSO regions
(Border, Mid-East, Dublin) were not reconcilable with
three of the old health board regions (North-West,
North-East, Eastern). An adjustment factor based on the
2006 Census was applied to form the North-West,
North-East and Eastern regions to conform to the old
health board regions.
Coverage 2007 was estimated from the PCRS annual
report and CSO population projections. Medical card
coverage was 30.1 per cent (1,276,178 persons) of the
population in 2007 [17] increasing to 36.9 per cent
(1,694,063) in 2011 [5]. The minimum, mean and max-
imum 2007 scenarios were calculated based on historical
coverage data between 1996 and 2010. Three scenarios
were estimated for 2011 based on historical coverage
data between 1996 and 2011 to form three coverage sce-
narios by region, gender and age cohort (RGA).
Coverage projections for 2016, 2021 and 2026 were es-
timated using 2011 coverage data, as this was the most
up to date data available at the time of projections. The
projected mean population was used to estimate the
coverage and the number of eligible persons for each
scenario by RGA in 2016, 2021 and 2026. If the older
age cohorts (70–74, >75) for each region and gender
exceeded 1.00, an adjustment factor was applied with
lambda taking any value between 0 and 0.99. For example,
if the projected population for >75 in a given region is 100
but the number of projected GMS eligible persons is 105,
GMS coverage rate is 1.05. As this value exceeds 1.00, the
adjustment factor below was applied to scale the value
below 1.00.
Adjustment Factor ¼Min >75 – λ 1:00 – 70‐74 age cohortð Þð Þ
The claims rate was estimated using both the PCRS
2007 annual report and a sample 2007 PCRS database.
For this analysis, the claims rate is the proportion of med-
ical card holders who make a claim. Of the 1,276,178
medical card holders in 2007, 1,225,131 made a claim on
the card giving a claims rate of 96 per cent in 2007. A 95
per cent confidence interval was applied, establishing a
lower bound (minimum scenario) and upper bound (max-
imum scenario) around the mean claims rate. For this
analysis, the claims rate was assumed to remain at the
2007 level throughout the lifetime of the projections . This
is borne out by It was found that the introduction of a 50
cent co-payment charge in 2010 did not affect patient de-
mand for drugs [18]. Furthermore, the national claims rate
has not changed since the co-payment introduction. 93
per cent of eligible GMS persons availed of services in
2010 and 2011 [5,19].
The average cost (ac) per claim was determined from
the sample 2007 PCRS database which is the total cost of
claimants divided by the number of claimants. More than
96 per cent of all GMS eligible persons availed of services
in 2007 with an average pharmacy cost of €856.14 per per-
son [17]. A 95 per cent confidence interval was applied,
establishing a lower bound (minimum scenario) and upper
bound (maximum scenario) around the mean cost per
claim. Historical ac per claim growth rates were deter-
mined and we assumed the historical growth evolution
would continue in estimating the ac per claim for 2011
and projections between 2016 and 2026.
The utilisation and expenditure on drugs are difficult to
forecast due to uncertainties about the rate of adoption of
new medicines and various ongoing health care reforms
and activities to improve the quality and efficiency of
prescribing. The Monte Carlo Simulation (MCS) model
employs statistical sampling to forecast under uncertainty.
MCS generates a large number (100,000) of outcomes
which is representative of your decision and assesses
your decisions and the impact of risk, allowing for better
decision making under uncertainty. Taking a large number
of simulations as we have done, gives an excellent ap-
proximation to the true distribution of projected cost.
The equation used for simulations is;
Probable cost ¼ Expected cost þ error
where error is an ensemble for the Monte Carlo simu-
lation, having a normal distribution with zero mean and
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standard deviation of 5% of cost. It was found that using
an MCS model avoided bias in health economic model-
ling [20]. The MCS model identifies uncertain variables
(explanatory variables) and uncertain functions (dependent
variables). The uncertain variables are population, cover-
age, claims rate and ac per claim and the uncertain func-
tion is the total costs of GMS scheme. For this analysis, the
MCS model was adopted to forecast GMS costs through
to 2026.
Empirical probability (proportion) was determined by
each RGA class. The cumulative probabilities were cal-
culated which gives a weight for the occurrence of find-
ing a person in an RGA class. A macro was written in
Visual Basic Editor in Microsoft Excel to run the simula-
tions. An MCS with 100,000 iterations was used to
propagate the uncertainty in the model. It’s important to
assign an appropriate probability distribution to uncertain
variables in developing a comprehensive MCS model [21].
A Normal distribution was applied to estimate costs to
allow for uncertainty in the model. The MCS results were
imported into Minitab 16 for statistical analysis. Descrip-
tive and statistical analysis was performed in Minitab for
each scenario and an overall analysis was carried out com-
paring all three scenarios by region, gender and age co-
hort. Statistical analysis included a histogram of cost,
main effects plot, interval plot of cost by region, gender
and age cohort.
Results
The population of Ireland is projected to grow rapidly
with a sharp increase in both the birth rate and in the
elderly population. The total population is projected to
grow by 96.3 per cent over the lifetime of the projec-
tions. The projections indicate that the population will
increase from 4.3 million in 2007 to 5.7 million in 2026
(32.6% increase). The male population is estimated to
increase by 33.4 per cent increase and the female popu-
lation is estimated to increase by 30.2 per cent by 2026.
In the 70 to 74 age category, there is an estimated 85.4
per cent increase between 2007 and 2026. The over 75 s
shows the largest increase over the lifetime of the pro-
jections where the population more than doubles from
208,756 in 2007 to 422,589 in 2026 (102.4%). Over 70s
projected population will increase in the first three time
periods (2007–2011, 2011–2016 and 2016–2021) and
will grow at a slower rate of 22.6 per cent between 2021
and 2026.
In terms of regional population change, the Eastern re-
gion constituted 35.5 per cent of the overall population in
2007. That proportion is projected to increase to 38.2 per
cent by 2026 whereas the Southern region will decrease
from 14.6 per cent in 2007 to 13.6 per cent in 2026. The
remaining regions will see a decrease in population apart
from the Western region which will remain constant.
We have estimated that coverage will be approximately
34.7 per cent in 2016, 37.5 per cent in 2021 and 37.2 per
cent in 2026 (Figure 1). It is estimated that the number
of eligible GMS persons will be approximately 1.8 million
in 2016, 2 million in 2021 and 2.1 million in 2026. The es-
timates of the mean claims rate and the ac per claim for
2007 are detailed in Tables 1 and 2.
The MCS model projects total pharmacy cost will
rise to €1,317 million in 2016, €1,626 million in 2021
and €1,985 million in 2026 (Figure 2), given the as-
sumptions around the 4 variables. The descriptive ana-
lysis of 100,000 simulations for scenario 2 in 2016
projected an average cost per claimant of €272.31. This
is projected to be €312.61 in 2021 and €366.81 in 2026
(Table 3). Statistical analysis for the 3 scenarios in
2016 and the main effects plot for scenario 2, 2016 show
the effect the three categorical variables have on the aver-
age cost per claimant in 2016. The main factors driving
30.1
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Figure 1 Percentage GMS coverage rate projections, Ireland 2016–2026.
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costs in 2016 were found to be: age, and in particular
those aged 0–11, and those aged 70+, being resident in
the midlands region and being female. These key findings
were replicated in 2021 and 2026. The main effects plot il-
lustrates age as the most significant driver of cost com-
pared to the other two variables, gender and region
(Figure 3). These results show a similar picture for
2021 and 2026 (Figure 4).
Discussion
Population growth, aging population and high fertility
rates will be drivers of future health costs in Ireland.
Population growth is the effect of changes in the size of
the population on total drug spending. Other things be-
ing equal, an increase in population size will increase
total drug spending. It is well documented in the litera-
ture that population is a driver of Irish health care ex-
penditure [22,23]. We estimate that the Irish population
will have increased by approximately 33 per cent by
2026. Population aging is the effect of changes in the age
distribution of the population on spending. An aging
population will result in increased spending as the use
and cost of drugs increase with age for the average in-
dividual within the population. Furthermore, Ireland
has the highest fertility rate (2.05) in the European
Union (EU27) as of March 2013. According to Eurostat,
Ireland has on average two live births per woman [24].
The CSO recorded 72,225 births in 2012, a 19.3 per cent
increase on 2002 births, indicating fertility will be a driver
of population growth going forward [25]. This is com-
pounded in our results with the 0–11 age cohort as a key
driver of future health care costs. A Canadian study found
population growth and population aging had the least ef-
fect on drug spending with volume effects and the mix of
drugs having the most significant effect of the six cost
drivers [7].
It is argued that a shift in the proportion of the popu-
lation being elderly causes a shift in the health care ex-
penditure in fifteen EU countries [26]. That is, as people
are living longer, it represents a shift in expenditure
from one age group to another. According to the latest
CSO life tables, male life expectancy has increased by
Table 1 Mean scenario claims rate (Claims rate = Number of claimants/GMS population) 2007
Region 0 – 11 12 – 15 16 – 24 25 – 34 35 – 44 45 – 54 55 – 64 65 – 69 70 – 74 >75 Total
Eastern
Males 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Females 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Midland
Males 1.00 0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Females 1.00 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mid-Western
Males 0.93 0.88 0.90 0.91 0.91 0.94 0.96 0.9 0.97 0.99 0.93
Females 0.93 0.88 0.93 0.93 0.93 0.95 0.96 0.98 0.98 0.98 0.95
North-Eastern
Males 0.88 0.82 0.85 0.86 0.87 0.91 0.93 0.95 0.94 0.95 0.90
Females 0.88 0.82 0.91 0.90 0.90 0.92 0.95 0.94 0.96 0.95 0.91
North-Western
Males 0.87 0.81 0.83 0.83 0.84 0.88 0.91 0.93 0.95 0.94 0.88
Females 0.85 0.81 0.87 0.88 0.88 0.90 0.92 0.94 0.95 0.94 0.90
South-Eastern
Males 0.96 0.94 0.94 0.95 0.96 0.97 0.98 0.98 0.98 0.99 0.96
Females 0.97 0.94 0.96 0.97 0.97 0.97 0.98 0.99 0.99 0.99 0.97
Southern
Males 0.97 0.95 0.96 0.96 0.97 0.98 0.98 0.99 0.99 0.99 0.97
Females 0.97 0.95 0.97 0.97 0.98 0.98 0.99 0.99 0.99 0.99 0.98
Western
Males 0.87 0.81 0.83 0.85 0.87 0.89 0.92 0.93 0.94 0.95 0.88
Females 0.87 0.81 0.89 0.88 0.89 0.91 0.93 0.94 0.95 0.95 0.90
Total 0.93 0.90 0.93 0.93 0.93 0.95 0.96 0.97 0.97 0.98 0.95
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Table 2 Mean scenario average cost per claim (€) by gender, age & region 2007
Region 0 – 11 12 – 15 16 – 24 25 – 34 35 – 44 45 – 54 55 – 64 65 – 69 70 – 74 >75 Total
Eastern
Males 228.09 352.31 468.36 663.13 715.28 1024.07 1225.56 1301.78 1111.03 1261.80 835.14
Females 250.13 314.96 370.39 434.52 622.62 1036.64 1182.49 1339.82 1233.99 1565.85 835.14
Midlands
Males 252.32 346.52 570.72 862.57 843.18 1053.12 1212.19 1306.25 1374.38 1483.05 930.43
Females 286.53 287.65 433.68 527.21 784.65 1039.87 1280.93 1344.24 1510.02 1809.51 930.43
Mid-Western
Males 312.55 518.26 632.72 780.04 943.63 946.39 1122.24 1150.38 1145.96 1224.23 877.64
Females 331.60 391.68 381.46 574.27 779.34 1001.62 1261.18 1233.93 1298.71 1522.60 877.64
North-Eastern
Males 287.17 387.18 546.40 807.66 811.09 919.99 1136.46 1141.29 1192.14 1363.01 859.24
Females 290.24 438.25′ 324.13 502.04 671.81 970.68 1129.80 1329.20 1337.70 1598.56 859.24
North-Western
Males 224.88 313.54 411.39 607.13 721.31 792.40 909.40 976.33 958.41 1216.81 713.16
Females 257.50 264.09 294.35 388.02 566.78 767.27 1016.47 1076.26 1102.82 1398.05 716.16
South-Eastern
Males 272.48 397.70 591.81 817.17 846.95 1009.93 1087.12 1150.66 1200.19 1286.47 866.05
Females 247.29 389.64 380.57 454.17 753.83 1114.55 1223.04 1277.73 1314.70 1504.99 866.05
Southern
Males 310. 32 407.65 617.11 884.82 891.47 1039.17 1228.63 1315.09 1223.99 1265.83 918.41
Females 357.49 454.20 416.13 583.39 754.74 1132.37 1240.35 1375.76 1380.47 1489.19 918.41
Western
Males 298.90 375.46 555.50 865.61 822.04 935.52 1069.00 1199.25 1124.97 1307.75 855.40
Females 321.00 322.29 339.24 563.25 744.94 1035.37 1123.41 1238.10 1330.83 1535.57 855.40
Total 283.03 372.59 458.37 644.69 767.10 988.69 1153.02 1234.75 1240.02 1427.08 856.14
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Figure 2 Historical projections and projected pharmacy cost (€’000 m) to 2026.
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5.8 years between 1996 and 2006 and 4.9 years for fe-
males [27]. This may justify the addition of a 12th HSE
age cohort, the >80s and renaming >75 s to 75–79 to
represent a shift in population where people are living
longer.
Population growth, aging population and high fertility
rates under existing policies will have a knock on effect
on future GMS coverage rates. That is, more people will
be eligible for medical cards. Since July 2001, everyone
over the age of 70 had a free entitlement to a medical
card. In 2005, General Practitioner Visit Cards (GPVC)
were introduced for persons who did not qualify for a
medical card. This card allows one to obtain free general
practitioner services subject to eligibility criteria. This
initiative was extended to all children under five years of
age in the Irish budget, 2014. In 2005, 5,079 people were
entitled to a GPVC [28] but by 2011 this increased to
125,657 [5].
In January 2009, eligibility for the GMS scheme chan-
ged for the over 70s. New medical card income limits
were introduced. A single person with an income of
€700 per week (€36,500 per year) or a couple with an in-
come of €1,400 per week (€73,000 per year) were no lon-
ger entitled to a free medical card [23]. Budget 2014
reduced the income limits to €500 per week for a single
person and €900 per week for a married couple [29].
This policy change will reduce the eligibility rates and
reduce overall coverage rates, holding all other factors
constant. Since the introduction of this policy change, it
is difficult to quantify the impact of this policy as the
Irish economy is still in recession with more people eli-
gible for the medical card due to their economic circum-
stances. Due to the three drivers of future health costs
as mentioned above, GMS coverage is likely to increase
thus increasing health costs. To counter this increase,
the Irish government may need to consider further de-
creasing the income limits for medical cards or other
measures.
The Midlands region is the most expensive and the
North-West is the least expensive old health board region
Table 3 Descriptive analysis of average cost per claimant (€) 2016 – 2026 (Scenario 2)
Year # of Simulations Mean SE Mean St. Dev Min Q1 Median Q3 Max
2016 100,000 272.31 0.912 149.32 69.63 106.19 167.59 286.14 1541.72
2021 100,000 312.61 0.994 314.45 78.65 121.29 190.43 330.86 1579.73
2026 100,000 366.81 1.18 272.28 86.68 135.56 241.10 371.60 1602.28
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between 2003 and 2009 in terms of the average pharmacy
cost per eligible GMS person. The Midlands cost ranged
from €649.14 in 2003 to €943.28 in 2009 and the North-
West ranged from €521.91 and €787.19 over the same
time period [30]. Our results show that this trend is fore-
casted to continue to 2026. This regional variation in cost
may be explained by the following two studies. The distri-
bution of chronic conditions was examined across the old
health board regions and it was found the Midlands had
the highest prevalence of chronic conditions with the
Western and North-Western regions having the lowest
[15]. The prescribing prevalence of insulin dependent and
non-insulin dependent diabetes was examined across re-
gions [16]. They found the Midlands and the Mid-Western
regions had the highest prescribing ratios for both types of
diabetes and the North-Western region had the lowest pre-
scribing ratio. It is well documented that females visit doc-
tors more regularly than men, hence prescribing rates are
higher for females with a resulting effect of higher health
costs. Our results verify this, with females forecasting
higher costs than males for all scenarios.
The claims rate, i.e. the proportion who make a claim
on a medical card, has been above 90% since 2002. The
Irish government introduced a patient co-payment sys-
tem in October 2010 for medical card holders with a 50
cent per prescription charge, capped at €10 per month
and in Budget 2014, this was increased to €2.50 per
prescription item, with a monthly cap of €25 [29]. The
prescription charge was introduced to reduce the claims
rate and the average cost per claim. Research found the 50
cent co-payment charge did not affect patient demand for
drugs [18]. No research has been done on subsequent in-
creases in the patient co-payment Irish system. More ex-
pensive co-payment charges exist in the UK [31], Italy
[32] and Australia [33]. These studies show that an expen-
sive co-payment system can affect the utilisation and de-
mand for drugs. It is well documented in the literature
that co-payment charges can reduce the utilisation of both
essential and non-essential medicines in vulnerable popu-
lations such as the poor, elderly and chronically ill [34,35].
Therefore the Irish government needs to be mindful of
the ill-effects of future increases in prescription charges as
these groups comprise the GMS population in Ireland.
Limitations of Data: It is important to note the limita-
tions of this research. The PCRS sample data lacked a
unique user identifier. There is a possibility of some data
appearing twice in the dataset as we can’t identify indi-
vidual claims, but the influence of such cases is small
given the size of the sample database (192,000). The old
health board regions (8) are no longer comparable to the
current HSE regional structure (4), which was changed
in 2010. Further research with more recent data and cost
projections using the current regional structure would
prove very useful.
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Conclusions
Over the next decade, Ireland’s population will experi-
ence rapid growth. This growth coupled with an aging
population will result in an increase in both the coverage
rate and the claims rate, thus the projected increase in
overall prescribing costs. However, these costs can be
contained by government policy initiatives. A downward
adjustment of the income eligibility limits can be used to
curtail the coverage rates and upward adjustments to
the co-payment patient prescription charges can be uti-
lised to reduce the claims rate, thus curbing the overall
average cost per claim. Age (youngest and oldest), fe-
males and the Midlands region were found to have the
most significant effect on future drug costs in Ireland.
These projections remain subject to substantial uncer-
tainty given the variable nature of future economic
trends and policy decisions.
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Table C.1: Estimated Population 2012
Age
Category
Males Females Total
0–5 185,325 177,354 362,679
5–11 229,507 218,653 448,160
12–15 123,150 116,725 239,874
16–24 252,276 247,006 499,281
25–34 357,708 377,413 735,120
35–44 349,906 348,394 698,300
45–54 292,101 294,467 586,567
55–64 234,072 233,831 467,903
65–69 90,045 90,827 180,872
70–74 64,207 68,302 132,510
> 75 96,062 139,060 235,122
Total 2,274,357 2,312,031 4,586,388
Table C.2: Estimated Population 2016
Age
Category
Males Females Total
0–5 186,413 177,680 364,093
5–11 251,805 239,589 491,394
12–15 129,355 123,560 252,915
16–24 240,406 230,798 471,204
25–34 301,780 322,493 624,273
35–44 359,539 369,682 729,221
45–54 312,373 313,957 626,330
55–64 249,772 253,377 503,149
65–69 101,894 103,796 205,690
70–74 76,737 81,001 157,738
> 75 109,443 151,340 260,783
Total 2,319,517 2,367,273 4,686,790
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Table C.3: Estimated Population 2021
Age
Category
Males Females Total
0–5 162,669 155,122 317,791
5–11 266,416 253,946 520,362
12–15 144,615 137,587 282,202
16–24 274,686 264,216 538,902
25–34 266,174 271,655 537,829
35–44 342,450 369,664 712,114
45–54 337,028 340,150 677,178
55–64 275,814 282,301 558,115
65–69 110,555 115,057 225,612
70–74 93,251 98,364 191,615
> 75 136,637 178,011 314,648
Total 2,410,295 2,466,073 4,876,368
Table C.4: Estimated Population 2026
Age
Category
Males Females Total
0–5 143,237 136,596 279,833
5–11 240,966 229,549 470,515
12–15 156,883 149,547 306,430
16–24 308,137 297,023 605,160
25–34 285,374 285,051 570,425
35–44 296,909 322,549 619,458
45–54 356,130 369,725 725,855
55–64 303,107 308,245 611,352
65–69 123,101 128,915 252,016
70–74 102,328 109,722 212,050
> 75 173,655 217,145 390,800
Total 2,489,827 2,554,067 5,043,894
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Table C.7: Scenario 1, Claims Rate 2012
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 70–74 >75 Total
Eastern
Males 0.74 0.52 0.61 0.66 0.70 0.76 0.83 0.90 0.91 0.95 0.76
Females 0.67 0.52 0.70 0.74 0.74 0.78 0.86 0.87 0.90 0.88 0.77
Midlands
Males 0.91 0.86 0.88 0.89 0.90 0.92 0.95 0.95 0.95 0.96 0.92
Females 0.90 0.85 0.90 0.91 0.91 0.93 0.94 0.95 0.94 0.94 0.92
Mid–Western
Males 0.89 0.81 0.84 0.86 0.87 0.91 0.94 0.95 0.95 0.98 0.90
Females 0.87 0.81 0.88 0.88 0.88 0.91 0.93 0.95 0.95 0.95 0.90
North–Eastern
Males 0.82 0.74 0.77 0.79 0.80 0.86 0.89 0.92 0.91 0.92 0.84
Females 0.79 0.72 0.84 0.82 0.83 0.85 0.89 0.89 0.90 0.90 0.84
North–Western
Males 0.83 0.76 0.78 0.79 0.80 0.84 0.88 0.90 0.92 0.91 0.84
Females 0.79 0.75 0.82 0.83 0.83 0.84 0.87 0.90 0.90 0.90 0.84
South–Eastern
Males 0.86 0.77 0.79 0.81 0.84 0.88 0.93 0.95 0.94 0.97 0.87
Females 0.85 0.74 0.84 0.86 0.85 0.87 0.92 0.94 0.94 0.95 0.88
Southern
Males 0.91 0.85 0.88 0.88 0.90 0.93 0.95 0.96 0.96 0.98 0.92
Females 0.89 0.84 0.91 0.90 0.92 0.93 0.96 0.96 0.96 0.97 0.92
Western
Males 0.82 0.75 0.78 0.80 0.83 0.85 0.88 0.90 0.91 0.92 0.84
Females 0.81 0.74 0.84 0.83 0.83 0.85 0.88 0.89 0.90 0.90 0.85
Total 0.83 0.75 0.82 0.83 0.84 0.87 0.91 0.92 0.93 0.94 0.88
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Table C.8: Scenario 3, Claims Rate 2012
Region 0–11 12–15 16–24 25–34 35–44 45–54 55–64 65–69 70–74 >75 Total
Eastern
Males 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Females 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Midlands
Males 1.00 0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Females 1.00 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mid–Western
Males 0.93 0.88 0.90 0.91 0.91 0.94 0.96 0.97 0.97 0.99 0.93
Females 0.93 0.88 0.93 0.93 0.93 0.95 0.96 0.98 0.98 0.98 0.95
North–Eastern
Males 0.88 0.82 0.85 0.86 0.87 0.91 0.93 0.95 0.94 0.95 0.90
Females 0.88 0.82 0.91 0.90 0.90 0.92 0.95 0.94 0.96 0.95 0.91
North–Western
Males 0.87 0.81 0.83 0.83 0.84 0.88 0.91 0.93 0.95 0.94 0.88
Females 0.85 0.81 0.87 0.88 0.88 0.90 0.92 0.94 0.95 0.94 0.90
South–Eastern
Males 0.96 0.94 0.94 0.95 0.96 0.97 0.98 0.98 0.98 0.99 0.96
Females 0.97 0.94 0.96 0.97 0.97 0.97 0.98 0.99 0.99 0.99 0.97
Southern
Males 0.97 0.95 0.96 0.96 0.97 0.98 0.98 0.99 0.99 0.99 0.97
Females 0.97 0.95 0.97 0.97 0.98 0.98 0.99 0.99 0.99 0.99 0.98
Western
Males 0.87 0.81 0.83 0.85 0.87 0.89 0.92 0.93 0.94 0.95 0.88
Females 0.87 0.81 0.89 0.88 0.89 0.91 0.93 0.94 0.95 0.95 0.90
Total 0.93 0.90 0.93 0.93 0.93 0.95 0.96 0.97 0.97 0.98 0.95
313
Table C.9: Population Weightings for Coverage Parameter
Region Sex <5 5–11
Eastern Male 0.462947371 0.537052629
Eastern Female 0.463567094 0.536432906
Midlands Male 0.437800834 0.562199166
Midlands Female 0.436041083 0.563958917
Mid–Western Male 0.441812013 0.558187987
Mid–Western Female 0.436505228 0.563494772
North–Eastern Male 0.441924222 0.558075778
North–Eastern Female 0.449205238 0.550794762
North–Western Male 0.423576073 0.576423927
North–Western Female 0.428054754 0.571945246
South–Eastern Male 0.434129262 0.565870738
South–Eastern Female 0.433216229 0.566783771
Southern Male 0.444482546 0.555517454
Southern Female 0.448557235 0.551442765
Western Male 0.436259237 0.563740763
Western Female 0.435169787 0.564830213
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Figure C.1: No. of Eligible Persons Projections Updated 2016 – 2026
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Figure C.2: Pie Chart of Cost (e), Scenario 2 2021
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Figure C.3: Pie Chart of Cost (e), Scenario 2 2026
Figure C.4: Histogram of Cost (e), Scenario 2 2021
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Figure C.5: Histogram of Cost (e), Scenario 2 2026
Figure C.6: Interval Plot of Cost by Region, Scenario 2 2021
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Figure C.7: Interval Plot of Cost by Region, Scenario 2 2026
Figure C.8: Interval Plot of Cost by Age Cohort, Scenario 2 2021
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Figure C.9: Interval Plot of Cost by Age Cohort, Scenario 2 2026
Figure C.10: Interval Plot of Cost by Sex, Scenario 2 2021
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Figure C.11: Interval Plot of Cost by Sex, Scenario 2 2026
Figure C.12: Main Effects Plot 0–11, Scenario 2 2026
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Figure C.13: Main Effects Plot 0–11, Scenario 2 2021
Figure C.14: Main Effects Plot >70, Scenario 2 2026
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Figure C.15: Main Effects Plot >70, Scenario 2 2021
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Irish population and GMS coverage projections by health board region, sex and 
age cohort out to 2026. 
 
Abstract 
This paper projects population and GMS coverage rates and is disaggregated by old 
health board region, sex and age cohort in five year time intervals between 2016 and 
2026.  Data is drawn from the Primary Care Reimbursement Service (PCRS) and the 
Central Statistics Office (CSO).  2012 is the base year for projections and three 
scenarios are estimated for each projected year; mean scenario, lower bound scenario 
and an upper bound scenario.  The Irish population is estimated to grow by 
approximately 10% between 2012 and 2026, whereas the over 70s are expected to 
grow by 64%.  The Eastern region is expected to grow at the expense of the other 
regions.  37% of the population is estimated to live in the Eastern region in 2026.  
GMS coverage is estimated to lie between 33% and 46% in 2026.  Increased coverage 
rates are likely given an increase in population and the over 70s living longer. 
 
 
Keywords  population projections, GMS projections, Ireland, regions  
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Introduction 
This paper details the methodology used and the assumptions made in deriving population 
and coverage projections for five year intervals between 2016 and 2026 disaggregated by the 
old heath board region, age cohort and sex.  Central Statistics Office (CSO) population data 
form the basis of the population projections for this paper (CSO, 2013).  The population 
projections are used in conjunction with the Primary Care Reimbursement Service (PCRS) 
data to build General Medical Services (GMS) coverage rates by the old heath board region, 
age cohort and sex in Ireland.  GMS coverage is the proportion of the population who are 
eligible for a medical card.  The analysis is based on 2011 CSO census data and 2012 PCRS 
data and the projection years include 2016, 2021 and 2026. Population and coverage rates are 
estimated under three scenarios; minimum (scenario 1), mean (scenario 2) and maximum 
(scenario 3).  Current CSO population projections are not suitable for this research as the data 
is provided by CSO region.  Population projections by the old health board regions is 
required for GMS coverage projections.  Therefore, this research uses the CSO population 
data and develops population projections by the old health board region, age cohort and sex.   
This is the main contribution of this paper.  The old health board regions will be referred to as 
HSE regions for the remainder of the paper.  The paper is structured as follows.  The 
background section provides a brief description of population projection models and the 
GMS scheme in Ireland.  The methodology section discusses the principal data sources and 
methods used.  The results are summarised in the results sections and the discussion section 
analyses the findings and policy implications.  The final section concludes. 
 
 
Background 
In terms of the existing literature, the CSO has been the main source of Irish population 
projections and research data.  Blackwell & Associates (2001) were commissioned by the 
Department of the Environment and Local Government to produce population forecasts, 
labourforce and housing demand forecasts for the national spatial strategy.  Projections were 
based on CSO data (1999 – 2000) and forecasts were produced in five year intervals out to 
2030 by CSO regions.  Twelve models were developed in total, some of which were used for 
sensitivity analysis.  Connell & Pringle (2004) developed four forecasts (A1-A4) around the 
assumptions of births, deaths, net migration, marital status and living alone in five year 
intervals out to 2021 by county.  This report compares population projections produced in 
1995 for the National Council for the Elderly with actual population using Census 2002 and 
census 2006 data.  Morgenroth (2009) developed population projections for 27 Irish counties 
using 2006 census data as a starting point and made assumptions around mortality, fertility 
and migration.  Previous research has focused on national and county trends.  Conway et al 
(2014) assessed the implications of demographic change and policy scenarios on future GMS 
costs in Ireland from 2007 through to 2026.  Their estimated population projections using 
CSO regional population projections 2011 – 2026 and census 2006 data.  They projected 
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GMS coverage rates from 2007 to 2026.  This research adds value as it produces population 
and GMS coverage projections in five year intervals between 2016 and 2026 by the old 
health board region, sex and Health Service Executive (HSE) age cohorts.  No previous 
research has published population and GMS coverage projections by these three variables 
using CSO Regional Population Projections 2016-2031 and Census 2011 data.  These 
projections will facilitate further research in determining the effect of population and GMS 
coverage changes on future GMS costs. 
The GMS scheme is the largest of the community drug schemes in Ireland with 40.40% of 
the population (1,853,877 persons) eligible in 2012, the highest it has been since data was 
published in 1998 (1,252,385, 34.54%) (PCRS Annual reports, 1998 & 2012).  This 
represents an increase of 48% between 1998 and 2012.  Those who are eligible for the GMS 
scheme (medical card holders) are entitled to free prescription drugs and appliances.  This 
paper focuses on persons who are eligible for a full medical card.  In 2012, Ireland spent 14% 
of total government expenditure on health which is comparable with the European Union 
(EU) average, EU28.  Irish health spending accounted for 8.9% of Gross Domestic Product 
(GDP), just above the EU28 average of 8.7% (OECD, 2014).  Since the economic crisis 
began in 2008, the number of persons eligible for medical cards increased.  A person may 
apply for  a medical card if they fall within certain eligibility criteria.  1,352,120 persons 
were eligible for the GMS scheme in 2008 and this increased to 1,853,877 in 2012, an 
increase of 37.11%.  This augmented pressure on the Irish health budget at a time when 
contractionary fiscal measures were being implemented.  According to the WHO report 
(2014), 26.1% (€16,156m) of the total government budget was spent on health  in 2008 and 
this fell to 25.9% (€14,469m) in 2012.  This report also finds that government health 
spending between 2008 and 2012 fell by 10.4%.  Thomas et al (2012) reported more than €2 
billion in cuts to the public health system between 2010 and 2012. During this time period, 
the total cost of GMS medicines increased by 12.5% from €1,145m in 2008 to €1,288m in 
2012 (PCRS, 2008 & 2012).   
 
As detailed in table 1, health care prices increased between 2008 and 2012.  Ireland 
experienced a deflationary period between 2009 and 2010 as indicated in table 1 but health 
price inflation increased during this time.  In 2009 and 2010, hospital and dental services 
were driving health price inflation and hospital services have a high expenditure weighting in 
the index (CSO, 2012a). According to the WHO report (2014), Irish health inflation was the 
highest except for the Netherlands amongst 15 EU countries between 2005 and 2012.  Public 
spending on health was reduced during this recessionary period, with a backdrop of rising 
health inflation, population growth and growth in entitlements for community drug schemes 
e.g. GMS scheme. 
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Table 1: Consumer Price Index (CPI) (All items, health items) 2008 – 2012, Ireland  
(Base Dec2011 = 100) 
Year   2008  2009  2010  2011  2012 
All Items  102.4  97.9  96.9  99.4  101.1 
Annual % Change  4.1  -4.5  -1.0  2.5  1.7 
In CPI 
Health Items  92.9  96.2  96.8  100.0  100.5 
Annual % Change 6.0  3.5  0.6  3.4  0.5 
In CPI 
Source: (CSO, 2012a) 
From July 2001, any person over the age of 70 was entitled to a free medical card.  Due to 
health budget cutbacks, this automatic entitlement was removed.  In January 2009, any 
person over 70 earning more than €700 per week or €1,400 for a married couple were no 
longer automatically entitled to a free medical card.  These income limits were reduced 
further in 2013 to €600 for a single person and €1,200 per week for a married couple and to 
€500 for a single person and €900 for a married per week since the 1st of January 2014.  The 
Irish government has generated further savings in the cost of medicines during this time 
period due to some drugs coming off patent and the substitution from proprietary to generic 
prescribing (Conway et al, 2014). 
 
Methodology 
CSO national and regional population projections and PCRS annual statistical reports were 
used for this research. Data management and analysis was carried out in Microsoft Excel 
2010.  The CSO Regional Population Projections 2016-2031 provided population projections 
based on the 2011 Irish census.  Data was detailed by year of age, sex, county and region, 
taking account of mortality, international migration (M2, M3), fertility (F2) and internal 
migration (Recent, Traditional & Modified) assumptions between regions.  The national 
mortality assumption was applied across all regions.  The national mortality rate for men will 
decrease by 3.5% and 2.5% for women per annum.  Under the M2 scenario, CSO project 
population growth across all regions, whereas under the M3 scenario, the CSO forecast net 
negative international migration between 2011 and 2031 and varying regional population 
growth, where some regions will not envisage any growth. The fertility assumption (F2) 
represents a decrease in the Total Fertility Rate from 2.1 in 2010 to 1.8 by 2026 and remain 
constant thereafter. The CSO identified three internal migration scenarios; recent, traditional 
and modified.  The traditional scenario which is used in this research refers to a gradual 
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reversal to the 1996 pattern of inter-regional flows to 2021 and will remain constant 
thereafter.  The CSO developed six scenarios for their regional population projections  (CSO, 
2013).  The M2F2T scenario was used to develop the population projections for this research.   
This was deemed the most appropriate
1
 scenario to use at the time of population projections.  
The data was initially aggregated by sex and age cohort.  The population data was aggregated 
into eleven HSE age cohorts ranging from the under 5s to the over 75s.  An adjustment factor 
based on the 2011 census was applied as three of the CSO regions (Border, Mid-East, Dublin) 
did not conform to three of the HSE regions (North-West, North-East, Eastern).   
 
For example, to estimate the HSE Eastern region (Dublin, Kildare and Wicklow), the 2012 
CSO Mid-East (Meath, Kildare and Wicklow) and Dublin data was aggregated.  From the 
2011 CSO census, the number of persons in the counties of Meath, Kildare, Wicklow and 
Dublin were aggregated by age cohort and sex.  County Meath was expressed as a proportion 
of the total region to form a weighting by age cohort and sex.  This weighting was multiplied 
by the Eastern region 2012 to estimate Meath 2012 by age cohort and sex.  Meath values 
were subtracted from the Eastern region to estimate the HSE Eastern region (Dublin, Kildare 
& Wicklow) 2012.  The same methodology using the 2011 census data was applied to 
estimate the HSE North-West and North-East regions.  Regional and national population 
projections were estimated for 2016, 2021 and 2026 by age cohort, sex and HSE region.  We 
also developed a lower and upper bound scenario.  The CSO M3F2T scenario was used to 
develop projections for the lower bound scenario.  An upper bound scenario was estimated as 
follows; (M2F2T – M3F2T) + M2F2T.  The adjustment factor was applied in both scenarios 
for the relevant regions to form projections between 2016 and 2026. 
 
GMS coverage is the proportion of the population who are eligible for the GMS scheme.   
2012 coverage rates were estimated using the PCRS Statistical Analysis of Claims and 
Payments annual report and the estimated population projections generated through this 
research.  The mean coverage rate is the number of eligible GMS persons (table 7, 2012 
PCRS report) divided by the estimated population for 2012.  2012 minimum, mean and 
maximum coverage rates by the HSE regions, sex and age cohort were estimated.   Minimum 
and maximum 2012 coverage rates were estimated using historical data (national coverage 
rates) between 1996 and 2012.  The national coverage rates are illustrated in figure 1.   
 
 
 
 
                                                          
1
 Personal Communication:  A conversation took place between a CSO population statistician and the 
researcher to confirm the M2F2T was the most appropriate scenario to use. 
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Figure 1: National Coverage rates (%) between 1996 and 2012 
 
Source: Various PCRS Reports 1996 - 2012 
The historical yearly coverage percentage change was determined between 1996 and 2012 
and the minimum, mean and the maximum yearly percentage rate were calculated.  The mean 
coverage rate was scaled down by the minimum yearly percentage rate and scaled up by the 
maximum yearly percentage rate to formulate scenario 1 and scenario 3, 2012 coverage rates 
by HSE region, sex and age cohort.  In the over 75 age category, some of the values exceeded 
1.00 so an adjustment factor was applied, with lambda taking any value between 0 and 0.99.  
For example, if the projected population for >75 in a region is 100 but the number of GMS 
eligible persons is 105, GMS coverage rate is 1.05.   As this value exceeds 1.00, the 
adjustment factor below was applied to scale the value below 1.00. 
Adjustment Factor = Min (>75 – λ (1.00 – 70-74 age cohort))                   (1) 
Coverage projections 2016 through to 2026 were based on the reference year 2012 as this 
was the most up to date data available at the time of projections. In order to project coverage 
2016, three scenarios; minimum, mean and maximum were calculated based on the historical 
coverage data between 1996 and 2012.  The minimum value (0.2885) was multiplied by the 
projected total population for 2016 (scenario 2, the most likely population) of 4,686,790. This 
generated an estimated number of eligible persons of 1,352,139. The difference between the 
total number of eligible persons, 2012 (1,853,877) and 2016 (1,352,139) was derived and 
expressed as a proportion (0.729357). This value was uniformly multiplied by coverage 2012 
to generate scenario 1 coverage 2016 by HSE region, gender and age cohort.  Coverage 2016 
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was multiplied by population 2016 to determine the number of eligible persons, 2016 
(scenario 1) by HSE region, gender and age cohort.  
 
The mean value (0.3243) was multiplied by the projected total population for 2016 (scenario 
2, the most likely population) of 4,686,790. This generated an estimated number of eligible 
persons of 1,519,926. The difference between the total number of eligible persons, 2012 
(1,853,877) and 2016 (1,519,926) was derived and expressed as a proportion (0.819863). 
This value was uniformly multiplied by coverage 2012 to generate scenario 2 coverage 2016 
by HSE region, gender and age cohort.  Coverage 2016 was multiplied by population 2016 to 
determine the number of eligible persons, 2016 (scenario 2) by HSE region, gender and age 
cohort. 
 
The maximum value (0.404) was multiplied by the projected total population for 2016 
(scenario 2, the most likely population) of 4,686,790. This generated an estimated number of 
eligible persons of 1,893,463. The difference between the total number of eligible persons, 
2012 (1,853,877) and 2016 (1,893,463) was derived and expressed as a proportion 
(1.021353). This value was uniformly multiplied by coverage 2012 to generate scenario 1 
coverage 2016 by HSE region, gender and age cohort.  Coverage 2016 was multiplied by 
population 2016 to determine the number of eligible persons, 2016 (scenario 3) by HSE 
region, gender and age cohort.  Coverage 2012 formed the basis of projections for 2021 and 
2026.  The same methodology for 2016 coverage rates was applied for 2021 and 2026 
coverage projections.  Three scenarios were calculated for each year.  2021 and 2026 
coverage projections were based on the most likely projected population of 4,876,368 and 
5,043,894 respectively. 
 
Results 
The population of Ireland is projected to grow significantly over the lifetime of the projection 
period. The following results are based on the most likely population scenario, M2F2T.  
Figure 2 estimates the population of Ireland will increase from 4,586,388 in 2012 to 
5,043,894 in 2026, an estimated increase of 9.47%. The male population is estimated to 
increase from 2,274,357 in 2012 to 2,489,827 in 2026, an increase of 9.98%. The female 
population is estimated to increase from 2,312,031 in 2012 to 2,554,067 in 2026, an increase 
of 10.47%.  The female population is increasing at a marginally faster rate than the male 
population as illustrated in Figure 2.  The male and female population will increase by 3.91% 
and 4.17% between 2016 and 2021. Post 2021, both the male (3.30%) and female (3.57%) 
population increase at a decreasing rate. The national population is estimated to increase by 
4.04% between 2016 and 2021 and by 3.43% between 2021 and 2026.  
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Figure 2: Irish Population Estimates and Projections, 2012 - 2026 
 
 
The over 70s population is of particular interest for this research as they are entitled to a free 
GMS card subject to eligibility criteria.  The over 70s includes two age cohorts; 70-74 and 
>75.  These two age cohorts were summed together for the purpose of this analysis.  Figure 3 
shows that the total over 70s population is projected to grow by 63.98% over the lifetime of 
the projections.  The male population is expected to grow at a higher rate of 72.20% 
compared to the female population, which is expected to grow by 57.63% between 2012 and 
2026.   
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Figure 3: >70 Irish Population Estimates and Projections, 2012 - 2026 
 
 
Regional population is expressed as a proportion of total national population. The Eastern 
region will see an increase in population and the Western region will remain relatively 
constant over the lifetime of the projections. The six other regions will see a reduction in 
population between 2012 and 2026. The Eastern region is projected to grow from 35.26% in 
2012 to 37.17% of the population in 2026 as illustrated in figure 4. This increase is at the 
expense of all other regions except the Western region. The Western region experiences the 
largest decrease over the lifetime of the projection period from 9.60% in 2012 to 9.03% in 
2026. 
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Figure 4: Regional Population Proportion (%) 2012 and 2026 
 
Table 2 shows the 2026 population projections by age cohort, sex and HSE region.  This table 
shows the most likely scenario for 2026.  Three scenarios were estimated in this format for 
2016, 2021 and 2026. 
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Table 2: National and Regional Population Projections 2026 by old health board region, Sex and Age Cohort 
____________________________________________________________________________________________________________________ 
Region  < 5       5 – 11        12 – 15         16 – 24       25 – 34       35 – 44      45 – 54      55 – 64      65 – 69    70 – 74     >75      Total 
   
Eastern 
Males  53,461         87,037         56,329            118,799      118,384        115,796       134,160      103,928        40,016       32,487       54,245  914,642 
Females              50,800          83,273         54,256            124,437      119,363        124,371       140,582      108,703        43,970       37,623       72,784  960,162 
 
Midlands 
Males   9,071           15,617         10,181            17,600            15,602          18,021          21,773        19,397          8,024         6,598        10,723  152,607 
Females  8,707           14,963         9,679              15,712            15,740          19,909          22,633        19,500          7,977         6,620        12,867  154,307      
 
Mid-Western 
Males  11,336         19,124         12,610            26,998            24,889          21,645          27,157        24,919          10,740       9,103         15,599  204,120          
Females  10,778         18,002         11,653            21,594            21,703          22,580          27,711        24,977          10,754       9,527         19,211  198,490         
 
North-Eastern 
Males  15,004          24,984        15,697            27,752            25,477          29,346          34,490        28,163          10,895       8,835         14,622  235,265          
Females  14,458          23,678        15,073            26,771            26,663          31,767          34,344        27,493          11,345       8,957         17,930  238,478            
 
North-Western 
Males  6,907           11,976          8,379            16,336             13,088         13,861          18,269         18,144          7,723         6,711         11,776  133,171           
Females  6,597           11,426          7,844            15,167             13,665         15,515          19,521         18,372          7,888         6,735         13,399  136,127            
 
South-Eastern 
Males  15,752          26,409          17,097         32,037             27,699         30,296          37,667        34,325           14,465       12,090       20,956  268,793           
Females  15,082          25,168          16,140         27,037             28,145         34,904          38,996        35,142           14,882       12,529       25,529  273,554         
 
Southern 
Males  20,817          34,747    21,979        40,900             34,411         38,673           49,728       44,786           18,546       15,605        26,864 347,056 
Females  19,835          33,170    21,104        41,376             41,592         47,409           52,854       45,209           19,222       16,495        33,532 371,798  
 
Western 
Males  10,889          21,073   14,611        27,715             25,824         29,270           32,887        29,445          12,691        10,898       18,869 234,172 
Females  10,340          19,870   13,798        24,929             18,180         26,094           33,085        28,849          12,877        11,236       21,893 221,151 
 
Total  279,833       470,515          306,430     605,160            570,425       619,458         725,855      611,352        252,016      212,050     390,800 5,043,894 
______________________________________________________________________________________________________________________________ 
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Number of eligible persons and coverage projections are presented in Table 3.  
Table 3: GMS Coverage & Eligible Persons Projections, 2016-2026 
 
 
Scenario             Year         No.of Eligible Persons        Population       Coverage (%)                                                                                                             
 
 
Minimum            2016            1,366,229                                                            29.15 
Mean                                       1,557,570                               4,686,790             33.23 
Maximum                               2,016,889                                                            43.03 
 
Minimum             2021           1,512,215                                                            31.01 
Mean                                       1,724,002                                4,876,368            35.35 
Maximum                               2,082,718                                                            42.71 
 
Minimum            2026            1,646,661                                                            32.65 
Mean                                       1,877,198                                5,043,894            37.22       
Maximum                               2,345,123                                                             46.49 
____________________________________________________________________________ 
 
In table 3, coverage rates are based on the most likely population level for each year.  It is 
estimated that the number of eligible GMS persons will lie between 1.4 million and 2.0 
million in 2016, 1.5 million and 2.0 million in 2021 and 1.6 million and 2.3 million in 2026.  
Coverage is estimated to be approximately 33.23% in 2016, 35.35% in 2021 and 37.22% in 
2026 as illustrated in Figure 5. 
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Figure 5: GMS Coverage (%) Projections 2016 - 2026 
 
 
Table 4 illustrates the 2026 coverage rate projections by age cohort, sex and HSE region.  
The Eastern region is projected to have the lowest coverage rates in 2026 and the North-
Western region is projected to have the highest coverage rates for all eleven age cohorts.  The 
older age cohorts (70-74, >75) have higher coverage rates in comparison to the younger age 
cohorts as frequency of medical cards increases with age.  We estimate the majority of people 
over 70 will retain their medical card which is based on 2012 data.  
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Table 4: Coverage rate projections by age cohort, sex and old health board region, 2026 - Scenario 2: Mean 
____________________________________________________________________________________________________________________ 
Region < 5 5 - 11    12 – 15 16 – 24 25 – 34 35 – 44 45 – 54 55 – 64 65 – 69        70-74     >75
    
Eastern 
Males  0.28 0.37  0.34         0.23              0.16         0.21  0.22  0.24      0.32          0.70        0.70        
Females  0.28        0.36  0.34         0.27             0.21         0.25  0.22  0.26     0.43          0.75        0.75        
 
Midlands 
Males  0.35        0.43 0.41         0.34              0.29         0.30  0.30  0.31      0.41          0.75        0.80         
Females  0.35        0.43 0.41         0.40             0.34         0.34  0.31  0.35              0.55          0.80        0.82 
 
Mid-Western 
Males  0.33        0.39 0.37         0.33              0.29         0.29  0.29  0.31      0.43          0.76        0.80 
Females  0.33      0.39 0.37         0.37              0.33         0.32  0.29  0.34      0.52          0.79        0.83 
 
North-Eastern 
Males  0.33        0.40 0.40         0.34             0.27         0.29  0.28  0.31  0.42          0.77        0.85 
Females  0.33        0.41 0.40         0.38              0.32         0.33  0.30  0.34  0.54          0.82        0.86 
 
North-Western 
Males  0.39        0.47 0.47         0.44              0.37         0.37  0.37  0.40  0.49          0.82        0.88             
Females  0.40        0.48 0.45         0.47              0.41         0.40  0.37  0.42  0.61          0.81        0.86      
 
South-Eastern 
Males  0.36        0.42 0.41         0.37              0.32         0.32  0.31  0.35  0.46          0.77        0.82      
Females  0.35        0.42 0.40         0.41              0.36         0.35  0.32  0.38  0.57          0.81        0.85 
 
Southern 
Males  0.30        0.37 0.34         0.29              0.25         0.26  0.26  0.30  0.42          0.75        0.79            
Females  0.30        0.37 0.34         0.31              0.29         0.29  0.27  0.33  0.52          0.79        0.83             
 
Western 
Males  0.34        0.43 0.41         0.37              0.30         0.31  0.32  0.36  0.46          0.76        0.80             
Females  0.34      0.42 0.40         0.42                0.34         0.33  0.32  0.37  0.57          0.81        0.84             
___________________________________________________________________________________________________________________________________________  
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Discussion 
Ireland experienced population growth of 2.24% between 2008 and 2012, despite the 
recession. The population increased from 4,485,100 in 2008 to 4,585,400 in 2012, an increase 
of 100,300 persons (CSO 2012b).  A lot of research has been done in Ireland on the factors 
driving population increases and population projections.  Table 5 compares population 
projections where time intervals are comparable.  Blackwell & Associates (2001) and 
Morgenroth (2009) were not included in this table as time projection intervals were not 
comparable to this research. 
Table 5: Population Projections 2016 – 2026 
 
 
Projection Model                                                          2016                  2021              2026       
     
 
Connell & Pringle A1   4,441,002 4,569,854 - 
Connell & Pringle A2  4,544,518 4,701,365 - 
Connell & Pringle A3  4,594,138 4,750,639 - 
Connell & Pringle A4  4,675,912 4,913,637 - 
CSO M2F2 Traditional  4,687,000 4,876,000 5,044,000 
CSO M2F2 Recent  4,687,000 4,875,000 5,043,000 
CSO M2F2 Modified  4,687,000 4,875,000 5,043,000 
CSO M3F2 Traditional  4,669,000 4,778,000 4,853,000 
CSO M3F2 Recent  4,606,000 4,764,000 4,884,000 
CSO M3F2 Modified  4,669,000 4,778,000 4,853,000 
Conway et al – Min 
(CSO M2F1 Traditional) 
 4,879,485 5,265,206 5,554,739 
Conway et al – Mean 
(CSO M2F1 Traditional) 
 5,095,004 5,451,088 5,696,000 
Conway et al – Max 
(CSO M2F1T Traditional) 
 5,769,583 6,027,268 6,066,810 
Conway & Woods – Min  
(CSO M3F2 Traditional) 
 4,602,428 4,761,773 4,918,805 
Conway & Woods – Mean  
(CSO M2F2 Traditional) 
 4,686,790 4,876,368 5,043,894 
Conway & Woods – Max 
(CSO MF2T – M3F2T) +M2F2T 
 4,807,241 5,154,809 5,372,251 
 
___________________________________________________________________________ 
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Connell & Pringle (2001) results range from their lowest scenario (A1) to their highest 
scenario (A4).  Their projections lie between 4.4 million and 4.6 million for 2016.  The CSO 
population estimates for 2016 are approximately 4.6 million for all 6 scenarios, whereas our 
population projections are estimated to lie between 4.6 million and 4.8 million. Connell & 
Pringle (2001) estimate the national population will lie between 4.5 million and 4.9 million in 
2021 where our estimates lie between 4.7 million and 5.1 million and CSO projections lie 
between 4.7 million and 4.8 million.  2026 projections will lie approximately between 4.9 
million and 5.3 million, whereas CSO projections will lie between 4.8 million and 5.0 
million.  Our current population projections are more conservative across all three scenarios 
than Conway et al (2014) projections. Conway et al (2014) project Irish population will grow 
by 32.6% between 2007 and 2026 whereas this research projects the total population will 
grow by approximately 10% between 2012 and 2026.  Table 6 compares regional 
proportional projections for the year, 2021.  Connell & Pringle (2001) analysis is based on 
CSO regions where our research is based on the old health board regions.     
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Table 6: Regional Population Projections 2021 (% of population in each old health board region) 
____________________________________________________________________________________________________________________ 
Model     Border Dub ME M MW SE SW (S) W E NE NW  
        
 
Connell & Pringle A1 2021  11.4  23.6 13.1 6.8 8.2 11.9 14.8  10.2  
Connell & Pringle A2 2021  11.3  23.9 13.2 6.7 8.2 11.7 14.7  10.3  
Connell & Pringle A3 2021        11.2  24.1 13.2 6.7 8.2 11.7 14.6  10.3 
Connell & Pringle A4 2021  11.0  24.4 13.4 6.7 8.3 11.5 14.5  10.3 
Conway et al 2021       5.80 8.0 10.5 13.9  9.7 37.4 9.3 5.4   
(CSO M2F1 Traditional)        
Conway & Woods 2021      6.2 8.1       10.9 14.4    9.2 36.3 9.5 5.4   
(CSO M2F2 Traditional) 
___________________________________________________________________________________________________________________________________________  
The CSO South-West region is comparable to the HSE Southern region, which is comprised of counties Cork and Kerry.  Our research estimates 
that 6.2% of the national population will live in the Midlands region, 8.1% in the Mid-West, 10.9% in the South-East region, 14.4% in the 
Southern region and 9.2% in the Western region in 2021 which are lower than Connell & Pringle estimates.  Comparing previous (Conway et al, 
2014) and current research, current regional projections have higher proportions except for the East and Western regions which are projected to 
have 37.4% and 9.2% of the population respectively.  The North-Western region is projected to have the same proportion of 5.4% of the 
population of Ireland under both projection models as presented in table 6.   
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Comparing Conway et al (2014) coverage projections with current research in table 7, current 
coverage projections are tighter around the most likely annual coverage rate.  Conway et al 
(2014) estimates coverage projections will lie between 24.49% and 42.28% in 2016, whereas 
current research estimates between 29.15% and 43.03%.  Previous research estimates 2021 
coverage rates will lie between 26.85% and 45.64% compared to current research estimates 
of 31.01% and 42.71%.  2026 coverage projections were estimated to lie between 28.76% 
and 48.22% compared to current research estimates of 32.65% and 46.49%.  This variation 
may be explained by conservative population projections using census 2011 in this research.  
This research may become redundant if a single-tier health service supported by universal 
health insurance is introduced in Ireland.  In 2011, free medical care to all was a key 
objective for the current government (GOI, 2011).  In budget 2015, the Irish government 
went partially towards meeting this objective, by announcing free General Practitioner (GP) 
care for all children under 6 years of age.   A limitation of this research is that the population 
and coverage projections are produced in the format of the old health board regions.  The old 
health board regions (8) are no longer comparable to the current HSE regional structure (4), 
which was changed in 2010.  Personal communication took place between researchers and a 
CSO population statistician, but were advised the population data was not available at local 
health office level but by county level only.  If population data was available in this format, 
this would prove beneficial for future GMS coverage and cost projections.  
 
Table 7: Coverage Projections (%) Comparisons 2016 – 2026 
 
 
Projection Model                                                          2016                  2021              2026       
     
 
Conway et al – Min 
 
 24.49 26.85 28.76 
Conway et al – Mean 
 
 34.70 37.49 37.23 
Conway et al – Max 
 
 42.28 45.64 48.22 
Conway & Woods – Min  
 
 29.15 31.01 32.65 
Conway & Woods – Mean  
 
 33.23 35.35 37.22 
Conway & Woods – Max  43.03 42.71 46.49 
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Conclusion 
This paper has estimated population by the old health board regions, sex and age cohort and 
the likely effect an increasing population will have on future GMS coverage rates between 
2016 and 2026 under various scenarios.  The Irish population is estimated to grow by 10% 
between 2016 and 2026 whereas the over 70s population is estimated to grow by 64% during 
this projection period, compounding the pressure on GMS coverage rates.  Coverage rates are 
projected to lie between 33% and 46% in 2026.  Population growth combined with increased 
coverage rates will add additional pressure to future health costs.  
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Abstract
Introduction: Ireland had one of the highest pharmaceutical spends per capita in the EU in 2012. The General
Medical Services (GMS) scheme is the largest community drug scheme in Ireland with approximately 40% of the
population eligible for free drugs and appliances in 2012. The total cost of GMS prescriptions increased by 414%
between 1998 and 2012. This paper projects Irish GMS cost from 2016 to 2026 and examines the implications of the
estimated impact on GMS expenditure.
Method: Central Statistics Office (CSO) population projections (2013) and HSE-PCRS GMS population
prescription data (2012) were used to develop four variables; population, GMS coverage, average cost per claimant
and claims rate. A Monte Carlo Simulation (MCS) model simulated the effect of these four variables on GMS costs,
by health board region, age cohort and sex.
Results: Irish population is projected to grow by approximately 10% between 2012 and 2026. The over 70s
population is estimated to grow by 64% with the proportion of males growing by 72%. GMS expenditure is estimated
to increase by 64%, from €1.1 billion in 2016 to €1.8 billion by 2026. Age is a key driver of GMS expenditure,
specifically those aged under 11 and over 70. The MCS results project that males, the Mid-Western and South-
Eastern regions are driving GMS costs in the under 11s. Females, Midlands and Southern regions are driving GMS
costs in the over 70s.
Conclusion: Population growth coupled with an aging population will impact future GMS costs. Targeted GMS
policy changes such as co-payment charges, reference pricing, and generic substitution can help to contain future
GMS expenditure.
Keywords: Monte carlo modelling; Drug prescribing;
Pharmaceutical expenditure; GMS
Introduction
In 2012, Ireland spent 14% of total government expenditure on
healthcare which is comparable with the European Union (EU)
average, EU28. The Netherlands had the highest proportion at 20%
and Cyprus had the lowest proportion at 8%. Irish health spending
accounted for 8.9% of Gross Domestic Product (GDP), just above the
EU28 average of 8.7%. Netherlands recorded the highest value at 11.8%
and Romania the lowest at 5.6% [1]. According to a 2015 Organisation
for Economic Co-Operation and Development (OECD) report, Ireland
spent 1.3% less on health between 2007 and 2013 [2]. Irish
pharmaceutical expenditure per capita relative to other OECD
countries has increased significantly since 2000. Ireland’s position has
moved from 20th highest of 27 countries in 2000 to 3rd highest of 25
countries in 2010. In 2010, Irish per capita spending on
pharmaceuticals was the highest in the EU and was 34% above the EU
average [3]. The Irish government has introduced cost containment
measures during the economic crisis to combat this trend such as co-
payment charges for patients, GMS eligibility criteria, reference pricing
and generic substitution promotion [4]. Despite these cost
containment measures, Irish pharmaceutical spending per capita in
2012 was the third highest amongst EU countries at €500, 40% above
the EU average (€350) [1].
There are eleven community drug schemes in Ireland, where a
person has entitlement to free or subsidised healthcare. The four most
expensive schemes are the General Medical Services Scheme (GMS),
Drug Payments Scheme (DPS), High Tech Drug Scheme (HTDS) and
Long Term Illness (LTI) scheme. The GMS scheme is the largest
community drug scheme in Ireland. 40.40% of the population
(1,853,877 persons) were eligible for the GMS (also known as medical
card scheme) in 2012, the highest it has been since data was published
in 1996 (1,252,385-34.5%) [5]. Any eligible GMS person is entitled to
free medicines and appliances. Eligibility is determined by income
guidelines and persons who are affected by certain medical conditions.
The GMS scheme is financed by the state with a contribution from
each GMS eligible person. Since October 2010, each person on the
scheme incurred a €0.50 charge for every prescription item dispensed
up to a maximum of €10 per family per month. This was subsequently
increased to €1.50 in 2013 and is currently €2.50 per prescription item
up to a maximum of €25 per family per month.
GMS coverage rates (proportion of the population who has a
medical card) peaked in 2012 and have fallen to 1,849,380 (40.3%) in
2013 and to 1,804,376 (39.3%) in July 2014. This decrease may be
partly attributed to a reduction in the number of discretionary medical
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cards issued, which decreased from 63,126 in 2012 to 50,294 in 2013
[6]. Discretionary medical cards are awarded when significant medical
costs are incurred as a result of illness and are unable without undue
hardship to arrange GP medical and surgical services for themselves
[7]. The total cost of GMS prescriptions has increased from €249
million in 1998 to €1.28 billion in 2012, a 414% increase (various
annual PCRS Reports – 1998-2012). GMS prescription expenditure
rose rapidly after 2000. It increased by 290% from approximately €328
million in 2000 to €1.28 billion in 2012. GMS expenditure accounted
for 9% of the overall health budget in 2012 [8]. There are number of
factors identified in the literature that influence drug expenditure;
population, population aging, inflation, price effects, volume effects,
mix of drugs, sex and age [9-12].
Modelling health and drug expenditure varies considerably
internationally. A number of studies on health expenditure projections
based on historical trends have been carried out in the US [13-15]. The
three studies estimated national health expenditure based on
assumptions around economic (varying levels of economic growth)
and demographic variables for a 10 year period. Another US study
developed projections on drug expenditure and incorporated historical
trends in drug expenditure and expected changes in the drugs market
that may influence drug expenditure in 2015 [16]. A French study
forecasted national drug expenditure based on demographic and
epidemiological factors out to 2029, using a Markovian micro-
simulation model [17]. A Swedish study forecasted drug expenditure
in the region of Stockholm over a two year period, 2010-2011. They
used a linear regression analysis and applied it to historical drug sales
between 2006 to 2009 [18]. Based on expert opinion and a review of
the literature, a Monte Carlo Simulation (MCS) was deemed to be the
most appropriate model to use.
A 2014 study by Conway et al [19] projected GMS costs for Ireland
in five year intervals to 2026, using 2008 Central Statistics office (CSO)
population projections. This study estimated that GMS expenditure is
estimated to increase from €1.1 billion in 2011 to €1.9 billion by 2026.
The conclusions drawn were that age (<11 and >70), females and the
Midlands region were found to have the most significant effect on
future GMS costs in Ireland. Since then, the CSO [20] has revised its
population projections downwards and following the onset of the
financial crisis, the Irish government has introduced cost containment
measures. This paper adds to the literature by utilising updated CSO
population projections and 2012 GMS population prescription data.
The aim of this paper is to project Irish GMS cost from 2016 to 2026
and to examine the implications of the estimated impact on GMS
expenditure.
Method
To estimate GMS costs to 2026, we used a MCS model to simulate
various scenarios, using the latest CSO population projections and
2012 Health Service Executive-Primary Care Reimbursement Service
(HSE-PCRS) population GMS prescription data. From this data, four
variables were developed; population, GMS coverage rates, claims rate
and average cost per claimant. Three scenarios were formulated for
each variable; low variable growth (best case scenario - minimum),
average variable growth (most likely scenario - mean) and high
variable growth (worst case scenario - maximum).
CSO population data
The CSO regional population projections 2016-2031 [20] provided
updated projections based on the 2011 Irish census. Data was detailed
by year of age, sex, county and region, incorporating assumptions
around mortality, fertility, international and internal regional
migration. The revised downward CSO population projections are
mainly driven by a fall in fertility. We aggregated the population data
into ten HSE cohorts so comparisons can be made with earlier research
[19]. An adjustment factor based on the 2011 census was applied as
three of the CSO regions (Border, Mid-East, Dublin) did not conform
to three of the old health board regions (North-West, North-East,
Eastern). There are eight regions (Eastern, South-Eastern, Southern,
Western, Mid-West, Midlands, North-West and North-East) within the
old health board structure in Ireland.
GMS coverage rates
GMS coverage rates are the proportion of the population who have
a medical card. 2012 mean coverage rates by the old health board
region, sex and age cohort were estimated using the 2012 PCRS annual
report and CSO population projections. The minimum, mean and
maximum coverage rates were estimated using historical data between
1996 and 2012. These three scenarios formed the basis of projections
for 2016, 2021 and 2026. The projected mean population was used to
estimate the coverage rates and the number of eligible persons for each
scenario in 2016, 2021 and 2026.
GMS HSE-PCRS database
HSE-PCRS population GMS dataset (2009-2012) and N=60 million
for each year. The data is detailed per prescription item (observation).
There are 40 variables in the database, of which seven are specific to
this research. These include; HSE Local Health Office (LHO) number,
year of age, sex, dispense number and total cost (ingredient cost, Value
Added Tax (VAT) and dispensing fee). Any person can register with
their LHO (32 offices) to determine eligibility for the GMS scheme. A
unique dispense number is allocated to each GMS claimant for all
prescription items in an individual year. A claimant is a person who
has a GMS medical card and makes a claim on that card. If a claimant
is issued a replacement medical card within any specific year, they will
be allocated a new dispense number. The data was aggregated and
analysed by the old health board region (8). The data was cleaned as
some data had no sex or age. The year of age variable was aggregated
into the eleven HSE age cohorts ranging <5’s to the >75’s. For the
purpose of comparison, the age cohorts, <5 and 5-11 were summed
together for the four variables. Data management and analysis was
carried out in Microsoft Excel and R-Studio version 2.15.3. HSE-PCRS
population GMS dataset (2009-2012), combined with the annual 2012
PCRS report [5] was used to formulate the average cost per claimant
and claims rate variables.
Claims rate
The claims rate is the proportion of the GMS population who make
a claim. 1,853,877 held medical cards in Ireland in 2012, of which,
1,649,950 made a claim (claims rate=89%). Historical national and
regional claims rates were calculated to determine lower and upper
bound values around the mean claims rate. Between 2005 and 2012,
the lowest national claims rate was 88% and the highest national claims
rate was 95% (2007 levels) and these formed the minimum and
maximum scenarios respectively. The mean claims rate in 2012 was
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scaled by the minimum national and regional claims rate values to
determine the lower bound claims rate scenario 2012 by region, sex
and age cohort. 2007 claims rate values by region, sex and age cohort
were taken as the upper bound scenario for 2012 [19]. For this analysis,
the claims rate was assumed to remain at 2012 estimated levels (3
scenarios) over the lifetime of the projections.
Average cost per claimant
The average cost per claimant is the total cost of claimants divided
by the number of claimants and this was calculated using the 2012
HSE-PCRS population dataset. The average cost per claimant variable
was updated using HSE-PCRS 2009 to 2012 population data and this
formed the basis of our projections whereas the previous research [19]
was based on a sample 2007 HSE-PCRS GMS database. Historical
average cost per claimant data was determined from the HSE-PCRS
population database between 2009 and 2012. There is considerable
variation in the data year on year. The minimum, mean and maximum
growth rates between 2009 and 2012 were calculated by age cohort and
sex. This variation may be explained by the Irish economic crisis, an
increase in GMS eligibility rates and health expenditure cuts.
Therefore, a four year average cost per claimant between 2009 and
2012 was deemed appropriate given the variability in the data and this
formed the most likely scenario for 2012 and the base for projections
of this variable. Upper bound and lower bound 2012 scenarios were
estimated around the mean cost per claimant. Initially, various
percentiles and the inter-quartile range were determined, but showed
significant variation in the data. Therefore, we estimated lower and
upper bounds for 2012 around the mean cost per claimant (mean ±
5%).
The four year average cost per claimant ± 5% formed the basis of
projections between 2016 and 2026. For average cost per claimant
projections, the minimum, mean and maximum annual growth rates
were determined between 2009 and 2012. As the historical data
showed significant variation between 2009 and 2012, projections based
on these growth rates were not deemed appropriate. A four year
average of the health inflation rate between 2009 and 2012 was
calculated (2%) and this was applied annually between 2012 and 2026
[21]. The minimum 2012 average cost per claimant (scenario 1) values
by region, sex and age cohort were uniformly increased by 2% to
determine 2016 scenario 1 average cost per claimant by region, sex and
age cohort. For example, a male in the Eastern region in the 0-11 age
cohort has an average cost per claimant value of €107.80 in 2012. This
value was increased annually by 2% up to 2016 to estimate the average
cost per claimant of €116.69 for 2016. The following formula (Eq1) was
applied to each of the 160 cells (age cohorts (10), sex (2) and regions
(8));
Min ac per claimant 2016=min ac per claimant 2012 (1+0.02)4 (1)
This methodology was applied to all three scenarios to determine
three 2016 scenarios. Using the same methodology average cost per
claimant 2016 (3 scenarios) and 2021 (3 scenarios) was increased by
2% uniformly across region, sex and age cohort to determine average
cost per claimant 2021 and 2026 respectively.
The Cost projection model (Eq 2) is as follows;
Total Cost=f (Population, GMS Coverage, AC per Claimant, Claims
Rate) (2)
and average cost per claimant based on 2012 data. MCS was employed
to propagate the parameter uncertainty through 100,000 iterations.
Each input variable is comprised of age cohorts (10), sex (2) and
regions (8) giving a total of 160 cells to be modelled for each variable.
The dependent variable is the projected total GMS cost for 2016, 2021
and 2026. Taking a large number of simulations (100,000), gives an
approximation to the true distribution of projected cost. The equation
(Equation: 3) used for simulations is;
Probable cost=Expected cost+error (3)
In order to prepare the data for Monte Carlo Simulations, the
probability and cumulative probability of finding a person within each
region, sex and age cohort class were calculated. A macro was written
in Visual Basic Editor in Microsoft Excel to run the simulations. It’s
important to assign an appropriate probability distribution to
uncertain variables in developing a comprehensive MCS model [22]. A
normal distribution was applied to estimate costs to allow for
uncertainty in the model. The Central Limit Theorem was applied,
which states that the sum of random variables will be approximately
distributed [23]. The MCS results were imported into Minitab for
analysis. All statistical analyses were performed using Minitab
statistical package (Minitab 17).
Results
This section includes a descriptive analysis followed by an empirical
analysis.
National population projections
The population of Ireland is estimated to grow from 4.6 million to
5.0 million, an increase of almost 10% between 2012 and 2026 in
Figure 1. The female population is estimated to grow by 10.5%,
whereas the male population is estimated to grow by 9.5%. The
updated population projections in Table 1 are more conservative than
the Conway et al. [19] projections.
Year Current Projections Conway et al (2014) Population
Projections
2012 4.6 4.7
2016 4.7 5.1
2021 4.9 5.4
2026 5.0 5.7
Source: [19]
Table 1: Comparison current population projections (Million) with
Conway et al (2014) Projections.
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Figure 1: Estimated Population Growth 2012–2026.
The elderly population is those aged 65+ but this paper focuses on
the over 70’s population as this age group is entitled to free medical
care on the GMS scheme. The over 70’s include two age cohorts, 70-74
and >75’s. The over 70s population is estimated to grow by 64%
between 2012 and 2026 in Figure 2. The male population is estimated
to grow by 72.2% and the female population is expected to grow by
57.6%1.
Figure 2: Estimated Population Growth for those aged 70 and over,
2012–2026.
The dependency ratio (ratio of population aged 65+ to the
population aged 18-64) indicates the likely impact of population aging.
The dependency ratio is estimated to increase from 0.21 in 2016, to
0.24 in 2021 and 0.27 in 2026. The inverse (ratio of population aged
18-64 to the population aged 65+) shows those of working age who
support the older population of 65+. It decreases from 4.54 in 2016, to
3.95 in 2021 to 3.49 in 2026.
Regional population projections
Regional population is expressed as a proportion of the national
population2. In 2012, we estimated that 35.3% of the population live in
the Eastern region but this is projected to increase to 37.2% by 2026.
Three regions, Midlands, North-West and the South-East region are
estimated to grow slightly between 2012 and 2016 and decrease
thereafter. The remaining four regions are forecasting a population
decrease over the lifetime of the projections.
GMS coverage projections
GMS coverage projections were produced by old health board
region, sex, age cohort and three scenarios in five year intervals
between 2016 and 20263. Figure 3 estimates GMS coverage rates will
lay between 29% and 43% in 2016, 31% and 43% in 2021 and 33% and
46% in 2026. Coverage rates are estimated to be lower in 2016 due to
slower population growth. The 2012 estimates of the mean claims rate
and the average cost per claimant are available in the supplementary
information file. The 2012 average cost per claimant for a male and
female in the >75 age category is 15 and 18 times the average cost per
claimant of a male and female in the 0-11 age category in the Eastern
region, highlighting the variation in cost by age cohort.
Figure 3: GMS Coverage Projections (%) 2016–2026.
GMS cost projections
GMS cost projections are estimated to be €1.1 billion in 2016, €1.4
billion in 2021 and €1.8 billion in 2026 (most likely scenario) as
illustrated in Figure 4. Lower CSO population projections based on
lower fertility rates contributed to more conservative GMS cost
projections.
Figure 4: GMS Cost (€m) Projections 2016–2026.
1 Personal Communication: with a CSO population Statistician advised that males are experiencing higher growth rates than females in
older age cohorts, as there more males than females in earlier age cohorts.
2 See Supplementary Information file for region (population proportion - %) Population Projections 2012 – 2026
3 See Supplementary Information file for 2026 GMS projections, most likely scenario.
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Monte carlo simulation results - descriptive and statistical
analysis
The descriptive analysis of 100,000 simulations for 2016, 2021 and
2026 is detailed in Table 2. There is considerable variation in the cost
results with 25% of the data lying below €46.02 and 75% of the data
lying above €253.43 in 2016. The average cost per claimant is estimated
to be €249.96 with the median estimated to be €106.22. The histogram
plots the distribution of cost with a higher frequency of claimants
having a lower average cost per claimant as illustrated in Figure 5.
Figure 5: Histogram of Cost and Main effects Plot, Mean Scenario,
2016.
The histogram reiterates the descriptive analysis in Table 2, there is
significant variation in cost with the lowest claim of €21.25 and the
highest claim of €1573.57 in 2016. In Figure 5, the main effects plot
examines the differences between the three categorical variables; old
health board region, sex and age cohort. Sex is showing no main effect
with all regions showing some effect except Eastern and North-
Eastern. Age cohorts show the greatest response, especially under 11s,
65-69 and over 70s. Researchers further analysed these age groups and
found that males, Mid-Western and South-Eastern regions are driving
costs in the under 11s age group as illustrated in Figure 6.
Figure 6: Main effects Plot by Sex and Old Health Board Region <11
and >70, Mean Scenario, 2016.
In Figure 6, females, the Midlands and Southern regions are driving
costs in the over 70s. These results were also found in 2026.
Year ♯ of Simulations Mean St. Dev Min Q1
2016 100,000 249.96 348.24 21.25 46.02
2021 100,000 307.45 418.28 24.58 53.49
2026 100,000 384.13 508.22 28.14 62.3
Table 2: Descriptive Analysis of Average Cost per Claimant (€) 2016–
2026 (Scenario 2- most likely scenario).
Average cost per claimant (€) by sex and region – Scenario 1-
Scenario 3
In Figure 7, the Midlands and the Southern regions are the most
expensive and the Eastern and Western regions are the least expensive
regions for all three scenarios. Females are driving costs more than
males for all three scenarios. The under 11s and increasing age are
driving costs for all three scenarios. Similar trends were found for sex
and age cohort in 2021 and 2026. In 2021 and 2026, the South-Eastern
and the Midlands regions are estimated to be the most expensive and
the North-Eastern and Eastern regions are estimated to be the least
expensive regions.
Figure 7: Average Cost per Claimant by Age Cohort, Region and
Sex, and Scenarios 1-3 2016.
Discussion
The key findings of this research are; population growth, significant
growth in the over 70s population, age, sex and region and the
implications they will have in fuelling GMS costs. Irish population is
projected to grow by approximately 10% between 2012 and 2026. The
over 70s population is estimated to grow by 64% with males over 70
estimated to grow by 72% over the projection period. A combination
of falling rates of fertility and mortality produces a greater proportion
of older people in society.An aging population will significantly
contribute to overall GMS costs and has the potential to cause an
increase in GMS coverage rates, claims rates and average cost per
claimant. According to a WHO report, a key driver of health care costs
is growth in the overall size of the population. Population aging is also
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a driver of health care costs, but not to the same extent [24]. An Irish
study on aging reported that the dependency ratio was 0.18 in 2011
rising to 0.23 in 2021 [25]. Our estimates for 2021 show a similar
finding, with a dependency ratio of 0.24. This Irish study argued the
inverse of the dependency ratio was more informative and they
estimated a value of 5.7 in 2011 falling to 4.4 in 2021 [25]. In our study,
the inverse is estimated to be 3.95 in 2021. An aging population,
leading to an increased dependency ratio, will put financial pressures
on future health costs. A French study found an increase in aging
population and changes in health status will increase French drug
expenditure annually by between 1.1% and 1.8% for the over 25s [17].
A US study estimated health spending will grow on average by 5.8%
annually to $2.4 trillion between 2012 and 2022 based on a sluggish
economic recovery in 2013 coupled with an expansion in coverage due
to the Affordable Care Act and an aging population [13]. Two US
studies projected drug expenditure and one study projected 12% to
14% increases in US total drug expenditures in clinics, and 5% to 7%
increases in hospitals [16]. The other study predicted drug expenditure
(ambulatory and hospital) would increase by 2% in 2010 and 4% in
2011 [18]. The current GMS cost projections are more conservative
than the previous Irish projections [19]. Previous research estimated
GMS cost projections will rise to €1.3 billion in 2016, €1.6 billion in
2021 and €1.9 billion in 2026. This research estimated GMS cost
projections will rise to €1.1 billion in 2016, €1.4 billion in 2021 and
€1.8 billion in 2026 [19].
This research [19] found that females, age (≤ 11 and ≥ 70) and the
Midlands region were driving GMS costs out to 2026. This paper
confirms those findings and contributes the following; males, the Mid-
Western and South-Eastern regions are driving GMS costs in the under
11s in 2016. Females, Midlands and Southern regions are driving GMS
costs in the over 70s in 2016. Our results show that younger male
children (≤ 11 years) are a driver of GMS costs in Ireland. This may be
explained by a higher incidence of drug prescribing amongst male
children. An Irish study investigating prescribing antibiotics trends in
a paediatric sub-population found that male participants (0-4 age
cohort) were more likely to receive an antibiotic prescription than
female participants [26]. A Spanish study examined how gender and
age influenced prescription drug use and found a higher prevalence of
prescription drugs in males aged 0-4 and 5 to 14 years of age [11]. A
Swedish study found more drugs were dispensed amongst males under
10 years [27]. In 2011, a new government was formed in Ireland with
an objective of implementing a single-tier health service through the
introduction of universal health insurance with free medical care for all
[28]. In Budget 2015, the Irish government partially met this objective,
by announcing free General Practitioner (GP) care for all children
under 6 years of age. As this is one of the most expensive age groups,
the Irish government may have been better advised to implement this
policy in a less expensive age group such as adolescents as a pilot
measure. Females over 70 years are driving GMS costs in Ireland. In
Spain [11], Sweden [27] and British Colombia [29], there is a higher
incidence of prescribing amongst females compared to males. The
Spanish study found drug prescribing is 23% higher in females than
males and that age is statistically more significant than sex (P<0.05)
[11]. In British Colombia, they found that population aging only
explained 1 point of the observed annual drug expenditure growth
[29]. The drug expenditure growth is largely explained by the increase
in the age/sex specific numbers of prescriptions filled per patient and
mix of products selected per prescription.
The Midlands region is the most expensive region and the Eastern
region is the least expensive region for GMS costs. Upon further
investigation at age cohort level, GMS costs differ across the eight
regions. The Mid-Western and South-Eastern are the most expensive
regions for the under 11s, the Midlands for the over 70s and the
Eastern region is the least expensive region for both age cohorts. A
high prevalence of chronic conditions in the Midlands region [30]
coupled with Usher et al. [31] findings that the Midlands and the Mid-
Western regions had the highest prescribing rates for type 1 and type 2
diabetes may explain high GMS expenditure in this region.
In terms of policies on cost containment, in November 2012, a three
year agreement was formulated between the Irish Pharmaceutical
Healthcare Association (IPHA), the Department of Health and the
HSE. The agreement applies to medicines prescribed and reimbursed
on the community drugs scheme, including the GMS. This agreement
led to reductions in the cost of in-patent and off-patent
pharmaceuticals [32]. It was widely reported that this agreement would
yield over €400 million for the Irish state over three years. The Irish
government estimated €16 million in drug savings in 2012 across all
community drug schemes4, €116 million in 2013, €136 million in 2014
and €150 million in 2015 [33]. According to a recent WHO report [4],
the agreement resulted in actual savings of €190 million. Co-payments
were introduced as a revenue raising measure. Two Irish studies found
both co-payments (€0.50 and €1.50) were associated with larger
reductions in adherence to less--essential medicines than essential
medicines, with anti-depressant and anxiolytic/hypnotic medicines
being the exception [34,35]. In 2013, a number of cost containment
measures were introduced. GMS eligibility income criteria were
lowered, co-payment charges were increased and new legislation was
enacted on reference pricing and generic substitution. These policy
changes will reduce future GMS expenditure.
Limitation
The researchers investigated the possibility of developing estimates
of the variables by the current regional HSE structure, which
incorporates four regions (Dublin Mid-Leinster, Dublin North-East,
and West and South). However, this was not possible for the
Population variable5. Further research investigating the 2013 policy
changes and the impact of the IPHA agreement on GMS expenditure
would be very useful.
Conclusion
Growth in population and population aging will contribute to future
GMS expenditure through the channels of increased average cost per
claimant, GMS coverage and claims rates. However, cost containment
measures; co-payment charges, generic substitution, reference pricing
and GMS eligibility criteria can decelerate the pace of GMS
expenditure growth. Co-payment charges are likely to reduce claims
rates. Reference pricing and generic substitution are likely to reduce
average cost per claimant and eligibility criteria will lower GMS
4 Minister for Health, James Reilly stated a breakdown in projected savings was not available by community drug scheme.
5 Personal Communication: with a CSO population Statistician and we were advised that the population data was only available by county
but we required further disaggregation. For example, North Tipperary resides in HSE West and South Tipperary resides in HSE South.
Therefore the research was based on the 8 old health board regions when further disaggregation was not available.
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coverage rates. The health sector in Ireland has a rapidly changing
policy environment and this research went in some way to address
these changes given the data that was at our disposal.
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Figure F.1: Log of Total Cost, non–linear relationship with age
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Figure F.2: Model 1: Test for Normality, Histogram
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Figure F.3: Model 2: Test for Normality, Histogram
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Figure F.6: Model 1: Test for Homoscedasticity, Scatter Plot
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Figure F.7: Model 2: Test for Homoscedasticity, Scatter Plot
395
Figure F.8: Model 3: Test for Homoscedasticity, Scatter Plot
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Table F.1: Respiratory GMS Expenditure (e) by Region and Sex, 0–15
Region Total Cost Female Male
(Under 5)
Dublin ML 490,104 (24%) 194,707 (24%) 295,397(25%)
Dublin NE 385,862 (19%) 154,078 (19%) 231,784(19%)
West 505,946 (25%) 195,501 (24%) 310,445(26%)
South 626,880 (31%) 261,969 (32%) 364,911 (30%)
Total 2,008,792 806,255 1,202,537
(5–11)
Dublin ML 1,046,911 (24%) 417,999 (24%) 628,912 (24%)
Dublin NE 831,261 (19%) 326,158 (19%) 505,103 (19%)
West 1,149,931 (27%) 455,184 (27%) 694,747 (27%)
South 1,302,602 (30%) 517,314 (30%) 785,288 (30%)
Total 4,330,705 1,716,656 2,614,050
(12–15)
Dublin ML 538,298 (25%) 202,551 (24%) 335,747 (26%)
Dublin NE 361,847 (17%) 147,628 (17%) 214,218 (16%)
West 588,265 (27%) 232,378 (27%) 355,887 (27%)
South 665,464 (31%) 263,584 (31%) 401,880 (31%)
Total 2,153,874 846,141 1,307,733
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Table F.2: Nervous System GMS Expenditure (e) by Region and Sex, 16–44
Region Total Cost Female Male
(16-24)
Dublin ML 2,280,228 (24%) 1,196,155 (25%) 1,084,073 (24%)
Dublin NE 1,590,883 (17%) 863,657 (18%) 727,226 (16%)
West 2,584,789 (28%) 1,296,588 (27%) 1,288,201 (28%)
South 2,864,634 (31%) 1,438,294 (30%) 1,426,340 (32%)
Total 9,320,534 4,794,694 4,525,839
(25-34)
Dublin ML 7,377,677 (27%) 3,867,736 (28%) 3,509,941 (27%)
Dublin NE 5,063,062 (19%) 2,737,957 (19%) 2,325,105 (18%)
West 6,608,161 (24%) 3,389,633 (24%) 3,218,528 (25%)
South 8,061,683 (30%) 4,053,397 (29%) 4,008,286 (31%)
Total 27,110,583 14,048,723 13,061,860
(35-44)
Dublin ML 10,360,932 (26%) 5,763,904 (27%) 4,597,028 (25%)
Dublin NE 7,498,266 (19%) 4,187,232 (19%) 3,311,034 (18%)
West 10,190,016 (26%) 5,355,278 (25%) 4,834,738 (27%)
South 11,783,437 (30%) 6,406,327 (30%) 5,377,110 (30%)
Total 39,832,651 21,712,741 18,119,910
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Table F.3: Nervous System GMS Expenditure (e) by Region and Sex, 45–64
Region Total Cost Female Male
(45-54)
Dublin ML 12,010,286 (26%) 6,894,640 (27%) 5,115,646 (25%)
Dublin NE 8,215,300 (18%) 4,796,099 (18%) 3,419,201 (17%)
West 11,815,477 (26%) 6,457,822 (25%) 5,357,655 (27%)
South 13,991,055 (30%) 7,782,006 (30%) 6,209,049 (31%)
Total 46,032,118 25,930,567 20,101,551
(55-64)
Dublin ML 12,268,141 (26%) 7,096,581 (27%) 5,171,560 (26%)
Dublin NE 7,749,063 (17%) 4,481,581 (17%) 3,267,482 (16%)
West 12,130,746 (26%) 6,810,817 (26%) 5,319,929 (27%)
South 14,177,364 (31%) 7,948,561 (30%) 6,228,803 (31%)
Total 46,325,314 26,337,540 19,987,774
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Table F.4: Cardiovascular GMS Expenditure (e) by Region & Sex, 65+
Region Total Cost Female Male
(65-69)
Dublin ML 7,573,354 (24%) 4,104,470 (25%) 3,468,884 (23%)
Dublin NE 5,844,488 (19%) 3,186,472 (19%) 2,658,016 (18%)
West 8,295,246 (26%) 4,204,591 (25%) 4,090,655 (27%)
South 9,874,051 (31%) 5,152,926 (31%) 4,721,125 (32%)
Total 31,587,139 16,648,459 14,938,680
(70-74)
Dublin ML 11,144,503 (26%) 5,729,760 (26%) 5,414,743 (25%)
Dublin NE 9,063,055 (21%) 4,696,475 (21%) 4,366,580 (20%)
West 10,400,332 (24%) 5,159,332 (23%) 5,241,000 (24%)
South 13,006,557 (30%) 6,531,322 (30%) 6,475,235 (30%)
Total 43,614,447 22,116,889 21,497,558
(>75)
Dublin ML 24,722,360 (26%) 14,583,086 (27%) 10,139,274 (26%)
Dublin NE 18,711,796 (20%) 10,867,735 (20%) 7,844,061 (20%)
West 23,719,404 (25%) 13,521,598 (25%) 10,197,806 (26%)
South 26,817,007 (29%) 15,374,622 (28%) 11,442,385 (29%)
Total 93,970,567 54,347,041 39,623,526
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Table F.5: Respiratory System usage by Sex and Age Cohort
Age Cohort Female Male
<5 21,341 26,322
5–11 26,236 32,790
12–15 13,093 15,133
16–24 31,046 22,510
25–34 37,944 22,331
35–44 40,189 26,358
45–54 35,906 24,721
55–64 38,886 27,831
65–69 23,667 16,101
70–74 26,165 21,834
>75 58,316 40,947
Total 352,789 276,878
401
Table F.6: Cardiovascular System usage by Sex and Age Cohort
Age Cohort Female Male
<5 713 797
5–11 643 901
12–15 529 541
16–24 5,296 3,033
25–34 12,315 7,431
35–44 19,796 18,008
45–54 32,489 32,114
55–64 54,388 48,959
65–69 40,062 30,189
70–74 49,341 44,522
>75 114,761 77,140
Total 330,333 263,635
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Table F.7: Nervous System usage by Sex and Age Cohort
Age Cohort Female Male
<5 6,751 7,899
5–11 4,046 5,433
12–15 8,231 7,593
16–24 41,657 26,878
25–34 64,761 40,938
35–44 68,275 49,679
45–54 59,848 46,143
55–64 61,868 47,230
65–69 36,823 23,804
70–74 43,240 31,994
>75 107,607 62,286
Total 503,107 349,877
403
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RESEARCH Open Access
Factors influencing the variation in GMS
prescribing expenditure in Ireland
A. ConwayLenihan1*, S. Ahern2, S. Moore2, J. Cronin2 and N. Woods2
Abstract
Background: Pharmaceutical expenditure growth is a familiar feature in many Western health systems and is a
real concern for policymakers. A state funded General Medical Services (GMS) scheme in Ireland experienced an
increase in prescription expenditure of 414 % between 1998 and 2012. This paper seeks to explore the rationale
for this growth by investigating the composition (Anatomical Therapeutic Chemical (ATC) Group level 1 & 5) and
drivers of GMS drug expenditure in Ireland in 2012.
Methods: A cross-sectional study was carried out on the Health Service Executive-Primary Care Reimbursement
Service (HSE-PCRS) population prescribing database (n = 1,630,775). Three models were applied to test the
association between annual expenditure per claimant whilst controlling for age, sex, region, and the pharmacology of
the drugs as represented by the main ATC groups.
Results: The mean annual cost per claimant was €751 (median = €211; SD = €1323.10; range = €3.27–€298,670). Age,
sex, and regions were all significant contributory factors of expenditure, with gender having the greatest impact (β =
0.107). Those aged over 75 (β =1.195) were the greatest contributors to annual GMS prescribing costs. As regards
regions, the South has the greatest cost increasing impact. When the ATC groups were included the impact of gender
is diluted by the pharmacology of the products, with cardiovascular prescribing (ATC ‘C’) most influential (β =
1.229) and the explanatory power of the model increased from 40 % to 60 %.
Conclusion: Whilst policies aimed at cost containment (co-payment charges; generic substitution; reference
pricing; adjustments to GMS eligibility) can be used to curtail expenditure, health promotional programs and
educational interventions should be given equal emphasis. Also policies intended to affect physicians’ prescribing
behaviour include guidelines, information (about price and less expensive alternatives) and feedback, and the use
of budgetary restrictions could yield savings in Ireland and can be easily translated to the international context.
Background
Pharmaceutical expenditure is a considerable and growing
cost to health care systems in Western European Union
(EU) countries, including Ireland. Consequently, it is
important to identify the factors influencing this rise in
expenditure so as to ensure the sustainability of health
systems going forward. Information on pharmaceutical
expenditure trends is necessary to facilitate informed
decision making about efficient resource allocation,
optimum budget allocation, and future policy decisions.
Pharmaceutical expenditure growth is not a recent
phenomenon as it has been growing faster than Gross
Domestic Product (GDP) in all European countries since
the 1980s [1]. A systematic review of the factors influen-
cing pharmaceutical expenditure identified that drug
utilisation; drug therapies; price; and new drugs; are the
main drivers of pharmaceutical expenditure [2], and
population growth and aging have been found to be add-
itional factors in Ireland [3]. In 2012, Ireland spent 14 %
of total government expenditure on health which is
comparable with the EU average (EU 28 average). Irish
health spending accounted for 8.9 % of GDP, just above
the EU28 average of 8.7 % [4].
Approximately 14 % of public health expenditure in
Ireland was spent on pharmaceuticals in 2012 [5]. Irish
pharmaceutical expenditure per capita relative to other
Organisation for Economic Co-Operation and Develop-
ment (OECD) countries increased significantly from 20th
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highest of 27 countries in 2000 to 3rd highest of 25
countries in 2010 [6]. In 2012, the state accounted for
€2.6 billion (19 %) of overall health expenditure
(€13.71bn) in Ireland through its publicly funded Com-
munity Drug Schemes (CDS). There are eleven CDS
schemes. The General Medical Services (GMS) scheme
accounted for €1.28 billion, 50 % of community drug
expenditure, the High Tech Drugs scheme accounted
for 385 million (15 %) and the Drug Payments scheme
accounted for 126 million (5 %). This paper focuses on the
GMS scheme, the largest community drug scheme [7].
The most significant contributor to pharmaceutical
expenditure in Ireland is the GMS (medical card)
scheme. This is a community drug scheme, whereby
drugs, medicines and appliances supplied under the
Scheme are provided through retail pharmacies. All
GMS claims are processed and paid by the Primary
Care Reimbursement Service (PCRS). The scheme is
means tested and eligibility is based on income. Persons
who are affected by certain medical conditions are also
eligible for the scheme. Those who are unable without
undue hardship to arrange general practitioner medical
and surgical services for themselves and their depen-
dants are eligible to receive free general medical service
under the scheme and are issued with a medical card.
The scheme is financed by the state with a co-payment
from each eligible person introduced in 2010. Since
October 2010, each person on the scheme has in-
curred a €0.50 charge for every prescription item dis-
pensed. This was subsequently increased to €1.50 in
2013 and is currently €2.50 per prescription item up to
a maximum of €25 per family per month. Between July
2001 and December 2008, all persons over 70 were
granted a free medical card. Due to the economic crisis,
eligibility criteria were introduced on the 1st of January
2009 so that all persons ≥70 were means tested.
Since 2000 GMS expenditure on pharmaceuticals has
been rising rapidly, as illustrated in Fig. 1. The govern-
ment introduced cost containment measures during the
economic crisis to combat this trend such as co-
payment charges for claimants,1 adjustments to GMS
eligibility criteria, reference pricing and the promotion
of generic substitution [8]. Despite these measures,
Irish pharmaceutical spending per capita in 2012 was
the third highest amongst EU countries at €500, 40 %
above the EU average (€350) [4]. The total cost of GMS
prescriptions has increased from €249 million in 1998
to €1.24 billion in 2009 (400 % increase) as illustrated
in Fig. 1. GMS expenditure accounted for 9 % of the
overall health budget in 2012 [9].
The total cost of GMS prescriptions decreased in 2010
and 2011, due to government cut backs and the intro-
duction in cost containment measures, before increasing
again to €1.28 billion in 2012, at a time when GMS
coverage rates2 increased from 35 % of the population in
1998 to over 40 % in 2012. A study of projected GMS
costs for Ireland found that GMS expenditure could rise
to €2.5 billion by 2026 [10].
Between 1998 and 2012, between 67 % and 70 % of
total annual GMS expenditure has been accounted for
by four of the Anatomical Therapeutic Chemical (ATC)
groups; Nervous (N) system, Cardiovascular (C) system,
Alimentary Tract and Metabolism (A) system and Re-
spiratory (R) system (Annual (PCRS) Reports, 1998–
2012). In 2012, €872 million of total GMS expenditure
(€1288.82 million) was recorded across the four ATC
groups equating to 68 % of GMS expenditure [7]. Table 1
reports the findings of previous studies.
The objective of this research is to investigate the sig-
nificant drivers of GMS expenditure whilst controlling
for age, gender, regional disparities, and the main thera-
peutic use of the main active ingredient of medicinal
Fig. 1 Total Cost (€m) of GMS Prescriptions between 1998 and 2012
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products i.e., ATC groups. The main contribution of this
paper will identify the ATC groups by gender, age and
region generating the highest level of cost. It will identify
the ATC Level 5 i.e., specific drug within the ATC group
that are generating the highest cost. We make recom-
mendations on what policies that can be introduced to
reduce cost and generate savings. These policies that will
reduce cost can be translated internationally and would
yield savings in the international context.
Methods
Study design and data
A cross-sectional study was carried out on the Irish
Health Service Executive (HSE)-PCRS pharmacy claims
database for the year 2012 (n = 1.63 million claimants).
Each GMS claimant is identified by a unique dispense
number. There are approximately 60 million observations
in the database and the data was aggregated to create one
observation per claimant. There are 40 variables in the
database, of which seven are included in this research.
These include demographic information (age, sex, region),
cost data (ingredient cost, Value Added Tax (VAT), dispens-
ing fees) and ATC group. For the purpose of this analysis,
total annual cost is the sum of ingredient cost, VATand dis-
pensing fees for 2012. The pharmacology is coded using
the World Health Organisation (WHO) ATC classification
system3 [11]. The analysis of the pharmacology is under-
taken at the 1st level of the ATC classification system.
Modelling health and drug expenditure varies inter-
nationally [2]. A number of studies have used Ordinary
Least Squares (OLS) to model the variation in drug and
health costs [12–18]. Following a review of the literature
and expert opinion, the OLS regression model was
deemed the most appropriate model to use.
Table 1 Previous Studies
Country Author Findings
British Colombia (2006) Morgan [24] A population study on drug expenditure in 1996 and 2002 found 75 % of total drug costs
were accounted for by 5 ATC groups in descending order of expenditure, ‘C’, ‘N’, ‘A’, ‘G’
(Genito Urinary System & Sex Hormones) and ‘J’ (Anti-infectives for Systemic Use).
Sweden (1998) Gerdtham et al. [34] This study identified ATC group ‘N’ contributed the most to drug expenditure.
Sweden (2004) Gerdtham & Lundin
[35]
This study identified ATC groups ‘N’, ‘C’ ‘and ‘A’ contributed the most to drug expenditure.
Sweden (2003) Klarin et al. [36] A study carried out on an elderly population (84+) found ‘C’, ‘N’ and ‘A’ were the most
commonly prescribed drugs.
Spain (2011) Vivas et al. [13] This study reported the cost of drugs used to treat hyperlipidemia (from ATC ‘C’), respiratory
illnesses, asthma (from ATC ‘R’) and diabetes (from ATC ‘A’) represents 37 % of total
pharmaceutical expenditure on chronic conditions in Valencia.
Ireland (2006) Naughton et al. [21] A study based on an elderly Irish population (≥70 years) found that Cardiovascular Disease (CVD)
is the most prevalent condition across all regions using a 2006 PCRS pharmacy database.
Various Studies [3, 10, 20, 26, 30, 37] A number of studies have identified age as a factor influencing pharmaceutical spending.
United States (1997) Mueller et al. [30] A study in the United States found the elderly (65+) accounted for 34 % of total pharmaceutical
expenditure, children (≤17) accounted for 9 %, and those aged (18–64) accounted for the
remaining 57 %. Of total drug expenditure, 41 % was spent on cardiovascular and renal drugs
and 14 % on respiratory tract drugs.
3 European Countries
(2008)
Sturkenboom et al. [20] This study found that respiratory drugs were the most prescribed drugs and cardiovascular
drugs were the least prescribed drugs for children (≤18).
Spain (2008) Fernandez et al. [26] A study in Catalonia, investigated how age influenced drug utilisation and found drug use
was highest among infants (0–4) and those aged 55 and older.
Ireland (2015) Conway et al. [10] A recent study identified children (≤11) and the over 65 s as the two key drivers of future
GMS costs in Ireland.
Various Studies [2, 13, 23, 37] Several studies have reported that females are more likely to utilise drugs than males.
United States (2000) Steinberg et al. [37] Males aged 65 and over were 50 % more likely not to be prescribed any drugs.
Sweden (2013) Loikas et al. [23] This study examined gender differences in drug prescribing and found 59 % of men and 76 %
of women were dispensed at least one drug. Females were found to be prescribed more
nervous drugs and males more lipid lowering (cardiovascular) drugs.
Various Studies [12, 14, 15] Geographical location is also considered in international studies as a predictor of pharmaceutical
expenditure.
United States (2003) Wrobel et al. [12] A Medicare study examined the predictability of drug expenditure and found demographic
variables (age, sex, disability & geographic location), explained only 5 % of the variation in
drug expenditure. The inclusion of health status measures improved the explanatory
power considerably.
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Empirical analysis
Three models were developed to investigate the associ-
ation between the total annual GMS cost per claimant
and the independent variables. The cost data is positively
skewed (skewness = 16.140) and a log transformation
was applied to normalise the data. This approach has
been previously used [17, 19]. In the first model we esti-
mate the impact on the log of annual total cost per
claimant using OLS regression whilst controlling for age,
sex, and the 4 HSE regions (Dublin Mid-Leinster (ML),
Dublin North East (NE), South and West). The square
and cube of age were considered as age has a non-linear
relationship with the log of total cost. The inclusion of
these two variables does not add to the explanatory
power of the model and were excluded.
In the first model we estimate the impact of age, sex
and region on the log of total cost.
LogTC ¼ β0 þ β1X1 þ β2X2 þ β3X3 þ…þ β5X5 þ ε
where β0 is the constant, X1 = age, X2 = female, X3 =
Dublin ML, X4 =West and X5 = South, (Reference cat-
egory = Dublin NE, Male).
In the second model in addition to the demographic
variables, we estimate the impact of pharmacology on
the log of total cost by including the main ATC groups.
LogTC ¼ β0 þ β1X1 þ β2X2 þ β3X3 þ…þ β8X8 þ ε
where X1 = age, X2 = female, X3 = Dublin ML, X4 =West,
X5 = South, X6 = ‘A’ ATC group, X7 = ‘C’ ATC group and
X8 = ‘N’ ATC group (Reference category = Dublin NE, ‘R’
ATC, Male).
In the third model in addition to the demographic and
pharmacological variables, we estimate the model using 11
age categories, to ascertain the impact of age categories
on cost.
LogTC ¼ β0 þ β1X1 þ β2X2 þ β3X3 þ…þ β17X17 þ ε
where X1 = female, X2 =Dublin ML, X3 =West, X4 = South,
X5 = ‘A’ ATC group, X6 = ‘C’ ATC group and X7 = ‘N’ ATC
group, plus 10 dummy variables for age cohort (X8-X17).
(Reference category Age = 12–15, Dublin NE, ‘R’ ATC
group, Male)
The models were estimated by OLS regression. Each
model was tested for normality, homoscedasticity and
linearity. The Variance Inflation Factor (VIF) and toler-
ance factors were obtained to test for multicollinearity.
All statistical tests were two-sided at the 5 % significance
level. Aggregation by GMS claimant was carried out in
R Studio version 2.15.3. Statistical Analysis was per-
formed using SPSS 22.
Results
Statistical analysis
The mean annual cost per claimant was €751
(median = €211; SD = €1323.10; range = €3.27–€298,670).
As regards age, 14 % were 75 or over, with 4 % between
12 and 15. Over 55 % of claimants were female. In terms
of their regional distribution, 28 % were located in the
Southern region, 26 % in both Western and Dublin ML,
and 20 % in Dublin NE. With reference to pharmacol-
ogy, 52 % were prescribed an ‘N’ prescription item, 45 %
an ‘A’ item, 39 % an ‘R’ item and 36 % a ‘C’ prescription
item. In 2012, 19 % of claimants were prescribed items
from ATC groups other than ‘A’ ‘C’ ‘N’ or ‘R’accounting
for almost €19 million of the total annual cost.
The following descriptive analysis is based on claim-
ants (n = 1,313,825) who were prescribed an ‘N’, ‘C’, ‘A’ or
‘R’ prescription item. Table 2 presents GMS expenditure
(€) by claimants categorised by age category and ATC
group.
Table 2 shows that 51 % of claimants in the under 5’s
were prescribed ‘R’ prescription items, whereas just 2 %
were prescribed ‘C’ items. Of those aged 25–34, 42 %
were prescribed ‘N’ items, whereas 8 % were prescribed
‘C’ items. For those aged 75 and over, 30 % were pre-
scribed ‘C’ items with 16 % prescribed ‘R’ items. Analysis
of expenditure by ATC level 2 identified that respiratory
drugs, principally for the treatment of obstructive airway
diseases such as asthma, recorded the highest proportion
of claimants and total expenditure for those up to the
age of 15. Nervous system drugs predominantly for the
treatment of depression, anxiety, psychotic conditions,
and epilepsy, recorded the highest proportion and ex-
penditure for those between 16 and 64 years. Cardiovas-
cular drugs, particularly statins, recorded the highest
proportion and expenditure for those over 65.
Of overall expenditure in 2012, 55 % was due to pre-
scribing claims by females with the proportion of ner-
vous system items (31 %) the major component of this
expenditure (Table 3). There was a higher proportion of
male claimants up to age 15 in ATC groups ‘R’, and a
higher proportion up to age 11 for ATC ‘N’.
Table 4 shows that the South region contributed over
€240 m (29 %) to the overall prescribing expenditure in
2012 and was the most expensive region across the four
ATC groups. Drugs for the treatment of the nervous sys-
tem records the highest proportion across the four re-
gions. Dublin ML and Dublin NE record the highest
percentage of claimants for the nervous and respiratory
system and the West and South record the highest per-
centage of cardiovascular claimants. Of the 427,257
claimants in Dublin ML, incorporating Dublin City, 31 %
were prescribed nervous system items, whereas just 20 %
were prescribed cardiovascular items, largely explained by
a relatively younger population in Dublin ML.
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Results of empirical analysis
In Table 5 the results of the empirical analysis are pre-
sented based on estimates from three models. Model 1
shows that whilst age, sex and regions are all significant
drivers of expenditure, gender (female) had the greatest
impact (β = 0.107). Additional claimants in the South re-
gion will have greatest cost increasing impact. However,
when the ATC groups were included in model 2, the
impact of gender was diluted, with cardiovascular prescrib-
ing most influential (β = 1.229) and the explanatory power
of the model increases from 40 % to 60 %. The inclusion of
age dummies in model 3 expectedly shows those aged over
75 (β =1.195) added most to GMS costs. Multicollinearity
was not violated as VIF values did not exceed ten, Toler-
ance values were greater than 0.1. Mahalanobis and Cook’s
distances tests were carried out to check for outliers. For
the residuals output, the max value for Cook’s distances did
not exceed 1 and the max value for Mahalanobis distances
did not exceed the critical χ2 value.
Discussion
Our investigation identified significant factors [age, sex,
region and pharmacology of the drugs] influencing mean
GMS expenditure per claimant in Ireland for 2012. This
research also identified the drugs (ATC level 5) that
incur the highest level of expenditure by age group. The
impact of age on expenditure followed a similar pattern
as observed in the literature, highest expenditure on re-
spiratory drugs for those under 15, highest on nervous
system drugs for those between 16 and 64, and highest
on cardiovascular drugs for those aged 65 and over. A
recent study reported that children (0–11) and the elderly
(70+) will be a key driver of future drug costs in Ireland
[3]. A three country study (UK, Italy & Netherlands)
found the respiratory system to be one of 3 ATC groups
with the highest prevalent rates in children [20]. A study
in Ireland found that cardiovascular disease is the most
prevalent condition in an elderly population aged 70 and
over, indicating the trend has continued between 2004 and
2012 [21]. However, a study in Denmark found treatment
intensity and prevalence contributed to drug expenditure
costs rather than population aging [22].
In terms of gender differences in prescribing, females
account for more than half of GMS claimants in 2012,
and were found to be more expensive across the 4 ATC
groups with the highest expenditure for nervous system
drugs and the smallest for cardiovascular. A study on a
Swedish population in 2010 concurs with our findings,
which found a greater proportion of men were prescribed
cardiovascular drugs whilst a greater proportion of women
Table 3 Percentage of GMS Claimants & GMS Expenditure (€m) by ATC group and Sex (2012)
Sex N C A R Total (€m) Total GMS
% (€m) % (€m) % (€m) % (€m) N,C,A,R Cost (€m)
Females 31 178.02 20 125.31 27 96.23 22 62.80 462.37 687.12
Males 29 124.82 22 113.75 25 76.53 23 52.54 367.64 537.74
% of Total 36 302.85 29 239.06 21 172.76 14 115.34 830.01 1224.86
N Nervous System, C Cardiovascular System, A Alimentary Tract & Metabolism, R Respiratory System
The most expensive group (females) is highlighted in bold The underlined data in Table 3 shows the highest prescribing frequency for females (N,A) and males (C,R)
Table 2 Percentage of GMS Claimants & Expenditure Euro million (€m) by ATC group and Age Category (2012)
Age Cohort N C A R Total (€m) Total GMS
% (€m) % (€m) % (€m) % (€m) N,C,A,R Cost (€m)
<5 16 0.57 2 0.35 32 0.88 51 2.01 3.81 12.35
5–11 10 1.78 2 0.29 24 1.13 64 4.33 7.53 9.46
12–15 28 1.87 2 0.11 20 0.97 50 2.15 5.10 4.76
16–24 40 9.32 5 0.52 25 3.44 31 3.91 17.20 17.12
25–34 42 27.11 8 1.80 26 7.29 24 5.32 41.52 23.69
35–44 39 39.83 13 6.83 26 12.39 22 7.62 66.68 28.19
45–54 34 46.03 21 19.31 26 19.79 19 11.32 96.45 35.65
55–64 29 46.33 27 40.68 26 29.53 18 18.56 135.11 55.41
65–69 26 23.58 30 31.59 26 19.27 17 13.06 87.49 37.30
70–74 26 27.10 32 43.61 26 23.28 16 15.22 109.21 51.13
>75 27 79.32 30 93.97 27 54.78 16 31.85 259.92 119.79
% of Total 36 302.85 29 239.06 21 172.76 14 115.34 830.01 394.86
N Nervous System, C Cardiovascular System, A Alimentary Tract & Metabolism, R Respiratory System
The most expensive age category by ATC group is highlighted in bold
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were prescribed nervous system drugs [23]. A higher
female per capita expenditure was reported for nervous
and alimentary tract and metabolism drugs in a study
in British Colombia with males highest expenditure on
cardiovascular drugs [24]. Coronary artery disease was
more common in men over 60 than females in Sweden
[25]. We reported that males under 11 years were pre-
scribed more prescription items than female which
concurs with higher drug usage in adolescent males
compared to females in both Catalonia and Sweden
[23, 26].
In terms of regional variation, the South region recorded
the highest prescribing expenditure and Dublin NE the
lowest. Dublin ML recorded the highest proportion of ner-
vous prescription items and Dublin ML recorded the low-
est for cardiovascular items. Two Irish studies [27, 28]
found variations for Ischaemic heart disease and diabetes
respectively, in prescribing by old health board regions.4
They found high prescribing rates in the Midlands and
Eastern regions and low prescribing rates in the Western
and North-Western regions. Furthermore, an Irish study
found variation in projected drug costs by old health
board regions where the Midlands region was the most
expensive region which is now part of the Dublin ML re-
gion [3]. Research on prescribing in Canada reported that
individual characteristics and living environment affect
prescription use and may explain regional variations in
prescription use. For example, area level measures of
population health and socioeconomic status affected the
likelihood of prescription use [29].
In examining the factors driving expenditure, we also
investigated the most costly prescription items. Drugs
for the treatment of the nervous system were the great-
est contributor to prescribing expenditure in 2012. An
important finding of this paper identified the most
Table 4 Percentage of GMS Claimants and Expenditure (€m) by
ATC group and HSE Region (2012)
Region N C A R Total
% (€m) % (€m) % (€m) % (€m) (€m)
Dublin ML 31 79.85 20 61.18 26 46.26 23 31.39 218.67
Dublin NE 31 56.05 21 46.45 26 33.05 23 22.46 158.01
West 30 78.91 22 60.38 26 44.25 22 29.36 212.91
South 30 88.04 22 71.05 26 49.20 22 32.13 240.42
% of Total 36 302.85 29 239.06 21 172.76 14 115.34 830.01
N Nervous System, C Cardiovascular System, A Alimentary Tract & Metabolism,
R Respiratory System
The most expensive group (South) is highlighted in bold
Table 5 Estimates from Multivariate Regression Models 1–3
Variables Model 1 Model 2 Model 3
β C1 95 % t-stat β C1 95 % t-stat β CI 95 % t-stat
Constant 3.339 3.288 3.324
Sex (F) 0.107 (0.103;0.112) a47.84 0.018 (0.015;0.022) a10.07 0.025 (0.021;0.029) a13.66
Age 0.044 (0.044;0.045) a1043.44 0.015 (0.015;0.015) a306.74
Dublin ML 0.026 (0.019;0.032) a7.76 −0.003 (−0.008;0.002) a-1.16 −0.003 (−0.009;0.002) −1.20
West −0.017 (−0.024;-0.011) a-5.16 0.008 (0.003;0.014) a3.07 0.009 (0.003;0.014) a3.21
South 0.056 (0.050;0.063) a17.08 0.038 (0.033;0.043) a14.21 0.037 (0.032;0.043) a14.00
Alimentary 0.911 (0.907;0.915) a440.64 0.903 (0.899;0.907) a436.51
Cardiovascular 1.229 (1.224;1.234) a478.42 1.193 (1.188;1.198) a452.28
Nervous 0.927 (0.923;0.931) a456.61 0.947 (0.943;0.951) a454.63
<5 0.117 (0.106;0.128) a21.57
5–11 0.103 (0.092;0.113) a19.23
16–24 0.237 (0.227;0.247) a45.55
25–34 0.370 (0.360;0.381) a72.09
35–44 0.475 (0.465;0.485) a92.06
45–54 0.706 (0.696;0.717) a131.29
55–64 0.957 (0.946;0.968) a172.64
65–69 1.071 (1.059;1.083) a173.49
70–74 1.126 (1.114;1.137) a189.07
>75 1.195 (1.184;1.206) a215.44
Adjusted R2 0.402 0.604 0.605
aStatistically significant at 5 % level
The dependent variable was the logarithim of annual total GMS cost (€) per claimant
Baseline - Males, age category 12–15, Dublin NE and ATC ‘R’. (least cost variables)
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expensive drugs in each ATC group by age cohort. Escita-
lopram which treats depression and anxiety accounts for
the highest expenditure (€0.74 m; 1 % of ‘N’) for 16 to
24 year olds and Olanzapine which treats psychotic condi-
tions such as schizophrenia and bipolar disorder accounts
for the highest expenditure (€2.48 m; 1 % of ‘N’) for 25 to
34 year olds. Expenditure on Pregabalin (€16.95 m; 10 %
of ‘N’) in 35 to 64 year olds for the treatment of conditions
such as epilepsy contributed to 10 % of prescription items
for ATC ‘N’.
Respiratory drugs was the main contributor to GMS
drug expenditures in children up to the age of 15 and
this is corroborated by the literature [26, 30]. With an
increasing incidence of asthma in developed countries,
it’s not surprising that drugs for the treatment of obstruct-
ive airway diseases, such as Montelukast (€2.4 m; 29 % of
‘R’), and inhalers such as Salbutamol and Beclometasone
are amongst the greatest contributors to expenditure for
ATC group ‘R’. A childhood study in Ireland reported that
cigarette smoke, atopy, and the presence of certain furry
pets, are determinants of respiratory symptoms in chil-
dren [31].
Cardiovascular prescription expenditure in 2012 was
mainly influenced by the prescribing of statins (Atorva-
statin, Rosuvastatin, Pravastatin, Simvastatin and Fluvasta-
tin) [7]. Atorvastatin has since come off patent, which
should help reduce costs associated with high cholesterol.
The greater promotion of generic prescribing for these
drugs would lead to cost savings.
Expenditure on Esomeprazole (€31.25 m; 18 % of ‘A’),
a Proton Pump Inhibitor (PPI) which is used to treat
certain stomach and oesophagus conditions, such as ul-
cers and acid reflux, contribted 18 % of expenditure on
alimentary tract and metabolism items. In 2012, PPI’s
were the second most expensive group of medicines
after statins [7]. An Australian study investigated the
utilisation of PPI’s and found Esomeprazole to be the
second most prescribed PPI and the second most expen-
sive group of medicines after statins [32]. An Irish study
on the GMS scheme investigated whether cost savings
could be made by changes in prescribing practice. They
found if Esomeprazole was substituted with a less expen-
sive alternative, it would create savings of approximately
€3.3 million [33].
Our analysis highlighted a significant difference between
the mean expenditure per claimant and the median. This
is explained by high cost users of prescription items in our
population. The characteristics of high cost users need
further investigation. An important strength of this study
is that it provides a population based overview of drug
utilisation and expenditure across four ATC groups.
This study is subject to certain limitations. The HSE-
PCRS has pre-defined age cohorts, therefore making it
difficult to re-construct age cohorts to make comparisons.
The age band widths are not equal across the 11 HSE age
cohorts. The HSE-PCRS database lacks a unique health
identifier, which precludes the link between pharmacy data
and other health data such as mortality data. The analysis
is limited to the HSE-PCRS database which relates to pub-
lic patients only.
Conclusion
All European countries have common concerns about
growing drug expenditures. The growing proportion of
the elderly, the increase in the incidence and duration of
chronic diseases, the continuing development of health
technologies, and the increase in health expectation of
society, are common factors across all countries. Our re-
search indicates that growth in the proportion of elderly
claimants and associated levels of cardiovascular pre-
scribing, particularly for statins, will present difficulties
for Ireland in terms of cost containment. The primary
prevention of CVD is dependent on the effective reduction
of the major risk factors, particularly tobacco control and
a healthier diet. Policies aimed at population-wide CVD
prevention, such as legislating for smoke-free public
spaces, banning dietary transfats, or halving daily dietary
salt intake are generally effective and cost saving. Based on
prevalence rates and related prescribing costs of asthma
among children up to the age of 15, it is imperative that
public health resources and educational efforts are tar-
geted to improve asthma control and reduce the disease
burden on both the healthcare system and society. Ex-
penditure on nervous system drugs in Ireland are high-
est for those aged between 16 and 64, in particular,
drugs for the treatment of anxiety and depression. The
treatment of anxiety and depression is vitally important
with the growth in suicidal related deaths in Ireland.
Whilst pharmacological treatments are often necessary,
changes in prescribing practice combined with psycho-
logical therapies, cognitive methods, and self-help strat-
egies, can yield cost savings. Since October 2013, a
generic substitute for Esomeprazole is now available
which could generate substantial savings in alimentary
tract prescribing. Whilst policies aimed at cost containment
such as co-payment charges, generic substitution, reference
pricing, and adjustments to GMS eligibility can be used to
curtail expenditure, health promotional programs and
educational interventions should be given equal emphasis.
Furthermore, policies intended to affect physicians’
prescribing behaviour include guidelines, information
(about price and less expensive alternatives) and feedback,
and the use of budgetary restrictions could also yield
significant savings.
Endnotes
1A claimant is a person who is eligible for a GMS card
and makes a claim.
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2GMS coverage refers to the proportion of the population
who have a medical card.
3In the Anatomical Therapeutic Chemical (ATC) clas-
sification system, the active substances are divided into
different groups according to the organ or system on
which they act and their therapeutic, pharmacological
and chemical properties. Drugs are classified in groups
at five different levels. The drugs are divided into four-
teen main groups (1st level), with pharmacological/thera-
peutic subgroups (2nd level).
4The 8 Health Service Executive (HSE) regions were
restructured to 4 Regions (Dublin ML; Dublin NE; South;
West) in 2010.
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